uniprotid	 uniprotresno	 mutation	 pubmed	 notes
Q9Y239	41	V->A	10329646	Abolishes interaction with RIPK2/RICK.
O43189	41	W->A	23142980	Abolishes histone H3K36me3-binding and localization at double-strand breaks (DSBs).
Q62768	121	I->N	16704978	Abolishes binding to RIMS1.
O00255	283	M->W	22327296	Loss of interaction with KMT2A and JUND.
P84103	86	R->E	17036044	Abolishes interaction with NXF1.
P84103	88	R->E	17036044	Abolishes interaction with NXF1.
P84103	90	R->E	17036044	Abolishes interaction with NXF1.
Q8IYV9	148	W->A	27309818	Abolishes interaction with IZUMO1R.
Q8IYV9	157	H->A	27309818	Nearly abolishes interaction with IZUMO1R.
Q8IYV9	160	R->A,E	27309818	Nearly abolishes interaction with IZUMO1R.
Q62074	70	W->A	12813044	Loss of interaction with SQSTM1.
Q62074	72	D->A	12813044	Loss of interaction with SQSTM1.
Q62074	74	E->A	12813044	Loss of interaction with SQSTM1.
Q62074	76	D->A	12813044	Loss of interaction with SQSTM1.
Q62074	85	E->A	12813044	Loss of interaction with SQSTM1.
Q80TS3	323	Y->A	26235031	Abolishes FLRT3 binding.
P20138	340	Y->A	10206955	Abolishes binding to PTPN6 and PTPN11. Increases binding of red blood cells.
Q8WTX7	121	D->A	27487210	No effect on arginine-binding. No effect on homodimerization. Loss of interaction with the GATOR2 complex which constitutively activates the TORC1 signaling pathway.
Q8WTX7	261	E->A	27487210	No effect on arginine-binding. No effect on homodimerization. Loss of interaction with the GATOR2 complex.
Q8WTX7	292	D->A	27487210	No effect on arginine-binding. No effect on homodimerization. Loss of interaction with the GATOR2 complex.
Q9UNE7	30	K->A	23973223	Loss of interaction with FOXP3 and its ability to ubiquitinate FOXP3. Loss of interaction with SMAD3, HSPA8, HSP90AA1 and HSP90AB1.
Q53EZ4	184	W->A	18948538	Abolishes interaction with PDCD6IP.
Q53EZ4	187	Y->A	18948538	Abolishes interaction with PDCD6IP.
Q53EZ4	191	R->A	18948538	Abolishes interaction with PDCD6IP.
Q53EZ4	192	E->A	18948538	Abolishes interaction with PDCD6IP.
S0F332	117	D->A,N	24825175	Mutant does not bind to the arginine- phosphorylated substrate.
Q6VMQ6	1224	L->R	15691849	Abolishes interaction with MBD1 and subsequent transcriptional repression.
Q9Y6N9	103	R->H	20142502	Strongly reduced affinity for USH1G.
Q9V637	210	L->A	23622245	Abolishes interaction with Tnks, PSMD5 and PSMD9.
Q9V637	241	F->A	23622245	Abolishes interaction with Tnks, PSMD5 and PSMD9.
Q9NWS0	54	F->A	22368283	Abolishes binding to histone H4.
Q9NWS0	57	K->A	24656813	Abolishes binding to TELO2.
Q9NWS0	64	K->A	24656813	Abolishes binding to ECD, EFTUD2, RPB1, TELO2 and UBR5.
Q9NWS0	168	R->A	24656813	Abolishes binding to TELO2.
Q86YT9	54	K->E	12869515	Loss of the ability to homodimerize, loss of interaction with CXADR and loss of function in cell-cell adhesion.
O75475	365	I->A	15895093	Loss of interaction with human HIV-1 integrase; reduced interaction with POGZ and CDCA7L.
O75475	366	D->A	19244240	Loss of interaction with human HIV-1 integrase; no effect on interaction with CDCA7L and POGZ.
O75475	366	D->N	15895093	Loss of interaction with human HIV-1 integrase; no effect on interaction with KMT2A.
O75475	406	F->A	15895093	Loss of interaction with human HIV-1 integrase and POGZ; reduced interaction with CDCA7L.
O15350	487	Y->A	15070730	Loss of interaction with WWOX.
Q62888	770	Y->A	19755106	Abolishes interaction with GPHN.
P03129	67	L->R	10228159	Complete loss of interaction with HDAC1 and transformation ability.
P03129	91	C->G	10228159	Complete loss of interaction with HDAC1 and transformation ability.
P36897	193	L->G	9233797	Loss of interaction with FKBP1A.
P36897	194	P->K	9233797	Loss of interaction with FKBP1A.
P13864	162	Q->E	17576694	Abolishes interaction with PCNA. No effect on activity.
P13864	169	F->S	17576694	Abolishes interaction with PCNA. No effect on activity.
Q22875	233	C->Y	9674433	In ku242; suppresses an activated ras mutation and dramatically enhances phenotypes of mpk-1 MAP kinase and ksr-1 mutations. Abolishes interaction with let-60.
O94826	192	R->A	12526792	Unable to induce IRF3 activation upon Sendai virus infection. Loss of interaction with HSPA8 and HSP90AA1. No effect on mitochondrial location.
Q80XF5	66	Y->A	19285080	Abolishes IL22-binding.
Q80XF5	118	R->A	19285080	Abolishes IL22-binding.
Q53630	23	D->N	9915819	Abolishes binding to elastin.
P49758	297	D->A	10339615	Loss of interaction with GNB5.
Q07879	133	C->A	10508157	Complete loss of covalent binding to ATG12.
Q9XUS7	413	I->S	25775511	Abolishes binding to cdc-42 and rescues the endosomal cargo sorting defect in the double toca-1 and toca-2 mutant.
Q9XUS7	585	W->K	25775511	Abolishes binding to wve-1 and rescues the endosomal cargo sorting defect in the double toca-1 and toca-2 mutant.
Q6DN72	356	Y->F	17213291	No change of phosphorylation implicated in interaction with PTPN11. Loss of interaction with INPPD5, INPPL1 and GRB2.
Q6DN72	371	Y->F	17213291	Loss of phosphorylation implicated in interaction with PTPN11. Loss of interaction with PTPN11, PTPN6 and INPPL1.
Q9BYE9	1310	L->R	24725409	Loss of interaction with USH1C.
Q15025	472	D->N	21606507	Abolishes binding to polyubiquitin ('K-63'- linked and linear).
Q15025	552	Y->F	17632516	Abolishes interaction with PI3K p85 regulatory subunit and abolishes interaction between SELPLG and PI3K p85 regulatory subunit.
O70469	351	Y->F	10508618	No loss of binding to SH2 domain of RASGAP. Complete loss of binding to SH2 domain of NCK.
Q9P258	439	K->E	25074804	Loss of interaction with RAC1 and loss of regulation of RAC1 activation.
Q9GRW0	111	V->A	16362048	Loss of interaction with PPO1 and PPO2.
Q9LKX9	654	C->F	12602870	Loss of interaction with RPD3I or CYCD3-1, but not with RBAP1.
O22265	204	Y->A	18621669	Loss of interaction with LHCP.
Q12830	2869	Y->T	16728978	Abolishes binding to histone H3K4me3.
Q12830	2876	Y->T	16728978	Strongly reduces binding to histone H3K4me3.
Q12830	2882	Y->S	16728978	Abolishes binding to histone H3K4me3.
Q12830	2884	G->E,L	16728978	Strongly reduces binding to histone H3K4me3.
Q12830	2886	D->N,A	16728978	Abolishes binding to histone H3K4me3.
Q12830	2889	Q->K	16728978	Strongly reduces binding to histone H3K4me3.
Q12830	2891	W->E,F	16728976	Abolishes binding to histone H3K4me3.
Q09349	448	C->Y	27669035	Loss of interaction with cdc-48.1. Constitutive localization to foci. Decrease in the number of apoptotic corpses in the germline in response to ionizing radiation-mediated DNA damage. No defect in catalytic activity.
Q70KF4	3197	L->P	17499862	Complete loss of PRKAR2A-binding.
Q70KF4	3309	L->P	17499862	Complete loss of PRKAR2A-binding.
Q70KF4	3437	C->P	17499862	Important loss of PRKAR2A-binding.
Q9BSI4	258	F->A	18202258	Abolishes interaction with TERF1.
Q9UBS4	169	C->S	17976514	Drastic loss of interaction with denatured substrates.
Q9UBS4	171	C->S	17976514	Drastic loss of interaction with denatured substrates.
Q9UBS4	193	C->S	17976514	Drastic loss of interaction with denatured substrates.
Q9UBS4	196	C->S	17976514	Drastic loss of interaction with denatured substrates.
Q15561	297	K->A	20123908	Important loss of interaction with YAP1 and complete loss of transforming ability.
Q15561	299	W->A	20123908	Important loss of interaction with YAP1 and complete loss of transforming ability.
Q15561	429	Y->A,H	18579750	Loss of interaction with YAP1 and also activation by YAP1.
Q15561	429	Y->A	18579750	Important loss of interaction with YAP1 and complete loss of transforming ability.
Q70EL2	199	C->A	25538220	Catalytically inactive. Loss of ability to deubiquitinate ERCC1. Loss of interaction with SPDL1 and ability to deubiquitinate SPDL1.
Q12834	132	R->A	19098431	Loss of interaction with MAD2L1.
Q460N5	1055	G->E	23473667	Abolishes interaction with PARP10.
Q9LT31	184	A->K	20833725	Loss of interaction with RABF2B.
Q9LT31	185	D->A	20833725	Loss of interaction with RABF2B. Decreases GEF activity 12-fold.
Q9LT31	185	D->E	20833725	Loss of interaction with RABF2B.
Q9LT31	225	Y->A	20833725	Loss of interaction with RABF2B. Decreases GEF activity 25-fold.
P51875	212	W->A	26659249	Abolishes binding to gbas-1.
P51875	216	F->A	26659249	Abolishes binding to gbas-1.
Q5CZ52	388	A->E	26150102	Abolishes interaction with bbs-5. Unable to target to cilia.
P63010	815	Y->A	16516836	Strongly reduces interaction with SNAP91, EPS15, AMPH and BIN1 and clathrin heavy chain.
P63010	841	W->A	15728179	Abolishes interaction with LDLRAP1 and ARRB1. Greatly reduces DENND1B-binding.
P63010	879	R->E	10944104	Strongly reduces interaction with EPN1. Reduces interaction with SNAP91 and clathrin. No effect on EPS15 binding.
P63010	888	Y->V	10944104	Strongly reduces interaction with SNAP91, EPN1 and clathrin. No effect on EPS15 binding. Abolishes interaction with ARRB1 and with DENND1B.
P63010	902	E->A	16516836	Strongly reduces interaction with LDLRAP1 and ARRB1. No effect on DENND1B-binding.
P63010	917	K->Q	10944104	Strongly reduces interaction with LDLRAP1. SNAP91 and clathrin. Reduces interaction with EPN1. No effect on EPS15 binding.
P40616	31	T->N	21239483	Loss of interaction with ARFIP1 and ARFIP2.
O75154	737	Y->S	17030804	Abolishes Rab11-binding.
O75154	738	I->E	15601896	Abolishes Rab11-binding.
O75154	739	D->A	17030804	Abolishes Rab11-binding.
O75154	746	M->S	17030804	Abolishes Rab11-binding.
O75154	747	E->A	17030804	Abolishes Rab11-binding.
Q8IVG9	6	F->A	14561895	Abolishes binding to IGFBP3.
Q8IVG9	9	L->R	11717357	Abolishes binding to BAX.
Q91Y57	432	Y->F	11171044	Abolishes binding to PTPN6 and PTPN11.
Q9CW03	807	L->P	9528857	Abolishes interaction with MXI1.
Q03001	7548	K->Q	19632184	Loss of interaction with MAPRE1 and association with microtubule growing ends.
P27812	32	C->S	15814704	Loss of Klrb1b-mediated inhibition of natural killer cell cytotoxicity. Reduced LCK binding, loss of PTPN6 binding and loss of inhibition of Ca(2+) influx upon activation of natural killer cells.
O43914	50	D->A	23715743	Reduced cell surface expression of KIR2DS1. Severely impairs formation of homotrimers and homotetramers. Abolishes interaction with TREM2 and stabilization of TREM2-CTF. Impairs the expression of KLRD1-KLRC2 on the cell surface.
O95628	16	L->A,E	11823428	Abolishes interaction with E2 ubiquitin ligases.
O95628	17	C->A	11823428	Abolishes interaction with E2 ubiquitin ligases.
O95628	33	C->R	11823428	Abolishes interaction with E2 ubiquitin ligases.
O95628	45	I->A,W	11823428	Strongly reduces interaction with E2 ubiquitin ligases.
O95628	57	R->E	11823428	Strongly reduces interaction with E2 ubiquitin ligases.
Q61006	553	Y->F	16794080	Loss of interaction with DOK7.
Q05066	136	K->R	15297880	Abolishes acetylation. Does not abolish interaction with EP300. Does not abolish DNA-binding. Enhances cytoplasmic localization. Abolishes interaction with KPNB1.
P36006	1158	W->S	10648568	Abolishes interaction with LAS17 and causes severe mislocalization of the protein.
Q9R080	631	F->R	10559191	Loss of interaction with GNAI2 and GNAI3.
Q9R080	639	Q->A	10559191	Loss of interaction with GNAI2 and GNAI3.
Q9R080	647	R->F	10559191	Loss of interaction with GNAI2 and GNAI3.
P39984	266	L->E	24835250	Abolishes interaction with HAT1.
P46937	86	M->A	20123905	Complete loss of interaction with TEAD1.
P46937	89	R->A	20123905	Complete loss of interaction with TEAD1.
P46937	91	L->A	20123905	Complete loss of interaction with TEAD1.
P46937	94	S->A	18579750	Loss of interaction with TEAD1, TEAD2, TEAD3 and TEAD4. Loss of transcriptional coactivation activity towards TEAD1, TEAD2, TEAD3 and TEAD4 but no effect on its activity towards RUNX2 and ERBB4. Abolishes suppression of ciliogenesis.
P46937	95	F->A	20123905	Complete loss of interaction with TEAD1.
P46937	96	F->A	20123905	Loss of interaction with TEAD1.
P46937	129	P->D	17974916	No effect on phosphorylation but loss of interaction with YWHAB.
Q99LE1	56	F->P	23798443	Loss of interaction with MYO5A.
Q99LE1	59	V->Q	23798443	Loss of interaction with MYO5A.
Q7TSA3	44	L->H	18178834	Loss of interaction with TNFRSF14.
Q7TSA3	48	R->D	18178834	Loss of interaction with TNFRSF14.
Q7TSA3	65	P->A	18178834	Loss of interaction with TNFRSF14.
Q7TSA3	136	H->D	18178834	Loss of interaction with TNFRSF14.
Q9UHD2	693	L->A	21931631	Almost abolishes interaction with TANK.
Q9UHD2	711	L->A	21931631	Almost abolishes interaction with TANK.
Q6PIZ9	79	Y->F	9687533	Abolishes interaction with PIK3R1.
Q69559	11	Y->A	29535361	Complete loss of interaction with host ITCH.
O88898	543	Y->F	18806757	Abolishes interaction with WWP1.
Q5VWG9	23	W->R	11438666	Loss of interaction with TAF10.
A6P320	367	Y->A	17604280	Abolishes interaction with AP1M1.
P41743	72	D->A	15143057	Loss of interaction with ECT2, PARD6A and with SQSTM1.
P54725	333	P->E	11087358	Abolishes interaction with HIV-1 vpr.
P03427	447	Q->A	30666459	Loss of interaction with ANP32A.
P03427	450	G->A	30666459	Loss of interaction with ANP32A.
Q97WH1	295	I->E	22135300	Does not interact with HerA. Does not affect dimerization. Strong decrease in nucleolytic activity.
P45697	24	Y->G	12705833	Complete loss of toxicity to mice, and 70-fold decrease in the binding affinity for insect sodium channels.
P45697	30	N->A	12705833	Complete loss of toxicity to mice, 380-fold decrease in the binding affinity for insect sodium channels.
P13233	417	C->S	7884818	Abolishes binding to myelin.
O97593	966	S->A	16043481	Abolishes binding with RPGR.
Q9FZK4	38	E->K	16428596	Loss of interaction with RAN1 leading to impaired nuclear protein import activity.
Q9FZK4	91	E->K	16428596	Loss of interaction with RAN1 leading to impaired nuclear protein import activity.
P08018	96	P->S	7624781	In PBS2-13; loss of SH3-domain interaction.
O75420	294	W->A	31439631	Abolishes interaction with DDX6.
P32458	40	N->E	12665577	Temperature-sensitive; no effect at 23 degrees Celsius but loss of function at 37 degrees Celsius; abolishes interaction with itself.
Q8IWE5	828	G->D	18996344	Loss of interaction with sifA.
Q8IWE5	830	R->D	18996344	Loss of interaction with sifA.
Q8IWE5	869	C->D	18996344	Loss of interaction with sifA.
Q24459	517	C->S,A	11571280	Abolishes interaction with E(z).
Q96DZ1	207	R->A	18264092	Abolishes interaction with SEL1L.
Q96DZ1	379	G->S	16531414	Abolishes binding to KREMEN2.
Q96DZ1	428	R->A	18264092	Abolishes interaction with SEL1L.
O95149	27	R->A	16030253	Abolishes interaction with KPNB1 and m3G-cap U1 snRNP import receptor activity.
Q3UND0	260	Y->F	11063873	Abolishes interaction with FYN, phosphorylation by FYN, and effects on cell growth.
Q5FBB7	61	N->I	16580887	Loss of interaction with PPP2CA and PPP2R1A and loss of centromeric localization.
P52734	159	P->A	12913069	Abolishes binding to DBNL.
P52734	162	P->A	12913069	Abolishes binding to DBNL.
Q9R0P9	30	D->K	12913066	Abolishes enzymatic activity and ubiquitin binding.
Q13625	1098	W->K	10646860	Loss of interaction with APC2.
P15498	696	R->L	8986718	Loss of interaction with SYK.
O00206	714	P->H,R,E	11081518	Abolishes MYD88-binding and LPS-response.
Q9NRR4	1194	L->R	26748718	Abolishes interaction with DGCR8.
Q9NRR4	1243	V->D	26748718	Abolishes interaction with DGCR8.
Q9Z2D6	302	P->R	23770565	Abolishes interaction with NCOR2.
Q9Z2D6	304	K->E	23770565	Abolishes interaction with NCOR2.
Q9Z2D6	305	K->R	23770565	Abolishes interaction with NCOR2.
Q9Z2D6	306	R->C	23770565	Abolishes interaction with NCOR2. Mice exhibit a severe neurological Rett syndrome-like phenotype.
Q9NZD8	109	S->A	11113139	Abolishes interaction with CD4.
Q00202	455	Y->D	12588984	Abolishes interaction with palA. Severely reduces proteolytic processing of the full-length translation product by signaling protease, causing a stringent loss-of-function, acidity-mimicking phenotype.
Q00202	662	Y->N	12588984	Abolishes interaction with palA. Partially reduces proteolytic processing of the full-length translation product by signaling protease, causing a weak loss-of-function phenotype.
P06663	26	W->A	20439431	Complete loss of interaction with host AGO1 and AGO4. Complete loss of silencing suppression.
P06663	274	W->A	20439431	Complete loss of interaction with host AGO1 and AGO4. Complete loss of silencing suppression.
P39007	208	W->A	15781470	Lethal; abolishes interaction with OST1 and WBP1.
P39007	404	R->A	15781470	Lethal; abolishes interaction with OST1 and WBP1.
P12931	419	Y->F	19307596	Loss of kinase activity. Loss of interaction with PDLIM4.
Q96CV9	178	F->A	21617041	Abolishes interaction with MAP1LC3A and GABARAPL1, no effect on binding to linear ubiquitin.
Q9Y678	776	W->S	14690497	Loss of interaction with ZNF289/ARFGAP2.
Q04439	1123	W->S	10944111	Abolishes interaction with BBC1 and VRP1.
P97764	162	Y->A	11042109	Abolishes interaction with NEDD4.
P97764	176	Y->A	11042109	Abolishes interaction with NEDD4.
Q03145	958	R->C,K	29749928	Abolishes interaction with INPPL1 SAM domain.
P33896	526	S->A	14532120	Abolishes interaction with FBXW11. Prevents interalization from the cell membrane and lysosomal degradation.
Q9C030	15	C->A	24882218	Abolishes binding of polyubiquitin to IKBKE.
Q9BY43	214	L->A	18511562	Abolishes interaction with PDCD6IP.
Q9BY43	217	L->A	18511562	Abolishes interaction with PDCD6IP.
Q9BY43	220	W->A	18511562	Abolishes interaction with PDCD6IP.
P46108	150	D->K	8662907	Abolishes interaction with DOCK1.
P46108	169	W->K	31311869	Abolishes interaction with PEAK3.
P46108	169	W->L	12432078	Abolishes interaction with DOCK5. Abolishes RAP1 activation.
O00167	532	A->R	23435380	Abolishes interaction with SIX1.
Q45Z47	76	D->K	16669624	Complete loss of neurotoxicity and catalytic activity, no change in binding affinity to M-type receptors, 1230-fold decrease in binding affinity to N-type receptors.
P17870	391	F->A	11876640	Abolishes interaction with AP2B1; no effect on interaction with CLTC.
P17870	395	R->E	11876640	Abolishes interaction with AP2B1; impairs interaction with CLTC.
P56192	64	A->R	26472928	Loss of interaction with EEF1E1.
P56192	86	E->R	26472928	Loss of interaction with EEF1E1.
Q676U5	17	I->W	25484072	Abolishes interaction with ATG5.
Q676U5	21	L->W	25484072	Abolishes interaction with ATG5.
Q676U5	24	R->D	25484072	Abolishes interaction with ATG5.
Q676U5	139	S->A	26083323	Abolishes phosphorylation. Impairs interaction with ATG12-ATG5 complex.
Q9Z351	345	R->E	12223552	Loss of interaction with calmodulin.
Q9NRA8	30	Y->A	10856257	Abolishes interaction with EIF4E and EIF4E2. Impaired ability to repress mRNA translation.
P38862	333	G->A	10233150	Loss of interaction with ATG8 and ATG12, and no more ATG12-ATG5 conjugate. Defect in Cvt pathway and autophagy.
P38862	443	R->A	22055191	Loss of interaction with ATG8.
P38862	507	C->A	10233150	Loss of interaction with ATG8 and ATG12 and no more formation of ATG12-ATG5 conjugate. Defect in Cvt pathway and autophagy.
P38862	550	R->A	22055191	Loss of interaction with ATG8.
P15702	347	S->D	21289089	No loss of phosphorylation or localization to the uropodium. Loss of interaction with EZR.
Q24120	1049	K->A,D	21730168	Abolishes interaction with spir.
Q24120	1051	R->A,D	21730168	Abolishes interaction with spir.
Q24120	1055	R->A,D	21730168	Abolishes interaction with spir.
Q6PID8	409	A->P	23102700	Loss of interaction with CUL2. No effect on MAP3K5 activation.
P46672	26	A->R	16914447	Abolishes interaction with MES1.
P46672	100	R->A	16914447	Abolishes interaction with GUS1.
Q01968	668	F->V	22543976	Does not interact with RAB8A. Does not localize to cilia.
Q7LBR1	192	L->A	17928862	Abolishes interaction with VPS4B.
Q7LBR1	195	L->A	17928862	Abolishes interaction with VPS4B.
Q84L31	8	L->A	21764993	Abolishes interaction with RPN10.
Q84L31	47	I->A	21764993	Abolishes interaction with RPN10.
P52490	55	E->A	11440714	Strongly reduces MMS2 binding and interferes with error-free DNA repair.
Q96I25	319	D->K	17589525	Abolishes interaction with SF3B1, SF1 and U2AF2. Abolishes regulation of alternative splicing.
Q96I25	375	R->A	17589525	Impairs interaction with SF3B1, SF1 and U2AF2. Abolishes regulation of alternative splicing.
Q96I25	376	Y->A	17589525	Impairs interaction with SF3B1, SF1 and U2AF2. Abolishes regulation of alternative splicing.
Q96I25	377	F->A	17589525	Impairs interaction with SF1 and U2AF2 and abolishes interaction with SF3B1. Abolishes regulation of alternative splicing.
Q13127	1009	E->A	18354482	Loss of interaction with BTRC.
Q13127	1013	S->A	18354482	Loss of interaction with BTRC.
Q9UKT5	341	C->W	20159592	Abolishes interaction with TERF1.
Q9UKT5	345	A->R	20159592	Abolishes interaction with TERF1.
Q9HBW0	348	D->A	16904289	Abolishes interaction with MAGI3.
Q9HBW0	349	S->A	16904289	Abolishes interaction with MAGI3.
Q9HBW0	351	L->A	16904289	Abolishes interaction with MAGI3.
P53141	114	G->D	15210731	In MLC1-11; abolishes interaction with MYO2 and IQG1 and reduces interaction with MYO1. Leads to mislocalization of IQG1 and a severe defect in cytokinesis.
Q07157	209	K->A	18636092	Abolishes interaction with GJA1.
Q96RJ3	26	D->A	12755599	Strongly reduced affinity for TNFSF13B.
Q96RJ3	28	L->A	12755599	Strongly reduced affinity for TNFSF13B.
Q5T2T1	38	L->S	17332497	Abolishes interaction with DLG1.
Q9R0Q1	14	E->A	12590134	Abolishes interaction with RAB27A.
Q9R0Q1	18	I->A	12590134	Abolishes interaction with RAB27A.
Q9R0Q1	21	V->A	12590134	Abolishes interaction with RAB27A.
Q9R0Q1	32	D->A	12590134	Abolishes interaction with RAB27A.
Q8N292	139	P->A	18559951	Abolishes interaction with GRB2.
Q8N292	141	P->A	18559951	Abolishes interaction with GRB2.
Q8N292	145	P->A	18559951	Abolishes interaction with GRB2.
Q80XA6	423	P->A	12149250	Abolishes interaction with ASAP1.
Q80XA6	426	P->A	12149250	Abolishes interaction with ASAP1.
P00519	735	T->A	15696159	Abolishes phosphorylation. Loss of binding YWHAS and YWHAZ. Localizes to the nucleus. No effect on kinase activity.
Q8NAV1	145	D->A	26673105	Loss of interaction with MFAP1.
Q06263	122	W->A	18194651	Abolishes interaction with VSP60 and DID2.
Q06263	152	K->A	18194651	Abolishes interaction with VSP60 and DID2.
Q06263	299	K->A	16505166	Abolishes interaction with VSP4.
Q06263	302	K->A	16505166	Abolishes interaction with VSP4.
Q06263	303	Y->A	18194651	Abolishes interaction with VSP4, no effect on dimerization.
Q06263	310	Y->A	18194651	Abolishes interaction with VSP4, no effect on dimerization.
Q06263	311	E->A	18194651	Abolishes interaction with VSP4 and dimerization.
Q06263	312	D->A	18194651	Abolishes interaction with VSP4 and dimerization.
Q7X9V3	107	I->T	16461385	Complete loss of interaction with CaLCuV NSP protein.
Q7X9V3	136	K->E	16461385	Complete loss of interaction with CaLCuV NSP protein.
Q7X9V3	194	D->G	16461385	Complete loss of interaction with CaLCuV NSP protein.
P9WNK5	94	L->A	16973880	Abolishes interaction with EccCb1, but not with EsxA.
P9WNK5	98	M->A	16973880	Abolishes interaction with EccCb1, but not with EsxA. No change in stability, but loss of secretion.
P9WNK5	99	G->A	16973880	Abolishes interaction with EccCb1, but not with EsxA.
P9WNK5	100	F->A	16973880	Abolishes interaction with EccCb1, but not with EsxA. No change in stability, but loss of secretion.
Q16513	974	F->A	10226025	Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'.
Q16513	977	F->A,L	10226025	Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'. Reduces catalytic activity by 90%.
Q16513	978	D->A,S	10226025	Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'.
Q16513	979	Y->A	10226025	Abolishes interaction with PDPK1 and prevents the phosphorylation of AKT1 at 'Ser-473'.
P60766	17	T->N	10934474	Constitutively inactivated. Abolishes interaction with PARD6 and DOCK11. Inhibits filopodia formation.
Q06890	343	L->P	12551933	Abolishes interaction with XRCC6.
Q06890	361	L->R	12551933	Abolishes interaction with XRCC6.
O48915	4	Q->A	17012600	Loss of interaction with RIN4.
O48915	5	N->A	17012600	Loss of interaction with RIN4.
Q9NQR1	379	D->A,N	15933070	Abolishes histone H4 binding and methyltransferase activity.
P11691	103	E->A	12177465	Movement defective. Loss of interaction with host protein HFI22. No effect on association with host membrane.
P11233	47	K->E	15920473	Strongly reduces interaction with EXOC8.
P11233	48	A->W	15920473	Strongly reduces interaction with EXOC8.
P11233	50	S->W	15920473	Strongly reduces interaction with EXOC8.
P10507	89	E->A	9299349	Loss of catalytic activity and loss of binding to MAS2.
P10507	234	K->A	9299349	Loss of catalytic activity and loss of binding to MAS2.
A2RT67	554	S->A	25925668	Abolishes interaction with 14-3-3 proteins.
Q9BV36	14	E->A	12062444	Abolishes RAB27A binding.
Q9BV36	32	E->A	12062444	Abolishes RAB27A binding.
P18011	61	N->A	17719540	Loss of interaction with human MAD2L2.
Q68DC2	798	E->K	24998259	Loss of interaction with ANKS3.
Q68DC2	811	D->K	24998259	Loss of interaction with ANKS3.
Q68DC2	823	R->W	24998259	Loss of interaction with ANKS3.
Q9Y6R1	1003	D->N	15218065	Abolishes interaction with CA2.
P29066	412	S->D	9388255	Impairs interaction with SRC; impairs ADRB2- mediated ERK phosphorylation and IGFR1-mediated MAP kinase phosphorylation of GAB1; impairs sequestration of ADRB2 and IGFR1; abolishes interaction with clathrin; no effect on interaction with ADRB2 and IGFR1.
Q9JLN9	2035	S->R	7809080	Abolishes interaction with the FKBP1A- rapamycin complex.
Q9Y3D7	94	L->Q	20053669	Substantial loss of protein translocation into mitochondria in a heterologous system. Substantial loss of DNAJC19-binding. Partial loss of inhibition of DNAJC19 stimulation of HSPA9 ATPase activity.
F5HAY6	131	C->R	11427719	Complete loss of interaction with Pro-caspase 8.
Q8CBD1	1068	P->A	12549917	Abolishes binding to RAR, RXR and RAR/RXR.
Q8CBD1	1073	M->K	12549917	Abolishes binding to RAR, RXR and RAR/RXR.
P04637	15	S->A	17967874	Loss of interaction with PPP2R5C, PPP2CA AND PPP2R1A.
P04637	359	P->D	16402859	Abolishes binding to USP7.
P04637	361	G->E	16402859	Abolishes binding to USP7.
P04637	362	S->A	16402859	Abolishes binding to USP7.
A0A024B7W1	2772	K->R	32699085	Loss of sumoylation and more than 80% loss of binding to host STAT2.
Q9SYM2	72	D->A	18796637	Abolishes interaction with HY5.
Q9SYM2	81	D->A	18796637	Abolishes interaction with HY5.
O54924	228	A->W	15920473	Strongly reduces interaction with RALA.
P43405	297	S->A	21469132	Abolishes YWHAG binding.
P43405	630	Y->F	18369315	Loss of interaction with BLNK.
A0A0H3K686	47	F->A	16709567	Complete loss of binding toepithelial cells.
A0A0H3K686	48	Y->A	16709567	Complete loss of binding toepithelial cells.
O75081	494	V->P,A	11823486	Loss of interaction with PRKAR2A.
P06463	158	V->A	11000240	Complete loss of binding to MPDZ protein.
G5EE56	165	R->A	16024786	Loss of interaction with unc-5.
G5EE56	416	Y->F	19210548	Abolishes phosphorylation which results in loss of kinase activity. Loss of interaction with ina-1 and ced-2.
P09234	6	C->S	1826349	Abolishes the binding to U1 snRNP.
P09234	9	C->S	1826349	Abolishes the binding to U1 snRNP.
P09234	24	H->Q	1826349	Abolishes the binding to U1 snRNP.
P09234	30	H->Q	1826349	Abolishes the binding to U1 snRNP.
P11474	124	T->A	16150865	Binds DNA predominantly as a monomer. Loss of interaction with PPARGC1A.
P11474	315	R->A	18441008	Almost complete loss of interaction to L2 or to L3 of PPARGC1A.
P11474	338	D->A	18441008	Almost complete loss of interaction to L2 or to L3 of PPARGC1A.
O08623	7	K->A	15143057	Loss of interaction with PRKCI.
Q8VDF2	148	F->A	21489993	Abolishes binding to histone H3K9me3 and ability to repress transcription of target genes.
Q9Y6D6	105	K->D	27373159	Loss of interaction with ARL1.
Q9Y6D6	109	Y->K	27373159	LLoss of interaction with ARL1.
Q9Y6D6	156	L->D	27373159	Loss of interaction with ARL1.
Q9Y6D6	200	Q->E	27373159	Loss of interaction with ARL1.
O91464	1655	R->A	22258260	Complete loss of myristoylation; loss of interaction with host ACBD3. Loss of activation of host PI4KB in vitro.
O91464	1657	I->A	22258260	Loss of interaction with host ACBD3 and PI4KB.
Q9DCH6	30	C->S	21980954	Abolishes interaction with PEX6 and ubiquitin. Impairs interaction with PEX5.
O75969	131	L->P	11278869	Abolishes interaction with ROPN1.
P09619	634	K->A,R	1314164	Loss of kinase activity. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.
P09619	771	Y->F	10454568	Loss of interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.
P09619	857	Y->F	10454568	Reduces kinase activity. No effect on interaction with GRB10. Abolishes interaction with RASA1. No effect on phosphatidylinositol 3-kinase activity.
P31582	24	S->N	12724533	Dominant negative (GDP-bound form); loss of targeting to the prevacuolar compartment. Inhibits vacuolar trafficking. No effect on the interaction with VPS9A. Loss of interaction with EREX.
P31582	69	Q->L	15509844	Constitutively active (GTP-bound form); no effect on the targeting to the prevacuolar compartment. Loss of interaction with VPS9A.
Q9HBL8	37	R->A	19254724	Impairs binding to NADPH; abolishes the ability to dimerize; enhances binding to ASS1; reduces perinuclear localization.
Q9HBL8	81	Y->A	19254724	Impairs binding to NADPH; abolishes the ability to dimerize; enhances binding to ASS1; reduces perinuclear localization.
Q8VHH5	140	S->N	16461359	Abolishes interaction with PML.
Q96PJ5	493	Y->F	14597715	Loss of interaction with PTPN6 and PTPN11 and partial loss of function and phosphorylation.
Q946J8	132	W->G	16361394	Loss of interaction with 'K-9' of H3 and loss of chromocenter localization and punctuated distribution inside the nucleus.
Q8TAF3	170	S->Y	26388029	Strongly reduces interaction with USP46 and abolishes stimulation of USP46 enzyme activity.
O43353	444	R->E	17054981	Abolishes interaction with NOD1.
O43353	483	R->E	17054981	Abolishes interaction with NOD1.
O43353	488	R->E	17054981	Abolishes interaction with NOD1.
Q9BTE7	195	D->N	24192928	Loss of interaction with RBX1, CUL1 and CAND1.
Q9BTE7	225	D->N	24192928	Loss of interaction with RBX1, CUL1, CUL2, CUL3 and CAND1. Does not affect interaction with UBE2M and NEDD8. Fails to augment Cul3 neddylation beyond basal levels.
Q9BTE7	226	E->A	24192928	Loss of interaction with RBX1, CUL1, CUL2, CUL3 and CAND1. Does not affect interaction with UBE2M and NEDD8. Fails to augment Cul3 neddylation beyond basal levels.
P17948	861	K->M	9299537	Abolishes enzyme activity. Abolishes interaction with PLCG.
P17948	1169	Y->F	9299537	Loss of phosphorylation site. Abolishes interaction with PLCG.
P17948	1213	Y->F	9722576	Loss of phosphorylation site. Abolishes interaction with PIK3R1.
P17948	1333	Y->F	15001553	Loss of phosphorylation site. Abolishes interaction with CBL.
P51692	684	T->A	9428692	Abolishes interaction with INSR.
P62993	203	G->R	8493579	Ineffective in DNA synthesis. Abolishes interaction with SOS1.
Q13263	651	C->A	18082607	Complete loss of the PHD finger-mediated stimulatory effect on sumoylation. Loss of binding UBE2I.
P25822	1330	G->D	11336677	In Pum680; abolishes interaction with brat and translational repression activity but not RNA-binding activity.
P25822	1365	C->R	11336677	Abolishes interaction with brat.
P25822	1366	T->D	11336677	Abolishes interaction with brat.
P25822	1367	F->S	11336677	Abolishes interaction with nos.
P25822	1368	N->S	11336677	Abolishes interaction with brat.
Q93ZM9	107	I->A	19151223	Loss of dimerization, loss of interaction with TIFY11B/JAZ6 and strongly decreased interaction with AFPH2/NINJA.
Q93ZM9	111	G->A	19151223	Loss of dimerization and loss of interaction with TIFY11B/JAZ6.
Q94AI7	176	N->H	16763149	In tpl-1; temperature sensitive gain of function; transforms the shoot pole into a second root pole. No effect on the interaction with IAA12 od HAD19, but loss of interaction with AP2.
Q99665	800	Y->F	10198225	Loss of STAT4 activation. Abolishes SOCS3 binding.
Q99665	801	L->A	10415122	Abolishes in vitro STAT4 binding to a phosphorylated Y-800 peptide.
P29376	544	K->M	8084603	Loss of interaction with PLCG1, PI3-kinase subunit p85, Ras GTPase-activating protein and RAF1.
P29376	753	Y->F	9223670	Abolishes interaction with PI3-kinase subunit p85, impairs PI3 kinase activity and leads to apoptosis (demonstrated with chimeric EGFR-LTK).
A0A142I5B9	328	K->R	32641828	Complete loss of binding to host HAVCR1.
A0A142I5B9	1249	E->A	31662457	Complete loss of virus production by impairing NS2A binding to prM/E and NS2B/NS3.
Q6P5G0	330	I->K	19473979	Abolishes binding to MAPKAPK5.
P61586	34	Y->A	10066731	Abolishes interaction with DGKQ.
Q6PDM1	498	E->R	21217699	Abolishes interaction with KAT8.
Q6PDM1	505	F->R	21217699	Abolishes interaction with KAT8.
Q6PDM1	509	H->R	21217699	Abolishes interaction with KAT8.
O14656	108	K->A	15505207	Loss of ATP-binding. No effect on interaction with KLHL14. Increases interaction with TOR1AIP1 and TOR1AIP2. Abolishes interaction with SLC6A3.
O14656	171	E->Q	19339278	Loss of ATP hydrolysis. Loss of interaction with KLHL14. Localizes in the nuclear envelope. No effect on interaction with TOR1AIP1.
Q9H0U4	73	I->N	9437002	Abolishes interaction with REP1/CHM. No prenylation. Much lower GDP/GTP ratio.
Q9H0U4	78	Y->D	11389151	Abolishes interaction with REP1/CHM and GDI1. No prenylation. Much lower GDP/GTP ratio. No membrane association.
Q9H0U4	81	A->D	9437002	Abolishes interaction with REP1/CHM. No prenylation. Lowers GDP/GTP ratio by half.
P52701	103	Y->A	23622243	Abolishes binding to H3K36me3 and DNA mismatch repair activity.
P31749	176	Y->F	20333297	Significant loss of interaction with TNK2. Loss of membrane localization. Significant reduction in phosphorylation on Ser-473.
O43918	295	N->A	19293276	Abolishes interaction with histone H3.
O43918	297	D->A	18292755	Strongly reduces interaction with unmethylated histone H3 and abolishes interaction with histone H3 trimethylated at 'Lys-4'. No effect on doted nuclear localization. Dominant-negatif effect on target gene transcription.
O43918	303	R->P	19293276	Alters protein folding and abolishes interaction with histone H3. No effect on doted nuclear localization. Dominant-negatif effect on target gene transcription.
O43918	312	D->A	18292755	Abolishes interaction with histone H3.
Q8BMP4	375	V->A	23300088	Loss of interaction with DLG4.
O43464	134	A->M	11583623	Loss of interaction with XIAP. Loss of inhibition of XIAP activity.
Q92973	468	W->A	24753571	Abolishes interaction with the ADAR nuclear localization signal. Abolishes ADAR nuclear import.
Q92973	738	W->A	24753571	Abolishes interaction with the ADAR nuclear localization signal. Abolishes ADAR nuclear import.
Q8CD10	410	C->A	24560927	Abolishes interaction with MICU2.
Q9VKM1	10	R->A	29531043	Abolishes binding to papi.
Q9VKM1	10	R->K	29531043	Abolishes binding to papi.
O75530	97	F->A	20974918	Abolishes binding to H3K27me3.
O75530	148	Y->A	20974918	Abolishes binding to H3K27me3.
O75530	364	W->A	20974918	Abolishes binding to H3K27me3.
O75530	364	W->L	20974918	Abolishes binding to H3K27me3.
O75530	365	Y->A	20974918	Abolishes binding to H3K27me3.
Q9Y572	50	K->A	10339433	Abolishes kinase activity. Loss of PGAM5- and MLKL-binding. No effect on RIPK1-binding. Loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of STUB1-mediated ubiquitination.
Q9Y572	182	T->A	29883609	Abolishes kinase activity. Loss of interaction with PELI1 and PELI1-mediated ubiquitination. No loss of interaction with STUB1 and STUB1-mediated ubiquitination. No loss of interaction with RIPK1. Loss of ability to mediate TNF-induced necroptosis. Loss of autophosphorylation at Ser-227.
Q9Y572	185	Y->A,F	29883609	Loss of interaction with PELI1 and PELI1- mediated ubiquitination.
Q92854	395	K->E	20877282	Strongly reduces PLXNB1 binding.
Q9BUI4	312	L->K	21358628	Loss of interaction with POLR3G and POLR3GL. No effect on interaction with POLR3F.
P17564	549	V->E	11381086	Abolishes interaction with PP1.
Q9NWQ8	317	Y->F	10790433	No effect on interaction with FYN. Abolishes interaction with CSK.
O15164	840	C->W	21164480	Abolishes interaction with histone H3.
Q62839	990	N->A	9628863	Strongly impairs interaction with GORASP1/GRASP65.
Q62839	991	D->A	9628863	Strongly impairs interaction with GORASP1/GRASP65.
Q62839	996	M->A	9628863	Strongly impairs interaction with GORASP1/GRASP65.
P24928	1810	R->A	21454787	Misexpression of a variety of small nuclear RNAs and small nucleolar RNAs. Loss of interaction with TDRD3 and SMN1/SMN2.
O75208	240	W->D,K	25339443	Abolishes interaction with COQ7.
O75208	241	Y->D,K	25339443	Abolishes interaction with COQ7.
O95342	1311	Y->A	22262466	Loss of interaction with AP2A1 and AP2A2. Promotes ABCB11 plasma membrane trafficking. Does not affect plasma membrane localization. Inhibits ABCB11 internalization.
Q9VPQ6	231	C->A	11080638	Abolishes interaction with GATA-type zinc fingers.
Q13573	66	E->A,R	20007319	Abolishes interaction with PPIL1.
Q13573	76	M->A	20007319	Abolishes interaction with PPIL1.
O43294	287	C->A	23145173	Abolishes interaction with CBLC and enhancement of CBLC E3 ubiquitin-protein ligase activity.
P31750	176	Y->F	20333297	Significant loss of interaction with TNK2. Loss of membrane localization. Significant reduction in phosphorylation on Ser-473.
P61006	22	T->N	19864458	Loss of interaction with MICALL1.
Q5ICL9	321	H->Y	15634206	Abolishes interaction with TGA2 or with TGA7.
P03165	98	L->F	11531405	Complete loss of interaction with human DDB1.
Q0D2I5	512	M->R	31548606	Loss of interaction with XRCC4.
Q0D2I5	515	C->R	31548606	Loss of interaction with XRCC4, loss of localization at the sites of DNA damages and loss of ability to immobilize broken ends.
Q86500	1165	R->D	20086014	Complete loss of interaction of p150 with host CALM1.
Q86500	1904	C->R	10073691	Complete loss of human RB1 binding and virus replication.
Q6PCD5	543	W->A	28575657	Abolishes interaction with the RPA complex and subsequent recruitment at DNA damage sites.
P52189	442	E->A	16855024	Abolishes interaction with TAX1BP3.
P52189	443	S->A,D	16855024	Abolishes interaction with TAX1BP3.
P52189	445	I->A	16855024	Abolishes interaction with TAX1BP3.
Q66765	1035	L->A	21145089	Complete loss of interaction with host EIF4E.
Q9HD67	795	F->A	18570893	Abolishes interaction with CALM3.
Q9HD67	2002	F->K	21642953	Abolishes interaction with DCC.
P52565	99	K->A	26646181	Loss of interaction with NGFR.
P52565	199	K->A	26646181	Loss of interaction with NGFR.
P03682	117	L->A	8617213	60% loss of transcription activation from the A3 promoter and 60% loss of transcription repression from the A2c promoter. Poor interaction with host RNAP.
P03682	120	R->Q	8617213	80% loss of transcription activation from the A3 promoter and 80% loss of transcription repression from the A2c promoter. Complete loss of interaction with host RNAP.
P46109	160	W->L	19004829	Abolishes interaction with DOCK5.
Q14003	592	G->R	26997484	Loss of interaction with ACTR3. No effect on voltage-dependent channel opening or current amplitude, but decreased rate of inactivation during prolonged depolarization.
Q9BTC0	291	W->T	23831028	Abolishes binding to H3K4me3.
Q9ULV0	1714	Y->E	21282656	Abolishes interaction with RAB11A; has no effect on RAB8A interaction.
Q9ULV0	1748	Q->R	21282656	Abolishes interaction with RAB11A; has no effect on RAB8A interaction.
P55016	96	T->A	25967121	Loss of interaction with PPP3CB.
P55016	101	T->A	25967121	Loss of interaction with PPP3CB.
P55016	114	T->A	25967121	Loss of interaction with PPP3CB.
P29355	201	G->R	1372395	In n2195; loss of interaction with soc-1. Partially restores normal vulva induction in let-60 n1046gf mutant. Partially rescues fluid accumulation in crl-1 e1745ts mutant. Partially prevents constitutive dauer formation in daf-2 m577 mutant.
Q5T6S3	50	W->A	23104054	In muthPhf19; abolishes histone H3K36me3- binding and impaired activity of the PRC2 complex and subsequent H3K27me3 methylation.
Q9UIB8	279	Y->F	12928397	Reduced tyrosine phosphorylation, reduced binding of SH2D1B and loss of binding of SH2D1A.
O43597	115	S->A	17974561	Abolishes interaction with GRB2.
O43597	252	R->D	16877379	Abolishes interaction with CAV1.
P48023	275	F->L	9228058	Abolishes binding to TNRFSF6 and cytotoxicity.
Q15464	435	R->K	9484780	Loss of interaction with CD3Z. Alters LAT, PLCG1, VAV1 and LCP2 phosphorylation, MAP kinase signaling, Rac1 and JNK activation, intracellular calcium increase, activation of the nuclear factor for activation of T-cells and subsequent interleukin-2 expression which normally occur upon T-cells stimulation.
Q61625	920	S->A	15207857	Abolishes interaction with SHANK1 and SHANK2.
P70425	34	S->N	10545207	Dominant negative. Loss of interaction with AFDN, RLF and RALGDS.
Q5SW96	165	F->A	12221107	Abolishes LDLR cytoplasmic tail binding.
Q5SW96	165	F->V	12221107	Abolishes LDLR cytoplasmic tail binding.
Q5SW96	214	D->A	12221107	Abolishes clathrin binding.
Q5SW96	216	E->A	12221107	Abolishes clathrin binding.
Q5SW96	256	D->R	16903783	Abolishes interaction with AP2B1.
Q5SW96	266	R->A	12221107	Abolishes AP-2 complex binding.
Q13158	12	S->R	16762833	Loss of interaction with CASP8.
Q13158	25	F->R	16762833	Loss of interaction with FAS. Loss of self- association. Abolishes induction of apoptosis.
Q13158	38	R->A	16762833	Loss of interaction with CASP8.
Q13158	44	D->R	16762833	Loss of interaction with CASP8. Abolishes induction of apoptosis. Decreased interaction with FAS.
Q13158	51	E->R	16762833	Loss of interaction with CASP8.
Q13158	117	R->E	20935634	Loss of interaction with FAS.
Q13158	121	V->N	7538907	Loss of interaction with FAS.
Q13158	123	D->R	20935634	Strongly decreased interaction with FAS.
Q13158	135	R->E	20935634	Strongly decreased interaction with FAS.
Q13158	172	L->A,E	19118384	Loss of interaction with FAS.
Q13158	172	L->K	20935634	Strongly decreased interaction with FAS.
Q13158	175	D->K	20935634	Strongly decreased interaction with FAS.
Q99MR1	506	F->A	12771153	Abolishes binding to GRB10.
Q3V6T2	1686	F->A	19211784	Abolishes interaction with and activation of GNAI3 and also abolishes recruitment of GNAI3 to EGFR. Reduced EGFR autophosphorylation and SH2 adapter recruitment, reduced localization of EGFR at the cell membrane following ligand stimulation with increased endosomal localization, reduced cell migration and increased cell proliferation. Abolishes enhancement of AKT signaling. Abolishes interaction with GNAS.
Q3V6T2	1689	E->A	19211784	Abolishes interaction with GNAI3.
Q3V6T2	1723	K->E	25187647	Abolishes binding to phosphorylated EGFR.
Q3V6T2	1746	R->K,L	25187647	Abolishes binding to phosphorylated EGFR.
Q3V6T2	1750	K->E	25187647	Abolishes binding to phosphorylated EGFR.
Q3V6T2	1778	Q->E	25187647	Abolishes binding to phosphorylated EGFR.
Q9Y618	2128	R->A	20543827	Abolishes interaction with the apo LBD of RARA. Restores some interaction on the addition of inverse agonist BMS493.
Q9Y618	2130	V->P	20543827	Abolishes interaction with the apo LBD of RARA. No change on interaction on the addition of inverse agonist BMS493.
Q9Y618	2131	T->G	20543827	Abolishes interaction with the apo LBD of RARA. Restores some interaction on the addition of inverse agonist BMS493.
Q9D4G2	204	R->T	32345962	Abolishes interaction with BRCA2 and location to double-strand breaks in chromosomes.
Q86WV1	232	Y->F	11909961	Abolishes interaction with PTPRC, translocation to cell membrane upon T-cell stimulation and activation of the MAP kinase pathway. No effect on interaction with FYN or GRB2.
Q86WV1	271	Y->F	11909961	No effect on interaction with PTPRC and translocation to cell membrane upon T-cell stimulation. Abolishes interaction with FYN and GRB2 and activation of the MAP kinase pathway.
Q90738	71	P->A	9350057	Abolishes interaction with SRC SH3 domain and decreases tyrosine phosphorylation.
Q2G0X7	338	R->A	22714643	About 75% loss of human TLR2 binding.
P67999	28	F->A	11967149	Complete loss of activity. Abolishes interaction with RPTOR. Reduces phosphorylation. Loss of phosphorylation at T-412 and T-444.
O88522	305	F->A	19303852	Abolishes linear polyubiquitin-binding, impairs 'Lys-63'-linked polyubiquitin-binding and impairs of NF-kappa-B activation.
O88522	316	V->P	17728323	Loss of interaction with TRAF6 and TRAF6- induced polyubiquitination.
Q9XUB2	186	T->A	18199581	Abolishes phosphorylation. Reduced embryo viability and, pie-1 and mex-5 degradation in embryonic somatic cells. Severe reduction in binding to plk-1 and plk-2. Prevent subsequent phosphorylation by plk-1.
Q9XUB2	186	T->D,E	18199581	Phosphomimetic mutant which severely abolishes interaction with plk-1 and plk-2.
P48994	702	P->Q	11514552	Abolishes interaction with Fkbp59.
P48994	709	P->Q	11514552	Abolishes interaction with Fkbp59.
O01382	29	A->V	18166655	Abolishes binding to Diap2 but has no effect on Drice processing or activity.
O43567	243	C->W	23378536	Abolishes ER stress-induced JNK activation and apoptosis. Abolishes interaction with ERN1. Does not affect localization to endoplasmic reticulum.
Q9BXW9	561	K->R	11239454	Abolishes ubiquitination; impairs chromatin binding, foci formation and DNA repair. Abolishes interaction with MTMR15/FAN1. No effect on S-222 phosphorylation by ATM.
P77692	65	F->S	28931012	Loss of interaction with FtsZ.
P32182	153	R->K	14500912	Abolishes interaction with AKT1.
P15891	569	W->A	11668184	Abolishes protein binding.
P9WGI1	515	R->H	11880648	Loss of interaction with WhiB3.
Q15257	305	E->A	16916641	Abolishes interaction with the PP2A(D) complex.
Q15257	325	G->D	16916641	Abolishes interaction with the PP2A(D) complex.
Q15257	329	M->D	16916641	Abolishes interaction with the PP2A(D) complex.
P16054	346	S->A	18604201	Loss of interaction with YWHAB and defects in the completion of cytokinesis.
P16054	368	S->A	18604201	Loss of interaction with YWHAB and defects in the completion of cytokinesis.
Q86YS3	627	D->A	16148947	Abolishes Rab11-binding.
Q92913	207	P->Q	21566136	Loss of interaction with SCN1A.
Q8WUM4	199	F->D	17428861	Does not support cytokinesis; loss of normal midbody formation; loss of CHMP4A-, CHMP4B- and CHMP4C- binding in a yeast two-hybrid assay; no effect on localization to the midbody; abolishes rescue of PTAP-type L domain-deficient HIV-1 p6.
Q8WUM4	212	I->D	17350572	Does not support cytokinesis; loss of normal midbody formation; loss of CHMP4A-, CHMP4B- and CHMP4C- binding in a yeast two-hybrid assay; impairs rescue of PTAP-type L domain-deficient HIV-1 p6; no effect on localization to the midbody.
Q8WUM4	216	L->D	17428861	Abolishes interaction with CHMP4B and abolishes rescue of PTAP-type L domain-deficient HIV-1 p6.
Q8WUM4	509	V->D	17277784	Abolishes interaction with HIV-1 p6; impairs rescue of PTAP-type L domain-deficient HIV-1 p6.
Q8WUM4	676	F->A	22660413	Loss of interaction with SDCBP.
Q8WUM4	676	F->D	17277784	Abolishes interaction with HIV-1 p6 and EIAV p9; abolishes rescue of PTAP-type L domain-deficient HIV-1 p6; no effect on cytokinesis, nor on midbody formation.
Q8WUM4	720	P->L	17350572	Abolishes interaction with TSG101; no effect on rescue of PTAP-type L domain-deficient HIV-1 p6.
Q8WUM4	806	Y->A	18948538	Abolishes interaction with CEP55.
P87074	663	C->R	18676809	Disrupts dimer formation, but not gamma-H2A binding.
P87074	666	S->R	18676809	Disrupts dimer formation, but not gamma-H2A binding.
Q9Z297	74	D->A	12456656	Abolishes MAPK1 binding and the blocking of Ras-mediated inhibition of integrin activation.
Q9Z297	121	I->A,R	12456656	Abolishes MAPK1 binding.
Q9Z297	123	L->A,R	12456656	Abolishes MAPK1 binding.
Q9Z297	128	K->A,E	12456656	Abolishes MAPK1 binding.
Q9Z297	129	K->A,R	12456656	Abolishes MAPK1 binding.
P18754	182	D->A	12194828	Abolishes interaction with Ran and impairs chromosome localization.
P05161	99	R->A	29100055	Strongly reduces ISG15 signaling and abolishes interaction with ITGAL.
P05161	101	T->A	29100055	Strongly reduces ISG15 signaling and abolishes interaction with ITGAL and activation of SRC family tyrosine kinases.
P05161	103	T->A	29100055	Strongly reduces ISG15 signaling and abolishes interaction with ITGAL.
P70451	606	F->A	16732323	Abolishes interaction with PPP1CA.
Q9Y615	31	A->Y	21278383	Abolishes interaction with TES.
Q9Y615	41	A->Y	21278383	Abolishes interaction with TES.
P53041	32	K->A	22399290	Loss of interaction with HSP90AA1. No effect on interaction with S100A1, S100A2 and S100A6.
P53041	74	R->A	22399290	Loss of interaction with HSP90AA1. No effect on interaction with S100A1, S100A2 and S100A6.
P53041	97	K->A	16892053	Loss of interaction with HSP90AA1. No effect on interaction with S100A1, S100A2 and S100A6. Loss of interaction with RAF1.
P53041	101	R->A	22399290	Loss of interaction with HSP90AA1. No effect on interaction with S100A1, S100A2 and S100A6.
Q10QA5	205	W->A	24131983	Decreased enzymatic activity toward strigolactone and loss of strigolactone-dependent interaction with SLR1.
Q10QA5	297	H->A	24131983	No effect on strigolactone binding, but decreased enzymatic activity toward strigolactone and loss of interaction with SLR1.
Q792Q4	101	V->A	10570482	Abolishes interaction with DLG4. Does not redistribute DLG4 to microtubules. Associates with microtubules.
Q96L92	114	H->A	20733053	Abolishes interaction with ADRB2, sorting and recycling of ADRB2.
Q9QXE7	382	D->A	28348241	Affects recruitment to heterochromatin by MECP2. Does not interact with MECP2. Is efficiently incorporated in N-Cor repressor complex.
Q9QXE7	457	P->R	28348241	Does not interact with MECP2. Affects recruitment to heterochromatin by MECP2. Is efficiently incorporated in N-Cor repressor complex.
Q9XZ56	60	K->A	11389445	Strongly decreased interaction with eIF4E1.
Q9BVC4	192	G->D	12718876	Abolishes interaction with MTOR.
Q92730	45	T->A	11940653	Abolishes interaction with UBXD5.
P22892	753	A->D	12176391	Strongly reduces interaction with EPS15 and SYNRG.
P22892	762	L->E	12176391	Strongly reduces interaction with EPS15 and SYNRG.
P62826	24	T->N	18591255	Has low binding affinity for GTP and GDP. Almost completely abolishes interaction with BIRC5.
P25054	2841	T->L	16611247	Loss of interaction with SCRIB.
P25054	2843	V->Q	16611247	Loss of interaction with SCRIB.
Q86YC2	14	K->A	19369211	Loss of interaction with BRCA1 but no effect on interaction with BRCA2.
Q86YC2	21	L->A	19369211	Loss of interaction with BRCA1 but no effect on interaction with BRCA2.
Q86YC2	28	Y->A	19369211	Loss of interaction with BRCA1 but no effect on interaction with BRCA2.
Q86YC2	35	L->A	19369211	Loss of interaction with BRCA1 but no effect on interaction with BRCA2.
Q86YC2	42	E->A	19369211	Loss of interaction with BRCA1 but no effect on interaction with BRCA2.
Q04721	2416	T->A	29149593	Loss of interaction with FBW7. Results in decreased ubiquitination and degradation.
Q8WV92	69	M->D	23045692	Abolishes interaction with CHMP1A, CHMP1B and CHMP2A.
Q8WV92	73	E->A	23045692	Abolishes interaction with CHMP1A, CHMP1B and CHMP2A. Abolishes location at the midbody.
Q155Q3	648	D->A	21189423	Loss of interaction with DVL2. Abolishes activation of Wnt signaling.
Q155Q3	651	F->A	21189423	Loss of interaction with DVL2. Abolishes activation of Wnt signaling.
Q155Q3	655	K->A	21189423	Loss of interaction with DVL2. Abolishes activation of Wnt signaling.
Q9UKC9	420	C->S	15893726	Loss of geranylgeranylation and association to membranes. Loss of interaction with NS5A, PIK3R1 and PIK3R2. No effect on interaction with PTPN13.
Q9WTL8	97	S->A	19330005	Impaired nuclear accumulation, decreased interaction with CLOCK and disruption of circadian clock function.
Q9UNT1	35	S->N	28428259	GDP-locked form; mild defects in ciliary assembly. Loss of interaction with the intraflagellar transport (IFT) complex B via the IFT74-IFT81 heterodimer. Loss of interaction with CEP19. Loss of localization to the centrosome. Loss of localization to the base of the cilium.
Q9UNT1	73	D->G	28428259	Mild defects in ciliary assembly. Loss of interaction with the intraflagellar transport (IFT) complex B via the IFT74-IFT81 heterodimer. Interacts with CEP19.
Q9R062	315	Y->A	24982189	Severe loss of interaction with GYS2.
Q9R062	321	F->A	24982189	Severe loss of interaction with GYS2.
Q9R062	324	I->A	24982189	Severe loss of interaction with GYS2.
Q9R062	328	L->A	24982189	Severe loss of interaction with GYS2.
Q8IUC6	434	P->H	12539043	Abolishes interaction with TLR3.
P15208	989	Y->F	10207032	Abolishes interaction with IRS1 but not with IRS2.
Q84L30	8	L->A	21764993	Abolishes interaction with RPN10.
Q84L30	46	I->A	21764993	Abolishes interaction with RPN10.
Q8VDL9	175	C->A	17289029	Abolishes interaction with CTNNB1. No effect on nuclear localization.
Q9Y4D1	698	I->A	17482208	Abolishes actin-binding.
Q9R012	504	W->A	18498738	Abolishes interaction with SIPA1L1.
P05928	80	R->A	10359081	Complete loss of G2/M cell cycle arrest. 66% loss of LTR transactivation. Complete loss of human TFIIB binding.
O48791	131	V->D	22356912	Loss of dimerization and loss of actin-binding activity.
O48791	138	V->D	22356912	Loss of dimerization and loss of actin-binding activity.
O48791	141	L->E	22356912	Loss of dimerization and loss of actin-binding activity.
Q9WV71	238	L->D	17636018	Abolishes interaction with HIF1AN.
Q9WV71	239	L->D	17636018	Abolishes interaction with HIF1AN.
Q9WV71	246	N->A	17636018	Abolishes interaction with HIF1AN.
Q9WV71	256	L->D	17636018	Abolishes interaction with HIF1AN.
Q9JKD8	313	K->R	23616576	Significant loss of ubiquitination. Loss of phosphorylation at T-302 causing loss of its ability to interact with NFATC2. Loss its ability to activate IFN- gamma transcription due to loss of DNA-binding activity. Loss of its ability to suppress IL-2 and Th2 cytokine production. Increased protein stability. Localization seen in both the nucleus and cytoplasm. No loss of interaction with GATA3 and RELA.
Q9JKD8	525	Y->F	15662016	No loss of interaction with RUNX1. Loss of interaction with ITK and GATA3.
Q8BLU0	170	H->E,N	25374360	Abolishes interaction with UNC5D.
P63167	67	T->A	18650427	Abolishes interaction with PAK1.
P63167	88	S->E	15193260	Abolishes homodimerization. Abolishes interaction with BCL2L11 isoform 1 and isoform 2.
O60716	401	K->M	20371349	Complete loss of cadherin interaction.
O60716	478	N->A	20371349	Complete loss of cadherin interaction.
B2D6M2	371	G->E	17409073	In allele lin-61(n3807); abolishes binding to histone H3 trimethylated at 'Lys-9'; multivulva phenotype in combination with lin56(n2728).
P17309	82	K->E	8244025	In rES40 and rBB9; r-type (rapid lysis) plaque morphology. Loss of interaction with holin. No effect on homooligomerization.
Q63226	952	F->A	14572453	Loss of interaction with AP4M1.
Q63226	954	F->A	14572453	Loss of interaction with AP4M1.
Q63226	957	V->E	14572453	Loss of interaction with AP4M1.
Q9VR35	598	L->D	26294658	Abolishes interaction with eIF4E1.
Q9VR35	602	W->D	26294658	Abolishes interaction with eIF4E1.
Q9VR35	605	M->D	26294658	Abolishes interaction with eIF4E1.
Q66478	1136	I->K	17182608	Loss of interaction with RTN3 and reduced viral cytopathicity.
O70263	183	L->A	9535908	Abolishes binding to NUMB protein.
O70263	185	N->A	9535908	Abolishes binding to NUMB protein.
O70263	188	Y->A	9535908	Abolishes binding to NUMB protein.
O95931	234	F->D	20696397	Loss of interaction with RNF2.
P57075	317	W->A	15159412	Loss of interaction with CBL.
P57075	317	W->L	15159412	Abolishes binding to dynamin.
Q14980	1910	E->A	21816348	Abolishes interaction with GPSM2.
Q9UN37	13	V->D	18606141	Abolishes interaction with CHMP6, no effect on interaction with CHMP1A.
Q9UN37	64	L->A,D	18606141	Abolishes interaction with CHMP1B; diminishes interaction with IST1.
Q86TM6	503	R->L	28827405	Loss of interaction with FAM8A1, HERPUD1, OS9 and UBE2J1, impaired degradation of immature core- glycosylated basigin/CD147.
G5EG86	35	F->A	16843491	Abolishes interaction with rad-51, but binding to ssDNA is retained. Loss of D-loop formation in the presence of rad-51. Loss of inhibition of ATP hydrolysis by rad-51.
G5EG86	43	I->A	16843491	Abolishes interaction with rad-51, but binding to ssDNA is retained. Loss of D-loop formation in the presence of rad-51. Loss of inhibition of ATP hydrolysis by rad-51.
Q94BT6	119	G->D	16428597	In ztl-21; long-period phenotype, decreased interaction with SKP1A/ASK1 and loss of binding to GI, NFXL2 and APRR1/TOC1, but no effect on binding to PHYB.
Q94BT6	203	E->K	16428597	In ztl-22; long-period phenotype and loss of binding to NFXL2, but no effect on binding to GI or PHYB.
Q94BT6	452	G->D	16428597	In ztl-27; long-period phenotype and loss of binding to APRR1/TOC1, but no effect on binding to GI or PHYB.
Q9QZS8	787	Y->E	17174122	Abolishes interaction with NEDD9. Abolishes interaction with BCAR1. Abolishes phosphorylation of NEDD9. Abolishes promotion of migration and adhesion in T cells.
P97836	990	T->A	10433268	Abolishes interaction with SHANK1.
P97836	991	R->D	10433268	Abolishes interaction with SHANK1.
P97836	992	L->A	10433268	Abolishes interaction with SHANK1.
Q94981	150	C->Y	10880484	In ari1-2; lethal phenotype and loss of interaction with Ubc10.
Q9NW38	309	I->A	24389026	Loss of interaction with UBE2T.
Q9NW38	311	Y->A	24389026	Loss of interaction with UBE2T.
Q9NW38	341	W->A	24389026	Loss of interaction with UBE2T.
Q9NW38	341	W->G	16916645	Abolishes interaction with UBE2T and ubiquitin ligase activity.
Q93052	610	T->A	15649318	Abolishes binding to SCRIB.
Q93052	612	L->A	15649318	Abolishes binding to SCRIB.
Q9S7U9	99	K->R	27679653	Loss of interaction with MEKK1. Phosphorylated by MAPKKK5.
P43618	74	S->D	23334295	Abolishes interaction with SPC24-SPC25.
Q9JI85	318	F->A	21653697	Abolishes binding to and activation of GNAI3.
Q5EBL4	291	R->L,E	29125462	Loss of interaction with RAB8A and RAB10.
Q5EBL4	293	R->L,E	29125462	Loss of interaction with RAB8A.
Q5EBL4	310	K->L,E	29125462	Loss of interaction with RAB8A.
G5EEM6	364	A->P	11323434	Abolishes interaction with mom-4.
Q15796	368	W->A	20129061	Loss of interaction with PMEPA1.
Q5XIX0	538	C->S	11331877	Loss of interaction with DRD1.
Q80ZJ1	17	S->N	9523700	Loss of affinity for GTP and loss of interaction with RUNDC3A.
Q80ZJ1	35	T->A	9523700	Loss of interaction with RUNDC3A.
Q9ULT6	103	P->A	22575959	Abolishes interaction with RSPO1 and prevents subsequent membrane clearance.
Q9NRD5	27	K->E	15247289	Abolishes interaction with GRIA2, but not with PRKCA.
Q02858	1100	Y->F	10521483	Reduced levels of autophosphorylation. Abolishes interaction with GRB2 and GRB7. Abolishes phosphorylation of GRB7 and PIK3R1.
P62745	39	F->G	10508588	Abolishes binding to PKN1 and trafficking of EGF receptor.
Q2M2I8	74	K->A	12952931	Inhibits autophosphorylation and phosphorylation of AP2M1. Does not affect NUMB localization. Does not interact with monoubiquitinated NOTCH1.
P16790	135	I->A	14671097	Complete loss of interaction with UL54.
Q9NPB6	19	K->A	15590654	Loss of interaction with ECT2 and PRKCI.
Q9Y6K9	68	S->E	17977820	Abolishes interaction with IKBKB; abolishes TNF-alpha induced NF-kappa-B activity.
Q9Y6K9	329	L->P	16547522	Abolishes binding to polyubiquitin.
Q9Y6K9	414	V->S	19033441	Abolishes binding to polyubiquitin.
O60885	140	N->A	22464331	Abolishes binding to acetylated histones.
O60885	433	N->A	22464331	Abolishes binding to acetylated histones.
P40855	29	F->A	20554521	Abolishes binding to PEX3.
Q9Y316	16	W->A	18045866	Abolishes interaction with ERBB2.
Q9Y316	49	H->A	18045866	Abolishes interaction with ERBB2.
Q9Y316	81	H->A	18045866	Abolishes interaction with ERBB2.
Q9Y316	192	H->A	18045866	Abolishes interaction with ERBB2.
Q9Y316	244	C->A	18045866	Abolishes interaction with ERBB2.
Q8IV16	109	W->S,Y,H,A,F	25387803	Loss of interaction with LPL. Only slightly increased formation of dimers and oligomers. No effect on number of monomers.
Q09472	1399	D->Y	12586840	Abolished acetyltransferase and acyltransferase activities. Abolishes autoacetylation. Does not interact with TFAP2A and inhibits transcriptional coactivation of TFAP2A by CITED2. Does not inhibit interaction with CITED2, DNA-binding of TFAP2A or nuclear localization of TFAP2A or CITED2. No enhancement of FOXO1- mediated transcriptional activity. No inhibition of insulin-mediated translocation to the cytoplasm. No acetylation of RXRA.
Q09472	2088	R->K	15731352	Abolishes interaction with NCOA2.
Q09472	2142	R->K	15731352	Strongly reduces interaction with NCOA2.
P55737	42	A->T	19487680	In hsp90.2-6; Loss of RPM1 function and accumulation. Loss of ATPase activity. Loss of dimerization. Loss of interaction with RAR1 and SGT1B.
P55737	80	D->N	14592967	In hsp90.2-3/lra2-3; Loss of RPM1 function and accumulation. Loss of ATPase activity. Loss of dimerization. Loss of interaction with RAR1 and SGT1B.
P55737	95	G->E	14592967	In hsp90.2-1/lra2-1; Loss of RPM1 function and accumulation. Loss of ATPase activity. Loss of dimerization. Loss of interaction with RAR1 and SGT1B.
P55737	100	S->F	14592967	In hsp90.2-4/lra2-4; Loss of RPM1 function and accumulation. Loss of ATPase activity. Loss of dimerization. Normal interaction with RAR1. Loss of interaction with SGT1B.
P42566	154	V->E	18200045	Loss of interaction with STON2 NPF motifs.
P42566	169	W->A	18200045	Loss of interaction with STON2 NPF motifs.
Q9Z2F5	41	A->E	12805226	Strongly reduces interaction with E1A.
Q9Z2F5	55	V->R	12805226	Strongly reduces interaction with E1A.
P40344	234	C->A	11100732	Loss of interaction with ATG8 and defect in autophagy and Cvt pathway.
P10114	39	F->S	15342639	Loss of RASGEF1A- and RASGEF1B-mediated GDP to GTP exchange. Complete loss of interaction with MAP4K4, MINK1 and TNIK, and loss of ubiquitination by NEDD4.
P03079	324	Y->F	8985339	70% loss of interaction with host Fyn.
Q94420	94	C->Y	23918937	Severe loss of interaction with ppfr-1 and mei-1.
Q13114	459	Y->A	14517219	Abolishes interaction with LTBR, CD40 and TANK.
Q13114	512	F->E	14517219	Abolishes interaction with LTBR, CD40 and TANK.
Q13114	521	F->A	14517219	Abolishes interaction with LTBR, CD40 and TANK.
O35144	165	F->A	20619712	Abolishes interaction with DCLRE1B/Apollo, leading to activate the ATM signaling pathway.
Q9H0F6	272	I->A	21455181	Abolishes interaction with RNF31 and ability to mediate linear polyubiquitination.
Q9JIY5	134	A->G	11604410	Loss of interaction with XIAP.
Q92793	1162	N->E,R	24616510	Abolishes interaction with ASF1A.
Q92793	1165	W->A	24616510	Abolishes interaction with ASF1A.
Q92793	1180	K->E	24616510	Abolishes interaction with ASF1A.
Q92793	1183	E->R	24616510	Abolishes interaction with ASF1A.
P21784	415	Y->A	18033247	Abolishes binding to H3K4me3 without affecting phosphoinositide-binding.
P21784	443	M->A	18033247	Abolishes binding to H3K4me3 without affecting phosphoinositide-binding.
P21784	453	W->R	18033247	Abolishes binding to H3K4me3 without affecting phosphoinositide-binding. Impairs enzymatic activity of the RAG complex.
Q7XHR2	764	I->E	16192280	Abolishes calmodulin binding.
Q969X0	130	R->E	29125462	Loss of interaction with RAB8A, RAB10 and RAB12.
Q969X0	132	R->E	29125462	Loss of interaction with RAB8A, RAB10 and RAB12.
Q969X0	149	K->E	29125462	Loss of interaction with RAB8A, RAB10 and RAB12.
Q6ZNA4	382	V->A	23086935	Abolishes SUMO binding.
Q6ZNA4	383	V->A	23086935	Abolishes SUMO binding.
Q6ZNA4	384	D->A	23086935	Abolishes SUMO binding.
Q6ZNA4	385	L->A	23086935	Abolishes SUMO binding.
Q6ZNA4	386	T->A	23086935	Abolishes SUMO binding.
Q5FWF4	625	W->A	22759634	Abolishes interaction with 'Lys-63'-linked polyubiquitin.
Q5FWF4	632	Y->A	22759634	Abolishes interaction with 'Lys-63'-linked polyubiquitin.
Q5FWF4	634	N->A	22759634	Abolishes interaction with 'Lys-63'-linked polyubiquitin.
Q9DB10	60	P->A	27001609	Abolishes calcium uptake into mitochondria. Abolishes interaction with MCU.
Q8C8R3	3575	E->K	27718357	Loss of interaction with RABGAP1L. Localizes on motile vesicles, but does not cotransport with RABGAP1L. Loss of polarized transport of PI3P-positive organelles to the leading edge of the migrating fibroblasts. Expression of mutant protein does not rescue ITGB1 recycling deficit of ANK2 null mutant fibroblasts nor the impaired haptotactic response of the fibroblasts.
Q00536	119	S->A	22184064	Strongly reduces interaction with CCNY.
Q00536	153	S->A	22184064	Constitutively activated, due to loss of an inhibitory phosphorylation site. Increases interaction with CCNY.
Q00536	153	S->D	22184064	Abolishes interaction with CCNY.
P13285	74	Y->F	9733815	Loss of interaction with human SYK.
P13285	85	Y->F	9733815	Loss of interaction with human SYK.
Q9Y6B2	178	L->S	11223246	Abolishes RB1 binding.
Q9Y6B2	180	C->G	11073990	Abolishes RB1 binding.
Q9Y6B2	182	E->Q	11223246	Abolishes RB1 binding.
Q15637	22	W->A	12718882	Abolishes interaction with U2AF2.
P29326	597	A->E	15557331	Complete loss of dimeric interactions.
P29326	598	V->E	15557331	Complete loss of dimeric interactions.
P29326	599	A->E	15557331	Complete loss of dimeric interactions.
P29326	601	L->E	15557331	Complete loss of dimeric interactions.
P29326	602	A->E	15557331	Complete loss of dimeric interactions.
Q05127	239	F->A	23870315	Complete loss of interaction with host PRKRA and subsequent immune response inhibition.
Q05127	312	R->A	15464838	Complete loss of IRF3 promoter inhibition; dsRNA-binding and interaction with host PRKRA.
Q9Y2K1	536	C->A	24657165	Abolishes binding to ubiquitin; Abolishes recruitment to DNA lesion sites.
Q9Y2K1	539	C->A	24657165	Abolishes binding to ubiquitin; Abolishes recruitment to DNA lesion sites.
Q8TAP9	120	T->A	17310276	Abolishes interaction with PLK1 in mitosis.
P61972	19	Y->A	11038179	Loss of interaction with GDP-bound RAN. Loss of GDP-bound RAN nuclear import.
P61972	42	E->D	11038179	Loss of interaction with GDP-bound RAN. Loss of GDP-bound RAN nuclear import.
P61972	42	E->K	9368653	Loss of interaction with GDP-bound RAN. No effect on interaction with nucleoporins. Loss of GDP-bound RAN and other proteins nuclear import.
P61972	64	I->A	15522285	No effect on homodimerization. Decreased interaction with GDP-bound RAN. Loss of interaction with nucleoporins and localization to the nuclear pore complex.
P61972	64	I->Q	15522285	No effect on homodimerization. Loss of interaction with GDP-bound RAN. Decreased interaction with nucleoporins and localization to the nuclear pore complex.
P61972	66	H->A	9368653	Loss of interaction with GDP-bound RAN. No effect on interaction with nucleoporins. Decreased proteins nuclear import.
P03077	257	S->A	9420259	Complete loss of interaction with host Ywhaz.
Q6PHN9	22	S->N	20159556	Loss of interaction with MICALL1.
O23617	5	S->A	16771775	Abolishes binding to GRF/14-3-3.
O23617	32	T->A	16771775	Abolishes binding to GRF/14-3-3.
Q9Z340	827	S->E	22579248	Abolishes binding to PKCI.
Q9Z340	829	S->E	22579248	Abolishes binding to PKCI.
Q9VHA0	834	I->T	9343432	Complete loss of function. Significant loss of self-binding activity. Moderate loss of ph-p binding activity.
Q9VHA0	836	G->D	15280237	Complete loss of function. Complete loss of self- and ph-p binding activity.
Q9VHA0	851	M->R	15280237	Complete loss of function. Complete loss of self- and ph-p binding activity.
Q9VHA0	860	K->E	15280237	Complete loss of function. Partial loss of self-binding activity. Complete loss of ph-p binding activity.
Q92834	323	R->E	24981858	Abolishes interaction with RPGRIP1.
Q7Z589	106	L->A	14651845	Abolishes interaction with ZMYND11.
Q23973	40	T->A	18052611	Abolishes interaction with polo and ability to maintain G2 arrest.
P05532	571	Y->F	9528781	Abolishes interaction with PTPN11/SHP-2.
P05532	573	Y->F	9528781	Abolishes interaction with PTPN6/SHP-1.
P05532	723	Y->F	7527401	Abolishes interaction with PIK3R1.
Q9H040	473	D->A	22894931	Abolishes binding to ubiquitin.
Q9LQZ7	20	D->A	17965270	Abolishes interaction with HY5.
Q9LQZ7	75	D->A	17965270	Abolishes interaction with HY5.
Q9LQZ7	84	D->A	17965270	Abolishes interaction with HY5.
O15455	759	Y->F	17178723	Reduced activation of NF-kappa-B in response to ds-RNA. Reduced induction of IL-8 in response to ds-RNA. Loss of interaction with WDFY1.
O15455	858	Y->F	25736436	Loss of interaction with WDFY1.
Q8NFY9	74	Y->A	26399832	Abolishes CUL3-binding and ability to mediate monoubiquitination of NOLC1 and TCOF1.
Q03160	483	Y->F	17318180	Strongly reduced tyrosine phosphorylation. Abolishes interaction with FHL2.
Q03160	495	Y->F	17318180	Strongly reduced tyrosine phosphorylation. Abolishes interaction with FHL2.
P78560	27	L->F	8985253	Loss of interaction with CASP2.
P78560	65	G->A	8985253	Loss of interaction with CASP2.
P78560	121	N->D	17289572	Loss of interaction with PIDD1.
P78560	125	Q->A	17289572	Loss of interaction with PIDD1.
P78560	146	Y->A	17289572	Loss of interaction with PIDD1. Decreased PIDDosome assembly. Decreased CASP2 activation.
P78560	147	R->A	17289572	Loss of interaction with PIDD1. Decreased PIDDosome assembly. Decreased CASP2 activation.
P78560	147	R->E	17289572	Loss of interaction with PIDD1. Loss of PIDDosome assembly. Loss of CASP2 activation.
P78560	149	K->E	17289572	Loss of interaction with PIDD1.
P78560	156	V->D	17289572	Loss of interaction with PIDD1. Loss of PIDDosome assembly. Loss of CASP2 activation.
P78560	169	Q->E	17289572	Loss of interaction with PIDD1.
P47122	106	D->A	21844196	Impairs nuclear localization of RNAPII. Completely abolishes RNAPII binding.
Q15303	1056	Y->A	19561640	Abolishes interaction with NEDD4 and impairs ubiquitination. Promotes nuclear translocation of ERBB4 intracellular domain E4ICD1.
Q15303	1301	Y->A	12807903	Abolishes interaction with NEDD4 and impairs ubiquitination.
O88838	120	Y->A	16369487	Loss of interaction with PARW. No effect on interaction with MET. Loss of interaction with NOS2.
O88838	120	Y->F	20603330	Loss of interaction with NOS2.
O88838	206	V->A	16369487	Loss of interaction with PARW. No effect on interaction with MET. Loss of interaction with NOS2.
O88838	207	W->A	20603330	Significant loss of interaction with NOS2.
P53846	162	W->A	26182403	Abolishes interaction with the CIA complex. No effect on interaction with YAE1. Strongly decreases iron incorporation into RLI1.
G5ECU1	140	M->I	18718460	In sm151; weak loss of function mutation, does not bind to sel-10 protein.
P43146	1432	L->S	21642953	Abolishes interaction with MYO10.
P43146	1439	L->S	21642953	Abolishes interaction with MYO10.
Q13190	245	I->A	18843296	Loss of interaction with SEC24C.
Q13190	247	M->A	18843296	Loss of interaction with SEC24C.
Q9XTY6	175	F->L	11134024	Prevents binding to pkc-3.
Q9XTY6	221	F->L	11134024	Prevents binding to pkc-3.
Q8XAL7	189	G->A	23516580	Abolishes interaction with CASP4 and CASP8. Strongly reduces CASP9 binding. Reduces inhibition of host cell apoptosis.
O70161	635	F->A	19287005	Abolishes interaction with AP2B1.
O70161	642	W->A	19287005	Abolishes interaction with AP2B1.
O70161	644	Y->F	14691141	Loss of phosphorylation by CSK. Abolishes interaction with AP-2 complex. Cannot rescue the effect PIP5K1C knockdown on EGF-stimulated cell migration.
O70161	646	P->F	16707488	Abolishes interaction with AP-2 complex.
O70161	647	L->V	16707488	Abolishes interaction with AP-2 complex.
Q63511	392	K->D	17828261	Abolishes interaction with SNX27.
Q63511	393	V->I	17828261	Abolishes interaction with SNX27.
O08747	568	Y->F	11533026	Abolishes interaction with PTPN11, leading to an increased level of phosphorylation.
Q9XI47	140	Y->A	23636332	Loss of interaction with H3K9 and DNA methylation defects.
O75164	945	D->R	16601153	Abolishes binding to H3K4me3.
O75164	967	W->H	16601153	Abolishes binding to H3K4me3.
O75164	973	Y->A	16601153	Abolishes binding to H3K4me3.
Q9K0U9	251	D->A	22327295	Nearly complete loss of binding to human transferrin (TF).
O95445	22	Q->A	17525477	Introduces a signal cleavage site. Abolishes interaction with lipoprotein particles. Leads to rapid elimination from plasma.
P0DTC6	58	M->R	33097660	Complete loss of binding to the NUP98-RAE1 complex and IFN antagonistic function.
Q6ZW49	676	W->A	17690115	Abolishes interaction with TP53BP1; prevents recruitment to DNA damage foci.
Q6ZW49	910	R->Q	17690115	Abolishes interaction with TP53BP1; impairs intact cellular response to DNA damage.
Q6ZW49	929	W->A	17690115	Abolishes interaction with TP53BP1; prevents recruitment to DNA damage foci.
P16109	129	E->D	28011641	Impairs interaction with SELPLG. Abolishes cell rolling on glycan ligands.
P46655	148	R->A	16914447	Abolishes interaction with ARC1.
E9Q612	1220	Y->F	20398064	Loss of tyrosine phosphorylation. Abolishes interaction with FYN and GRB2.
P56559	27	T->N	19409876	Does not interact with alpha tubulin.
P56559	72	Q->L	19409876	Does not interact with alpha tubulin. Activates transferrin transport from early endosome to recycling endosome.
O88339	72	R->A	11161217	Abolishes ZNF145 binding.
Q9MAQ0	452	E->K	25710501	No effect on activity, but loss of interaction with PTST.
O14641	257	T->A	25805136	Almost abolishes interaction with FOXK2.
O14641	259	S->A	25805136	Almost abolishes interaction with FOXK2.
O14641	262	S->A	25805136	Almost abolishes interaction with FOXK2.
Q6VGS5	2007	G->A	14750955	Abolishes binding to DVL1.
Q6VGS5	2009	V->A	14750955	Abolishes binding to DVL1.
Q08345	740	Y->F	16337946	Abolishes interaction with PTPN11.
O60907	111	V->N	21240272	Reduced interaction with NCOR2 and GPS2. Abolished ability to repress transcription.
Q9UHJ3	180	W->A	23592795	Abolishes histone-binding.
Q1MX18	78	W->A	22074847	Abolishes interaction with GPSM2.
O14503	65	R->A	15560782	Loss of interaction with ARNTL/BMAL1 and E-box binding. Significant reduction in its repressor activity against the CLOCK-ARNTL/BMAL1 heterodimer.
P13498	157	P->Q	12716910	Loss of interaction with NOXO1.
P9WIA1	146	L->A	22087003	Retains phosphatase activity but does not bind V-ATPase subunit H. Fails to inhibit V-ATPase trafficking to phagosomes and shows impaired intracellular survival.
Q1MX30	705	T->A,E	20118235	Abolished autophosphorylation and loss of interactions with target proteins (e.g. WRKY62/XB10, XB3, XB15 and XB24). Loss of positive impact on innate immunity toward X.oryzae pv. oryzae (Xoo).
Q9UBS8	220	C->S	11322894	Loss of interaction with UBE2E2 and of autoubiquitination.
Q9UQF2	709	Y->A	11238452	Abolishes KNS2 binding.
Q8VDU0	210	N->F	21816348	Nearly abolishes interaction with NUMA1.
Q8VDU0	254	F->E	21816348	Abolishes interaction with INSC.
Q8VDU0	290	N->E	21816348	Abolishes interaction with INSC.
P18090	466	V->A	16316992	Abolishes interaction with MAGI3.
P43357	170	D->A	8113684	Abolishes HLA-A1 binding.
P43357	176	Y->A	8113684	Abolishes HLA-A1 binding.
Q969Z4	350	F->A	16530727	Loss of interaction with STK39.
P11078	2	G->A	1548757	Complete loss of myristoylation and binding to sigma-3 protein.
O43561	161	Y->F	11368773	Abolishes interaction with PLCG1.
P08069	980	Y->F	10454568	Reduces tyrosine phosphorylation. Abolishes interaction with IRS1 and SHC1. Does not abolish interaction with PIK3R1, nor with GRB10.
P08069	1033	K->A	7541045	Kinase inactive. Abolishes tyrosine phosphorylation and abolishes interaction with IRS1, SHC1 and PIK3R1.
Q9UDY8	653	E->A	15125833	Abolishes binding to TRAF6.
Q9UDY8	806	E->A	15125833	Abolishes binding to TRAF6.
Q15326	294	W->A	24675531	Abolishes interaction with Histone 3. Diffused distribution in the nucleus.
Q949Y0	175	W->R	15987637	Abolishes the calmodulin-binding.
Q949Y0	178	L->K	15987637	Abolishes the calmodulin-binding.
B6KAM0	213	Y->A	21778402	Abolishes interaction with RON2.
Q92844	182	Q->A	12005438	Abolishes interaction with TRAF2 and TRAF3.
Q92844	184	T->A	12005438	Abolishes interaction with TRAF2 and TRAF3.
Q92844	185	D->A	12005438	Abolishes interaction with TRAF2; greatly diminishes interaction with TRAF3.
P9WI75	41	K->M	11496007	Loss of kinase activity. Abolishes interaction with Rv1747.
P9WI75	173	T->A	16040957	Abolishes interaction with Rv1747. Impairs autokinase activity.
Q01094	132	L->E	20176812	Abolishes interaction with and repression of CEBPA and inhibition of adipogenesis.
P47074	382	E->K	10704439	Abolishes interaction with BUB3. Benomyl- sensitive phenotype.
Q14790	73	D->A	15592525	Abolishes binding to FLASH. Induces NF-kappa-B activation.
Q14790	360	C->S	28602583	Abolishes interaction with UBR2.
Q14289	402	Y->F	8849729	Abolishes autophosphorylation. Abolishes interaction with SRC.
Q14289	859	P->A	11493697	Loss of interaction with NPHP1.
Q12341	197	W->E	24835250	Abolishes interaction with HAT2.
Q12341	199	Y->E	24835250	Abolishes interaction with HAT2.
Q12341	205	F->E	24835250	Abolishes interaction with HAT2.
Q6P549	1222	D->A	29749928	Abolishes interaction with EPHA2 SAM domain.
Q6P549	1226	F->A,L	29749928	Abolishes interaction with EPHA2 SAM domain.
Q9UQB8	267	I->N	11157984	Loss of interaction with CDC42. Loss of stimulation of neurite growth.
P55265	801	R->A	24753571	Abolishes interaction with TNPO1, TNPO1- mediated nuclear import and nuclear location.
Q9H9B1	905	E->A	18264113	Abolishes binding to histone H3K9me.
P51610	30	P->S	10629049	Severely reduces VP16-induced complex (VIC) formation, but retains association with VP16. Unable to rescue proliferation in temperature-sensitive arrested cells. Abolishes interaction with CREB3.
Q76N32	332	S->A	25503564	Prevents binding to BTRC and down-regulation of CEP68 during mitosis.
P78527	1510	L->P	9679063	Loss of interaction with C1D.
Q96MH2	143	T->A	15713662	Loss of interaction with P-TEFb.
Q96MH2	143	T->D	15713662	Loss of interaction with P-TEFb.
Q9TZI4	660	F->A	26659249	Abolishes binding to goa-1 and ability of gbas-1 to activate goa-1.
Q9TZI4	661	L->A	26659249	Abolishes binding to goa-1.
O14653	118	I->A	18843296	Loss of interaction with SEC24C.
O14653	120	M->A	18843296	Loss of interaction with SEC24C.
H2L099	55	R->G	19826475	Severe loss of interaction with mpk-1 (isoform a).
H2L099	64	I->N	19826475	Loss of interaction with mpk-1 (isoform a).
O75928	469	V->A	16204249	Abolishes binding to SUMO1.
O75928	470	I->A	16204249	Abolishes binding to SUMO1.
O75928	472	L->A	16204249	Abolishes binding to SUMO1.
Q62985	555	R->E	10377387	Reduces interaction with JAK2 and abolishes JAK2 kinase activity; reduces GH-stimulated cell motility; abolishes interaction with PDGFRA.
Q9BZX4	18	L->A	11278869	Abolishes interaction with AKAP3.
P08887	121	C->S	8467812	Complete loss of ligand-binding.
P08887	132	C->A	8467812	Complete loss of ligand-binding.
P08887	134	W->L	8467812	Complete loss of ligand-binding.
P08887	165	C->L	8467812	Complete loss of ligand-binding.
P08887	176	C->A	8467812	Complete loss of ligand-binding.
P08887	193	C->D	8467812	Complete loss of ligand-binding.
P08887	217	D->V	8467812	Complete loss of ligand-binding.
P08887	279	I->D	8467812	Complete loss of ligand-binding.
P08887	291	Q->K	8467812	Complete loss of ligand-binding.
P08887	293	R->G	8467812	Complete loss of ligand-binding.
Q9HBI1	256	V->Q	22869380	Abolishes interaction with PXN.
Q9HBI1	299	F->D	22869380	Abolishes interaction with ILK. Abolishes location at focal adhesion sites.
P25604	254	M->D	17442384	Defective in ESCRT-I cargo sorting; reduces MVB12 localization to MVBs; abolishes interaction with MVB12; reduces interaction with SRN2.
Q3U1F9	429	L->A	11777944	Abolishes interaction with SLC9A3R1 and effect on synapse formation.
P62331	44	T->N	22841714	Inactive GDP-bound form which does not bind TJAP1.
P62331	76	H->A	22522702	Slightly impaired interaction with KIF23. Abolishes interaction with GGA1, SPAG9 and RAB11FIP4.
P62331	77	Y->A	22522702	Loss of interaction with KIF23, GGA1, SPAG9 and RAB11FIP4.
Q13332	233	Y->S	25385546	Abolishes interaction with NTRK3.
P58233	67	L->E	11685226	Abolishes Tir binding.
P58233	70	L->E	11685226	Abolishes Tir binding.
P58233	74	L->E	11685226	Abolishes Tir binding.
P58233	75	W->E	11685226	Abolishes Tir binding.
P58233	83	Y->E	11685226	Abolishes Tir binding.
P58233	126	V->E	11685226	Abolishes Tir binding.
O94762	550	R->A	20231364	Impairs protein folding and abolishes interaction with POLR2A.
O94762	584	E->A,D	20231364	Abolishes interaction with POLR2A.
O94762	602	L->D,E	20231364	Abolishes interaction with POLR2A.
O94762	666	F->A	20348101	Abolishes interaction with RAD51.
P04861	181	F->S	9400614	Complete loss of virulence and STAT1-binding.
O43521	156	G->A	11997495	Retains the ability to induce apoptosis. Abolishes interaction with BAX; in isoform Bim-alpha3 and isoform BimS. No effect on interaction with BCL2.
O43521	156	G->E	11997495	Abolishes induction of apoptosis. Abolishes interaction with BAX and BCL2; in isoform Bim-alpha3 and isoform BimS. Loses the ability to induce the conformationally active form of BAX.
O43521	160	N->A	11997495	Retains the ability to induce apoptosis. Abolishes interaction with BCL2; in isoform Bim-alpha3 and isoform BimS. No effect on interaction with BAX.
Q8K4V4	51	Y->L	21422294	Abolishes interaction with KCNJ9.
P49407	388	F->A	16516836	Abolishes interaction with AP2B1.
P49407	390	D->P	16516836	Abolishes interaction with AP2B1.
P49407	393	R->A	16516836	Abolishes interaction with AP2B1.
P33892	2291	F->L	11350982	Does not interact with GCN2, impairs eIF-2- alpha phosphorylation and fails to derepress GCN4 translation in amino acid-starved cells.
P33892	2304	S->P	11350982	Does not interact with GCN2.
P33892	2353	L->P	11350982	Does not interact with GCN2.
O75925	351	C->A,S	11583632	Loss of UBE2I-binding; almost complete loss of promotion of TP53 sumoylation; no loss of SUMO1- and TP53-binding.
Q9NZC7	33	Y->R	12514174	Abolishes interaction with TP53, TP73, MAPK8 and ERBB4. Partial loss of interaction with TFAP2C. Loss of phosphorylation. Loss of the proapoptotic activity.
Q9ERH7	322	D->N	11034606	Impairs catalytic activity and abolishes interaction with DAXX.
P07567	57	R->F	18647839	Redirects assembly from host cytoplasm to plasma membrane. Loss of interaction with host DYNLT1.
O94782	444	E->K	26388029	Strongly reduces interaction with WDR48 and activation by WDR48.
O95398	412	D->A	21393242	Abolishes interaction with PDE3B.
O95398	415	E->A	21393242	Abolishes interaction with PDE3B.
O95398	417	F->A	21393242	Abolishes interaction with PDE3B.
O95398	420	D->A	21393242	Abolishes interaction with PDE3B.
O95398	421	F->A	21393242	Abolishes interaction with PDE3B.
P53350	414	W->F	17307877	Abolishes interaction with CDC25C and reduces centrosomal localization.
A1Z6E0	131	Y->A	16498413	Does not affect binding to Elongin BC complex. Abolishes interaction with vas.
A1Z6E0	147	G->Y	16498413	Does not affect binding to Elongin BC complex. Abolishes interaction with vas.
A1Z6E0	148	R->W	16498413	Does not affect binding to Elongin BC complex. Abolishes interaction with vas.
P41586	139	Y->A	17470806	Strongly reduced affinity for ADCYAP1.
Q9Y3P8	169	Y->F	11433379	Abolishes interaction with CSK and impairs inhibition of NF-AT activation.
O14828	67	P->L	19158374	Abolishes interaction with TSG101.
P06789	305	L->K	10365963	Complete loss of SMARCB1/INI1 binding.
Q9SII9	61	I->A	20059542	Abolishes interaction with RPN13.
Q8N539	415	H->G	19892701	Complete loss of binding to acetylated bovine serum albumin and chitin.
Q8N539	432	A->V	19892701	Complete loss of binding to acetylated bovine serum albumin and chitin.
O35274	451	F->A	10194355	Abolishes protein phosphatase 1 binding.
Q9UPS6	577	L->A	22927943	Abolishes interaction with RBM15.
Q9UPS6	579	D->A	22927943	Abolishes interaction with RBM15.
Q0KK55	461	L->A	21385318	Abolishes interaction with MAP2.
Q0KK55	474	L->A	21385318	Abolishes interaction with MAP2.
Q0KK55	477	L->A	21385318	Abolishes interaction with MAP2.
O15315	326	P->L	19657362	Abolishes interaction with BCR-ABL SH3 domain.
Q9WUU8	485	D->N	21606507	Abolishes interaction with polyubiquitinated IRAK1.
Q96MG7	180	M->A	21364888	Abolishes interaction with EID3.
Q96MG7	181	I->A	21364888	Abolishes interaction with EID3.
Q96MG7	185	L->A	21364888	Abolishes interaction with EID3.
Q96MG7	266	F->A	21364888	Abolishes interaction with EID3.
Q96MG7	270	V->A	21364888	Abolishes interaction with EID3.
Q9VHV5	34	T->N	30115618	Probably constitutively inactive (GDP-locked form). Abolishes interaction with CG11448.
Q7CPJ9	76	G->L	22782525	Loss of activity. Cannot bind acetyl-CoA. Does not interact with pro-PanD.
O60828	245	Y->D	24781215	Abolishes interaction with TXNL4A.
O60828	248	P->D	24781215	Abolishes interaction with TXNL4A.
O60828	251	V->D	24781215	Abolishes interaction with TXNL4A.
O60828	252	L->D	24781215	Abolishes interaction with TXNL4A.
Q7X6P3	281	K->G	19515790	Loss of interaction with RUS2.
Q7X6P3	349	K->G	19515790	Loss of interaction with RUS2.
P53281	90	W->S	21777813	Abolishes interaction with LAS17, but not with SUP35. Blocks colocalization with actin.
Q04637	612	Y->A,F	7651417	Abolishes binding to EIF4E.
P17844	53	K->R	17369852	Abolishes sumoylation, abolishes interaction with HDAC1, increases TP53 coactivation and promotes polyubiquitination.
P0ACJ8	102	K->E	15520470	Disrupts AR2. No activation of class II promoters, decreased interaction with RNAP, binds DNA.
O55000	401	W->A	12574161	Abolishes interaction with PPP1CA and PPP1CA inhibition.
Q9NY25	16	K->I	10449773	Abolishes interaction with TYROBP.
P07900	93	D->A	26517842	Impaired ATP-binding. Strong interaction with HIF1A, MET, KEAP1 and RHOBTB2. Loss of interaction with HSF1 and ERBB2. Los of interaction with TSC1.
P07900	313	Y->E	29127155	Loss of interaction with TSC1 and increases interacrion with AHSA1.
A3R064	331	Y->F	17290227	Strongly reduced tyrosine phosphorylation. Abolishes interaction with GRB2 and INPP5D/SHIP.
Q9I739	270	L->E	26456113	Complete loss of interaction with EF-Tu.
P16157	1824	T->P	12527750	Abolishes interaction with OBSCN (in isoform Mu17).
P16157	1826	K->E	12527750	Abolishes interaction with OBSCN (in isoform Mu17).
P16157	1829	R->G	12527750	Abolishes interaction with OBSCN (in isoform Mu17).
P16157	1830	K->E	12527750	Abolishes interaction with OBSCN (in isoform Mu17).
P17387	67	L->R	15016876	Complete loss of binding to HDAC1 and HDAC2. Complete loss of episomes. Impaired production of late transcripts.
Q3UV55	275	T->A	27238018	Loss of interaction with FBXW7 and loss of CDK1-mediated phosphorylation.
Q3UV55	279	S->A	27238018	Loss of interaction with FBXW7.
Q21738	56	Y->A	26779609	In xe29; lethal at 26 degrees Celsius at the L1 stage of larval development and abolishes xrn-2 binding.
Q8BKJ9	188	H->Y	18239138	Abolishes deacylase and deacetylase activities. Reduced interaction with SIRT1, without abolishing it.
Q0VGM9	1160	Q->A	24115439	Abolishes interaction with PCNA.
Q0VGM9	1163	I->A	24115439	Abolishes interaction with PCNA.
Q0VGM9	1166	F->A	24115439	Abolishes interaction with PCNA.
Q0VGM9	1167	F->A	24115439	Abolishes interaction with PCNA.
Q9Z0E3	299	D->A	18840680	Abolishes interaction with histone H3.
Q9Z0E3	312	C->W	18840680	Abolishes interaction with histone H3.
Q9Z0E3	313	C->Y	18840680	Abolishes interaction with histone H3.
Q9Y6I3	382	S->D	10764745	Abolishes phosphorylation by CDK1 and reduces REPS2 binding.
O94888	459	P->G	22537386	Abolishes interaction with VCP/p97.
P06213	996	N->A	7537849	Abolishes interaction with IRS1 and significantly reduces interaction with SHC1. Has no effect on interaction with PIK3R1.
P06213	997	P->A	7537849	Abolishes interaction with IRS1 and significantly reduces interaction with SHC1. Has no effect on interaction with PIK3R1.
P06213	999	Y->E	2842060	Abolishes interaction with IRS1 and SHC1.
P06213	999	Y->F	2842060	Has no effect on insulin-stimulated autophosphorylation, but inhibits the biological activity of the receptor. Abolishes interaction with IRS1 and almost completely prevents interaction with SHC1. Has no effect on interaction with PIK3R1. Abolishes interaction with STAT5B.
P06213	1057	K->A	10803466	Abolishes the kinase activity and abolishes interaction with IRS1, SHC1, GRB7 and PIK3R1.
Q9LVI4	181	I->A	19151223	No effect on dimerization, but loss of interaction with TIFY9/JAZ10.
Q9LVI4	185	G->A	19151223	Loss of dimerization and loss of interaction with TIFY9/JAZ10.
P13508	1043	G->E	16319922	In q224; at the restrictive temperature of 25 degrees Celsius, loss of interaction of lag-3 with lip-1 promoter. Loss of mpk-1 isoform b expression probably due to a lack of germline.
Q9SID1	20	D->A	23624715	Abolishes interaction with HY5.
Q9SID1	72	D->A	23624715	Abolishes interaction with HY5.
Q8K1Q4	701	T->A,S	16522626	Abolishes interaction with SHANK3.
Q8K1Q4	703	I->A,G,V	16522626	Abolishes interaction with SHANK3.
Q53H47	473	F->K	20521842	Abolishes homodimerization and DNA-binding and reduces cleavage of single-stranded DNA.
Q99K90	674	T->A	19927120	Loss of interaction with 'Lys-63'-linked ubiquitin.
Q99K90	675	F->A	19927120	Loss of interaction with 'Lys-63'-linked ubiquitin.
Q99K90	678	H->Q	19927120	Loss of interaction with 'Lys-63'-linked ubiquitin.
Q99K90	681	L->T	19927120	Loss of interaction with 'Lys-63'-linked ubiquitin.
Q99K90	685	E->V	19927120	Loss of interaction with 'Lys-63'-linked ubiquitin.
Q8VDS3	11	F->A	16537902	Abolishes binding to trimethylated histone H3.
Q8VDS3	35	W->A	16537902	Strongly reduced binding to methylated histone H3 (H3K27me3). Causes premature cellular senescence.
Q80UW2	177	F->A	14990996	Abolishes binding of glycoprotein targets.
Q80UW2	279	Y->A	14990996	Abolishes binding of glycoprotein targets.
Q80UW2	280	W->A	14990996	Abolishes binding of glycoprotein targets. Strongly reduced ubiquitination of glycoprotein targets.
P36711	417	P->E	10567268	Loss of interaction with CXADR.
P36711	418	P->E	10567268	Loss of interaction with CXADR.
P40458	114	S->A,N,G,Y	21757540	Abolishes mitophagy and impairs interaction with ATG11.
Q2MHQ9	172	E->A	16023795	Loss of interaction with traf6.
P05205	191	I->E	17875665	Abolishes piwi binding.
P05205	200	W->A	17875665	Abolishes piwi binding.
P55316	404	P->A	12657635	Abolishes interaction with KDM5B.
P75862	22	L->P	21216997	Does not interact with FtsZ, but shows affinity for itself. Reduces GTPase activity by less than 10%.
O13828	18	R->A	16341225	Abolishes interaction with dcp1.
Q6NUP7	501	R->W	18715871	Abolishes interaction with PPP4C.
Q6NUP7	618	V->D	18715871	Abolishes interaction with PPP4C.
Q9NY27	103	R->A	20154705	No effect on RPA2-binding; loss of PPP4C- binding.
A8K4G0	158	K->L	16920917	Abolishes interaction with TYROBP, and strongly reduces activation properties.
P13294	2	G->A	16604447	Complete loss of myristoylation and almost complete loss of interaction with UL56.
P28335	456	S->A	11150294	Loss of interaction with MPDZ.
P28335	458	V->A	11150294	Loss of interaction with MPDZ.
Q07954	4504	N->A	11729193	Loss of interaction with GULP1.
P17535	32	F->A	22327296	Loss of interaction with MEN1.
P17535	33	P->A	22327296	Loss of interaction with MEN1.
P17535	34	G->R	22327296	Loss of interaction with MEN1.
O14543	25	F->A	10421843	Complete loss of EPO-induced STAT5 signaling suppression. Abolishes binding to JH1.
O14543	30	E->R	10421843	Partial loss of EPO-induced STAT5 signaling suppression. No effect on LIF-induced signaling suppression. Abolishes binding to JH1. Inhibits JAK2 phosphorylation.
O14543	31	Y->A	10421843	Complete loss of EPO-induced STAT5 signaling suppression. No effect on LIF-induced STAT3 signaling. Abolishes binding to JH1.
O14543	41	L->R	10421843	Complete loss of EPO/LIF-induced signaling inhibition. Abolishes binding to JH1.
P53152	8	F->A	11440714	Strongly reduces UBC13 binding and interferes with error-free DNA repair.
P35329	822	Y->F	10373493	Abolishes binding to GRB2.
P00533	1069	Y->F	22888118	Abolishes interaction with CBLC.
Q14118	654	S->A	17905726	Abolishes autoproteolysis and enhances laminin-binding.
P21691	466	V->G	14701749	Abolishes interaction with ORC1.
P21691	469	R->G	14701749	Abolishes interaction with ORC1.
P21691	470	F->S	14701749	Abolishes interaction with ORC1 and SIR4.
P21691	477	L->P	14701749	Abolishes interaction with ORC1 and SIR4.
P21691	479	D->N	14701749	Abolishes interaction with ORC1.
P21691	480	L->P	14701749	Abolishes interaction with ORC1.
P21691	513	W->R	14701749	Abolishes interaction with ORC1 and SIR4.
P21691	571	C->R	14701749	Abolishes interaction with ORC1 and SIR4.
P21691	584	L->P,Q	14701749	Abolishes interaction with ORC1 and SIR4.
Q96HQ2	81	Y->A	26779609	Abolishes binding to XRN2.
P42260	883	V->A	17062563	Abolishes interaction with KLHL17. Abolishes actinfilin-mediated degradation.
P42260	884	I->A	17062563	Abolishes interaction with KLHL17. Abolishes actinfilin-mediated degradation.
Q9HCH5	11	E->A	18812475	Abolishes interaction with RAB27A.
Q9HCH5	32	R->A	18812475	Abolishes interaction with RAB27A.
Q12979	859	V->A	20962234	Abolishes interaction with DLG4. No effect on synaptic localization.
P48740	121	D->A,N	18596036	Loss of interaction with FNC2 and FCN3 and partial loss of interaction with MBL2.
P48740	237	H->A	18596036	Loss of interaction with FCN2, FCN3 and MBL2.
P48740	244	Y->A	18596036	Loss of interaction with FCN2, FCN3 and MBL2.
Q9BX79	255	L->A	22665496	Loss of interaction with RBP1.
Q8R0W6	42	Y->A	11042109	Abolishes interaction with NEDD4.
O75815	748	R->A	22081014	Abolishes interaction with BCAR1 and SRC.
A0A0H2XIE9	53	N->A	29473132	Complete loss of interaction with EsxD.
P03423	2	S->A	15958665	Complete loss of interaction with protein M.
P03423	6	D->A	15958665	Complete loss of interaction with protein M.
Q60841	2360	K->A	17548821	Abolishes ApoER2-binding.
Q60841	2467	K->A	17548821	Abolishes ApoER2-binding.
P79762	142	R->A	20970175	Impaired homodimerization and abolished secretion of processed zona pellucida sperm-binding protein 3.
Q05513	62	D->A	12887891	Loss of interaction with SQSTM1 and PARD6B.
Q05513	66	D->A	12887891	Loss of interaction with SQSTM1 and PARD6B.
P23246	687	T->A	20932480	Abolishes phosphorylation by GSK3B. Impairs interaction with THRAP3.
Q05776	23	F->D	26071601	Strongly impairs interaction with MDM35. Failure to complement the mitochondrial defects of UPS1- deficient cells.
Q05776	50	L->D	26071601	Strongly impairs interaction with MDM35. Failure to complement the mitochondrial defects of UPS1- deficient cells.
Q05776	84	V->E	26071601	Strongly impairs interaction with MDM35. Failure to complement the mitochondrial defects of UPS1- deficient cells.
Q06708	56	H->Y	19037259	Loss of interaction with ATG18 and VAC7.
Q06708	61	R->K	19037259	Loss of interaction with ATG18 and VAC7.
Q06708	101	Q->R	19037259	Loss of interaction with ATG18 and VAC7.
Q06708	149	L->R	19037259	Loss of interaction with ATG18, FAB1 and VAC7. No loss of interaction with FIG4.
P63165	36	F->A	16204249	Abolishes binding to PIAS2.
O04719	168	G->D	16571665	In abi2; reduced phosphatase activity, reduced affinity with magnesium ions, loss of interaction with the fibrillin precursor protein, impaired ABA-mediated binding to PYR1, and reduced negative control on fibrillin activity.
Q9Y253	652	D->A	16357261	Abolishes ubiquitin binding and localization to nuclear foci after UV-induced DNA damage but does not affect catalytic activity.
Q9EPL2	901	M->A	16760430	Almost completely abolishes KLC1-binding.
Q9EPL2	904	D->A	16760430	Almost completely abolishes KLC1-binding.
Q9EPL2	905	D->A	16760430	Almost completely abolishes KLC1-binding.
Q9UER7	220	S->A	23075851	Abolishes interaction with histones H3 and H4.
Q9UER7	222	Y->A,S	23075851	Abolishes interaction with histones H3 and H4.
Q9UER7	222	Y->E	23075851	Abolishes interaction with histone H3.3.
Q9UER7	251	R->A	23075851	Abolishes interaction with histones H3 and H4.
Q9UER7	317	F->A	23075851	Abolishes interaction with histones H3 and H4.
Q9UER7	328	R->A	23075851	Abolishes interaction with histones H3 and H4.
Q9UER7	331	D->A	23075851	Abolishes interaction with histones H3 and H4.
P12504	108	H->L	16076960	Complete loss of interaction with CUL5.
P12504	114	C->S	10074113	98% loss of viral infectivity. Complete loss of interaction with CUL5.
P12504	133	C->S	10074113	95% loss of viral infectivity. Complete loss of interaction with CUL5.
P12504	139	H->L	16076960	Complete loss of interaction with CUL5.
P12504	145	L->A	15574592	Complete loss of interaction with CUL5.
P20880	59	C->A	8676484	Complete loss of P-TEFb binding and reduced Tat phosphorylation.
P29067	396	R->A	10770944	Abolishes interaction with AP2B1.
P09455	22	R->A	28057518	No effect on retinol binding. Abolishes interaction with STA6 and the ability to enhance STA6- mediated vitamin A uptake.
P09455	31	R->A	28057518	No effect on retinol binding. Abolishes interaction with STA6 and the ability to enhance STA6- mediated vitamin A uptake.
P09455	32	K->A	28057518	No effect on retinol binding. Abolishes interaction with STA6 and the ability to enhance STA6- mediated vitamin A uptake.
Q8CGU1	17	F->A	16931570	Loss of interaction with p300 KIX domain; eliminated the autonomous transactivation function.
Q9CB01	93	Q->L	11532937	Constitutively active (GTP-bound form); no effect on targeting to plasma membrane. Loss of interaction with VPS9A.
Q8N0X7	24	F->D	20719964	Abolishes interaction with IST1. Does not localize to the midbody.
Q9UIS9	576	I->R	15691849	Abolishes interaction with ATF7IP and subsequent transcription repression activity.
O95278	25	S->A	21728993	Partial loss of phosphatase activity. Abolishes homodimerization. Abolishes interaction with NHLRC1, PPP1R3C and PRKAA2. Does not affect glycogen binding. Reduces stability of the protein.
O95278	168	S->A,D	21728993	Abolishes interaction with NHLRC1.
O95278	187	T->D	21728993	Abolishes interaction with NHLRC1.
O57173	100	V->A	18551131	Complete loss of binding to host BCL2L11.
O57173	125	I->A	18551131	Complete loss of binding to host BCL2L11.
O57173	140	G->F	18551131	Complete loss of binding to host BCL2L11.
O57173	148	F->A,E	18551131	Complete loss of binding to host BCL2L11.
Q9P0V3	92	W->A	16325581	Loss of function. Loss of targeting to the clathrin-coated pits and vesicles. Loss of interaction with DNM2, RRAGB and RRAGC. No effect on localization to the plasma membrane.
P35918	866	K->R	15673613	Loss of enzyme activity. Abolishes ubiquitination in response to VEGFA binding.
P35918	1173	Y->F	15026417	Loss of interaction with SHB.
P98082	720	R->A	14596919	Abolishes interaction with SH3KBP1.
P06730	73	W->A	17667941	Abolishes binding to EIF4EBP1. Impairs interaction with DDX3X.
P0DPI0	1266	W->L	14731268	Nearly complete loss of toxicity, heavy chain has very strongly reduced binding to synaptosomes, binds much less GT1b. Heavy chain no longer inhibits whole-toxin uptake and toxicity. RBD protects against neurotoxin considerably less well than wild-type.
P0DPI0	1267	Y->F	14731268	Nearly complete loss of toxicity, heavy chain has very strongly reduced binding to synaptosomes, binds much less GT1b.
P0DPI0	1267	Y->S	14731268	Nearly complete loss of toxicity, heavy chain has very strongly reduced binding to synaptosomes, binds much less GT1b. RBD protects against neurotoxin considerably less well than wild-type.
P0DPI0	1292	G->R	27294781	Nearly complete loss of toxicity, almost no binding of RBD to neurons.
O43586	232	W->A	14595024	Abolishes binding to MEFV. Cytoplasmic filaments are finer with fewer branches.
Q8LBL1	42	S->A	17764516	Loss of interaction with GRF6, but no effect on vacuolar targeting.
P46736	278	A->R	26344097	Abolishes interaction with UIMC1 and SHMT2.
Q96PU5	448	S->A	15677482	Abolishes interaction with 1433F.
O75663	71	D->L	17944932	Abolishes interaction with PPP2CA, PPP2CB and PPP4C.
O75663	136	I->T	17944932	Abolishes interaction with PPP2CA, PPP2CB and PPP4C.
O75663	196	M->V	17944932	Abolishes interaction with PPP2CA, PPP2CB and PPP4C.
O75663	198	D->N	17944932	Abolishes interaction with PPP2CA, PPP2CB and PPP4C.
O43189	47	Y->A	23142980	Abolishes histone H3K36me3-binding.
O43189	65	F->A	23273982	Abolishes histone H3K36me3-binding.
O43189	71	F->A	23273982	Abolishes histone H3K36me3-binding.
O82345	575	I->N,S	16003391	Abolishes interaction with CaM.
Q16512	181	R->A	24248594	Abolishes interaction with bacterial SspH1.
Q16512	185	R->A	24248594	Abolishes interaction with bacterial SspH1.
P89905	111	H->L	16076960	Complete loss of interaction with CUL5.
P89905	117	C->S	16076960	Complete loss of interaction with CUL5.
P89905	135	C->S	16076960	Complete loss of interaction with CUL5.
P89905	141	H->L	16076960	Complete loss of interaction with CUL5.
O95801	77	E->A	18320024	No effect on interaction with HSPA8 and HSP90AB1. Loss of interaction with CDC6.
O95801	152	K->E	18320024	Loss of interaction with HSPA8.
O95801	156	R->E	18320024	Loss of interaction with HSPA8.
O95801	217	N->K	18320024	No effect on interaction with HSPA8 and HSP90AB1. Loss of interaction with CDC6.
P51532	1539	F->A	17274598	Abolishes binding to 'Lys-15'-acetylated histone H3.
P51532	1540	N->A	17274598	Abolishes binding to 'Lys-15'-acetylated histone H3.
Q84940	42	C->A	28851847	Complete loss of interaction with host CUL1 and CUL3.
O75031	200	R->T	31242413	Abolishes interaction with BRCA2.
Q8IWA4	209	E->A	28114303	Abolishes dimerization. Loss of function in mitochondrial fusion. Abolishes GTPase activity, but has no effect on GTP binding.
Q8IWA4	238	R->A	28114303	Abolishes dimerization. Loss of function in mitochondrial fusion. Abolishes GTPase activity, but has no effect on GTP binding.
P08411	1787	F->A	25658430	Complete loss of interaction with host G3BP1.
P08411	1788	G->A	25658430	Complete loss of interaction with host G3BP1.
P08411	1789	D->A	25658430	Complete loss of interaction with host G3BP1.
P08411	1790	F->A	25658430	Complete loss of interaction with host G3BP1.
P08411	1804	F->A	25658430	Complete loss of interaction with host G3BP1.
P08411	1805	G->A	25658430	Complete loss of interaction with host G3BP1.
P08411	1806	D->A	25658430	Complete loss of interaction with host G3BP1.
P08411	1807	F->A	25658430	Complete loss of interaction with host G3BP1.
Q923U0	392	Y->F	11711534	Specifically abolishes interaction with GRB2; mild decrease in phosphorylation.
Q14524	1974	P->A	15548568	Strongly reduces interaction with NEDD4, NEDD4L or WWP2.
Q14524	1975	P->A	15548568	Strongly reduces interaction with NEDD4, NEDD4L or WWP2.
Q14524	1976	S->A	15548568	Strongly reduces interaction with NEDD4, NEDD4L or WWP2.
Q14524	1977	Y->A	15548568	Strongly reduces interaction with NEDD4, NEDD4L or WWP2.
P18509	150	V->G	17470806	Strongly reduced affinity for ADCYAP1R1.
P18509	153	Y->A	17470806	Strongly reduced affinity for ADCYAP1R1.
P18509	157	V->A	17470806	Strongly reduced affinity for ADCYAP1R1.
Q02763	1102	Y->F	14665640	Abolishes interaction with SHC1.
Q07869	370	L->R	10195690	Abolishes heterodimerization with RXRA. No DNA binding.
Q07869	391	L->R	10195690	Abolishes heterodimerization with RXRA. No DNA binding.
Q07869	433	L->R	7629123	Abolishes heterodimerization with RXRA, DNA binding and transactivation activity.
Q3HNM7	74	S->E	21816348	Abolishes interaction with GPSM2.
Q3HNM7	78	W->E	21816348	Abolishes interaction with GPSM2.
Q3HNM7	79	M->E	21816348	Abolishes interaction with GPSM2.
Q3HNM7	82	L->E	21816348	Abolishes interaction with GPSM2.
P62944	756	Q->A	19287005	Abolishes interaction with PIP5K1C.
P62944	804	Q->A	19287005	Abolishes interaction with PIP5K1C.
P62944	806	A->F	19287005	Abolishes interaction with PIP5K1C.
P62944	808	K->E	19287005	Abolishes interaction with PIP5K1C.
P62944	815	Y->A	19287005	Abolishes interaction with PIP5K1C.
Q9Y3Y4	350	V->E	18498752	Almost complete loss of interaction with H3K4me2.
Q9Y3Y4	356	A->E	18498752	Almost complete loss of interaction with H3K4me2.
Q9Y3Y4	357	I->R	18498752	Loss of interaction with H3K4me2.
Q9Y3Y4	360	E->A	18498752	Loss of interaction with H3K4me2.
Q9Y3Y4	366	W->E	18498752	Loss of interaction with H3K4me2.
Q9BVI0	97	W->A	22864287	Abolishes interaction with methylated p53.
Q9BVI0	103	Y->A	22864287	Abolishes interaction with methylated p53.
Q9VFC8	613	R->A	24265594	Abolishes interaction with Atg8a.
Q9VFC8	629	W->A	24265594	Abolishes interaction with Atg8a.
Q05323	197	E->R	27755595	Complete loss of interaction with nucleoprotein/NP.
Q05323	202	D->R	27755595	Complete loss of interaction with nucleoprotein/NP.
Q05323	203	Q->R	27755595	Complete loss of interaction with nucleoprotein/NP.
Q05323	229	Q->R	27755595	Complete loss of interaction with nucleoprotein/NP.
Q05323	230	W->F	27755595	Complete loss of interaction with nucleoprotein/NP.
Q05323	234	S->R	27755595	Complete loss of interaction with nucleoprotein/NP.
O00189	255	F->A	20230749	Abolishes interaction with APP.
O95210	203	W->A	21893048	Abolishes interaction with GABARAPL1.
O95210	206	V->A	21893048	Abolishes interaction with GABARAPL1.
P45481	600	R->N	8552098	Abolishes binding to CREB.
Q99549	80	W->A	20871592	Abolishes interaction with histone H3K9me3 and prevents recruitment of the HUSH complex to heterochromatin. Impaired ability to mediate silencing of unintegrated retroviral DNA.
A4ISV0	44	F->D	27551070	Loss of interaction with CsrA.
A4ISV0	123	Q->D	27551070	Loss of interaction with CsrA.
A4ISV0	125	I->D	27551070	Loss of interaction with CsrA.
Q15907	25	S->N	19244346	Dominant negative mutant locked in the inactive GDP-bound form; alters apical recycling. Does not interact with ZFYV2E and KIF5A.
P19814	348	S->A,D	10514494	Abolishes neurabin-1 and neurabin-2 binding.
Q9HCU8	8	T->D	24022480	Complete loss of PCNA binding.
P46933	655	C->F	19282473	Abolishes interaction with APP and impairs the function in DNA repair.
Q96PC5	697	K->A	27170179	Loss of interaction with PERB. Unable to recruit PERB to the endoplasmic reticulum exit sites. Loss of function in collagen VII transport. No effect on interaction with MIA3.
P28347	421	Y->A	20123905	Important loss of interaction with YAP1.
P61092	158	L->D,K	16615911	Strongly reduced binding of target proteins. Strongly reduced degradation of target proteins.
P61092	180	M->K	16615911	Strongly reduced binding of target proteins. Strongly reduced degradation of target proteins.
Q7XI96	156	S->G	17699623	Abolishes interaction with GF14C; increases nuclear localization and activity.
Q96KN7	1174	H->D	24981858	Abolishes interaction with RPGR.
Q13637	185	A->F	12186851	Abolishes binding to protein kinase A type II regulatory subunit.
Q13637	188	L->P	12186851	Abolishes binding to protein kinase A type II regulatory subunit.
Q92963	35	S->N	10545207	Dominant negative. Loss of interaction with AFDN, RLF and RALGDS.
Q77DJ5	197	E->A	30550789	Complete loss of binding to host RBBP6 and to NP.
Q77DJ5	230	W->A	30550789	Complete loss of binding to host RBBP6 and to NP.
Q99380	18	M->K	10677492	Severe growth defect; abolishes interaction with OST3 and STT3.
Q99380	19	M->K	10677492	Severe growth defect; abolishes interaction with OST3.
Q99380	20	T->K	10677492	Severe growth defect; abolishes interaction with OST3; disrupts interaction between OST3 and STT3.
Q99380	21	L->K	10677492	Abolishes interaction with OST3 and STT3; disrupts interaction between OST3 and STT3.
Q99380	23	V->K	10677492	Severe growth defect; abolishes interaction with OST3; disrupts interaction between OST3 and STT3.
Q80W00	401	W->A	20516061	Loss of interaction with PPP1CA but no effect on interaction with TOX4 or WDR82. Cell cycle arrest at mitosis and cell death. Exhibits normal association with chromosomes but shows defects in the process of chromosome decondensation at late telophase.
P0DTD1	164	K->A	32680882	Complete loss of ribosome binding and cellular translation inhibition.
P0DTD1	165	H->A	32680882	Complete loss of ribosome binding and cellular translation inhibition.
Q99732	23	Y->A	16118794	Abolishes interaction with NEDD4.
Q95Y80	252	K->R	24349540	Loss of interaction with smo-1 and ubc-9.
P0A3X1	43	D->N	26085102	Alters structural dynamics of free protein, loss of H-NS binding (tested with E.coli H-NS fragment 1- 64).
P01106	62	S->A	15103331	Impairs interaction with FBXW7 and subsequent degradation by the proteasome. Impaired inhibition of Ras- induced senescence. Abolishes phosphorylation by DYRK2, and subsequent phosphorylation by GSK3B at Thr-58.
P04909	129	S->A	15226425	Causes hypersensitivity to DNA-damage-inducing agents and impairs recruitment of crb2 to DSB sites. Loss of interaction with mdb1.
Q9Y484	113	D->A	28561066	Loss of interaction with AMPK. No effect on interaction with ATG2A.
P25445	250	R->E	20935634	Strongly decreased interaction with FADD.
P25445	261	E->K	20935634	Loss of interaction with FADD.
P25445	283	Q->K	20935634	Loss of interaction with FADD.
P25445	287	K->D	20935634	Strongly decreased interaction with FADD.
Q9NR00	86	K->Q	16424001	Abolishes interaction with CBY1. Forms irregular perinuclear cytoplasmic aggregates.
Q9NR00	88	T->K	16424001	Abolishes interaction with CBY1.
O17087	875	E->K	12239571	In h292; induces defects in entry into meiosis and abolishes interaction with gld-3.
P16287	38	Y->A	10074141	Complete loss of interaction with WW domain in vitro.
P30260	821	S->A	22139841	Abolishes binding to MCPH1.
P09581	614	K->M	10597251	Loss of kinase activity. Abolishes binding to THOC5.
P09581	697	Y->F	8262059	Abolishes interaction with GRB2.
P09581	721	Y->F	10597251	Abolishes interaction with PIK3R1. Strongly reduced phosphorylation of PLCG2. No effect on binding to THOC5.
Q5NBT9	67	R->A	26601214	Loss of interaction with EAR motif-containing full-length proteins.
Q5NBT9	68	Y->A	26601214	Loss of interaction with EAR motif-containing full-length proteins.
Q5NBT9	71	K->A	26601214	Loss of interaction with EAR motif-containing full-length proteins.
Q5NBT9	74	F->A	26601214	Loss of interaction with EAR motif-containing full-length proteins.
Q5NBT9	104	F->A	26601214	Loss of interaction with EAR motif-containing full-length proteins.
Q5NBT9	111	L->A	26601214	Loss of interaction with EAR motif-containing full-length proteins.
Q5NBT9	118	L->A	26601214	Loss of interaction with EAR motif-containing full-length proteins.
Q5NBT9	130	L->A	26601214	Loss of interaction with EAR motif-containing full-length proteins.
Q5NBT9	150	L->A	26601214	Loss of interaction with EAR motif-containing full-length proteins.
Q08AM6	777	D->A	17161399	Abolishes interaction with NOS1.
Q03519	16	D->K	26611325	Complete loss of interaction with TAPBP, resulting in impaired PLC assembly and antigen presentation.
P21457	39	C->D	24189072	Reduces binding affinity for calcium at both EF-hand 2 and EF-hand 3 domains. Abolishes interaction with GRK1.
Q923B3	15	K->R	16252010	Abolishes ubiquitination by TRAF6, binding to SQSTM1/p62, translocation to the nucleus and NGFR/p75(NTR)- mediated apoptosis.
P54753	614	Y->F	9674711	Partial loss of phosphorylation and loss of interaction with SH2-containing proteins.
Q24307	100	D->E	18166655	Loss of caspase-mediated cleavage, failure to protect against Drice-mediated cell death and loss of binding to Drice.
Q24307	249	C->G	18166655	Abolishes binding to Drice and fails to inhibit cell death. No effect on binding to Dredd.
Q9R194	339	D->R	23503662	Strongly reduces PER1 binding.
Q9R194	376	R->A	23503662	Impairs protein folding. Abolishes binding of ARNTL, PER1 and FBXL3. Strongly reduces SKP1 binding.
Q9R194	428	F->D	23503662	Abolishes binding of FBXL3 and SKP1. Strongly decreases CRY2 degradation.
Q9R194	499	I->D	23503662	Abolishes binding of FBXL3 and SKP1. Strongly decreases CRY2 degradation.
P10200	247	C->S	18715918	Complete loss of interaction with UL11.
P10200	269	C->S	18715918	Complete loss of interaction with UL11.
P10200	271	C->S	18715918	Complete loss of interaction with UL11.
P10200	275	C->S	18715918	Complete loss of interaction with UL11.
P30408	202	C->G	11102519	Abolishes interaction with SDCBP2. Loss of colocalization with SDCBP2 at the apical region of the cell.
Q14451	259	Y->F	18853468	Global loss of tyrosine phosphorylation. Abolishes interaction with FHL2 and HAX1.
Q14451	260	Y->F	18853468	Global loss of tyrosine phosphorylation. Abolishes interaction with FHL2 and HAX1.
Q14451	284	Y->F	18853468	Global loss of tyrosine phosphorylation. Abolishes interaction with FHL2 and HAX1.
Q14451	480	Y->F	18853468	Global loss of tyrosine phosphorylation. Abolishes interaction with FHL2 and HAX1.
Q14451	492	Y->F	18853468	Global loss of tyrosine phosphorylation. Abolishes interaction with FHL2 and HAX1.
P59594	348	C->A	14670965	Complete loss of human ACE2 binding in vitro.
P59594	452	E->A	14670965	90% loss of human ACE2 binding in vitro.
P59594	454	D->A	14670965	Complete loss of human ACE2 binding in vitro.
P59594	467	C->A	14670965	Complete loss of human ACE2 binding in vitro.
P59594	474	C->A	14670965	Complete loss of human ACE2 binding in vitro.
P06536	488	R->Q	12917342	Loss of chromatin specific function and reduces chromatin remodeling. Abolishes interaction with SMARD1.
P06536	500	C->Y	10480874	Abolishes interaction with POU2F2.
P06536	501	L->P	10480874	Abrogates DNA-binding and transcription transactivation. Abolishes interaction with POU2F1 and POU2F2.
P60510	64	E->K	18715871	Abolishes interaction with PPP4R4.
P60510	277	E->K	18715871	Abolishes interaction with PPP4R4; no effect on interaction with PPP4R1 and PPP4R2.
Q924X6	61	D->N	12899622	Lower affinity for RAP. Abolishes binding to Reelin.
Q9HBB8	845	I->R	24725409	Loss of interaction with USH1C.
Q63881	71	E->K	14980207	Abolishes interaction with KCNIP1.
Q63881	73	D->M	14980207	Abolishes interaction with KCNIP1.
Q63881	74	F->R	14980207	Abolishes interaction with KCNIP1.
Q63881	79	E->L,R	14980207	Abolishes interaction with KCNIP1.
P32849	914	C->S	10880451	Abolishes interaction with UBC13.
P32849	916	I->A	12496280	Abolishes interaction with UBC13.
P32849	944	Y->A	12496280	Abolishes interaction with UBC13.
P32849	959	N->A	12496280	Abolishes interaction with UBC13.
Q96T49	252	G->A	26497934	Strongly decreased interaction with EEF1A1.
P97434	857	L->P	15469989	Loss of interaction with PPP1R12C and PPP1R12A.
P97434	919	I->P	15469989	Loss of interaction with PPP1R12C and PPP1R12A.
Q6GTX8	281	Y->F	10764762	Reduced tyrosine phosphorylation and loss of binding to PTPN6. Partial inhibition of cytotoxic activity.
Q7Z2E3	43	R->A	20008512	Impairs interaction with XRCC1 and XRCC4. Abolishes localization at sites of DNA double-strand breaks. Loss of interaction with MDC1.
P78318	155	R->E	23591866	Abolishes interaction with PPP2CA.
P78318	158	K->D	23591866	Abolishes interaction with PPP2CA.
P78318	162	Y->D	23591866	Abolishes interaction with PPP2CA.
P78318	214	E->R	23591866	Abolishes interaction with PPP2CA.
P35169	1972	S->E,I	7606777	Confers resistance to rapamycin. Abolishes interaction with FKBP-rapamycin.
P35169	1972	S->R	7606777	In DRR1-1; confers resistance to rapamycin. Abolishes interaction with FKBP-rapamycin.
Q06449	91	W->S	21777813	Abolishes interaction with LAS17, but not with SUP35. Blocks colocalization with actin, aggregation, and prion-inducing ability.
O60516	40	Y->A	9593750	Loss of interaction with EIF4E.
O60516	45	L->A	9593750	Loss of interaction with EIF4E.
P05783	34	S->D,E	7523419	Abolishes binding to YWHAE and YWHAZ.
Q04323	13	M->T	20351172	Abolishes binding to 'Lys-6'-linked polyubiquitin chains and ability to inhibit E3 ubiquitin- protein ligase activity of the BRCA1-BARD1 heterodimer.
Q86XR7	117	C->H	14517278	Loss of ability to dimerize. Loss of RANTES- inducing activity and ability to induce NF-kappa-B activation. Inhibition of TLR4-dependent activation of IRF3 and IRF7. Loss of interaction with TLR4.
Q9P212	2150	R->L	16483931	Abolishes interaction with HRAS.
Q91X58	228	L->A	26876100	Decreased 'Lys-48'-linked polyubiquitin binding. Loss of interaction with BAG6. Decreased association with the proteasome complex.
Q91X58	254	C->S	18467495	Loss of localization to the endoplasmic reticulum membrane. Loss of interaction with BAG6. No effect on association with the proteasome complex.
O54967	650	Y->A	17182860	Loss of interaction with NEDD4 and drastic reduction in its ubiquitination.
Q64487	229	R->E	25989451	Abolishes interaction with SLITRK2.
Q64487	266	Y->A	25908590	No effect on interaction with SLITRK2. Decreases the affinity for IL1RAPL1. Abolishes interaction with IL1RAP.
O14980	474	R->I	14612415	Strongly abolishes interaction with Rex and RANBP3, abolishes Rex-mediated mRNA export.
O14980	481	H->Q	14612415	Strongly abolishes interaction with Rex and RANBP3, abolishes Rex-mediated mRNA export.
P35222	253	F->A	10966653	Abolishes or strongly reduces AXIN2 binding.
P35222	292	K->A	10966653	Abolishes or strongly reduces AXIN1 and AXIN2 binding.
P35222	312	K->E	11713475	Abolishes TCF7L2 binding.
P35222	345	K->A	10966653	Abolishes APC binding.
P35222	426	N->A	10966653	Abolishes TCF7L2 and LEF1 binding.
P35222	435	K->A	10966653	Strongly reduces or abolishes LEF1 binding.
P35222	435	K->E	10966653	Abolishes TCF7L2 binding.
P35222	469	R->A	10966653	Abolishes TCF7L2 binding, and strongly reduces or abolishes LEF1 binding.
P35222	470	H->A	10966653	Abolishes TCF7L2 binding, and strongly reduces or abolishes LEF1 binding.
P35222	508	K->A	10966653	Abolishes TCF7L2 and LEF1 binding.
P97765	200	Y->A	11042109	Abolishes interaction with NEDD4.
P04775	1975	Y->A	15548568	Abolishes interaction with NEDD4L.
Q9HAU5	858	E->R	15004547	Abolishes interaction with UPF3B and association with SMG1 and RBM8A; reduces phosphorylation of UPF1.
Q9HAU5	1171	F->E	19556969	Abolishes interaction with UPF1; reduces NMD efficiency.
Q9HAU5	1173	M->E	19556969	Abolishes interaction with UPF1.
Q9HAU5	1174	L->E	19556969	Abolishes interaction with UPF1; reduces NMD efficiency.
Q20010	397	R->C	15232593	In t2079; induces a monopolar spindle assembly during mitosis and failure in cell division. Abolishes interaction with sas-6.
A6ND01	45	E->A	27309818	Nearly abolishes interaction with IZUMO1.
A6ND01	45	E->K	27309818	Abolishes interaction with IZUMO1.
A6ND01	81	L->A	27309808	Abolishes interaction with IZUMO1.
Q15459	169	L->K	17098193	Abolishes binding to SF3A3.
P06847	196	C->G	7664747	Loss of interaction with the human retinoblastoma-like protein 2.
P06847	198	E->K	7664747	Loss of interaction with the human retinoblastoma-like protein 2.
O95376	158	H->A	16118314	Loss of effect in myelopoiesis. Abolishes interaction with UBE2L3.
O95994	81	C->S	19359471	Loss of interaction with MUC2.
Q9QPN3	108	D->A	10799608	Complete loss of Nef-PTE1 interaction and Nef- induced CD4 down-modulation.
Q9QPN3	111	D->G	10799608	Complete loss of Nef-PTE1 interaction and Nef- induced CD4 down-modulation.
Q9QPN3	112	L->D	10799608	Complete loss of Nef-PTE1 interaction and Nef- induced CD4 down-modulation.
Q9QPN3	121	F->G	10799608	Complete loss of Nef-PTE1 interaction and Nef- induced CD4 down-modulation.
Q9QPN3	122	P->R	10799608	Complete loss of Nef-PTE1 interaction and Nef- induced CD4 down-modulation.
Q9QPN3	123	D->G	10799608	In Nef*4; complete loss of Nef-PTE1 interaction, Nef-induced CD4 and MHC-I down-regulation and enhancement of infectivity.
Q9QPN3	123	D->V	10799608	Complete loss of Nef-PTE1 interaction and Nef- induced CD4 down-modulation.
Q9QPN3	124	W->R	10799608	Complete loss of Nef-PTE1 interaction and Nef- induced CD4 down-modulation.
Q14145	334	Y->A	16888629	Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5.
Q14145	380	R->A	16888629	Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Impaired interaction with SQSTM1/p62.
Q14145	382	N->A	16888629	Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Impaired interaction with SQSTM1/p62.
Q14145	415	R->A	16888629	Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5. Does not affect interaction with SQSTM1/p62.
Q14145	436	H->A	16888629	Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Does not affect interaction with SQSTM1/p62.
Q14145	483	R->A	16888629	Loss of interaction with NFE2L2/NRF2. Abolishes repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5. Does not affect interaction with SQSTM1/p62.
Q14145	525	Y->A	16888629	Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Abolishes interaction with SQSTM1/p62.
Q14145	572	Y->A	16888629	Loss of interaction with NFE2L2/NRF2. Strongly reduces repression of NFE2L2/NRF2-dependent gene expression. Loss of interaction with PGAM5. Abolishes interaction with SQSTM1/p62.
Q7M6U3	792	P->A	20176808	Abolishes interaction with CEP55.
Q7M6U3	797	Y->A	20176808	Abolishes interaction with CEP55.
P03421	87	F->A	29489893	Almost complete loss of viral transcription. Complete loss of interaction with host phospatase PP1.
P03421	98	F->A	29489893	Complete loss of interaction with protein M2- 1. Almost complete loss of viral transcription and loss of localization of protein M2-1 in inclusion bodies.
P03421	101	L->A	12970453	Complete loss of interaction with protein M2- 1. Almost complete loss of viral transcription and loss of localization of protein M2-1 in inclusion bodies.
P03421	102	Y->A	12970453	Complete loss of interaction with protein M2- 1. Almost complete loss of viral transcription and loss of localization of protein M2-1 in inclusion bodies.
P03421	105	T->A,D	29489893	Complete loss of interaction with protein M2-1. Almost complete loss of viral transcription and loss of localization of protein M2-1 in inclusion bodies.
P03421	106	I->A	29489893	Complete loss of interaction with protein M2- 1. Almost complete loss of viral transcription and loss of localization of protein M2-1 in inclusion bodies.
P03421	108	T->D	26474524	Loss of interaction with protein M2-1 and loss of localization of protein M2-1 in inclusion bodies.
P03421	109	F->A	12970453	Complete loss of interaction with protein M2- 1. Almost complete loss of viral transcription and loss of localization of protein M2-1 in inclusion bodies.
P03421	172	G->S	11861854	Almost complete loss of interaction with the nucleoprotein.
P03421	176	E->G	11861854	Complete loss of interaction with the nucleoprotein.
P03421	241	F->A	12970453	Complete loss of interaction with N and viral RNA synthesis.
A1Z1Q3	188	G->E	23474712	Abolishes interaction with ADP-ribosylated proteins. Strongly reduced ADP-ribosyl hydrolase activity.
Q96N21	470	L->A	26542808	Loss of interaction with AP4B1 n vitro.
Q96N21	471	F->A	26542808	Loss of interaction with AP4B1 in vitro.
Q96N21	518	S->A	26542808	Loss of interaction with AP4E1 in vitro.
Q96N21	519	A->D	26542808	Loss of interaction with AP4E1 in vitro.
Q96N21	520	F->A	26542808	Loss of interaction with AP4E1 in vitro.
Q96N21	522	F->A	26542808	Loss of interaction with AP4E1 in vitro.
Q96N21	523	L->A	26542808	Loss of interaction with AP4E1 in vitro.
Q99683	966	S->A	10411906	Enhanced induction of apoptosis, increased kinase activity, and loss of YWHAG binding.
Q15834	131	L->A	17873903	Loss of interaction with TCF7L2 and loss of suppression of CTNNB1 activity. Loss of cell growth inhibition.
Q8TBM8	136	H->Q	24732912	Abolishes interaction with HSPA8/Hsc70.
Q16531	561	W->A	16413485	Strongly impairs interaction with CUL4A.
Q01590	206	N->A	12941276	Loss of interaction with SEC23/SEC24 complex.
Q80U87	405	P->A	10982817	Abolishes interaction with the SH3 domain of STAM2.
Q80U87	409	R->A	10982817	Abolishes interaction with the SH3 domain of STAM2.
Q80U87	412	K->A	10982817	Abolishes interaction with the SH3 domain of STAM2.
Q80U87	413	P->A	10982817	Abolishes interaction with the SH3 domain of STAM2.
Q04206	254	T->A	14690596	Abolishes interaction with PIN1.
O14493	35	F->D	27647526	Abolishes interaction with Clostridium perfringens CPE.
Q6GNV6	496	R->A	20064462	Abolishes chromatin binding. Abolishes DNA- binding activity in vitro.
Q6GNV6	498	K->A	20064462	Abolishes chromatin binding. Abolishes DNA- binding activity in vitro.
Q96BK5	291	L->A	18202258	Abolishes interaction with TERF1.
O14669	175	L->A	17502622	Abolishes interaction with YAP1.
O14669	176	P->A	17502622	Abolishes interaction with YAP1.
O14669	177	T->A	17502622	Abolishes interaction with YAP1.
O14669	178	Y->A	17502622	Abolishes interaction with YAP1.
O14669	195	Y->A	17502622	Significantly impairs interaction with YAP1.
Q9JI78	41	N->P	16709668	Abolishes interaction with VCP.
Q9BZI7	52	K->E	15004547	Abolishes interaction with UPF2.
Q9WVK4	65	G->R	15930129	Abolishes interaction with PACSIN2.
Q9WVK4	485	W->A	15930129	Abolishes interaction with PACSIN2.
P03871	32	T->K	15169893	Abolishes interaction with REP2 and STB.
P03871	43	Y->A	15169893	Abolishes interaction with REP2, but not with STB.
P03871	50	A->D	15169893	Abolishes interaction with REP2, but not with STB.
P03871	78	V->K	15169893	Abolishes interaction with REP2, but not with STB.
P03871	93	S->Y	15169893	Abolishes interaction with REP2, but not with STB.
P03871	154	L->S	15169893	Abolishes interaction with STB, but not with REP2.
P03871	200	E->A	15169893	Abolishes interaction with REP2, but not with STB.
P03871	276	A->P	15169893	Abolishes interaction with REP2, but not with STB.
P03871	297	K->Q	15169893	Abolishes interaction with STB, but not with REP2.
P03871	301	Y->L	15169893	Abolishes interaction with REP2, but not with STB.
P03871	308	I->Y	15169893	Abolishes interaction with REP2, but not with STB.
P03871	317	Y->I	15169893	Abolishes interaction with STB, but not with REP2.
P03871	330	S->Y	15169893	Abolishes interaction with STB, but not with REP2.
Q9D7R2	210	Y->A	11042109	Abolishes interaction with NEDD4.
F4JD14	1616	R->E	25618824	Loss of interaction with GFS12.
F4JD14	1626	E->R	25618824	Loss of interaction with GFS12.
Q810C0	167	D->A	25989451	Abolishes interaction with PTPRD. Abolishes synapse assembly.
Q810C0	187	D->A	25989451	Abolishes interaction with PTPRD. Abolishes synapse assembly.
Q810C0	215	E->A	25989451	Abolishes interaction with PTPRD. Significantly reduces synapse assembly.
Q9Y468	423	D->N	17540172	Strongly impairs binding to monomethylated and dimethylated peptides. Abolishes binding to p53/TP53 monomethylated at 'Lys-382'.
Q9Y468	426	N->Q	18042461	Strongly impairs binding to monomethylated and dimethylated peptides. Abolishes binding to p53/TP53 monomethylated at 'Lys-382'.
Q9Y468	447	F->A	17540172	Abolishes binding to monomethylated and dimethylated peptides. Abolishes binding to p53/TP53 monomethylated at 'Lys-382'.
Q9Y468	450	W->L	20870725	Abolishes binding to p53/TP53 monomethylated at 'Lys-382'.
Q9Y468	454	Y->L	20870725	Abolishes binding to p53/TP53 monomethylated at 'Lys-382'.
P51450	500	Y->F	16148126	Abolishes interaction with NCOA1 and NCOA2.
Q9U1K1	232	Y->K	21730168	Abolishes interaction with capu.
P11881	2527	C->S	15652484	Complete loss of channel activity. Significant decrease of interaction with ERP44.
Q8NBJ7	156	C->A	15962010	Abolishes interaction with and inhibition of SUMF1. Can still form homodimers.
Q8NBJ7	290	C->A	15962010	Abolishes interaction with and inhibition of SUMF1. Can still form homodimers.
Q9NZ52	194	N->A	11301005	Loss of interaction with ARF1 and Golgi localization.
Q9NZ52	199	S->P	11301005	Loss of interaction with ARF1 and Golgi localization.
Q9NZ52	217	T->P	11301005	Loss of interaction with ARF1 and Golgi localization.
Q9NZ52	276	L->A	14660606	Loss of UBC-binding and ubiquitination. Abolishes binding to ubiquitin. Abolishes regulation of BACE1 degradation. No effect on interaction with NTRK1.
P63142	46	T->V	18003609	Abolishes interaction with KCNAB2 and strongly reduces cell surface expression. No effect phosphorylation in response to increased cAMP levels.
Q42379	252	D->N	26332741	Loss of nuclear localization; cytoplasmic localization; abolishes interaction with SAD2.
Q09312	28	P->A	27864381	Abolishes interaction with dlc-1.
Q09312	136	S->A,D	27864381	Abolishes interaction with dlc-1.
Q09312	137	K->A,D	27864381	Abolishes interaction with dlc-1.
P01130	828	Y->A	12944399	Abolishes interaction with ARRB2.
Q5T4F4	289	D->A	19289470	Loss of interaction with VAPA and loss of function in cell projections formation.
O00141	298	Y->A	11696533	Abolishes interaction with NEDD4 and NEDD4L.
Q9HC16	128	D->K	15054139	Resistant to HIV-1 Vif with complete loss of Vif-induced degradation and Vif binding.
P14906	652	T->A	15671059	Abolishes interaction with SEC62; defect in protein translocation.
P14906	654	T->A	15671059	Abolishes interaction with SEC62; defect in protein translocation.
Q96G27	141	Y->A	15064722	Abolishes interaction with WWOX.
Q96QV1	380	E->A	19561609	Abolishes SHH binding.
Q96QV1	382	M->A	19561609	Abolishes SHH binding.
Q96QV1	383	D->A,R	19561609	Abolishes SHH binding.
Q96QV1	387	D->A	19561609	Abolishes SHH binding.
P22829	348	L->V	8227042	Almost complete loss of NBRE binding.
Q9H7E2	598	E->K	18632687	Abolishes interaction with dimethylarginine- containing protein motifs and reduces association with mRNA stress granules.
P58004	190	S->W	26449471	Loss of interaction with GATOR2. No effect on leucine-binding. Unable to mediate leucine-induced inhibition of the TORC1 signaling pathway.
P58004	406	D->A	26612684	No effect on alkylhydroperoxide reductase activity. Loss of interaction with the GATOR2 complex. Unable to inhibit the TORC1 signaling pathway.
P58004	407	D->A	26612684	No effect on alkylhydroperoxide reductase activity. Loss of interaction with the GATOR2 complex. Unable to inhibit the TORC1 signaling pathway.
Q92784	358	W->E	18765789	Abolishes binding to acetylated histones H3 and H4.
Q63604	515	Y->F	10196222	Loss of interaction with SHC1.
Q99NE5	33	R->G	11431472	Abolishes interaction with RAB3A.
Q6NME7	77	G->E	21781195	In mdo1-1/ten1-3; strong developmental defects and loss of in vitro interaction with STN1.
A0A0H3H546	10	E->A	27260845	More than 90% loss of type II secretion due to loss of interaction with PulM.
A8MW95	80	I->S	23954414	Abolishes interaction with GPRASP1/GASP1 and ability to degrade G-protein coupled receptor. Does not affect function in autophagy.
Q8LA16	211	W->M	19154204	Abolishes binding to H3K4me2/3.
Q8LA16	215	D->N	19154204	Abolishes binding to H3K4me2/3.
Q9H4E7	18	L->N	17121847	Abolishes interaction with RAC1.
Q9H4E7	236	R->C	12923183	Abolishes PtdInsP3 binding.
G5EBV0	720	E->K	22405203	Loss of interaction with cysl-1 associated with a loss of hypoxia-mediated inhibition of behavior adaptation.
P69744	593	T->A	12660155	Abolishes interaction with S100A10, plasma membrane localization and channel activity.
P35240	64	L->P	15598747	Abolishes binding to AGAP2 and interaction with the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex.
Q9BWK5	11	R->A	28959974	Abolishes interaction with XRCC5/Ku80 and XRCC6/Ku70 and ability to inhibit classical non-homologous end joining (NHEJ).
Q9BWK5	14	P->A	28959974	Abolishes interaction with XRCC5/Ku80 and XRCC6/Ku70 and ability to inhibit classical non-homologous end joining (NHEJ).
Q9BWK5	16	W->A	28959974	Abolishes interaction with XRCC5/Ku80 and XRCC6/Ku70 and ability to inhibit classical non-homologous end joining (NHEJ).
Q8NCN4	673	A->G	22742833	Abolishes ubiquitin-binding.
P12978	385	L->A	11733528	Complete loss of interaction with host ZMYND11.
P12978	439	L->A	11733528	Complete loss of interaction with host ZMYND11.
P04797	225	K->A	15951807	Abolishes interaction with SIAH1.
Q53GL7	888	G->W	18851833	Abolishes catalytic activity; abolishes interaction with PARP14.
P35546	1063	Y->F	11470823	Abolishes interaction with DOK proteins.
O95429	424	D->A	12058034	Abolishes interaction with HSP70.
O95429	446	Q->A	12058034	Abolishes interaction with HSP70.
Q9H307	8	L->P	10809736	Abolishes interaction with KRT18.
Q9H307	19	L->P	10809736	Abolishes interaction with KRT18.
Q14643	241	R->Q	16793548	Abolishes interaction with AHCYL1.
Q14643	249	K->Q	16793548	Abolishes interaction with AHCYL1.
Q14643	269	R->Q	16793548	Abolishes interaction with AHCYL1.
Q14643	504	R->Q	16793548	Abolishes interaction with AHCYL1.
Q14643	506	R->Q	16793548	Abolishes interaction with AHCYL1.
Q14643	508	K->A	16793548	Abolishes interaction with AHCYL1.
Q14643	511	R->A	16793548	Abolishes interaction with AHCYL1.
Q14643	567	Y->A	16793548	Abolishes interaction with AHCYL1.
Q14643	568	R->Q	16793548	Abolishes interaction with AHCYL1.
Q14643	569	K->A	16793548	Abolishes interaction with AHCYL1.
P0AES4	462	R->C	1324324	In gyrA462; resistant to cytotoxic protein CcdB, but not to the quinoline antibiotic enoxacin, has no effect on DNA supercoiling. Does not interact with CcdB.
O14593	224	Y->A	22649097	Loss of interaction with RFX5.
P08922	2274	Y->F	12538861	Loss of phosphorylation at Y-2274 and loss of interaction with PTPN11.
P08922	2334	Y->F	12538861	Loss of phosphorylation at Y-2334 and loss of interaction with PTPN11.
Q9KI13	338	S->H	14567919	Loss of interaction with human fibrinogen.
Q9KI13	339	D->A	14567919	Loss of interaction with human fibrinogen.
Q9Z0W5	434	P->L	9950691	Abolishes interaction with DNM1, SYNJ1 and WASL.
Q9H400	167	Y->F	14610046	Abolishes binding to CSK.
Q9H400	254	Y->F	14610046	Abolishes binding to LCK and reduces binding to FYN.
Q9Y6D5	289	V->W	18625701	Abolishes interaction with PRKAR2B and impairs TNFRSF1A release.
Q9Y6D5	534	V->W	18625701	Abolishes interaction with PRKAR2B and impairs TNFRSF1A release.
O95760	149	D->K	23980170	Almost abolishes binding to IL1RL1.
P47025	148	L->P	16272155	Abolishes interaction with FIS1.
P47025	440	H->E,N	16272155	Abolishes interaction with DNM1.
P47025	605	H->E	16272155	Abolishes interaction with DNM1.
O95866	211	Y->F	11544253	Loss of tyrosine phosphorylation and loss of interaction with PTPN6 and PTPN11.
Q9SQR3	158	G->E	27479325	Loss of interaction with MAX2.
Q16832	52	W->A	20004161	Abolishes collagen binding.
Q15075	41	F->A	12493736	Strongly reduces interaction with RAB5C.
Q15075	42	I->A	12493736	Strongly reduces interaction with RAB5C.
Q15075	44	P->A	12493736	Strongly reduces interaction with RAB5C.
Q15075	47	M->A	12493736	Strongly reduces interaction with RAB5C.
Q15075	60	Y->A	12493736	Strongly reduces interaction with RAB5C.
Q5SXM2	94	Q->A	11056176	Abolishes SNAPC5 binding in the absence of SNAPC1. Minimal effect on SNAPC5 binding in the presence of SNAPC1.
Q5SXM2	94	Q->L	11056176	Abolishes SNAPC5 binding in the absence of SNAPC1. Minimal effect on SNAPC5 binding in the presence of SNAPC1.
Q5SXM2	115	Q->L	11056176	Abolishes SNAPC5 binding in the absence of SNAPC1. Minimal effect on SNAPC5 binding in the presence of SNAPC1.
Q5SXM2	1314	L->A	11056176	Abolishes SNAPC2-binding.
Q5SXM2	1355	L->A	11056176	Abolishes SNAPC2-binding.
Q5SXM2	1362	L->A	11056176	Abolishes SNAPC2-binding.
Q5SXM2	1364	L->A	11056176	Abolishes SNAPC2-binding.
Q9NZ56	1715	K->A,E	21730168	Abolishes interaction with SPIRE1.
P17813	278	S->P	28564608	Loss of interaction with GDF2.
P17813	282	F->V	28564608	Loss of interaction with GDF2.
P17813	650	T->A	17540773	Loss of interaction with ARRB2.
P15209	515	Y->F	12367511	Loss of interaction with SHC1.
P15209	816	Y->F	12367511	Loss of interaction with PLCG1.
P36108	221	L->D	17928861	Abolishes interaction with VPS4.
P36108	224	R->D	17928861	Abolishes interaction with VPS4. Impairs sorting.
P36108	225	L->D	17928861	Abolishes interaction with VPS4.
P36108	228	L->D	17928861	Abolishes interaction with VPS4.
P36108	229	K->D	17928861	Abolishes interaction with VPS4.
Q9UJY5	92	N->A	12060753	Abolishes interaction with IGF2R.
Q9UJY5	182	L->A	15143060	Abolishes interaction with ARF1, UBC and TSG101.
Q9UJY5	194	N->A	15143060	Abolishes interaction with ARF1 and RABEP1.
Q9UJY5	197	I->A	15143060	Abolishes interaction with ARF1, UBC and TSG101.
Q9UJY5	198	K->A	15143060	Abolishes interaction with ARF1.
Q9UJY5	200	M->A	15143060	Abolishes interaction with ARF1.
Q9UJY5	204	D->A	15143060	Abolishes interaction with ARF1.
Q9UJY5	259	M->K	15143060	Abolishes interaction with RABEP1.
Q9UJY5	260	R->E	15143060	Abolishes interaction with RABEP1 and UBC.
Q9UJY5	264	F->A	15143060	Abolishes interaction with RABEP1.
Q9UJY5	267	A->D	15143060	Abolishes interaction with RABEP1 and UBC.
Q9UJY5	277	L->A	15143060	Abolishes interaction with RABEP1, UBC and TSG101.
Q9UJY5	281	L->A	15143060	Abolishes interaction with RABEP1.
Q9UJY5	284	N->A	15143060	Abolishes interaction with RABEP1.
Q9UJY5	284	N->S	15143060	Abolishes interaction with RABEP1.
Q9UJY5	355	S->D	12060753	Abolishes interaction with IGF2R. No effect on the interaction with SORL1.
Q9UJY5	563	A->D	12808037	Abolishes interaction with CCDC91.
Q9UJY5	564	V->D	12808037	Abolishes interaction with CCDC91.
Q9UJY5	570	V->E	12808037	Abolishes interaction with CCDC91.
Q9UJY5	572	L->E	12808037	Abolishes interaction with CCDC91.
Q61644	434	P->L	11082044	Abolishes interaction with DNM1, MAPT, SYNJ1 and WASL.
P84080	71	Q->L	11703931	Mainly GTP-bound form; abolishes interaction with TMED10.
P0AAW9	30	G->R	23010927	Loss of chloramphenicol resistance, does not bind AcrB (dominant-negative to wild-type). Partially suppressed by AcrB H526Y.
Q9ET38	35	Y->S	25678664	Abolishes interaction with Clostridium perfringens CPE.
Q9ET38	39	A->R	25678664	Abolishes interaction with Clostridium perfringens CPE.
Q9ET38	40	I->A,S,L	25678664	Abolishes interaction with Clostridium perfringens CPE.
Q9ET38	40	I->V	25678664	Strongly reduces interaction with Clostridium perfringens CPE.
Q9ET38	41	I->A,S,V	25678664	Abolishes interaction with Clostridium perfringens CPE.
Q9ET38	150	N->A,D,Q,K	25678664	Abolishes interaction with Clostridium perfringens CPE.
Q9ET38	151	P->A,G	25678664	Abolishes interaction with Clostridium perfringens CPE.
Q9ET38	152	S->D	25678664	Abolishes interaction with Clostridium perfringens CPE.
Q9ET38	153	T->Y	25678664	Abolishes interaction with Clostridium perfringens CPE.
Q9ET38	154	P->D	25678664	Abolishes interaction with Clostridium perfringens CPE.
P27782	19	D->A	10966653	Strongly diminishes CTNNB1 binding and transactivation. Prevents nuclear translocation of CTNNB1.
P27782	24	F->A	10966653	Strongly diminishes CTNNB1 binding and transactivation. Prevents nuclear translocation of CTNNB1.
P55771	189	P->A	12657635	Abolishes interaction with KDM5B.
P17181	535	S->A	14532120	Abolishes interaction with FBXW11 and decreases ubiquitination.
P17181	539	S->A	15337770	Abolishes interaction with FBXW11 and decreases ubiquitination.
P08575	853	C->S	11909961	Loss of activity. Abolishes interaction with SKAP1.
P0DMV8	77	K->R	27708256	Significant loss of acetylation and ATPase activity. Decreased binding to HOPX and HSP90 and increased binding to STUB1 and NAA10. Impaired capacity for protein refolding during the early phase after stress but shows normal protein degradation activity in the late phase.
Q9NYJ8	675	F->A	19935683	Abolishes ubiquitin binding.
Q9NYJ8	678	H->A	19935683	Abolishes ubiquitin binding.
Q9NYJ8	681	L->A	19935683	Abolishes ubiquitin binding.
Q9NYJ8	685	E->A	19935683	Abolishes ubiquitin binding.
P43355	163	D->A	8113684	Abolishes HLA-A1 binding.
P43355	169	Y->A	8113684	Abolishes HLA-A1 binding.
O60331	650	S->D	15738269	Abolishes binding to TLN2. Affects localization to focal adhesions.
Q8W4D8	223	R->A	23313986	Loss of interaction with DCL1.
Q8W4D8	238	S->A	23313986	Loss of interaction with DCL1.
Q8CGC7	999	S->A	23071094	Loss of function in translation inhibition. Loss of interaction with SLC27A1. Mutant mice have no apparent developmental defect but display reduced adiposity associated with decreased insulin levels and adipocytes size. They also display increased lipolysis and fatty acid beta-oxidation and an extended lifespan. Adipocytes display decreased insulin-stimulated long-chain fatty acid uptake.
P17081	23	T->N	11162552	Loss of interaction with GOPC.
P17081	44	D->A	11162552	Loss of interaction with GOPC.
Q9Y239	53	E->K	17054981	No effect on activation of NF-kappa-B. Abolishes interaction with RIPK2.
Q9Y239	54	D->K	17054981	Abolishes activation of NF-kappa-B. Abolishes interaction with RIPK2.
Q9Y239	56	E->K	17054981	Abolishes activation of NF-kappa-B. Abolishes interaction with RIPK2.
Q9Y239	69	R->E	17054981	Abolishes activation of NF-kappa-B. Abolishes interaction with RIPK2.
Q9SN68	19	V->T	20833725	Loss of interaction with VPS9A. Loss of interaction with MON1. Loss of interaction with EREX.
Q9SN68	46	A->D	20833725	Loss of interaction with VPS9A.
Q9SN68	47	F->A	20833725	Loss of interaction with VPS9A.
Q9SN68	64	W->A	20833725	Loss of interaction with VPS9A.
Q9SN68	67	A->G	20833725	Loss of interaction with VPS9A.
Q9SN68	69	Q->E	11532937	Loss of interaction with VPS9A.
Q9SN68	69	Q->L	11532937	Constitutively active (GTP-bound form); loss of targeting to plasma membrane and interaction with VPS9A.
Q9SN68	74	S->A	20833725	Loss of interaction with VPS9A.
Q9SN68	75	L->A	20833725	Loss of interaction with VPS9A.
Q9SN68	78	M->A	20833725	Loss of interaction with VPS9A.
Q9SN68	79	Y->A	20833725	Loss of interaction with VPS9A.
P0A0L2	251	D->A	12467569	Loss of interaction with the beta chain of HLA-DR1 through the zinc-dependent site.
Q9C0D3	18	L->S	17304241	Abolishes interaction with ELOC.
Q9ULZ3	13	E->W	15456791	Abolishes interaction with NLRP2.
Q9ULZ3	36	Y->A	18362139	Abolishes interaction with PYDC1.
Q08214	24	S->A	12042306	Abolishes interaction with MLH1.
Q08214	26	Y->A	12042306	Abolishes interaction with MLH1.
Q08214	27	F->A	12042306	Abolishes interaction with MLH1.
P35228	27	N->A	21199876	Loss of interaction with SPSB1 and SPSB4.
Q3MII6	136	W->A	21383079	Abolishes interaction with GABARAP. Does not localize at autophagosomes.
P78543	65	Y->A	18974182	Abolishes interaction with CNOT7 and CNOT8.
P78543	75	D->A	23236473	Abolishes interaction with CNOT7 and CNOT8.
P78543	103	W->A	18974182	Abolishes interaction with CNOT7 and CNOT8; impairs anti-proliferative activity.
P0AFB1	103	G->D	15047720	Loss of interaction with Prc and IbpB leading to thermosensitivity.
P39081	66	A->D	12727883	Loss of interaction with RBP1 CTD.
O04197	85	R->A	20927106	Loss of interaction with TIFY10A.
O04197	88	M->A	20927106	Loss of interaction with TIFY10A.
O04197	89	F->A	20927106	Loss of interaction with TIFY10A.
O04197	121	R->A	20927106	Loss of interaction with TIFY10A.
O04197	301	L->A	20927106	Loss of interaction with TIFY10A.
O04197	302	Y->A	20927106	Loss of interaction with TIFY10A.
O04197	326	R->A	20927106	Loss of interaction with TIFY10A.
O04197	348	R->A	20927106	Loss of interaction with TIFY10A.
O04197	351	R->A	20927106	Loss of interaction with TIFY10A.
O04197	386	Y->A	20927106	Loss of interaction with TIFY10A.
O04197	409	R->A	20927106	Loss of interaction with TIFY10A.
O04197	444	Y->A	20927106	Loss of interaction with TIFY10A.
O04197	469	L->A	20927106	Loss of interaction with TIFY10A.
O04197	496	R->A	20927106	Loss of interaction with TIFY10A.
Q9H3P7	284	H->A	27009356	Almost complete loss of PI4KB- and TBC1D22B- binding.
Q9H3P7	285	Y->A	27009356	Differential loss of PI4KB- and TBC1D22B- binding, with PI4KB-binding being much more affected than TBC1D22B-binding.
Q9H3P7	288	Y->A	27009356	Almost complete loss of PI4KB- and TBC1D22B- binding.
Q9H3P7	525	Y->A	27989622	No effect on interaction with PI4KB but loss of interaction with Kobuviral (Aichi) 3A protein. Loss of ability to sensitize PI4KB activation by Kobuviral (Aichi) 3A protein.
O00257	434	S->A	21282530	Abolishes interaction with YWHAZ and YWHAE; impairs interaction with PCGF6 and BMI1; no effect on interaction with RNF2.
Q7YWN4	140	H->Q	27780040	In cas452; suppresses the anterior migration of mutant mig-13 expressing PQR cells, which are descendents of Q neuroblasts. Abolishes interaction with abl-1 in yeast two-hybrid assay.
H2KYQ5	400	R->A	24982189	Loss of interaction with gsy-1. Partial loss of gsy-1 function.
H2KYQ5	403	W->A	24982189	Loss of interaction with gsy-1. Partial loss of gsy-1 function.
H2KYQ5	410	Y->A	24982189	Loss of interaction with gsy-1. Partial loss of gsy-1 function.
H2KYQ5	416	F->A	24982189	Loss of interaction with gsy-1. Complete loss of gsy-1 function.
H2KYQ5	419	I->A	24982189	Loss of interaction with gsy-1. Complete loss of gsy-1 function.
H2KYQ5	423	L->A	24982189	Loss of interaction with gsy-1. Complete loss of gsy-1 function.
H2KYQ5	427	L->A	24982189	Loss of interaction with gsy-1. Partial loss of gsy-1 function.
P36130	88	L->A	17998537	Abolishes interaction with FIS1.
P36130	110	L->A	17998537	Abolishes interaction with FIS1.
P36130	111	F->A	17998537	Abolishes interaction with FIS1.
P36130	114	F->A	17998537	Abolishes interaction with FIS1.
O75943	143	K->E	10884395	Impairs phosphorylation on S-656. Abolishes interaction with the RAD1-RAD9-HUS1 complex; does not affect interaction with RFC3.
P11274	177	Y->F	15302586	Abolishes interaction with FES and GRB2.
P11274	1271	V->A	15494376	Reduces interaction with PDZK1. Abolishes interaction with DLG4. No effect on synaptic localization.
P02829	97	A->I	9632755	Abolishes interaction with SBA1.
P02829	170	G->D	7791797	Induces a total loss of function at 34 degrees Celsius. Abolishes interaction with SBA1.
P02829	485	S->Y	9632755	Abolishes interaction with SBA1.
P02829	525	T->I	8248264	Abolishes interaction with SBA1. Reduces client protein activation activity, leading to growth defect at high temperatures.
Q5VV43	995	Y->A	19419997	Loss of interaction with AP2M1 and impaired endocytosis.
P60761	38	R->A	23462742	Abolishes calmodulin binding, unable to potentiate synaptic transmission.
Q99IB8	2043	V->A	29352312	Complete loss of virus production. Disrupts the dimerization and localization of NS5A to lipid droplets. NS5A binding to HCV 3'UTR RNA.
Q99IB8	2121	P->A	29352312	Complete loss of virus production. Disrupts the dimerization and localization of NS5A to lipid droplets. Increased affinity of NS5A binding to HCV 3'UTR RNA.
Q96LC7	667	Y->F	12163025	Abolishes binding to PTPN6.
Q9QUN3	373	R->L	18369315	Abolishes binding to CD79A and SYK.
Q9H9V9	235	H->A	24486019	Loss of interaction with ETF1 and its ability to hydroxylate ETF1.
Q6VV64	264	S->A	18397886	Loss of interaction with YWHAH.
P42410	59	S->D	8682789	Loss of interaction with RsbT.
Q13363	52	A->E	23707407	Loss of interaction with SIMC1. No effect on its proteolytic processing mediated by CAPN3.
Q13363	66	V->R	23707407	Loss of interaction with SIMC1. Reduced proteolytic processing mediated by CAPN3.
Q9FL28	294	R->A	24114786	Abolishes flagellin-binding.
Q9FL28	316	H->A	24114786	Abolishes flagellin-binding.
Q9FL28	318	G->R	11340188	In fls2-24; abolishes flagellin-binding.
Q9FL28	342	T->Y	24114786	Abolishes flagellin-binding.
Q9FL28	1064	G->R	11340188	In fls2-17; abolishes kinase activity and strongly reduces flagellin-binding.
P03709	92	H->A	22801427	Complete loss of capsid protein binding.
Q9Z200	437	R->A	14690593	Abolishes interaction with phosphorylated INSR.
Q9Z200	457	K->N	14690593	Abolishes interaction with phosphorylated INSR.
P03372	539	L->A	12554772	Abolishes interaction with NCOA1, NCOA2 and NCOA3.
P15879	109	E->A	16177825	Loss of interaction with human RALA.
P70670	1952	L->A	12011100	Loss of interaction with SMYD1.
P08588	474	E->A,D	15358775	Loss of interaction with GOPC.
P08588	475	S->A	12391161	Loss of interaction with GOPC. Loss of interaction with RAPGEF2. Abolishes agonist-induced Ras activation.
P08588	475	S->D	12391161	Loss of interaction with RAPGEF2.
P08588	477	V->A,F,L,I,M	12391161	Loss of interaction with GOPC.
P08588	477	V->A	12391161	Loss of interaction with RAPGEF2. Abolishes agonist-induced Ras activation.
P51149	8	L->A	15933719	Abolishes interaction with RILP and reduces its localization to late endosomal/lysosomal compartments.
P51149	10	K->A	15933719	Abolishes interaction with RILP and localization to late endosomal/lysosomal compartments.
P51149	22	T->N	12944476	Abolishes localization on late endosomes, lysosomes and phagosomes and reduces phagosomal fusions. Abolishes association of RILP with the phagosomes. No loss of interaction with CLN5. No loss of interaction with PRPH. Reduced interaction with VPS13A.
P51149	180	V->A	15933719	Abolishes interaction with RILP and localization to late endosomal/lysosomal compartments.
Q96CA5	120	D->A	11084335	Abolishes inhibition of caspases, SMAC binding and anti-apoptotic activity.
Q96CA5	138	D->A	11084335	Abolishes inhibition of caspases, SMAC binding and anti-apoptotic activity.
Q9Y4K3	57	D->K	19465916	Loss of interaction with UBE2N.
Q9Y4K3	72	I->D	19465916	Loss of interaction with UBE2N. Has no effect on TRAF3IP2-mediated 'Lys-63'-linked polyubiquitination.
Q9Y4K3	74	L->E,K	19465916	Loss of interaction with UBE2N.
O88667	105	S->A	17525370	Loss of interaction with CACNB2. QT prolongation and ventricular arrhythmias, caused by the augmentation of L-type Ca(2+) channels in the heart.
Q9ULV8	244	Y->A	22888118	Abolishes interaction with EGFR. Decreases interaction with SRC and abolishes SRC ubiquitination.
Q9ULV8	264	R->A	22888118	Abolishes interaction with EGFR. Decreases interaction with SRC and abolishes SRC ubiquitination.
Q9ULV8	268	T->A	22888118	Abolishes interaction with EGFR. Decreases interaction with and ubiquitination of SRC.
Q9ULV8	276	G->E	14661060	No effect on interaction with RET. Binds slightly to SRC, this interaction is independent of SRC phosphorylation. Strongly decreases SRC ubiquitination. Abolishes interaction with EGFR.
P61964	47	A->E	16600877	Strongly reduced affinity for histone H3.
P61964	91	S->F	16600877	Strongly reduced affinity for histone H3.
P61964	107	D->A	16600877	Strongly reduced affinity for histone H3. Significant decrease in interaction with KMT2A.
P61964	107	D->N	16829960	Strongly reduced affinity for histone H3.
P61964	133	F->A	16829960	Strongly reduced affinity for histone H3. Significant decrease in interaction with KMT2A.
P61964	133	F->D	16600877	Strongly reduced affinity for histone H3.
P61964	133	F->L	16829960	Strongly reduced affinity for histone H3.
P61964	225	N->A	21220120	Loss of interaction with RBBP5 and reduced ability to stimulate KMT2A methyltransferase activity in association with RBBP5 and ASH2L.
P61964	240	L->K	21220120	Loss of interaction with RBBP5 and reduced ability to stimulate KMT2A methyltransferase activity in association with RBBP5 and ASH2L.
P61964	263	F->A	16829960	Strongly reduced affinity for histone H3. Significant decrease in interaction with KMT2A.
P61964	263	F->W	16829960	Strongly reduced affinity for histone H3.
P61964	321	L->A	16829960	Abolishes histone H3 binding.
P61964	322	E->A	16600877	Strongly reduced affinity for histone H3. No effect on interaction with KMT2A.
Q9NS37	306	Y->A	10871379	Does not interact with HCFC1 and is inefficient at inhibiting CREB3 transcriptional activity. Does not colocalize with CREB3 in promyelocytic leukemia protein nuclear bodies (PML-NB).
P24643	348	D->K	20801878	Abolishes interaction with PPIB.
Q9NXW2	138	H->Q	21148293	Abolishes interaction with HSPA8/Hsc70.
Q15750	213	D->A	17560374	Loss of interaction with XIAP.
Q15750	216	F->A	17560374	Loss of interaction with XIAP.
Q15750	484	F->A	11323434	Abolishes interaction with MAP3K7.
P39769	1513	W->A	9343432	Significant loss of Scm-binding activity.
P39769	1562	G->A	9343432	Significant loss of Scm-binding activity.
Q9ZNZ7	1270	L->F	19223513	In glu1-201; Abolishes interaction with SHM1. Displays photorespiratory chlorosis when grown at ambient CO2.
Q8IZQ1	3346	F->A	24668264	Abolishes interaction with GABARAP and MAP1LC3C.
Q99816	95	M->A	12006492	Reduces interaction with VPS37B and HIV-1 p6; abolishes interaction with PDCD6IP; impairs HIV-1 budding; inhibits down-regulation of EGFR. Abolishes MGRN1-binding. Loss of interaction with ARRDC1.
O14746	707	Y->F	12808100	Abolishes oxidative stress-induced phosphorylation and RAN binding. Impaired nuclear export and enhanced antiapoptotic activity against ROS-dependent apoptosis induction. Impaired interaction with PTPN11. No dephosphorylation by PTPN11.
Q9LIQ6	191	M->A	19154204	Abolishes binding to H3K4me2/3.
Q9LIQ6	195	D->A	19154204	Abolishes binding to H3K4me2/3.
Q9LIQ6	203	W->A	19154204	Abolishes binding to H3K4me2/3.
Q2Q1W2	675	H->L	23125361	Abolishes repression on mRNA. Abolishes interaction with AGO2, PABPC1 and PUM2. Increases interaction with HSP90AA1.
Q2Q1W2	702	Y->A	23125361	Decreases repression on mRNA. Decreases interaction with HSP90AA1. Abolishes interaction with PABPC1 and PUM2. Increases interaction with AGO2.
Q2Q1W2	751	R->A	23125361	Decreases repression on mRNA. Abolishes interaction with AGO2, HSP90AA1, PABPC1 and PUM2.
O95863	2	P->A	20389281	Abolishes repressor activity on E- cadherin/CDH1 promoter and binding to KDM1A.
O95863	3	R->A	20389281	Loss of interaction with KDM1A.
O95863	4	S->A	20389281	Loss of interaction with KDM1A.
O95863	5	F->A	20389281	Loss of interaction with KDM1A.
O95863	8	R->A	20389281	Loss of interaction with KDM1A.
O95863	9	K->A	20389281	Loss of interaction with KDM1A.
O95863	156	C->A	19386897	Abolishes binding to KPNB1, KPNA2, IPO7 and TNPO1 and nuclear localization.
O95863	182	C->A	19386897	Impairs binding to KPNB1, IPO7 and TNPO1 and abolishes binding to KPNA2. Localizes to cytoplasm and nucleus.
O95863	210	C->A	19386897	Impairs binding to KPNB1, IPO7 and TNPO1 and abolishes binding to KPNA2. Localizes to cytoplasm and nucleus.
O95863	238	C->A	19386897	Impairs binding to KPNB1 and IPO7 and abolishes binding to KPNA2 and TNPO1 and nuclear localization.
Q05128	13	Y->A	11095724	Complete loss of interaction with WW domain containing proteins.
O35615	344	T->A	15234987	Abolishes interaction with TACC3.
O35615	347	N->A	15234987	Abolishes interaction with TACC3.
O35615	350	R->A	15234987	Abolishes interaction with TACC3.
O35615	354	V->A	15234987	Abolishes interaction with TACC3.
O35615	698	C->A	9837943	Abolishes interaction with GATA1.
O35615	719	C->A	9837943	Abolishes interaction with GATA1.
P48559	206	I->N	12391144	Abolishes interaction with MYO2.
Q96EY5	204	Y->F	16895919	Abolishes interaction with CD2AP and CIN85/SH3KBP1.
Q12802	1265	A->P	1618839	Abolishes interaction with PRKAR2A.
Q12802	1565	S->A	15229649	Abolishes interaction with YWHAB, leading to constitutive activation of RHOA and MAPK14.
Q13241	112	Q->A	18083576	Abolishes binding to HLA-E.
Q13241	114	F->A	18083576	Abolishes binding to HLA-E.
Q13241	160	N->A	18083576	Abolishes binding to HLA-E.
Q13241	162	L->A	18083576	Abolishes binding to HLA-E.
O89019	498	N->A	12471060	Abolishes interaction with APC2.
P39687	189	E->A	30666459	Loss of interaction with influenza virus A PB2.
P39687	196	E->A	30666459	Loss of interaction with influenza virus A PB2.
Q9H0M4	300	E->A	20826339	Reduced histone H3K4me3 binding but complete loss of non-methylated histone H3K4 binding.
P09217	62	D->A	12813044	Loss of interaction with SQSTM1.
P53701	154	H->A,G,Y	23150584	Loss of holocytochrome C synthase activity. Loss of heme-binding. Loss of interaction with cytochrome C.
Q64008	82	K->Q	12475955	Abolishes interaction with RILP and localization to the peri-Golgi region.
Q9SU72	262	L->P	21434927	Loss of interaction with PAD4, but no effect on dimerization or interaction with SAG101.
Q9SU72	466	E->K	11574472	In eds1-1; loss of interaction with PAD4 and SAG101, but no effect on dimerization.
Q9Y3I1	253	V->E	18495667	Abolishes interaction with PSMF1.
Q7AKE4	56	D->A	12453210	Does not restore aerial hyphae formation in ramR deletion mutants. Does not activate RamC expression, does not bind ramC promoter, does not form homodimers.
Q7AKE4	56	D->N	16051268	Does not restore aerial hyphae formation in ramR deletion mutants, does not bind ramC promoter, forms homodimers.
Q7AKE4	105	K->A	16051268	Does not restore aerial hyphae formation in ramR deletion mutants, does not activate RamC expression, does not bind ramC promoter, does not form homodimers.
P87231	275	T->A	15805465	In allele mus81.T239A; abrogates phosphorylation in response to hydroxyurea and abolishes interaction with cds1.
P63000	17	T->N	11260256	Constitutively inactivated. Abolishes interaction with PARD6 proteins. No effect on NR3C2 transcriptional activity. No interaction with PPP5C. Doesn't activate PPP5C phosphatase activity and translocate PPP5C to the plasma membrane. Doesn't interact with CYRIB.
Q9UBF8	43	I->A	27009356	Loss of interaction with ACBD3.
Q9UBF8	44	D->A	27989622	Loss of interaction with ACBD3.
Q9UBF8	55	V->A	27009356	Loss of interaction with ACBD3.
Q9UBF8	56	L->A	27009356	Loss of interaction with ACBD3.
Q9E2H5	47	Y->A	29535361	Complete loss of interaction with host ITCH.
Q9H3S7	678	F->S,D	21757351	Abolishes interaction with UBAP1.
P61088	87	C->A	17130289	Loss of polyubiquitination of PCNA. Impairs interaction with SHPRH.
Q14678	325	S->A	18458160	Abolishes phosphorylation by PKB. Abolishes interaction with YWHAB; YWHAG; YWHAE; YWHAH; YWHAQ; YWHAZ and SFN.
Q9LKZ3	849	N->F	24302889	Abolishes interaction with HAT2.
O18334	71	Q->L	10459009	Impairs maturation of ninaE and Rh3. Causes accumulation of membranes at the base of the rhabdomeres and retinal degeneration. Abolishes interaction with Rich. Alters direction of bristle growth and produces aberrations in the circumferential ridges.
Q9SII8	87	V->A	21764993	Abolishes interaction with RPN10.
P12830	754	Y->F	22252131	Abolishes binding to CBLL1.
P18627	99	Y->F	30580966	Abolishes binding to MHC class II (MHC-II) without affecting interaction with FGL1.
P18479	618	P->A	9568986	Complete loss of aphid transmission and binding to virions.
P18479	619	T->A	9568986	Complete loss of aphid transmission and binding to virions.
P47873	168	W->A	10026196	Slightly increases IL11RA binding. Abolishes interaction with IL6ST. Abolishes stimulation of cell proliferation.
O43719	136	Y->D	11780068	Loss of interaction with U snRNPs.
Q86UR1	68	D->A	16636067	Loss of function and loss of interaction with RAC1.
Q86UR1	103	R->E	12716910	Loss of function and loss of interaction with RAC1. Loss of localization to membranes.
Q86UR1	436	W->R	12716910	Loss of interaction with NOXO1 and NCF1. Loss of localization to membranes. Partial loss of function.
B3EWH2	8	P->A	22613724	Complete loss of binding to nAChR from T.californica.
B3EWH2	9	H->A	22613724	Complete loss of binding to nAChR from T.californica.
P51142	317	N->T	11970895	Abolishes interaction with dact1-B/dpr.
P54762	594	Y->F	9430661	Loss of interaction with NCK1.
P54762	600	Y->F	12925710	Loss of interaction with SHC1 and SRC.
P54762	778	Y->F	12925710	Loss of interaction with SHC1.
Q7Z434	54	T->A	16125763	Impairs ability to induce IFN-beta. Loss of interaction with the ATG5-ATG12 conjugate.
P11279	76	N->S	24970085	Complete loss of interaction with Lassa virus protein GPC.
Q99PF4	27	R->I	20498078	Strongly reduced affinity for PCDH15.
P18654	386	S->E	10480933	Loss of interaction with PDPK1 and phosphorylation at S-227.
Q9GZU1	44	R->A	19864416	Abolishes interaction with PDCD6.
Q9GZU1	45	L->A	19864416	Abolishes interaction with PDCD6.
P08753	211	W->A	19211784	Abolishes binding to NUCB1. Dramatically decreases binding to CCDC88A. Does not affect GTP-binding activity but increases the basal exchange rate.
P08753	215	F->A	19211784	Abolishes binding to NUCB1. Dramatically decreases binding to CCDC88A. Does not affect GTP-binding activity but increases the basal exchange rate.
P08753	248	K->E	21653697	Abolishes binding to NUCB1.
O05877	74	G->R	19843229	Loss of GTP-synthesizing activity and lack of autophosphorylation. Does not interact with Ndk.
Q15811	1078	I->K,S	29887380	Abolishes interaction with FCHSD2.
Q15811	1119	R->A,E	29887380	Abolishes interaction with FCHSD2.
Q06455	125	K->A,D	16803958	Loss of interaction with TCF12.
Q06455	126	L->A	16803958	Loss of interaction with TCF12.
Q06455	128	R->D	16803958	Loss of interaction with TCF12.
Q06455	129	F->A	16803958	Loss of interaction with TCF12.
Q06455	178	R->A,D	16803958	Loss of interaction with TCF12.
Q06455	184	F->A	16803958	Loss of interaction with TCF12.
Q96ES7	194	D->A,R	21685874	Abolishes H3K4me3 binding.
Q96ES7	196	D->R	21685874	Abolishes H3K4me3 binding.
Q96ES7	242	T->A	21685874	Almost abolished H3K4me3 binding.
Q96ES7	245	Y->A	20850016	Abolishes H3K4me3 binding.
Q96ES7	264	F->A	20850016	Strongly reduced binding to H3K4me3.
Q96ES7	266	D->A,F,Y,W	21685874	Strongly reduced binding to H3K4me3.
Q03164	9	F->A	22327296	Loss of interaction with MEN1.
Q03164	1594	W->A	20677832	Abolishes interaction with histone H3K4me3.
Q03164	3765	R->A	18840606	Loss of interaction with the WRAD complex and WDR5.
P96621	61	Y->A	24120662	No longer prevents EndoA toxicity upon coexpression in E.coli, due to loss of EndoA-EndoAI interaction.
P16086	985	E->A	11971983	Abolishes interaction with ACP1.
P16086	1017	P->L	11971983	Abolishes interaction with ACP1.
P40482	230	R->A	12941277	Abolishes binding to and packaging of cargo protein BET1.
P40482	235	R->A	12941277	Abolishes binding to and packaging of cargo protein BET1.
P40482	559	R->M	12941277	Abolishes binding to and packaging of cargo protein BET1.
P40482	561	R->M	12941277	Abolishes binding to and packaging of cargo protein BET1.
P40482	616	L->W	12941277	Abolishes binding to and packaging of cargo protein BET1.
F4IVV0	37	H->D	11752391	Loss of interaction with ARAC11/ROP1.
O60566	159	A->W	17981135	Loss of interaction with KNL1.
O60566	175	F->A	17981135	Loss of interaction with KNL1.
P62827	24	T->N	18347012	No effect on RANBP10-binding. Loss of interaction with NEMP1.
P62827	42	T->A	25946333	Loss of interaction with NEMP1.
Q9UBU8	208	V->E	16407074	Abolishes binding to MRFAP1.
Q9XF57	124	T->I	20130089	In pex7-2; reduced sensitivity to indole-3- butyric acid and loss of interaction with PEX5 and PST2- cargo.
Q9NQG5	114	R->A	24997600	Complete loss of binding to POLR2A CTD in vivo.
P08238	88	D->A	26517842	Impaired ATP-binding. Strong interaction with HIF1A, MET, KEAP1 and RHOBTB2. Loss of interaction with HSF1 and ERBB2.
Q99497	51	V->A	14749723	Disrupts dimer formation and strongly reduces ability to eliminate hydrogen peroxide.
P0DTC1	164	K->A	32680882	Complete loss of ribosome binding and cellular translation inhibition.
P0DTC1	165	H->A	32680882	Complete loss of ribosome binding and cellular translation inhibition.
Q96AK3	268	L->D	23001005	Resistant to HIV-1 Vif and abolishes Vif binding.
Q96AK3	271	F->A	23001005	Resistant to HIV-1 Vif and abolishes Vif binding.
Q96AK3	282	Y->A	23001005	Resistant to HIV-1 Vif and abolishes Vif binding.
Q96AK3	302	E->K	23001005	Resistant to HIV-1 Vif and abolishes Vif binding.
Q96AK3	303	F->K	23001005	Resistant to HIV-1 Vif and abolishes Vif binding.
Q96AK3	307	H->D	23001005	Resistant to HIV-1 Vif and abolishes Vif binding.
Q96AK3	337	E->K	23001005	Resistant to HIV-1 Vif and abolishes Vif binding.
P49792	2632	V->K	15388847	Abolishes interaction with sumoylated RANGAP1.
P49792	2634	I->K	15388847	Abolishes interaction with sumoylated RANGAP1.
P49792	2635	V->K	15388847	Abolishes interaction with sumoylated RANGAP1.
P49792	2651	L->A	15378033	Abolishes binding to UBE2I and SUMO E3 ligase activity.
P49792	2653	L->A	15378033	Abolishes binding to UBE2I and SUMO E3 ligase activity.
P49792	2657	F->A	15378033	Abolishes binding to UBE2I and SUMO E3 ligase activity.
P49792	2658	F->A	15378033	Abolishes binding to UBE2I and SUMO E3 ligase activity.
P02545	358	E->K	31548606	Loss of interaction with IFFO1.
P02545	386	R->M	31548606	Loss of interaction with IFFO1.
P02545	661	C->S	10514485	Loss of interaction with NARF. Abolishes farnesylation.
P28223	463	G->V	14988405	Loss of interaction with PATJ.
P28223	471	V->A	14988405	Loss of interaction with PATJ, CASK, APBA1, DLG1 and DLG4.
P49682	112	D->A	16847335	Abolishes binding to CXCL10 and CXCL11. Reduces CXCL9-, CXCL10- and CXCL11-induced chemotaxis.
P49682	112	D->K	16847335	Abolishes binding to CXCL10 and CXCL11 and CXCL10- and CXCL11-induced chemotaxis. Reduces CXCL9- induced chemotaxis.
P49682	197	R->A	16847335	Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Reduces ligand-induced receptor internalization.
P49682	278	D->A	16847335	Abolishes binding to CXCL10 and CXCL11 and CXCL11-induced chemotaxis. Reduces CXCL9 and CXCL10-induced chemotaxis.
P49682	278	D->K	16847335	Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis.
P49682	282	D->A	16847335	Reduces binding to CXCL10 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis. Abolishes binding to CXCL11.
P49682	293	E->A	16847335	Reduces binding to CXCL10 and CXCL9- and CXCL11-induced chemotaxis. Abolishes binding to CXCL11 and CXCL10-induced chemotaxis.
P49682	293	E->K	16847335	Abolishes binding to CXCL10 and CXCL11 and CXCL9-, CXCL10- and CXCL11-induced chemotaxis.
Q08881	288	P->G	15308100	Complete loss of interaction with PPIA/CYPA.
Q9Y371	8	V->M	11161816	Abolishes interaction with BAX.
Q08ET2	362	R->A	17012248	Loss of interaction with TYROBP.
Q03431	135	I->K	20172855	Abolishes hormone binding and homodimerization.
P04512	120	E->A	18587047	Complete loss of interaction with integrin ITGA2.
P54843	334	L->P	9070273	Abolishes interaction with USF2.
Q95ZK7	327	G->R	19461891	Abolishes binding to gls-1.
Q62233	88	F->E	12050133	Loss of interaction with TLE5 and TLE4.
Q8H1F2	320	E->K	17951432	Loss of GTPase-accelerating activity, loss of interaction with GPA1 and loss of endocytosis.
Q5S007	1347	K->A	25201882	GTPase-dead mutant. Loss of interaction with SEC16A and impaired ability to recruit SEC16A to endoplasmic reticulum exit sites.
P0DSE2	49	D->A,S	18275829	Abolishes binding to M/matrix protein 1 peptide antigen.
P0DSE2	69	Q->A,E	18275829	Abolishes binding to M/matrix protein 1 peptide antigen.
P0DSE2	70	I->A,G,N	18275829	Abolishes binding to M/matrix protein 1 peptide antigen.
P0DSE2	115	R->A,H	18275829	Abolishes binding to M/matrix protein 1 peptide antigen.
O35718	22	L->D	10882725	Abolishes binding to JAK2. No effect on binding to EPOR.
O35718	25	F->A	10882725	Loss of LIF/EPO-induced signal transduction suppression. Abolishes binding to JAK2 and to EPOR.
O35718	45	G->A	10882725	Abolishes binding to EPOR. No effect on binding to JAK2.
O35718	71	R->K	10882725	Little effect on LIF-induced signal transduction suppression. Loss of EPO-induced signal transduction suppression. Abolishes binding to JAK2 and EPOR.
Q63HQ0	210	W->A	19706427	Loss of association with the Arp2/3 complex and endosomal colocalization. Abolishes interaction with KLC2, no effect on interaction with AP1G1.
Q13155	215	R->A	26472928	Nearly abolishes interaction with EPRS1.
Q13155	238	D->R	26472928	Nearly abolishes interaction with EPRS1.
Q08AE8	134	Y->K	21705804	Abolishes interaction with FMN2.
Q08AE8	138	D->N	21705804	Abolishes interaction with FMN2.
Q08AE8	146	E->A,K	21730168	Abolishes interaction with FMN2.
O60880	32	R->Q	11823424	Strongly reduced affinity for SLAMF1.
O15118	503	F->A,G	26771495	Loss of interaction with ebolavirus glycoprotein.
O15118	504	F->A,G	26771495	Loss of interaction with ebolavirus glycoprotein.
O15118	506	Y->A	26771495	Loss of interaction with ebolavirus glycoprotein.
P22681	80	S->D	10078535	Abolishes interaction with ZAP70.
P22681	82	P->A	10078535	Abolishes interaction with ZAP70.
P22681	229	D->Q	10078535	Abolishes interaction with ZAP70.
P22681	240	E->S	10078535	Abolishes interaction with ZAP70.
P22681	294	R->K	10078535	Abolishes interaction with ZAP70.
P22681	306	G->E	10078535	Abolishes interaction with ZAP70 and EPHB1, but does not affect interaction with SLA. Reduces ubiquitination and therefore proteasomal degradation of SPRED2.
P22681	731	Y->F	11997497	No effect on tyrosine phosphorylation by INSR. Loss of phosphorylation by SRC. Inhibition of bone resorption. Abolishes interaction with PIK3R1.
Q7KQM6	349	W->A	31439631	Abolishes interaction with me31B.
Q8BPQ7	256	L->A	25220469	Abolishes interaction with RAB9A.
Q8BPQ7	260	K->A	25220469	Abolishes interaction with RAB9A.
Q8BPQ7	261	N->A	25220469	Abolishes interaction with RAB9A.
Q8BPQ7	277	Y->A	25220469	Abolishes interaction with RAB9A.
Q8BPQ7	294	N->A	25220469	Abolishes interaction with RAB9A.
Q8BPQ7	297	M->A	25220469	Abolishes interaction with RAB9A.
O14713	135	L->A	11741908	Abolishes ITGB1 binding.
O14713	138	I->A	11741908	Abolishes ITGB1 binding.
O14713	139	I->A	11741908	Abolishes ITGB1 binding.
O14713	144	Y->T	11741908	Abolishes ITGB1 binding.
Q14019	75	K->A	11583571	Abolishes actin-binding activity.
Q14019	131	K->A	11297527	Abolishes 5LO-binding activity.
Q14019	131	K->E	11297527	Abolishes 5LO-binding activity.
Q80UL9	59	D->A,K,N	20813955	Loss of interaction with CXADR.
Q80UL9	72	Y->A	20813955	Loss of interaction with CXADR.
Q80UL9	75	F->A,W	20813955	Loss of interaction with CXADR.
Q80UL9	77	Y->A,F	20813955	Loss of interaction with CXADR.
Q80UL9	122	R->A	20813955	Loss of interaction with CXADR.
Q80UL9	355	Y->F	20813955	Loss of interaction with PI3 kinase.
Q63572	439	S->A	11555644	Abolishes interaction with YWHAB.
Q8R4L0	120	R->E	11891219	Abolishes interaction with ZAP70, and its inhibitory function.
O75554	150	W->A	19592703	Nearly abolishes activation of pre-mRNA splicing. Abolishes interaction with WBP11.
O75554	191	W->A	19592703	Nearly abolishes activation of pre-mRNA splicing. Abolishes interaction with WBP11.
O00512	358	H->A	17052462	Abolishes interaction with CTNNB1.
O00512	359	R->A	17052462	Abolishes interaction with CTNNB1.
P17693	66	C->S	12454284	Abolishes homodimerization and homotrimerization. Decreases functional interaction with LILRB1. Does not affect homodimerization of isoform 2 and its binding to LILRB2.
P08909	458	S->A,D	12682077	Loss of interaction with MPDZ.
Q9GZL7	78	E->A	26601951	Abolishes interaction with MDN1.
O08722	403	C->V	18582460	Abolishes palmitoylation. Impairs interaction with DAPK1. No effect on location on lipid rafts.
P63096	42	G->R	22383884	Abolishes switch to an activated conformation and dissociation from beta and gamma subunits upon GTP binding. Abolishes interaction with RGS family members.
P35570	106	W->A	11018022	Loss of interaction with PHIP.
Q13085	1263	S->A	16698035	Abolishes interaction with BRCA1.
P61020	34	S->N	11733506	Constitutively inactivated. Strongly reduces interaction with RIN2.
Q8NI17	708	Y->F	15194700	Abrogates STAT3 activation. Loss of interaction with STAT3. Mild effect on STAT1 activation. No effect on STAT5 activation.
O95835	559	Y->F	18158288	Loss of interaction with YAP1.
Q96RU8	358	V->I,A	27041596	Loss of interaction with COP1.
Q96RU8	359	P->A	27041596	Strongly decreased interaction with COP1.
P51159	23	T->N	15548590	GDP-locked. Abolishes interaction with UNC13D and localization to lysosomes. Increases interaction with DENND10. Disrupts late endocytic pathway homeostasis.
P51159	70	L->P	18812475	Abolishes interaction with SYTL2.
P51159	76	A->V	18812475	Abolishes interaction with SYTL2.
Q01484	1000	A->P	15262991	Prevents binding to SPTBN1.
Q00944	395	D->A	10212207	Abolishes interaction with PIK3R1.
Q8IUH5	100	N->A	28757145	Abolishes SNAP25 binding.
Q8IUH5	130	W->A	28757145	Abolishes SNAP25 and HTT binding.
P03406	147	P->A	7859737	Complete loss of binding to HCK SH3 domain and altered viral growth. No effect on Nef-induced CD4 down- modulation.
A0AAR7	30	G->E	16810257	In ccamk-3; Loss of autophosphorylation and loss of function; no nodulation. Abolishes binding to IPD3.
A0AAR7	44	K->A	19074278	Loss of catalytic activity. Abolishes binding to IPD3.
P42575	57	L->F	8985253	Loss of interaction with CRADD.
P42575	95	G->R	8985253	Loss of interaction with CRADD.
P42575	99	F->A	8985253	Loss of interaction with CRADD.
P42575	102	F->A	8985253	Loss of interaction with CRADD.
P42575	106	L->A	8985253	Loss of interaction with CRADD.
Q61539	259	K->A	23019124	Loss of self-renewal in embryonic stem cells in absence of LIF. Does not interact with NCOA3.
P36888	599	Y->F	16684964	Abolishes interaction with PTPN11/SHP2 and phosphorylation of PTPN11/SHP2.
Q6JAM9	46	S->A	20685870	Abolishes interaction with NGFR.
O54901	60	L->K	23602662	Abolishes binding to CD200R.
O54901	61	I->E	23602662	Abolishes binding to CD200R.
O54901	74	N->A	23602662	Abolishes binding to CD200R.
O54901	122	L->A	23602662	Abolishes binding to CD200R.
O54901	124	N->K	23602662	Abolishes binding to CD200R.
O54901	126	F->D	23602662	Abolishes binding to CD200R.
P11362	766	Y->F	12181353	Abolishes interaction with PLCG1 and SHB. Decreases phosphorylation of FRS2, activation of RAS and MAP kinase signaling and stimulation of cell proliferation.
P16220	119	S->A	15964553	Does not interact with TOX3 and inhibits induction of transcription by TOX3. Loss of phosphorylation by CaMK4. Loss of phosphorylation by TSSK4.
P09036	42	R->L	14645103	Abolishes trypsin inhibitor activity. No effect on sperm binding.
O00264	113	Y->F	26988023	Abolishes interaction with CYP1A1 and CYP3A4.
Q9Y6M7	1214	L->G	12444018	Loss of interaction with ATP6V1B1.
Q9WUL5	105	I->A	12719480	Abolishes the binding to PDCD1.
Q9WUL5	111	D->S	12719480	Abolishes the binding to PDCD1. Costimulates proliferation and IFNG production of T-cells.
Q9WUL5	113	K->S	12719480	Abolishes the binding to PDCD1. Costimulates proliferation and IFNG production of T-cells.
Q9NQC7	457	S->A	12917691	Abolishes binding to TRAF2.
B2RU80	1982	Y->F	20398064	Loss of tyrosine phosphorylation. Abolishes interaction with FYN and GRB2.
Q9V6L9	239	Y->A	20123973	Abolishes interaction with vas.
Q9UNS1	1081	R->G	26344098	Abolishes interaction with PARP1.
Q05397	397	Y->F	11331870	Abolishes autophosphorylation. Abolishes interaction with SRC and activation of BMX.
Q05397	928	V->G	9756887	Loss of interaction with TGFB1I1.
Q05397	1034	L->S	9756887	Loss of interaction with TGFB1I1.
O75531	6	K->A	11005805	Complete loss of LEMD3/MAN1 and histone H1/H3 binding.
O75531	6	K->E	11005805	Complete loss of dsDNA and LEMD3/MAN1 binding.
O75531	8	R->E	15681850	Complete loss of LEMD3/MAN1 binding.
O75531	25	G->E	12163470	Complete loss of dsDNA, EMD, histone H1/H3 and LEMD3/MAN1 binding.
O75531	25	G->Q	12163470	Complete loss of EMD binding and reduces dsDNA binding.
O75531	46	L->E	12163470	Complete loss of dsDNA, histone H1/H3 and LEMD3/MAN1 binding.
O75531	47	G->E	12163470	Complete loss of EMD, histone H1/h3 and LEMD3/MAN1 binding.
O75531	51	V->E	12163470	Complete loss of EMD, and histone H1/H3 binding. Reduces dsDNA and LEMD3/MAN1 binding.
O75531	53	K->E	11005805	Complete loss of EMD binding. Reduces LEMD3/MAN1 binding. Enhances histone H1/H3 binding.
O75531	62	W->A	11005805	Complete loss of LEMD3/MAN1 binding. Enhances histone H1/H3 binding.
Q14596	50	D->R	12813044	Loss of interaction with SQSTM1.
Q6WQJ1	975	P->C	17584991	Abolishes interaction with HOMER1. Does not affect enzymatic activity. Fails to associate with the plasma membrane.
Q6WQJ1	978	F->R	17584991	Abolishes interaction with HOMER1.
P03070	98	F->A	16140746	Complete loss of interaction with host CUL7.
P03070	701	T->A	15611062	Complete loss of interaction with host FBW7gamma isoform.
P26663	2322	P->A	10318918	Complete loss of binding to GRB2.
P26663	2323	P->A	10318918	Complete loss of binding to GRB2.
P26663	2326	P->A	10318918	Complete loss of binding to GRB2.
Q96FZ7	170	L->D	18606141	Abolishes interaction with VPS4A.
Q96FZ7	173	V->D	18606141	Abolishes interaction with VPS4A.
Q91ZE9	67	D->A	11546872	Loss of interaction with DLC2.
Q91ZE9	68	K->A	11546872	Loss of interaction with DLC2.
Q91ZE9	69	A->P	11546872	Loss of interaction with DLC2.
P38936	154	K->A	23213251	Loss of interaction with TRIM39.
P22455	754	Y->F	7518429	Loss of interaction with PLCG1.
P29477	23	D->A	20603330	Significant loss of interaction with SPSB2.
P29477	25	N->A,Q	20603330	Significant loss of interaction with SPSB2.
P29477	27	N->A,Q	20603330	Loss of interaction with SPSB2.
P9WI47	236	W->A	31375544	Does not interact with NCF2 and cannot inhibit ROS production.
Q92990	219	P->A	11164950	Loss of interaction with FKBP4 and FKBP1A.
Q9GYI0	209	D->A	20567261	Abolishes binding to H3K4me3.
Q9GYI0	254	W->A	20567261	Abolishes binding to H3K4me3.
Q9GYI0	258	D->A	20567261	Abolishes binding to H3K4me3.
Q9GYI0	261	Q->A	20567261	Abolishes binding to H3K4me3.
Q9GYI0	263	W->A	20567261	Abolishes binding to H3K4me3.
Q95RV2	298	P->E	12826664	Prevents binding to HP1 hinge domain but no effect on binding to HP1 chromoshadow domain.
D3RPC0	15	C->S	24648525	Loss of sulfur binding in the presence of sulfide. Loss of interaction with DsrEFH proteins.
Q6ZMT1	329	W->S	29078335	Loss of interaction with CACNA1S.
Q9UJ78	112	N->H	17126306	Abolishes interaction with ETV5. Abolished repression activity.
Q9UJ78	114	S->G	17126306	Abolishes interaction with ETV5. No effect on repression activity.
Q60838	17	I->A	21189423	Reduces oligomerization. Abolishes interaction with DIXDC1. Reduces activation of Wnt signaling.
Q60838	27	Y->D	21189423	Loss of oligomerization. Abolishes interaction with DIXDC1. Abolishes activation of Wnt signaling.
Q3UQN2	797	K->E	20448150	Loss of interaction with EPS15 and ITSN1.
O48726	47	L->A	20059542	Abolishes interaction with 'Lys-63'-linked polyubiquitin chains.
O48726	67	F->R	20059542	Abolishes interaction with 'Lys-63'-linked polyubiquitin chains and interaction with DSK2A.
O48726	70	E->Q	20059542	Abolishes interaction with 'Lys-63'-linked polyubiquitin chains and interaction with DSK2A.
O48726	88	F->R	20059542	Abolishes interaction with 'Lys-63'-linked polyubiquitin chains and interaction with DSK2A.
O15357	47	R->G	11158326	Abolishes interaction with p130Cas/BCAR1 and its ability to induce increased adhesion. Abolishes phosphorylation upon FCGR2A clustering.
Q9GZZ9	343	I->A	26929408	Abolished interaction with UFM1 and decreased interaction with GABARAPL2.
Q9GZZ9	345	L->A	26929408	Abolished interaction with UFM1 and decreased interaction with GABARAPL2.
Q9GZZ9	346	V->A	26929408	Abolished interaction with UFM1 and decreased interaction with GABARAPL2.
Q91X84	391	S->A,E	30611118	Abolishes phosphorylation. Abolishes interaction with PPP2CA and PPP2R1A. Slight increase in phosphorylation at Ser-273 and in the interaction with 14- 3-3 proteins.
Q91X84	392	P->A	30611118	Abolishes phosphorylation at Ser-391. Abolishes interaction with PPP2CA and PPP2R1A.
O22131	109	P->L	23430048	Loss of function in lateral root formation. Abolishes DNA-binding activity. Abolishes interaction with GIP1.
P26651	315	R->A	23644599	Abolishes interaction with CNOT1.
P26651	319	F->A	23644599	Abolishes interaction with CNOT1 and impairs TNF mRNA deadenylation.
P97318	114	S->T	12826668	Abolishes interaction with APLP1.
P97318	158	F->V	12826668	Abolishes interaction with APLP1.
Q05322	137	R->A	25121748	More than 90% loss of interaction with host KPNA5.
Q05322	170	V->A	28794491	Complete loss of interaction with NP.
Q05322	171	N->A	28794491	Complete loss of interaction with NP.
P03255	115	L->A	11733528	Complete loss of interaction with host ZMYND11.
P03255	122	L->I	8824223	Abolishes binding to UBE2I.
P16234	762	Y->F	10733900	Abolishes interaction with CRK.
Q9H816	14	D->N	19197158	In Apm3; abolishes exonuclease activity and function on telomere maintenance. Impairs interaction with SPAG5.
Q9H816	504	Y->A	18202258	Abolishes interaction with TERF2.
Q9H816	506	L->A	18202258	Abolishes interaction with TERF2.
Q9H816	508	P->A	18202258	Abolishes interaction with TERF2.
Q04207	38	C->S	22244329	Abolishes sulfhydration and impairs interaction with RPS3.
Q8VHY0	2325	Y->G	12458226	Loss of interaction with GRIP1 and GRIP2.
Q8VHY0	2326	W->G	12458226	Loss of interaction with GRIP1 and GRIP2.
Q8VHY0	2327	V->G	12458226	Loss of interaction with GRIP1 and GRIP2.
Q5IBH7	89	D->A	15611625	Abolishes interaction with CDK2.
Q5IBH7	102	M->A	15611625	Abolishes interaction with CDK2.
Q5IBH7	106	Y->A	15611625	Abolishes interaction with CDK2.
Q5IBH7	107	F->A	15611625	Abolishes interaction with CDK2.
Q9Y4X5	188	I->A	11278816	Loss of interaction with UBE2L3. Decreased E3 ligase activity. Strongly decreased ability to initiate ubiquitination of cullin-RING complexes.
Q9Y4X5	208	C->A,H	11278816	Loss of interaction with UBE2L3.
Q96QB1	475	F->G	19158340	Abolishes interaction with EF1A1.
Q96QB1	476	L->G	19158340	Abolishes interaction with EF1A1.
Q9QYK7	40	Y->A	11042109	Abolishes interaction with NEDD4.
O43639	148	W->K	11240126	Abolishes interaction with DOCK1.
O43639	234	W->K	11240126	Abolishes interaction with DOCK1.
Q96E14	24	K->A	18923083	Abolishes interaction with RMI1, TOP3A and BLM.
Q96E14	135	W->A	18923083	Abolishes interaction with RMI1, TOP3A and BLM.
P19490	855	R->E	18031684	Abolishes binding to PRKG2.
P19490	905	T->A	12070168	Loss of interaction with DLG1.
P19490	907	L->A	12070168	Loss of interaction with DLG1.
Q8BHJ5	313	D->N	28348241	Abolishes interaction with MECP2.
Q8BHJ5	369	D->A	28348241	Abolishes interaction with MECP2.
Q7TMI3	214	Y->A	21598301	Abolishes in vitro binding to H3K9me3. Prevents enrichment at pericentric heterochromatin.
Q7TMI3	217	Y->A	21598301	Abolishes in vitro binding to 'Lys-10' methylated H3, H3K9me3. Prevents enrichment at pericentric heterochromatin.
Q05BQ1	1177	T->A	15340156	Loss of interaction with MAGI2 and SHANK1 and loss of function.
Q9BRJ7	10	K->E	28241136	Abolishes interaction with TP53BP1.
Q9NQB0	16	D->A	10080941	Abolishes CTNNB1 binding.
Q9NQB0	48	L->A	10080941	Abolishes CTNNB1 binding.
Q14116	144	G->A	25500532	Abolishes binding of the preformed binary complex of IL18 and IL18R1 to IL18RAP.
Q14116	145	H->A	25500532	Abolishes binding of the preformed binary complex of IL18 and IL18R1 to IL18RAP.
Q14116	148	K->A	25500532	Abolishes binding of the preformed binary complex of IL18 and IL18R1 to IL18RAP.
Q9Y4G8	898	R->D	11598133	Does not inhibit interaction with NEDD4. Does not interact with HRAS. Reduces ubiquitination.
Q96706	150	E->G	15452236	Complete loss of interaction with Arabidopsis thaliana NSI protein. Reduced level of infectivity.
Q96706	164	I->T	15452236	Complete loss of interaction with Arabidopsis thaliana NSI protein. Reduced level of infectivity.
Q96706	187	D->G	15452236	Complete loss of interaction with Arabidopsis thaliana NSI protein. Reduced level of infectivity.
Q6VVB1	280	E->K	15930137	Loss of interaction with EP2MA.
Q9BY67	406	Y->A	21131357	Nearly abolishes EPB41L3 binding.
Q9D1N2	114	Q->P	19304573	Loss of interaction with LPL.
Q924V1	119	H->L	15322091	Loss of interaction with CYBA/p22phox.
Q96FW1	91	C->A	12704427	Prevents RNF128 autoubiquitination, and stabilizes RNF128 in vivo. Abolishes both ubiquitin-binding and adduct formation with ubiquitin-vinylsulfone.
O75150	109	L->S	10944455	Abolishes interaction with RB1.
O75150	111	C->M	10944455	Abolishes interaction with RB1.
O75150	113	E->Q	10944455	Abolishes interaction with RB1.
P61809	157	E->Q	11882646	Abolishes the binding to CDK5RAP1, CDK5RAP2, CDKRAP3, but not to CDK5.
P19456	931	S->D	17483306	Loss of interaction with 14-3-3 protein.
Q2HXU8	7	Y->F	17562706	Abolishes tyrosine phosphorylation. Abolishes interaction with PTPN6 and PTPN11. Abolishes protection against natural killer cell-mediated cytotoxicity.
P34756	864	G->E	19037259	Loss of interaction with VAC14. Failure to localize to the vacuole membrane.
P40078	90	Y->A	25404745	Abolishes interaction with RSA4. Blocks production of mature 60S subunits, and causes the accumulation of pre-60S particles.
Q9HAT8	106	R->A	19081057	Abolishes binding to IRAK1.
P69738	181	F->S	14599788	Complete loss of STAT1-binding.
P20340	27	T->N	23091056	Loss of APBA1-binding. No loss of RIC1- and RGP1-binding.
O14907	20	K->A	16855024	Abolishes interaction with KCNJ4.
O14907	90	H->A	16855024	Abolishes interaction with KCNJ4.
Q9BYF1	31	K->D	15791205	Abolishes interaction with SARS-CoV spike glycoprotein.
Q9BYF1	353	K->H,A,D	15791205	Abolishes interaction with SARS-CoV spike glycoprotein.
Q02750	311	F->S	29433126	Loss of interaction with BRAF and KSR1. Loss of BRAF-KSR1 dimerization.
O35464	393	K->E	20881961	Strongly reduced affinity for PLXNA2.
O75151	7	Y->A	20129925	Abolishes binding to H3K4me2 and H3K4me3.
O75151	29	W->A	20129925	Abolishes binding to H3K4me2 and H3K4me3.
P38297	200	K->A	16624808	Abolishes fusion function, MDM30-binding and MDM30-dependent ubiquitination. No effect on localization or interaction with UGO1.
P38297	201	S->N	16624808	Abolishes fusion function, MDM30-binding and MDM30-dependent ubiquitination, but not localization to mitochondrial outer membrane.
P38297	221	T->A	16624808	Abolishes fusion function, MDM30-binding and MDM30-dependent ubiquitination, but not localization to mitochondrial outer membrane.
Q9UGI8	328	C->A	21278383	Abolishes interaction with ACTL7A.
O14974	473	S->A	18477460	Abolishes binding to the POLO box domains of PLK1.
P17427	840	W->A	10380931	Abolishes AMPH, BIN1, DGKD, EPS15, EPN1, auxilin and SNAP91 binding.
P17427	907	E->A	10380931	Strongly reduces AMPH, SNAP91 and BIN1 binding. Slightly reduces EPS15 and auxilin binding.
P17427	920	R->A	10380931	Abolishes AMPH and BIN1 binding. Reduces EPS15, SNAP91 and auxilin binding.
O94955	498	A->T	19490898	Abolishes interaction with RAB9A.
O94955	532	D->E	19490898	Abolishes interaction with RAB9A.
O94955	533	I->K	19490898	Abolishes interaction with RAB9A.
P47102	862	L->S	12808035	Abolishes interaction with GMH1.
O95786	172	K->R	17392790	Complete loss of ubiquitination. No interaction with MAVS/IPS1. No induction of IFN-beta.
Q9VYG1	44	E->A	23622245	Abolishes interaction with PI31.
Q9VYG1	263	R->A	23622245	Abolishes interaction with PI31.
Q9EP73	67	F->A	12719480	Abolishes the binding to PDCD1. Costimulates proliferation and IFNG production of T-cells.
Q9EP73	115	I->A	12719480	Abolishes the binding to PDCD1.
Q9EP73	124	K->A	12719480	Abolishes the binding to PDCD1.
Q9EP73	126	I->A	12719480	Abolishes the binding to PDCD1. Costimulates proliferation and IFNG production of T-cells.
Q9EP73	129	K->S	12719480	Abolishes the binding to PDCD1.
O43157	1815	L->F,P	18275816	Abolishes interaction with RAC1 and RND1.
Q09490	28	R->C	26687600	In bp523; abolishes interaction with sqst-1 and impairs the interaction with epg-7, sepa-1 and unc-51. Defective degradation of sepa-1- and sqst-1-containing aggregates in embryos. No defects in lipidation or puncta formation.
Q8R316	370	L->D	15235594	Strongly reduces Sin3A binding.
Q8R316	373	M->D	15235594	Strongly reduces Sin3A binding.
P56524	351	L->A,G	22649097	Loss of interaction with ANKRA2.
P56524	352	P->A	22649097	Loss of interaction with ANKRA2.
P56524	354	I->G	22649097	Loss of interaction with ANKRA2.
O43791	131	W->A	19818708	Strongly reduced affinity for substrate proteins.
P49768	82	V->K,E	12058025	Loss of interaction with GFAP.
Q7Z333	65	E->K	24105744	Abolishes interaction with EXOSC9 and UBE2I and decreases sumoylation.
Q9BRG1	124	V->E	19686684	Abolishes binding to CHMP6.
Q9BRG1	126	T->K	19686684	Abolishes binding to CHMP6.
Q9H4M9	468	K->A	20106972	Loss of interaction with MICALL1.
P62937	55	R->A	25678563	Loss of peptidyl-prolyl cis-trans isomerase activity. No loss of its interaction with BSG/CD147 or its ability to induce leukocyte chemotaxis. No effect on its interaction with MAP3K5/ASK1. Loss of its ability to negatively regulate oxidative stress-induced apoptosis mediated by MAP3K5/ASK1. Reduced interaction with TARDBP. No loss of interaction with influenza A virus matrix protein 1 or its ability to inhibit viral replication.
P21541	18	L->S	17304241	Abolishes interaction with elc-1.
P21541	21	L->S	17304241	Abolishes interaction with elc-1.
Q92560	691	L->P	9528852	Abolishes interaction with BRCA1.
Q91XW8	254	K->A	22902560	Abolishes interaction with HSP90.
P53762	167	L->E	24001774	Highly reduces transcription activity. Impairs interaction with AHR. Impairs heterodimer formation with EPAS1. Impairs heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Compromise NPAS4:ARNT heterodimer stability. Compromise AHR:ARNT heterodimer stability.
P53762	168	I->D	24001774	Highly reduces transcription activity. Impairs interaction with AHR. Impairs heterodimer formation with EPAS1. Impairs heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Compromise NPAS4:ARNT heterodimer stability. Compromise AHR:ARNT heterodimer stability.
P34152	925	Y->F	7997267	Abolishes interaction with GRB2.
P34152	1034	L->S	12702722	Loss of interaction with ARHGEF28.
Q7Z7L7	9	L->S	17304241	Abolishes interaction with ELOC.
P83917	23	V->M	11242053	Abolishes interaction with SUV39H1.
P83917	26	V->R	11242053	Abolishes interaction with SUV39H1.
P83917	161	I->E	10747027	Abolishes homodimer formation.
P83917	164	Y->E	10747027	Abolishes homodimer formation.
Q96FA3	104	R->A	29883609	Loss of ability to ubiquitinate RIPK3. Loss of interaction with RIPK1, IRAK1 and RIPK3.
P26358	163	R->A	9302295	Abolishes interaction with PCNA.
P26358	164	Q->A	9302295	Abolishes interaction with PCNA.
P26358	166	T->A	9302295	Abolishes interaction with PCNA.
P26358	167	I->A	9302295	Abolishes interaction with PCNA.
P26358	170	H->V	9302295	Abolishes interaction with PCNA.
P26358	171	F->V	9302295	Abolishes interaction with PCNA.
Q9UMS4	405	Y->A	24332808	Loss of interaction with the RPA complex and loss of recruitment to sites of DNA damage.
P34808	99	P->L	19087961	In ct46; gain of function. Embryonic lethal. Abolishes interaction with mel-26 and probably mel-26- mediated degradation. Simultaneous RNAi-mediated knockdown of ppfr-1, pph-4.1 or ppfr-4, partially rescues embryonic lethality. Myosin thick filaments are disorganized in body wall muscles in an unc-29 (e1072) mutant background.
P07814	886	S->A	23071094	Abolishes release from the aminoacyl-tRNA synthetase multienzyme complex and association with the GAIT complex upon interferon-gamma treatment. Abolishes interaction with SYNCRIP.
Q9UKT7	358	C->S	17463251	Decrease in binding efficiency with CRY2 and of CRY2 ubiquitination efficiency, loss of binding with CRY1.
Q9CV60	29	L->A	25640239	Abolishes interaction with ATP2A1/SERCA1.
Q9CV60	30	F->A	25640239	Abolishes interaction with ATP2A1/SERCA1.
Q9CV60	33	F->A	25640239	Abolishes interaction with ATP2A1/SERCA1.
Q9BXJ7	59	L->P	29402915	Loss of interaction with CUBN and strongly reduced CUBN expression at the cell surface.
Q9BXJ7	254	G->E	29402915	Loss of interaction with CUBN and strongly reduced CUBN expression at the cell surface.
P51795	742	Y->A	15489223	Abolishes interaction with NEDD4 and NEDD4L.
O00429	637	S->A	17553808	Abolishes phosphorylation. Reduces interaction with MIEF1 and MIEF2. Promotes mitochondrial fission and cell vulnerability to apoptotic insults. Mostly mitochondrial. Disrupts, in vitro, binding to FIS1.
O95832	32	I->M	17325668	Loss of HCV receptor activity. Significant loss of interaction with CD81. Reduced interaction with OCLN.
P42844	111	D->A	17571076	Abolishes interaction with SSC1, and leads to self-aggregation of mtHSP70 and accumulation of uncleaved precursor proteins.
P04545	7	C->S	10846068	Complete loss of binding to N protein. Loss of phosphorylation.
P04545	10	E->G	10846068	Complete loss of binding to N protein.
P04545	15	C->S	10846068	Complete loss of binding to N protein.
O15392	65	E->A	18591255	Almost abolishes RAN-binding. Does not disrupt binding to AURKB or CDCA8. Disrupts mitotic spindle assembly. Does not disrupt nuclear export.
Q0DIQ5	651	W->A	28818372	Abolishes binding to histone H3K4me1/2/3.
Q0DIQ5	660	W->A	28818372	Abolishes binding to histone H3K4me1/2/3.
Q0DIQ5	676	W->A	28818372	Abolishes binding to histone H3K4me1/2/3.
Q96IZ0	71	N->A	20561531	Loss of interaction with SPSB1, SPSB2 and SPSB4.
Q96IZ0	72	N->A	17189197	Loss of interaction with SPSB1-Elongin BC complex and SPSB2 and SPSB4.
Q9JLJ0	23	Y->A	11042109	Abolishes interaction with NEDD4.
Q46953	65	F->S	28931012	Loss of interaction with FtsZ, no effect on interaction with MreB.
G5EGD2	621	P->G	11595184	Loss of egl-9-mediated hydroxylation resulting in the loss of interaction with vhl-1. Normal susceptibility to P.aeruginosa killing.
Q9UHC3	529	T->A	15317815	Loss of interaction with LIN7B, MAGI1.
Q9UHC3	530	Q->A	15317815	Loss of interaction with GOPC. No effect on interaction LIN7B and MAGI1.
Q9UHC3	531	L->A	15317815	Loss of interaction with LIN7B, MAGI1 and GOPC.
P32910	89	E->A	9312031	Cold-sensitive. Abolishes interaction with BRF1/TDS4.
P32910	135	K->A	9312031	Cold-sensitive. Abolishes interaction with BRF1/TDS4.
P78380	150	W->A	15939022	Abolishes binding to acetylated LDL (AcLDL), probably due to inappropriate homodimerization.
P22682	304	G->E	12024036	Abolishes interaction with ZAP70, but does not affect interaction with SLA.
Q9Y2K2	469	T->A	29211348	Loss of interaction with 14-3-3 proteins in response to cAMP signaling; inhibits cAMP signaling.
Q9Y2K2	469	T->E	29211348	Loss of interaction with 14-3-3 proteins in response to cAMP signaling; inhibits cAMP signaling.
Q9Y2K2	551	S->A	29211348	Loss of interaction with 14-3-3 proteins in response to cAMP signaling; inhibits cAMP signaling.
Q9Y2K2	551	S->E	29211348	Loss of interaction with 14-3-3 proteins in response to cAMP signaling; inhibits cAMP signaling.
Q8RX71	179	E->G	16636050	Abolishes interaction with HSP70-1.
Q8RX71	189	D->S	16636050	Abolishes interaction with HSP70-1.
Q9VWF4	126	C->S	18456458	Abolishes phosphatase activity. Loss of bsk/JNK binding. Reduced nuclear localization.
O35114	155	L->D	24162852	Abolishes interaction with GBA. No effect on normal location in lysosomes.
O35114	156	I->D	24162852	Abolishes interaction with GBA. No effect on normal location in lysosomes.
O35114	159	M->D	24162852	Abolishes interaction with GBA. No effect on normal location in lysosomes.
O35114	160	L->D	24162852	Abolishes interaction with GBA. No effect on normal location in lysosomes.
O35114	162	A->D	24162852	Abolishes interaction with GBA. No effect on normal location in lysosomes.
O35114	163	Y->D	24162852	Abolishes interaction with GBA. No effect on normal location in lysosomes.
O35114	166	K->D	24162852	Abolishes interaction with GBA. No effect on normal location in lysosomes.
O35114	184	I->D	24162852	Abolishes interaction with GBA. No effect on normal location in lysosomes.
O35114	187	L->D	24162852	Abolishes interaction with GBA. No effect on normal location in lysosomes.
O35114	191	F->D	24162852	Abolishes interaction with GBA. No effect on normal location in lysosomes.
Q13370	2	R->A	21393242	Abolishes interaction with RAPGEF3.
Q13370	3	R->A	21393242	Abolishes interaction with RAPGEF3.
Q13370	6	R->A	21393242	Abolishes interaction with RAPGEF3.
Q13370	9	K->A	21393242	Abolishes interaction with RAPGEF3.
Q13370	12	R->A	21393242	Abolishes interaction with RAPGEF3.
A2A8L1	361	D->A	23318260	Loss of interaction with histone H3 unmethylated at 'Lys-4'. Loss of the ability to repress target genes expression. Loss of the ability to negatively regulate cell proliferation.
A2A8L1	415	D->A	23318260	Loss of interaction with histone H3 unmethylated at 'Lys-4'. Loss of the ability to negatively regulate cell proliferation.
A2A8L1	434	D->A	23318260	Loss of interaction with histone H3 unmethylated at 'Lys-4'. Loss of the ability to repress target genes expression. Loss of the ability to negatively regulate cell proliferation.
P89079	122	A->D	11000240	Partial loss of transformation. Complete loss of binding to MPDZ. Localizes aberrantly in the nucleus.
P24588	392	L->P	1512224	Prevents or diminishes RII binding.
P24588	396	A->P	1512224	Prevents or diminishes RII binding.
P24588	400	V->P	1512224	Prevents or diminishes RII binding.
P24588	405	Q->P	1512224	Prevents or diminishes RII binding.
P24588	408	I->P	1512224	Prevents or diminishes RII binding.
D0ZVG2	325	Y->A	24248594	Abolishes interaction with host PKN1 and PKN1- mediated release from the autoinhibited state.
D0ZVG2	343	D->A	24248594	Abolishes interaction with host PKN1 and PKN1- mediated release from the autoinhibited state.
D0ZVG2	366	Y->A	24248594	Abolishes interaction with host PKN1 and PKN1- mediated release from the autoinhibited state.
Q7Z3B3	910	E->R	21217699	Abolishes interaction with KAT8.
Q7Z3B3	921	H->R	21217699	Abolishes interaction with KAT8.
Q96KQ7	786	W->A	18264113	Abolishes binding to histone H3K9me without affecting the histone methyltransferase activity.
Q96KQ7	791	W->A	18264113	Abolishes binding to histone H3K9me without affecting the histone methyltransferase activity.
Q96KQ7	794	E->A	18264113	Abolishes binding to histone H3K9me without affecting the histone methyltransferase activity.
Q96KQ7	824	W->A	18264113	Abolishes binding to histone H3K9me without affecting the histone methyltransferase activity.
O74958	112	W->A	30651569	Abolishes interaction with erh1. Abnormal poly(A)-site selection of ssm4. Increases the level and cytoplasmic localization of mating and meiosis specific transcripts. Decreases H3K9me2 levels at meiotic heterochromatin islands, decreases mating efficiency, cold sensitive, normal growth at high temperature.
P41182	260	S->A	17828269	Strongly reduces interaction with PIN1.
P83916	161	I->E	15947784	Abolishes homodimer formation and binding to EMSY.
P98170	80	V->D	17560374	Loss of interaction with TAB1/MAP3K7IP1. Reduced activation of MAP3K7/TAK1. Strongly reduced activation of NF-kappa-B.
P03700	47	E->A	12832614	Complete loss of interaction with the integrase.
Q32ZE1	3099	R->A	31090058	Disrupts dimer formation, subcellular localization as well as enzymatic activity.
Q04724	486	V->S	11731482	Abolishes HESX1 binding.
Q04724	532	Y->H	11731482	Abolishes HESX1 binding.
Q04724	702	L->S	11731482	Abolishes HESX1 binding.
Q04724	715	S->P	11731482	Abolishes HESX1 binding.
Q96NA2	252	L->A	15933719	Abolishes interaction with RAB7A and localization to late endosomal/lysosomal compartments.
Q96NA2	304	K->A	15933719	Abolishes interaction with RAB7A and localization to late endosomal/lysosomal compartments.
Q96NA2	305	M->A	15933719	Abolishes interaction with RAB7A and localization to late endosomal/lysosomal compartments.
Q96NA2	306	L->A	15933719	Abolishes interaction with RAB7A and localization to late endosomal/lysosomal compartments.
Q14526	244	L->A	16762039	Abolishes interaction with CTBP1 and CTBP2. Impairs transcriptional repression.
Q8BGT1	160	F->A,N	26235031	Abolishes interaction with ADGRL3.
Q8BGT1	165	H->N	25374360	Abolishes interaction with UNC5B.
Q94F62	317	K->E	12150929	Loss of kinase activity and loss of interaction with hopAB2/AvrPtoB, but no effect on the binding to the FHA domain of KAPP. Reduced interaction with BIR2.
Q94F62	451	A->E	22169508	Loss of kinase activity and loss of interaction with hopAB2/AvrPtoB. Reduced interaction with BIR2.
Q94F62	452	V->D	22169508	Strongly decreased kinase activity and loss of interaction with hopAB2/AvrPtoB.
Q94F62	455	T->N	22169508	Loss of kinase activity and loss of interaction with hopAB2/AvrPtoB.
Q94F62	456	I->D	22169508	Loss of kinase activity and loss of interaction with hopAB2/AvrPtoB.
Q94F62	458	H->D	22169508	Loss of kinase activity, loss of phosphorylation and loss of interaction with hopAB2/AvrPtoB.
Q94F62	464	L->D	22169508	Loss of kinase activity and loss of interaction with hopAB2/AvrPtoB.
Q94F62	495	A->E	22169508	Loss of kinase activity and loss of interaction with hopAB2/AvrPtoB.
Q7TSN2	195	K->A	17202337	Abolishes interaction with TYROBP or FcR gamma.
Q09436	190	T->A	18199581	Abolishes phosphorylation. Severe reduction in binding to plk-1 and plk-2.
Q09436	190	T->E	18199581	Phosphomimetic mutant which severely abolishes interaction with plk-1 and plk-2.
Q3V1H9	27	Y->F	29749928	Abolishes binding to EPHA5 SAM domain.
Q2MKA7	106	F->A	23756652	Abolishes activation of Wnt signaling. Abolishes LGR4 binding.
Q84L33	47	I->A	21764993	Abolishes interaction with RPN10.
Q9H9E1	188	W->A	22649097	Loss of interaction with CCDC8. Decreased affinity for HDAC4.
Q08379	987	F->A	26363069	Abolishes interaction with GORASP1. Abolishes membrane clustering.
Q08379	1002	I->R	26363069	Abolishes interaction with GORASP1. Abolishes membrane clustering.
Q16236	80	T->A	16888629	Loss of interaction with KEAP1.
Q8S8P5	362	D->A	22535423	Loss of interaction with VQ10 protein.
Q9JLU4	678	P->A	17304222	Almost abolishes interaction with ABI1.
Q9JLU4	679	P->A	17304222	Abolishes interaction with ABI1.
Q9JLU4	680	P->A	17304222	Abolishes interaction with ABI1.
Q9JLU4	684	P->A	17304222	Abolishes interaction with ABI1.
Q9JLU4	1311	P->L	10433269	Abolishes interaction with HOMER1 isoform 3.
Q9JLU4	1314	F->C	10433269	Abolishes interaction with HOMER1 isoform 3.
O76064	42	R->A	18001824	Abolishes interaction with ATM-phosphorylated MDC1. Abolishes interaction with human herpesvirus 1 ICP0. Abolishes recruitment to DNA damage sites after UV irradiation, ionizing radiation, or treatment with an alkylating agent.
P03186	61	C->A	20190741	Complete loss of ubiquitin and NEDD8 binding.
Q9GZV5	51	S->A,D	19324877	Loss of interaction with TEAD4.
P45973	165	I->E	20562864	No effect on interaction with POGZ. Abolishes interaction with TRIM28, CHAF1A and NIPBL.
P45973	174	W->A	20042602	Abolishes interaction with TRIM28, CHAF1A, NIPBL and HP1BP3, fails to localize to centromeres in mitosis.
P43583	2140	S->H	22025621	Abolishes binding to the proteasome.
P43583	2142	Y->A,V	22025621	Loss of function; abolishes binding to the proteasome.
P43583	2142	Y->V	22025621	Abolishes binding to the proteasome.
A0A0P0X9Z7	653	W->A	28818372	Abolishes binding to histone H3K4me3.
A0A0P0X9Z7	662	W->A	28818372	Abolishes binding to histone H3K4me3.
A0A0P0X9Z7	678	W->A	28818372	Abolishes binding to histone H3K4me3.
Q13239	111	R->K	10449770	Strongly reduces interaction with ZAP70, CD3Z, SYK and LAT.
P53566	193	S->A	15107404	No effect on DNA-binding. Loss of interaction with CDK2 and CDK4 as well as cell cycle inhibition.
O15381	173	W->A	31358741	Abolishes binding to MTREX.
O15381	311	K->M	16782053	Loss of ATP-binding. Significant reduction in interaction with TERT and in telomerase activity. Loss of interaction with MTREX.
Q2G1S6	205	T->P	21552524	Complete loss of interaction with GP1BA.
Q14203	68	K->A	17828275	Abolishes interaction with CLIP1.
Q14203	90	R->E	17828275	Abolishes interaction with CLIP1.
O35433	155	K->A	17582331	Abolishes ATP binding. Abolishes CALM binding. Impairs normal desensitization by repeated exposure to capsaicin.
O35433	160	K->A	17582331	Abolishes ATP binding. Abolishes CALM binding.
Q9NQS7	169	V->E	20562864	Abolishes interaction with CBX5.
Q9NQS7	171	I->E	20562864	Abolishes interaction with CBX5 and AURKB.
Q8GZM7	41	E->A	18539749	Loss of interaction with PHYB (Pfr form).
Q8GZM7	42	L->A	18539749	Loss of interaction with PHYB (Pfr form).
Q8GZM7	47	G->A	18539749	Loss of interaction with PHYB (Pfr form).
Q03518	92	D->K	26611325	Complete loss of interaction with TAPBP, resulting in impaired PLC assembly and antigen presentation.
Q86VZ6	60	Y->D	15302918	Abolishes interaction with NR2C2.
Q96RL1	508	C->A	19015238	Abolishes interaction with histone monoubiquitinated H2B without affecting the interaction with H2A.
P63244	52	Y->F	11279199	No effect on binding to SRC. Abolishes binding to PTK2/FAK1 and reduces cell adhesion and foci formation.
P03680	59	Y->F	11884636	Almost no effect on replication activity. About 20% loss of TP-DNA initiation, 20% loss of TP-DNA replication and 10% loss of TP-DNA amplification. Complete loss of interaction with TP.
P03680	59	Y->L	11884636	3 fold decrease in replication activity. About 80% loss of TP-DNA initiation, 70% loss of TP-DNA replication and 97% loss of TP-DNA amplification. Complete loss of interaction with TP.
P03680	61	H->L	11884636	5 fold decrease in replication activity. About 85% loss of TP-DNA initiation, 80% loss of TP-DNA replication and complete loss of TP-DNA amplification. Complete loss of interaction with TP.
P03680	61	H->R	11884636	100 fold decrease in replication activity. Complete loss of interaction with TP.
P03680	69	F->S	11884636	2 fold decrease in replication activity. About 50% loss of TP-DNA initiation, 40% loss of TP-DNA replication and 60% loss of TP-DNA amplification. Complete loss of interaction with TP.
P03680	69	F->Y	11884636	2 fold decrease in replication activity. About 80% loss of TP-DNA initiation, 50% loss of TP-DNA replication and almost 95% loss of TP-DNA. Complete loss of interaction with TP amplification.
P03680	128	F->Y	12473453	Almost complete loss of interaction with TP.
O54960	502	A->D	9459447	Abolishes interaction with NOS1.
O54960	503	V->A	9459447	Abolishes interaction with NOS1.
P70207	193	D->K	20881961	Abolishes interaction with SEMA6A.
P70207	221	F->A,R	20877282	Abolishes interaction with SEMA6A.
P70207	396	A->E	20877282	Abolishes interaction with SEMA6A.
Q9ULM3	259	H->A	27103431	Strongly reduced binding to histone H3 crotonylated at 'Lys-27' (H3K27cr).
Q9ULM3	262	Y->A	27103431	Strongly reduced binding to histone H3 crotonylated at 'Lys-27' (H3K27cr).
Q9ULM3	282	W->A	27103431	Strongly reduced binding to histone H3 crotonylated at 'Lys-27' (H3K27cr).
Q01167	137	L->A	25805136	Abolishes interaction with DVL2 and SUDS3 as well as DVL2 nuclear translocation.
Q01167	145	F->A	25805136	Abolishes interaction with DVL2 and SUDS3 as well as DVL2 nuclear translocation.
Q01167	154	F->A	25805136	Abolishes interaction with DVL2 and SUDS3 as well as DVL2 nuclear translocation.
Q95216	767	P->S,T	18584949	Abolishes binding to the RFBP isoform of ATP11B.
Q95216	768	V->R	18584949	Abolishes binding to the RFBP isoform of ATP11B.
Q95216	769	I->M,P	18584949	Abolishes binding to the RFBP isoform of ATP11B.
Q95216	771	H->D,K	18584949	Abolishes binding to the RFBP isoform of ATP11B.
Q95216	792	A->Q	18584949	Abolishes binding to the RFBP isoform of ATP11B.
Q95216	793	K->P	18584949	Abolishes binding to the RFBP isoform of ATP11B.
Q93ZW0	212	C->S	21309870	Abolishes interaction with G6PD1.
Q93ZW0	220	C->S	21309870	Abolishes interaction with G6PD1.
Q8WUA7	165	S->E	23572552	Complete loss of 14-3-3 protein-binding.
Q8WUA7	167	S->E	23572552	Complete loss of 14-3-3 protein-binding.
O43683	106	A->D,W	17981135	Loss of interaction with KNL1.
O43683	122	L->G	17981135	Loss of interaction with KNL1.
O43683	130	A->S	19487456	Partial rescue of the spindle-assembly checkpoint activity. Increased rate of chromosome congression errors. Impaired localization to kinetochores and loss of kinetochore binding of CENPF, SGO1 and BUBR1 but not of MCAK, MAD1L1 or MAD2L1.
P46414	90	R->G	10811608	Loss of interaction with NUP50. No cyclin E- mediated degradation of phosphorylated p27KIP1.
Q8IXJ9	1108	V->A	16606617	Abolishes interaction with RARA.
Q8IXJ9	1111	L->A	16606617	Abolishes interaction with RARA.
Q45VV3	145	S->A	18256197	Increased activity and nuclear localization, decreased sensitivity to Hpo/Wts-mediated inhibition, loss of interaction with 14-3-3epsilon and 14-3-3zeta.
Q0DRX6	27	W->A	28818372	Abolishes binding to histone H3K4me1/2/3.
Q0DRX6	36	W->A	28818372	Abolishes binding to histone H3K4me1/2/3.
Q0DRX6	52	W->A	28818372	Abolishes binding to histone H3K4me1/2/3.
P30561	119	A->D	24001774	Highly disrupts the dimerization ability of AHR. Reduces transcription activity. Impairs interaction with ARNT.
P30561	120	L->E	24001774	Highly disrupts the dimerization ability of AHR. Reduces transcription activity. Impairs interaction with ARNT.
P30561	124	V->D	24001774	Highly disrupts the dimerization ability of AHR. Reduces transcription activity. Impairs interaction with ARNT.
Q9NY46	1970	Y->A	15548568	Abolishes interaction with NEDD4L.
Q79FE1	125	L->E,R	25155747	Does not affect formation of the PE25/PPE41 dimer, but abolishes EspG5 binding to PE25/PPE41.
P38398	1655	S->A	15133502	Abolishes interaction with BRIP1.
P38398	1702	K->M	15133502	Abolishes interaction with BRIP1.
P38398	1738	G->E	15133502	Abolishes interaction with BRIP1.
P62314	58	L->K	11747828	Loss of interaction with CLNS1A.
P62314	60	I->R	11747828	Loss of interaction with CLNS1A.
O00159	736	S->A	24636949	Abolishes interaction with YWHAB.
Q148B6	305	V->M	15280373	Abolishes CDC20 binding.
Q148B6	469	L->P	15280373	Abolishes CDC20 binding.
Q9BUL8	135	A->D	20489202	Loss of interaction with CCM2.
Q9BUL8	175	S->D	20489202	Loss of interaction with CCM2.
P27958	399	L->R	22767607	Complete loss of E2 binding to host SCARB1; 5- 10-fold decrease of infectivity for the viral particles.
P27958	452	C->A	22278231	Complete loss of infectivity. Loss of heterodimerization with E1. No effect on CD81-binding function.
P27958	459	C->A	22278231	Complete loss of infectivity. Loss of heterodimerization with E1. 78% loss of CD81-binding function.
P27958	486	C->A	22278231	Complete loss of infectivity. No effect on CD81-binding function. Loss of heterodimerization with E1.
P27958	494	C->A	22278231	Complete loss of infectivity and CD81-binding function. Loss of heterodimerization with E1.
P27958	503	C->A	22278231	Complete loss of infectivity and CD81-binding function.
P27958	508	C->A	22278231	Complete loss of infectivity and CD81-binding function.
P27958	564	C->A	22278231	Complete loss of infectivity and CD81-binding function.
P27958	569	C->A	22278231	Complete loss of infectivity. No effect on CD81-binding function. Loss of heterodimerization with E1.
P27958	581	C->A	22278231	Complete loss of infectivity. No effect on CD81-binding function. Loss of heterodimerization with E1.
P27958	585	C->A	22278231	Complete loss of infectivity. No effect on CD81-binding function. Loss of heterodimerization with E1.
P27958	597	C->A	22278231	Complete loss of infectivity. Reduced CD81- binding function.
P27958	620	C->A	22278231	Complete loss of infectivity. Reduced CD81- binding function.
P27958	652	C->A	22278231	Complete loss of infectivity. Reduced heterodimerization with E1. No effect on CD81-binding function.
P27958	677	C->A	22278231	Complete loss of infectivity. Reduced heterodimerization with E1. No effect on CD81-binding function.
P00958	63	A->H	16914447	Abolishes interaction with ARC1.
Q40902	462	K->R	11500547	Reduced autophosphorylation and strongly decreased interaction with KIP1.
P70392	1022	R->E	11238945	Loss of interaction with Ras. Loss of Ras activation. Loss of ubiquitination.
Q8IVT5	72	E->K	29433126	Loss of interaction with BRAF and MAP2K1 and severe decrease in MAP2K1 phosphorylation levels.
Q8IVT5	831	W->R	29433126	Loss of the interaction with MAP2K1 resulting in loss of BRAF-KSR1 dimerization and BRAF activation. No effect on ATP binding or interaction with HSP90AA1, 14-3-3 and CDC37.
P03200	22	D->A	18786993	Complete loss of interaction with host CR2.
P03200	151	Y->A	18786993	Complete loss of interaction with host CR2.
P03200	160	I->A	18786993	Complete loss of interaction with host CR2.
P03200	162	W->A	18786993	Complete loss of interaction with host CR2.
P03200	296	D->A	18786993	Complete loss of interaction with host CR2.
P60953	17	T->N	11260256	Constitutively inactive. Does not interact with PARD6 proteins. Inhibits filopodia formation. No effect on NR3C2 transcriptional activity.
P03551	129	F->A	11324752	Complete loss of capsid binding.
Q8AXX8	52	K->R	16256735	Eliminates one of two sumoylated products. Abolishes interaction with sumoylation factors.
O75832	182	E->A	10613832	Abolishes interaction with RB1.
Q9P0R6	42	N->I	27484798	Abolishes interaction with PRKAR2A. Prevents the Wnt-induced transcription. Does not alter the phosphorylation of CTNNB1 in the presence of Wnt.
Q9P0R6	130	L->P	16981698	Loss of interaction with GSK3B. Abolishes GSK3B-mediated phosphorylation. Prevents beta-catenin accumulation in the cytoplasm and nucleus. Prevents the Wnt-induced transcription. Decreases PKA-mediated phosphorylation of GSK3B. Abolishes acquired resistance against oxidative stress-induced apoptosis under activated cAMP signaling. Decreases PKA-mediated DNM1L phosphorylation.
Q9NRW3	72	L->D	23001005	Resistant to HIV-1 Vif and abolishes Vif binding.
Q9NRW3	86	Y->A	23001005	Resistant to HIV-1 Vif and abolishes Vif binding.
Q9NRW3	107	F->D	23001005	Resistant to HIV-1 Vif and abolishes Vif binding.
Q9NRW3	141	E->K	23001005	Remains sensitive to HIV-1 Vif but abolishes Vif binding.
O60701	94	K->E	23106432	Loss of hexamer formation. Causes formation of stable dimers. Strongly reduced affinity for NAD and UDP- glucose, and strongly decreased catalytic efficiency at pH 8.6.
Q9P219	1675	F->A	26126266	Abolishes interaction with and activation of GNAI3 and abolishes release of the beta and gamma subunits from the heterotrimeric G-protein complex. Abolishes WNT5A- mediated activation of RAC1. Failure to induce apical cell constriction but does not affect localization to apical cell junctions.
Q9VQS6	46	R->C	12117814	In drm6; foregut proventriculus and hindgut morphologically and functionally defective. Abolishes lin binding. Abolishes lin-inhibiting activity.
Q9JM80	314	Y->F	10801129	Abolishes interaction with CSK.
P03314	2512	K->R	25211074	Completet loss of NS5 binding to STAT2 after IFN-I stimulation.
P63104	49	K->E	17913709	Loss of interaction with NOXA1.
P63104	184	S->A	15071501	On DNA damage, loss of MAPK8-mediated phosphorylation. Loss of binding ABL1. Attenuates ABL1- mediated apoptosis. No loss of interaction with BAX under stress conditions. Inhibits translocation of BAX to mitochondria.
Q53GT1	18	S->A	29769719	Loss of interaction with YWHAE. Loss of nuclear localization upon amino acid starvation.
Q9NZN3	485	W->A	16251358	Abolishes interaction with RAB11FIP2.
Q931F4	231	R->A	18550524	Abolishes binding to complement component C3 derivatives and inhibition of the alternative pathway.
Q931F4	238	N->A	18550524	Abolishes binding to complement component C3 derivatives and inhibition of the alternative pathway.
P06240	20	C->S	2107025	Complete loss of interaction with CD4 or CD8.
P06240	23	C->S	2107025	Complete loss of interaction with CD4 or CD8.
Q6DE87	54	K->A	12963733	Abolishes interaction with CLSPN. Abrogates phosphorylation at S-344 and kinase activation during checkpoint signaling.
Q6DE87	129	R->A	12963733	Abolishes interaction with CLSPN, abrogates phosphorylation at S-344 and abolishes kinase activity.
Q6DE87	153	T->A	12963733	Abolishes interaction with CLSPN. Abrogates phosphorylation at S-344 and kinase activation during checkpoint signaling.
Q6DE87	162	R->A	12963733	Abolishes interaction with CLSPN and kinase activation during checkpoint signaling. No effect on phosphorylation at S-344.
Q6DE87	377	T->A	11150524	Induces hyperphosphorylation and enhances kinase activity and cell cycle arrest. Abolishes interaction with CLSPN.
Q64321	21	L->S	22730529	Fails to repress CD8 expression. Abolishes interaction with HDAC4 and HDAC5. No effect on homodimerization and DNA binding.
P66817	190	L->A,P	17699754	Abolishes interaction with DnaA. Strongly reduces DnaA-dependent DNA synthesis.
P66817	191	F->L,S	17699754	Abolishes interaction with DnaA. Strongly reduces DnaA-dependent DNA synthesis.
Q6NZ36	164	D->A	22705371	Abolishes binding to ubiquitin.
Q6NZ36	170	C->A	22343915	Abolishes binding to ubiquitin.
Q9UGL1	351	W->A	24952722	Abolishes interaction with histone H3. Decreases by 28% demethylase activity and repression of tumor suppressor genes expression.
O32163	66	C->A	21236255	Does not interact with SufS, does not activate SufS; no effect in presence of wild-type protein. Binds about 15% Zn(2+).
O32163	128	C->A	20822158	Does not interact with SufS, does not activate SufS; no effect in presence of wild-type protein. Binds about 45% Zn(2+).
O43520	454	D->A	19731236	Greatly reduced expression due to proteosomal degradation; abolishes interaction with TMEM30A.
Q15006	28	R->A	32439656	Loss of interaction with EMC5.
Q15006	156	E->A	32439656	Loss of interaction with EMC5.
Q15006	160	E->A	32439656	Loss of interaction with EMC5.
Q15006	227	R->A	32439656	Loss of interaction with EMC5 and EMC8.
P07207	2328	Y->F	15620649	Abolishes interaction with Nedd4 and reduces ubiquitination.
Q82171	211	T->A	16014927	Complete loss of human eIF4H binding.
Q82171	214	T->I	16014927	Complete loss of human eIF4H binding.
Q82171	435	R->H	16014927	Complete loss of human eIF4H binding.
O15234	218	W->A	16170325	Abolishes interaction with EIF4A3, EJC formation and localization in nucleus speckles.
Q7TNS8	40	L->A	27863225	Abolishes interaction with the elongin BC complex.
P30203	295	Y->A	26146185	Abolishes interaction with ALCAM.
P30203	298	E->A	26146185	Nearly abolishes interaction with ALCAM.
P30203	327	Y->A	26146185	Nearly abolishes interaction with ALCAM.
P54274	115	L->R	20159592	Loss of interaction with FBXO4.
P54274	120	L->R	20159592	Loss of interaction with FBXO4.
Q9Y679	386	L->A	23223569	Abolishes interaction with UBE2G2.
Q9Y679	390	K->A	23223569	Abolishes interaction with UBE2G2.
Q9Y679	393	L->A	23223569	Abolishes interaction with UBE2G2.
Q9Y679	400	R->A	23223569	Abolishes interaction with UBE2G2.
Q9Y679	404	R->A	23223569	Abolishes interaction with UBE2G2.
Q08509	689	V->D	20532239	Abolishes barbed-end actin-binding without affecting actin bundling activity.
Q08509	693	L->D	20532239	Abolishes barbed-end actin-binding without affecting actin bundling activity.
Q9BSM1	191	Y->A	23523425	Abolishes interaction with BCOR and BCORL1.
Q9BSM1	193	R->A	23523425	Abolishes interaction with BCOR and BCORL1.
Q9BSM1	206	V->D	23523425	Abolishes interaction with BCOR and BCORL1.
Q27974	876	D->A	12741832	Loss of interaction with HSPA8.
Q9QYP6	236	Y->A	17568778	Abolishes interaction with TBK1 but not with IKBKE.
Q9QYP6	253	Q->A	17568778	Abolishes interaction with TBK1 and IKBKE.
Q9QYP6	257	L->A	17568778	Abolishes interaction with TBK1 and IKBKE.
Q9UNP9	51	F->D	20541251	Abolishes interaction with KMT2A. Abolishes inhibition of KMT2A activity.
Q8CI61	387	L->P	11909948	Abolishes interaction with HSP70 and TNFRSF1A.
Q8CI61	416	L->P	11909948	Abolishes interaction with HSP70 and TNFRSF1A.
Q8CI61	441	A->P	11909948	Abolishes interaction with HSP70 and TNFRSF1A.
P62743	62	Y->S	19140243	Abolishes interaction with CD4 endocytosis signal motif.
P62743	63	A->W	19140243	Abolishes interaction with CD4 endocytosis signal motif.
P62743	88	V->D	19140243	Abolishes interaction with CD4 endocytosis signal motif.
P62743	92	N->W	19140243	Abolishes interaction with CD4 endocytosis signal motif.
P62743	98	V->S	19140243	Abolishes interaction with CD4 endocytosis signal motif.
P62743	100	E->Y	19140243	Abolishes interaction with CD4 endocytosis signal motif.
P62743	103	L->S	19140243	Abolishes interaction with CD4 endocytosis signal motif.
P29506	174	F->E	10557206	In wdEx65; unable to crawl backwards. Abolishes interaction with unc-37.
P29506	188	G->D,S	10557206	In e26/e2307; unable to crawl backwards. Abolishes interaction with unc-37.
P29506	190	R->Q	10557206	In e2323; unable to crawl backwards. Abolishes interaction with unc-37.
P29506	197	R->K	10557206	In e26/e2307; unable to crawl backwards. Abolishes interaction with unc-37.
P49683	367	S->A	11641419	Abolishes binding to GRIP1.
P49683	368	V->A	11641419	Abolishes binding to GRIP1.
P49683	370	I->A	11641419	Abolishes binding to GRIP1.
Q9UIV1	141	M->R	22977175	Abolishes interaction with CNOT1.
P48059	42	F->A	19074270	Loss of interaction with ILK and loss of localization to focal adhesion.
Q02248	8	M->P	20086044	Loss of interaction with VCL.
P0DMV9	77	K->R	27708256	Significant loss of acetylation and ATPase activity. Decreased binding to HOPX and HSP90 and increased binding to STUB1 and NAA10. Impaired capacity for protein refolding during the early phase after stress but shows normal protein degradation activity in the late phase.
Q08752	227	K->A	12145316	Abolishes interaction with HSP90AB1 and impairs interaction with HSPA8.
Q08752	231	N->A	12145316	Abolishes interaction with HSP90AB1 and impairs interaction with HSPA8.
Q08752	278	N->A	12145316	Abolishes interaction with HSP90AB1.
Q08752	308	K->A	12145316	Abolishes interaction with HSP90AB1 and impairs interaction with HSPA8.
Q08752	312	R->A	12145316	Abolishes interaction with HSP90AB1 and impairs interaction with HSPA8.
A0JNT9	512	K->M	20360680	Abolishes Rab6-binding.
Q8IYM1	56	G->N	18443421	Abolishes binding to GTP and to SEPTIN11, and also abolishes the ability of SEPTIN12 to form filamentous structures.
O43865	66	S->A	16769890	Slightly decreases interaction with ITPR1. Slightly decreases phosphorylation. No effect on interaction with SLC4A4. Abolishes interaction with FIP1L1.
O43865	70	S->A	16769890	Highly decreases interaction with ITPR1. No effect on phosphorylation. No effect on interaction with SLC4A4. Abolishes interaction with FIP1L1.
O43865	77	S->A	16769890	Highly decreases interaction with ITPR1. Slightly decreases phosphorylation. Strongly decreases interaction with SLC4A4. Abolishes interaction with FIP1L1.
Q6Y7W6	288	W->A	31439631	Abolishes interaction with DDX6.
Q9QUN7	681	P->H	10548109	Abolishes MYD88-binding and response to microbial cell wall components.
P84092	176	D->A	10228163	Abolishes interaction with TTGN1 and EGFR.
P84092	421	W->A	10228163	Abolishes interaction with TTGN1 and EGFR.
P15927	248	F->A	28575657	Abolishes interaction with RFWD3, leading to impair DNA interstrand cross-links (ICL) repair.
P15927	252	E->A	28575657	Abolishes interaction with RFWD3, leading to impair DNA interstrand cross-links (ICL) repair.
P15927	254	H->A	28575657	Abolishes interaction with RFWD3, leading to impair DNA interstrand cross-links (ICL) repair.
P97801	131	E->K	11773003	Loss of interaction with SYNCRIP.
P97801	257	S->I	11773003	Loss of interaction with SYNCRIP.
P97801	267	Y->C	11773003	Loss of interaction with SYNCRIP.
P97801	269	T->I	11773003	Loss of interaction with SYNCRIP.
P97801	274	G->V	11773003	Loss of interaction with SYNCRIP.
Q7XV05	128	D->N	25372696	Abolishes binding capacity to BRI1.
O00571	102	S->A	23478265	Reduces total phosphorylation by 30%. Abolishes interaction with IRF3 and fails to enhance IFNB promoter induction. No effect on interaction with IKBKE.
Q9VFS8	9	E->A	23622245	Abolishes interaction with PI31.
Q9VFS8	187	R->A	23622245	Abolishes interaction with PI31.
P53039	70	E->V	15611160	In YIP1-42; temperature sensitive; abolishes binding to YPT1 and YPT31, and inhibits ER vesicle budding.
P53039	175	G->E	9724632	In YIP1-2; abolishes binding to YPT1 and YPT31, reduces binding to YIF1, blocks ER-Golgi protein transport, and causes a severe growth defect at 36 degrees Celsius.
P53039	177	C->S	15611160	In YIP1-18; abolishes binding to YIF1, YPT1 and YPT31.
P53039	180	P->G	15611160	In YIP1-19; lethal; abolishes binding to YPT1 and YPT31, and reduces binding to YIF1.
Q8H7F6	219	C->S	24203231	Decreased interactions with BOLA proteins and loss of interaction with SUFE1.
Q9R1E0	206	W->G	17627282	Loss of interaction with CEBPA.
Q9R1E0	212	H->P	17627282	Loss of interaction with CEBPA.
Q5SYB0	924	E->A	23318951	Abolishes interaction with GPSM2.
P97260	298	Y->C	10500160	Loss of sterol-dependent ER retention due to loss of interaction with INSIG. Constitutive interaction with COPII coat and maturation of SREBF.
P97260	315	L->F	12482938	Loss of sterol-dependent ER retention due to loss of interaction with INSIG. Constitutive maturation of SREBF.
P97260	443	D->N	12482938	Loss of sterol-dependent ER retention due to loss of interaction with INSIG.
Q61532	334	I->K	19473979	Abolishes binding to MAPKAPK5.
P29375	1625	W->A	19430464	Abolishes interaction with histone H3 di- and trimethylated at 'Lys-4'.
P38646	489	G->E	26702583	Significant loss of interaction with FXN and ISCU. Significant increase in interaction with NFS1.
P10275	721	K->A	15563469	Loss of transcription activation in the presence of androgen and of interaction with NCOA2.
Q7TSS2	351	C->A	18511602	Loss of ubiquitin binding. Normal dimer formation.
P12493	189	N->S	29997211	Reduces protein stability. Loss of binding to FG repeats of human NUP153. Loss of binding to CPSF6. Decreases virus ability to integrate in intrafenic regions compared to wild-type virus. Reduces infectivity to non- dividing cells; virus undergo reverse transcription but not nuclear translocation. Retains infectivity to dividing cells.
P12493	206	N->A	24130490	Loss of binding to NUP153 and CPSF6.
P12493	206	N->D	23523133	Loss of binding to CPSF6. Does not affect binding to NUP153. Retains infectivity to non-dividing cells.
P12493	305	R->A	29997211	Does not bind FG repeats of human NUP153. Loss of infectivity.
Q62768	1364	I->F	16271475	Loss of binding to STX1B and priming activity.
Q62768	1603	V->D	16271475	Loss of binding to STX1B and priming activity.
P56477	445	S->A	25326420	Abolished homodimerization and subsequent activation.
Q13526	34	W->A	22608923	Loss of binding to phosphorylated target proteins, including to phosphorylated RBBP8/CtIP; decrease in DNA repair of double-strand breaks by homologous recombination less efficient than that observed with wild- type protein.
Q8WTX7	202	I->E	27487210	No effect on arginine-binding. Loss of homodimerization. Decreased interaction with the GATOR2 complex which constitutively activates the TORC1 signaling pathway.
Q8WTX7	207	Y->S	27487210	No effect on arginine-binding. Loss of homodimerization. Decreased interaction with the GATOR2 complex which constitutively activates the TORC1 signaling pathway.
Q61097	809	C->Y	10409742	Associates almost exclusively with the membrane. Loss of MAP2K2 and MAP2K2 binding and recruitment to the membrane. Loss of MAP kinase-mediated inhibition of ELK1 phosphorylation. No effect on the interaction with YWHAE.
Q99FX5	484	F->A	27302953	Abolished interaction with host IRF3.
Q99FX5	486	L->A	27302953	Abolished interaction with host IRF3.
Q13501	338	W->A	17580304	Strong decrease in MAP1LC3B-binding, disrupts interaction with GABARAP.
Q13501	406	F->V	15340068	Loss of polyubiquitin-binding.
Q13501	417	L->V	15340068	Loss of polyubiquitin-binding.
Q6VMQ6	968	D->A	16757475	Abolishes the interaction with SUMO.
Q6VMQ6	969	L->A	16757475	Abolishes the interaction with SUMO.
P01391	27	D->R	10574958	31-fold decrease in affinity for Torpedo AChRs and 50-fold decrease in affinity for neuronal alpha- 7/CHRNA7 AChR.
P01391	29	F->A	10574958	12-fold decrease in affinity for Torpedo AChRs and 74-fold decrease in affinity for neuronal alpha- 7/CHRNA7 AChR.
P01391	33	R->E	10574958	767-fold decrease in affinity for Torpedo AChRs and 339-fold decrease in affinity for neuronal alpha- 7/CHRNA7 AChR.
P01391	49	K->E	10574958	3-fold and 53-fold decrease in affinity for Torpedo AChRs.
Q9H095	401	Q->A	24787902	Loss of calmodulin binding.
O13329	159	H->A	14645529	Abolishes RFB-binding, replication fork blocking activity and reduces recombination rate.
O13329	164	H->A	14645529	Abolishes RFB-binding, replication fork blocking activity and reduces recombination rate.
O13329	193	C->A	14645529	Abolishes RFB-binding, replication fork blocking activity and reduces recombination rate.
O13329	196	C->A	14645529	Abolishes RFB-binding, replication fork blocking activity and reduces recombination rate.
Q8LEA8	10	P->A	11316788	Disrupts interaction with SKP1A and SKP1B.
Q7L804	481	I->E	16905101	Abolishes the interaction with RAB11A and the vesicular localization.
Q8K3K8	50	E->K	20388642	Disrupts interaction with Rab8; accumulation in the retinal outer plexiform layer; loss of retinal ganglion cells and connecting synapses, degeneration of entire retina without elevation of intraocular pressure.
Q9WVG6	229	S->E	19843527	Abolishes dimerization.
Q6WKZ4	1255	I->E	15280022	Abolishes the interaction with RAB11A and RAB4A, homooligomerization and subcellular location.
P63159	106	C->A	20547845	Disrupts interaction with TLR4:LY96 receptor complex and abolishes TNF release from macrophages.
Q9K0V0	225	Q->A	22327295	Significantly decreased binding to TF.
P9WNK7	87	E->K	19854905	Abolishes EsxB-EsxA heterodimer interaction with EccCb1, maintains interaction with EspA, EccA2 and EccE2.
P26449	31	W->G	11726501	Abolishes checkpoint function and interaction with MAD2, MAD3 and CDC20. Benomyl-sensitive phenotype.
P26449	120	W->G	11726501	Abolishes checkpoint function and interaction with MAD2, MAD3 and CDC20. Benomyl-sensitive phenotype.
Q13439	2	F->A	29084197	Loss of TBC1D23-binding.
Q13439	2177	Y->A	10209123	Loss of localization at the Golgi apparatus. Loss of ARL1-binding.
P06702	3	C->A	25417112	Disrupts interaction with NOS2 and inhibits LDL(ox)-induced GAPDH S-nitrosylation; no effect on interaction with S100A8.
P03205	107	Y->A	15140992	Loss of HLA class II binding and fusion competence.
P03205	125	W->G	15140992	Loss of HLA class II binding and fusion competence.
P03205	160	E->A	15140992	Loss of HLA class II binding and fusion competence.
P03205	220	R->A	15140992	Loss of HLA class II binding and fusion competence.
P37107	537	R->G,Q,K,N	15632183	Loss of binding to CAO/cpSRP43.
P48552	446	K->Q	11509661	Disrupts interaction with CTBP1. Decreases lysine acetylation. Disrupts nuclear hormone receptor- dependent transcription repression.
P45974	261	Y->F	22216260	Loss of polyubiquitin binding.
P45974	435	D->A	18482987	Loss of polyubiquitin binding and hydrolysis.
Q8WXF7	77	R->E	21220294	Abolishes homodimerization.
Q8WXF7	191	Q->R	21220294	Abolishes homodimerization.
P19634	534	I->D,K	16710297	Strongly reduced interaction with CHP2.
P19634	537	I->K	16710297	Strongly reduced interaction with CHP2.
Q24008	442	M->K	7826638	In allele inaD-P215; slow recovery of light- induced responses and altered light sensitivity. Abolishes interaction with trp.
P42892	428	C->S	18992253	Abolishes dimerization.
Q9UBS4	53	H->Q	15525676	Loss of HSPA5-binding, but no effect on interaction with denatured substrates.
Q8IZD2	141	W->A	23798402	Loss of binding to tri-methylated 'Lys-4' of histone H3 (H3K4me3).
P0A6P1	148	H->A	9468511	At least 100-fold decrease in affinity between EF-Ts and EF-Tu and only small amount of GDP exchange activity.
Q1XH17	242	C->A	19043407	Dominant-negative mutant that abolishes homooligomerization and function in membrane repair.
Q9MUK5	516	N->A	16619024	Loss of HSP90 binding, but no effect on HSP70 binding.
O08773	333	R->L	19878719	Abolishes the inhibition of PDGF-mediated ERK1/ERK2 phosphorylation. Inhibits interaction with HRAS and does not colocalize with active GTP-bound form of HRAS at membranes. Does not inhibit interaction with BRAF or RAF1.
Q3U182	214	V->A	17805301	No interaction with COP1. Inhibition of degradation under exposure to FSK/INS.
Q3U182	215	P->A	17805301	No interaction with COP1. Inhibition of degradation under exposure to FSK/INS.
Q8IVG9	8	C->P	11717357	Abolishes neuroprotective activity and interaction with BAX.
Q9FR39	86	K->A	11485551	Strongly decreased affinity for G-actin.
Q68D10	641	M->A	26109053	Strongly reduces affinity for histones.
P20917	473	I->E	27922006	Abolishes homodimerization.
P27812	8	Y->F	15814704	Loss of PTPN6 binding and inhibition of Ca(2+) influx upon activation of natural killer cells.
Q2LAE1	865	W->A	21522130	Loss of histone tail binding.
Q2LAE1	874	W->A	21522130	Loss of histone tail binding.
Q2LAE1	891	W->A	21522130	Loss of histone tail binding.
Q2LAE1	908	Q->A	21522130	Loss of histone tail binding.
Q2LAE1	909	E->A	21522130	Loss of histone tail binding.
Q6NYC1	90	L->A	29176719	Nearly abolishes the interaction with the NET domain of BRD4.
Q6NYC1	91	K->A	29176719	Nearly abolishes the interaction with the NET domain of BRD4.
Q6NYC1	95	R->A	29176719	Nearly abolishes the interaction with the NET domain of BRD4.
Q969H4	493	W->A	14749388	No interaction with Rho.
Q92692	81	N->A	22927415	Abolishes homodimerization.
Q15051	549	A->K	23446637	Disrupts interaction with CEP290, no effect on interaction with BBS1, BBS2, BBS4, BBS8 and BBS9, abolishes ciliogenesis.
Q9LZD4	29	S->N	19903693	Loss of binding to PI5K2.
Q08215	22	L->F,S	12808025	No interaction with PEX6.
Q08215	47	Q->L	12808025	No interaction with PEX6.
Q08215	50	V->A	12808025	No interaction with PEX6.
Q99LE1	61	V->E	23798443	Abolishes homodimerization.
Q9EPI6	241	F->E	18303947	Loss of CABP1 binding.
E9Q8I9	2516	T->A	22753416	Loss of phosphorylation by CDK1. Loss of PLK1- binding.
E9Q8I9	2516	T->E	22753416	Loss of PLK1-binding.
Q53EL6	71	S->A	17053147	Strongly reduced interaction with BTRC. Strongly reduced ubiquitination.
Q53EL6	76	S->A	17053147	Strongly reduced interaction with BTRC. Strongly reduced ubiquitination.
Q53EL6	253	D->A	19153607	Strongly reduced interaction with EIF4A1. Strongly reduced inhibition of translation. Reduced inhibition of EIF4A1 helicase activity.
Q53EL6	358	H->A	19153607	Strongly reduced interaction with EIF4A1.
Q2PAY4	58	W->A	25055801	61-fold decrease of binding affinity to Nav1.4/SCN4A.
Q2PAY4	59	M->A	25055801	49-fold decrease of binding affinity to Nav1.4/SCN4A.
Q2PAY4	60	W->A	25055801	375-fold decrease of binding affinity to Nav1.4/SCN4A.
Q2PAY4	73	R->A	25055801	410-fold decrease of binding affinity to Nav1.4/SCN4A.
Q2PAY4	75	K->A	25055801	128-fold decrease of binding affinity to Nav1.4/SCN4A.
Q9UHD2	547	R->D	23453971	Decreases phosphorylation and kinase activity. Abolishes dimerization.
Q9UHD2	694	K->E	21931631	Strongly decreases interaction with TANK and TBKBP1. No effect on phosphorylation.
Q9UHD2	704	L->A	21931631	Strongly decreases interaction with AZI2, TANK and TBKBP1. No effect on phosphorylation.
P45697	27	K->D	12705833	118-fold decrease in toxicity to mice, and 250-fold decrease in the binding affinity for insect sodium channels.
P45697	81	K->E	12705833	71.4-fold decrease in toxicity to mice, and 170-fold decrease in the binding affinity for insect sodium channels.
P45697	83	H->A	12705833	3.8-fold decrease in toxicity to mice, and 180-fold decrease in the binding affinity for insect sodium channels.
P45697	83	H->D	12705833	43.9-fold decrease in toxicity to mice, and 96-fold decrease in the binding affinity for insect sodium channels.
Q96Q27	548	L->P	15590664	No interaction with Elongin BC complex.
Q96Q27	552	C->P	15590664	No interaction with Elongin BC complex.
O14079	392	S->A	24806815	Loss of in vitro interaction with phosphorylated hta1 peptide containing the S/T-Q motif. Abolishes ionizing radiation induced foci (IRIF) formation at nuclear DNA double strand breaks (DSBs). Localizes to mitotic spindle during early mitosis. Loss of midzone localization during late mitosis. Can not reverse the thiabendazole (TBZ) resistant phenotype of the deletion mutant of this protein.
O14079	434	K->M	24806815	Loss of in vitro interaction with phosphorylated hta1 peptide containing the S/T-Q motif. Abolishes ionizing radiation induced foci (IRIF) formation at nuclear DNA double strand breaks (DSBs). Loss of localization to mitotic spindle and midzone during early and late mitosis, respectively. Can not reverse the thiabendazole (TBZ) resistant phenotype of the deletion mutant of this protein.
Q9NRR4	1077	V->E	26748718	Loss of one DGCR8 interaction site; no effect on the second DGCR8 interaction site.
P0C2W0	156	H->Y	11080146	Loss of collagen-binding activity.
P0C2W0	159	H->Y	11080146	Loss of collagen-binding activity.
P80719	23	K->A	10888198	1000-fold decrease in affinity for shaker B.
Q96CV9	474	D->N	20085643	Significant reduction in ubiquitin binding and interaction with TBK1. Inhibits localization to recycling endosomes and disrupts interaction with TFRC. Loss of ability to inhibit the activation of the IFNB promoter in response to TLR3 or RIG-I signaling.
Q9UUJ6	80	G->A	12376568	No interaction with dis3; 10-fold increase in minichromosome loss.
G4YRX5	72	W->A	30963588	Abolishes the interaction with host target PINP1 and lowers the size of lesions in leaves after infection.
G4YRX5	100	Y->A	30963588	Abolishes the interaction with host target PINP1 and lowers the size of lesions in leaves after infection.
Q03145	736	Y->F	18387945	Inhibits EFNA1-induced vascular assembly and RAC1 activation in endothelial cells. No significant effect on kinase activity. Loss of binding to PI3-kinase p85 subunit.
Q03145	740	D->N	16782872	Loss of kinase activity and binding to VAV3.
Q03145	931	Y->F	18387945	Inhibits EFNA1-induced vascular assembly and RAC1 activation in endothelial cells. Inhibits kinase activity. Loss of binding to VAV3 and PI3-kinase p85 subunit.
J9U5U9	96	S->A	22959345	Loss of activity and abolish interaction with MAX2A.
Q08211	1163	K->A	16375861	Localizes in the cytoplasm and does not interact with the importin complex.
Q6ICB4	224	F->A	21233288	Loss of OCRL-binding.
Q6ICB4	228	H->A	21233288	Loss of OCRL-binding.
Q45Z47	57	G->S	16669624	Large decrease in neurotoxicity, 500-fold decrease in catalytic activity, no change in binding affinity to M-type receptors, 20'000-fold decrease in binding affinity to N-type receptors.
Q45Z47	75	H->Q	16669624	16-fold decrease in neurotoxicity, 500-fold decrease in catalytic activity, no change in binding affinity to M-type receptors, 50-fold decrease in binding affinity to N-type receptors.
P49427	70	Y->R	24316736	Loss of RBX1-binding.
P49427	117	T->E	24316736	Loss of RBX1-binding.
Q99496	69	H->Y	11513855	Loss of HIP2-binding and loss of ubiquitin ligase activity on histone H2A.
Q9UEU0	8	S->W	18033301	Abolished binding to CLINT1.
Q9UEU0	12	E->A	18033301	Abolished binding to CLINT1. Abnormal subcellular localization restricted to late endosomes and lysosomes.
Q9UEU0	23	E->R	18033301	Abolished binding to CLINT1. Rescued binding to CLINT1 E-146 mutant.
Q9UEU0	65	E->W	18033301	Abolished binding to CLINT1.
Q9UEU0	73	F->S	18033301	Abolished binding to CLINT1. Abnormal subcellular localization restricted to late endosomes and lysosomes.
P17728	27	K->A	9169449	74% loss of toxicity and 39.4-fold decrease in affinity to cockroach neuronal receptor.
P17728	29	Y->S	9169449	90% loss of toxicity and 114.3-fold decrease in affinity to cockroach neuronal receptor.
P17728	36	F->G	9169449	86% loss of toxicity and 160-fold decrease in affinity to cockroach neuronal receptor.
P17728	37	R->A	9169449	78% loss of toxicity and 231.4-fold decrease in affinity to cockroach neuronal receptor.
P17728	81	K->L	9169449	81% loss of toxicity and 220-fold decrease in affinity to cockroach neuronal receptor.
P17728	84	R->A	9169449	47% decrease in toxicity and 54.3-fold decrease in affinity to cockroach neuronal receptor.
P17728	84	R->D	9169449	95% decrease in toxicity and 2394-fold decrease in affinity to cockroach neuronal receptor.
P17728	84	R->N	9169449	6% increase in toxicity and 58.6-fold decrease in affinity to cockroach neuronal receptor.
Q9NRA8	958	W->A	29510985	Abolished interaction with LSM14A.
Q9NRA8	959	F->A	29510985	Abolished interaction with LSM14A.
Q9NRA8	978	V->A	29510985	Abolished interaction with LSM14A.
Q9NRA8	982	E->K	29510985	Abolished interaction with LSM14A.
Q9C0D6	180	I->A	26564798	Loss of actin-binding and ability to induce Golgi ribbon formation. Induces a significant increase in average cilia length.
Q9UH99	536	L->D	22632968	Disrupts interaction with SYNE2.
Q9UH99	542	D->N	22170055	Disrupts interaction with SYNE2.
Q9UH99	628	H->A	22632968	Disrupts interaction with SYNE2.
Q9UH99	707	Y->F	22632968	Disrupts interaction with SYNE2, impairs localization to the nuclear envelope.
A6QG59	131	R->A	18687868	Loss of host C3d binding stability.
A6QG59	138	N->A	18687868	Loss of host C3d binding stability.
Q38882	564	K->A	14594812	Loss of GPA1 binding.
A0A140LI88	1842	W->A	31003867	Abolished interaction with REC114.
Q06263	320	L->E	18194651	Abolishes dimerization.
Q06263	327	L->E	18194651	Abolishes dimerization.
P9WNK5	42	Q->P	19854905	Abolishes EsxB-EsxA heterodimer interaction with EccCb1 and EspA, maintains interaction with EccA2 and EccE2.
P9WNK5	62	A->S	19854905	Abolishes EsxB-EsxA heterodimer interaction with EccCb1, weaker interaction with EspA, maintains interaction with EccA2 and EccE2.
P9WNK5	95	S->T	19854905	Abolishes EsxB-EsxA heterodimer interaction with EccCb1, maintains interaction with EspA, EccA2 and EccE2.
P42568	59	F->A	25417107	Strongly decreased binding to crotonylated histone H3. Decreased binding to acetylated histone H3.
P42568	78	Y->A	25417107	Strongly decreased binding to crotonylated histone H3. Decreased binding to acetylated histone H3.
O25560	168	K->A	22179820	Abolishes GTP-dependent dimerization, but does not affect nickel-dependent dimerization. Loss of GTPase activity.
Q96B01	304	W->A	21903585	Abolished interaction with DMC1 without affecting interaction with RAD51.
Q61337	155	S->D	11717309	No pro-apoptotic activity, no interaction with Bcl-X(L).
A0A0H3MGR4	166	S->A	11260479	Loss of binding to 14-3-3 beta in vitro.
Q9D3P8	147	K->A	19897580	Disrupts binding to plasminogen.
Q60954	321	N->S	10523646	Loss of binding to other proteins.
P35914	323	C->S	12464283	Abolishes interchain homodimerization. Exhibits no DTT stimulated activity.
P45968	24	F->A	24685137	Disrupts binding to H3K9-methylated peptides.
Q92622	248	S->A	22423967	Disrupts interaction with YWHAB.
P04591	220	A->G	9223641	44-fold decrease of PPIA-binding affinity.
P04591	221	G->A	9223641	31-fold decrease of PPIA-binding affinity.
P04591	221	G->V	9223641	154-fold decrease of PPIA-binding affinity.
P04591	222	P->A	9223641	36-fold decrease of PPIA-binding affinity.
P04591	222	P->V	9223641	More than 150-fold decrease of PPIA-binding affinity.
Q8N697	465	E->K	25238095	Abolished transmembrane transporter activity. Abolished interaction with TASL.
Q14315	2669	M->D	15642266	Abolishes dimerization.
Q0ZLH2	328	C->S	30936319	Abolished interaction with MAP1LC3B and subsequent pexophagy.
Q0ZLH2	343	C->S	30936319	Abolished interaction with MAP1LC3B and subsequent pexophagy.
Q9BWF2	466	F->A	26711499	Abolished interaction with PCNA.
P38920	41	A->F	11555625	Defective in a mismatch repair assay. Abolishes heterodimer formation. Displays an increases spontaneous mutation accumulation.
P38920	98	G->V	10938116	Abolishes heterodimer formation. Displays an increase in spontaneous mutation accumulation.
Q9NVP2	36	D->A	22407294	Abolishes CDAN1 interaction.
Q9NVP2	37	D->A	22407294	Abolishes CDAN1 interaction.
P06935	14	V->A	23522008	Loss of interaction between capsid protein C and host EXOC1.
P08113	103	E->A	20865800	Loss of CNPY3-binding.
Q9QZ88	91	I->S	15965486	Disrupts interaction with VPS35.
Q9QZ88	152	L->E	24856514	Disrupts interaction with ANKRD27.
Q0ILQ6	70	Q->L	23723154	Abolishes the interaction with VPS9A.
Q8VCW4	412	H->R	16415873	Loss of function in TLR signaling. Impaired in its own transport from endoplasmic reticulum to endosome, lysosome and phagosome. Loss of the interaction with TLR3, TLR7, TLR9 and TLR13 and of the ability to transport them to endolysosome.
Q96PD4	77	R->A	28827714	Significantly decreases the affinity for IL17RA and IL17RC by nearly 5-fold and 200-fold, respectively.
O43889	81	Y->A	10623756	Does not retain HCFC1 in the cytoplasm, does not interact with HCFC1, does not activate promoter and fail to protect cells from a productive infection by HSV- 1.
Q9SZ15	395	F->A	25010425	Loss of SKD1 interaction.
Q19266	214	I->A	11134025	Prevents binding with num-1 (isoform a and isoform c).
Q19266	216	N->A	11134025	Prevents binding with num-1 (isoform a and isoform c).
Q19266	219	F->A	11134025	Prevents binding with num-1 (isoform a and isoform c).
Q9NP72	22	S->N	30970241	Loss of localization to lipid droplets and interaction with ZFYVE1.
O95684	74	V->F	16690081	Abolishes homodimerization and leads to aggregation.
Q9CZE3	92	V->A	21187289	Disrupts interaction with ANKRD27.
P13674	210	Y->A	15456751	Strongly reduced affinity for peptide substrate.
P13674	213	Y->A	15456751	Strongly reduced affinity for peptide substrate.
P13674	247	Y->A	15456751	Strongly reduced affinity for peptide substrate.
Q9LV87	84	S->A	18824048	Loss of binding to PEPR1 and of subsequent signaling.
Q9LV87	86	G->A,P	18824048	Loss of binding to PEPR1 and of subsequent signaling.
P40515	80	L->P	12163467	In fis1-L80P; no interaction with MDV1; mitochondrial fission is blocked; DNM1 assembly at punctate structures normal as in wild-type.
P01096	46	A->V	21192948	Strongly impairs F(1)F(o)-ATP synthase- binding.
P01096	47	F->A	21192948	Strongly impairs F(1)F(o)-ATP synthase- binding.
P01096	55	E->A	21192948	Strongly impairs F(1)F(o)-ATP synthase- binding.
P01096	58	Y->A	21192948	Strongly impairs F(1)F(o)-ATP synthase- binding.
P01096	69	A->V	21192948	Strongly impairs F(1)F(o)-ATP synthase- binding.
P01096	70	L->A	21192948	Strongly impairs F(1)F(o)-ATP synthase- binding.
Q9CWR8	297	F->A,E	18945701	Loss of binding to DNMT3A.
Q02775	217	E->K	12212850	Abolishes the interaction with PRP18, and temperature sensitive growth defect.
Q96EP0	82	Y->A	24726323	Abolished interaction with OTULIN.
Q96EP0	102	N->A	27458237	Abolished interaction with SPATA2.
Q96EP0	102	N->D	24726323	Abolished interaction with OTULIN.
Q99JB8	415	P->L	11082044	Loss of DNM1-, SYNJ1- and WASL-binding. Loss of effect on transferrin endocytosis.
Q60805	867	Y->F	9891051	Loss of GRB2 binding.
Q9NRW1	27	T->N	23737971	Loss of APBA1-binding.
Q86500	36	E->A	20696450	Loss of P150-P90 interaction. No effect on processing efficiency or fiber formation.
Q86500	49	I->A	20696450	Loss of P150-P90 interaction. No effect on processing efficiency or fiber formation.
Q02521	109	L->E,R	15542821	Loss of the interaction with PRP2.
Q8IXJ6	368	S->D	17488717	Abolishes CDK2-dependent phosphorylation. Inhibits interaction with a cyclin E-CDK2 complex. Reduces strongly histone deacetylation activity.
Q9HD67	893	L->Q	23012428	Abolishes dimerization.
Q9HD67	904	K->A	23012428	Abolishes dimerization.
O14966	73	M->S	29212815	Loss of LRRK2 binding. Does not stimulate LRRK2 kinase activity. Localized to the cytosol.
O14966	75	R->S	29212815	Loss of LRRK2 binding. Does not stimulate LRRK2 kinase activity. Localized to the cytosol.
Q9Y5L0	754	R->A	24449914	Abolished interaction with SRSF1.
P20339	57	F->A	15378032	Strongly decreases RABEP1 and ZFYVE20 binding affinity.
P20339	74	W->A	15378032	Strongly decreases RABEP1 binding affinity.
P20339	82	Y->A	15378032	Strongly decreases RABEP1 binding affinity. Impairs endosome fusion.
P20339	89	Y->A	15378032	Strongly decreases RABEP1 binding affinity.
A2RU30	185	F->A	23650607	Loss of ITPR1-binding.
Q9I9A7	7	T->A	19595719	Abolishes degradation by the proteasome due to the disrupted interaction with pcna.
Q9I9A7	8	D->A	19595719	Abolishes degradation by the proteasome due to the disrupted interaction with pcna.
P78504	207	F->A	18660822	Strongly reduced NOTCH1 binding.
Q9BY78	382	I->R	27368102	Strongly decreased E3 ubiquitin-protein ligase activity due to impaired interaction with E2 enzymes. Impaired ability to retain vesicles in the perinuclear cloud.
Q03020	134	P->A	15123690	Slow growth; no interaction with SSQ1.
Q03020	135	V->A	15123690	Wild-type growth; no interaction with SSQ1.
Q03020	136	K->A	15123690	No growth; no interaction with SSQ1.
P02640	814	W->A	16142894	Loss of F-actin binding.
Q8VYU8	353	Q->A	20832900	Loss of ROPs binding, but no effect on oligomerization.
P51587	2725	W->A	24013206	Disrupts interaction with SEM1.
Q13546	536	S->C	29681455	Strongly reduced homodimerization and interaction with RIPK3.
Q3V6T2	1675	S->A	27621449	Phosphorylation-deficient mutant which disrupts binding to GNAI3 and GNAS.
Q86WV1	333	W->R	12171928	Abolishes homodimerization, interaction with FYB1 and activation of the MAP kinase pathway.
P15319	29	R->A,G	9351822	Loss of chaperone activity, no interaction with PapG, no longer suppresses PapA P pilus subunit toxicity.
P15319	133	K->A	9351822	Loss of chaperone activity, no interaction with PapG.
P10844	1194	F->A	17167421	Greatly decreased binding of heavy chain to host SYT2, whole toxin about 40-fold less toxic.
P10844	1196	A->K	17167421	Greatly decreased binding of heavy chain to host SYT2, whole toxin about 1000-fold less toxic.
P10844	1204	F->A	17167421	Greatly decreased binding of heavy chain to host SYT2, whole toxin about 30-fold less toxic.
Q8WUM4	498	V->D	17350572	Reduces interaction with HIV-1 p6 and EIAV p9; abolishes rescue of PTAP-type L domain-deficient HIV-1 p6.
Q8WUM4	683	I->D	17350572	Reduces interaction with HIV-1 p6 and EIAV p9; abolishes rescue of PTAP-type L domain-deficient HIV-1 p6.
P87074	616	R->E	18676809	Disrupts gamma-H2A binding, but has no effect on dimer formation.
P87074	617	K->E	18676809	Disrupts gamma-H2A binding, but has no effect on dimer formation.
P87074	619	K->E	18676809	Disrupts gamma-H2A binding, but has no effect on dimer formation.
Q9C4Z7	135	L->E	17855384	Abolished interaction with MIND1.
Q9C4Z7	138	D->I	17855384	Abolished interaction with MIND1.
Q3E784	72	Y->A	12620189	Disrupts interaction with ARL3.
E0W5Q5	72	W->A	30963588	Abolishes the interaction with host target PINP1 and lowers the size of lesions in leaves after infection.
E0W5Q5	100	Y->A	30963588	LAbolishes the interaction with host target PINP1 and lowers the size of lesions in leaves after infection.
A4ITV2	107	F->A	21257773	Loss of heme b binding (by fragment with residues 55-162).
Q10QA5	186	F->A	24131983	Loss of strigolactone-dependent interaction with SLR1.
Q10QA5	245	F->A	24131983	Loss of strigolactone-dependent interaction with SLR1.
O60504	649	W->F	9885244	Loss of SOS-binding ability.
O60504	667	Y->V	9885244	Loss of SOS-binding ability.
Q9W6I1	40	L->A	25064856	Abolishes homodimerization and up-regulation of NOG mRNA levels. Loss of function in gastrointestinal smooth muscle cell differentiation and in gastrointestinal smooth muscle development.
Q96T37	795	K->A	22927943	Disrupts interaction with SETD1B.
Q96T37	898	K->A	22927943	Disrupts interaction with SETD1B.
Q96T37	923	F->A	22927943	Disrupts interaction with SETD1B.
Q9H267	249	G->V	23918659	Disrupts interaction with VIPAS39; no effect on interaction with STX7; impairs localization to VIPAS39- containing endosomal compartment.
Q9XZ56	54	Y->E,F	11389445	Abolished interaction with eIF4E1.
Q14140	238	L->A	18316374	Abolishes the interaction with XPO1 as well as the nuclear export and the subsequent proteasomal degradation.
Q08499	527	D->R	12387865	Abolishes homodimerization.
Q08499	563	R->D	12387865	Abolishes homodimerization.
Q84Y95	97	C->S	24203231	No effect on interactions with BOLA proteins, but strongly reduced interaction with SUFE1.
Q9QZS2	134	V->E	20681948	Abolishes homodimerization. Strongly reduced E3 ubiquitin ligase activity.
Q9QZS2	155	S->E	20681948	Abolishes homodimerization. Strongly reduced E3 ubiquitin ligase activity.
Q9QZS2	161	V->A	20681948	Abolishes homodimerization. Strongly reduced E3 ubiquitin ligase activity.
Q9QZS2	193	Y->A	20681948	Abolishes homodimerization. Loss of E3 ubiquitin ligase activity.
Q8IUC6	210	S->A	27302953	Abolished interaction with IRF3.
P38570	208	D->A	10837471	Loss of E-cadherin binding.
P38570	316	F->A	10837471	Loss of E-cadherin binding.
Q96CG3	178	E->A	12566447	Loss of binding to TRAF6 and activation of NF- kappa-B and JNK pathways.
P13612	1024	Y->A	10604475	Disrupts PXN binding.
O48791	74	V->A	22356912	Loss of actin-binding activity.
O48791	75	R->E	22356912	Loss of actin-binding activity.
O48791	81	F->A	22356912	Loss of actin-binding activity.
Q19541	61	R->C	24696453	In xf14; abolishes the interaction with pid-3. May abolish the interaction with erh-2. Reduces stability and reduces levels of a class of 21 nucleotide PIWI- interacting RNAs (piRNAs) that possess a uracil residue at the 5'-end (also called 21U-RNAs).
O60716	444	K->M	20371349	Severely disrupts cadherin interaction.
Q96QK1	108	L->P	23331060	Disrupts interaction with VPS26; no effect on interaction with VPS29.
Q96QK1	675	H->R	23331060	Disrupts interaction with VPS29. Does not effect interaction with VPS26.
P32354	245	Y->A	16782870	Inhibits interaction with POL30/PCNA and abolishes cell proliferation.
P32354	320	C->Y	12844493	In mcm10-43; abolishes self-association and diminishes interaction with MCM7.
P54116	197	V->P	22850675	Abolishes homodimerization and oligomerization. Abolishes regulation of ASIC2 and ASIC3 channel activity.
P32797	50	K->Q	10898792	Increase in length of X' and Y' telomeres. Disrupts interaction with POL1 but not FUN12.
P32797	72	I->T	10898792	Disrupts interaction with POL1 and FUN12.
P32797	124	C->R	10898792	Disrupts interaction with POL1 but not FUN12.
P32797	149	L->S	10898792	Disrupts interaction with POL1 but not FUN12.
P32797	228	S->P	10898792	Disrupts interaction with POL1 but not FUN12.
P32797	243	G->R	10898792	Disrupts interaction with POL1 and FUN12.
P32797	392	L->P	10898792	Disrupts interaction with POL1 but not FUN12.
P32797	523	I->V	10898792	Increase in length of X' and Y' telomeres. Disrupts interaction with POL1 but not FUN12.
Q5TYM5	125	W->R	18676834	Loss of UNG-binding.
P22412	377	C->G	8823187	Abolished disulfide-linked dimerization. Does not affect dipeptidase activity.
O95251	371	C->A	11278932	No interaction with MCM2 and ORC1.
Q94BT6	46	G->E	17704763	Loss of binding to GI.
Q94BT6	82	C->A	17704763	Loss of binding to GI, but no effect on FNM binding.
Q14008	1939	L->A,R	25596274	Disrupts interaction with TACC3.
Q14008	1942	L->A,R	25596274	Disrupts interaction with TACC3.
Q9QZS8	787	Y->E	15272013	Disrupts binding to BCAR1 and inhibits EGF- induced tyrosine phosphorylation.
Q9BVA6	258	L->D	25435325	Abolishes homodimerization.
P03950	29	R->A	10413501	Significantly decreases binding affinity for RNH1.
P03950	64	K->Q	10413501	Significantly decreases binding affinity for RNH1.
O81775	100	G->R	17157837	In log1-1; Disrupts the binding with LOG2; Abolishes its function.
O00300	400	C->S	9478964	Abolishes dimerization.
Q6ZS72	146	L->E	31311869	Abolishes homodimerization and interaction with CRK isoform CRK-II.
Q6ZS72	330	D->N	31311869	Strongly decreases homodimerization and interaction with CRK isoform CRK-II.
Q6ZS72	436	A->E	31311869	Abolishes homodimerization and interaction with CRK isoform CRK-II.
Q6ZS72	453	C->E	31311869	Abolishes homodimerization and interaction with CRK isoform CRK-II.
Q16526	387	D->N	22798407	Loss of binding to KL001.
Q16526	393	N->D	22798407	Loss of binding to KL001.
A9QM73	933	G->A	29073135	Abolished interaction with EXA1.
Q9UBQ0	152	L->E	20923837	Disrupts interaction with TBC1D5.
P34217	305	T->A	15024067	No interaction with RAD53.
Q15796	381	N->S	10615055	Loss of binding to SARA.
Q9Y6I9	273	F->A	31006537	Completely abolishes the interaction with LC3B.
Q9Y6I9	276	L->A	31006538	Completely abolishes the interaction with LC3B.
Q9BKB7	39	K->A	12151390	86.4-fold decrease in affinity to Kv11/ERG potassium channels.
Q9BKB7	41	R->A	12151390	70.6-fold decrease in affinity to Kv11/ERG potassium channels.
Q9BKB7	42	F->A	12151390	52.2-fold decrease in affinity to Kv11/ERG potassium channels.
P0AGB6	178	R->G	12016219	In SR1502; decreased sigma factor activity. Does not bind RseA, still binds RNAP.
P0AGB6	181	I->A	12016219	In SR1503; decreased sigma factor activity. Does not bind RseA, still binds RNAP.
P0AGB6	185	V->A	12016219	In SR1504; decreased sigma factor activity. Does not bind RseA, still binds RNAP.
P0DL50	42	D->A	16846229	317-fold decrease in binding affinity to cockroach sodium channels and correlated loss of toxicity to blowfly larvae.
P0DL50	51	L->A	16846229	209-fold decrease in binding affinity to cockroach sodium channels and correlated loss of toxicity to blowfly larvae.
Q8TDQ1	205	Y->F	15549731	No interaction with PTPN6.
Q5SQ64	281	Y->F	12852788	No phosphorylation. No interaction with GRB2 and GRB7. No phosphorylation increase of p42/44 MAP kinase.
Q8R5I7	534	I->T	12756293	Abolishes homodimerization.
Q8R5I7	537	L->T	12756293	Abolishes homodimerization.
Q8R5I7	541	L->T	12756293	Abolishes homodimerization.
O35973	448	W->E	22331899	Abolishes homodimerization.
Q9WV86	18	L->A	28436967	Disrupts KATNA1:KATNB1 interaction with ASPM.
Q9WV86	19	L->A	28436967	Disrupts KATNA1:KATNB1 interaction with ASPM.
Q8IV16	92	L->A	25387803	Only slightly increased formation of dimers and oligomers. No effect on number of monomers. Loss of LPL interaction.
Q8IV16	109	W->C,P,T	25387803	Promotes formation of dimers and oligomers reducing number of monomers. Loss of LPL interaction.
P08393	67	T->A	22405594	Abolishes interaction host RNF8.
P35613	P35613-2:211	P->A	15946952	Loss of interaction with PPIL2.
P55737	337	R->C	19487680	In hsp90.2-6; Decreased dimerization. Loss of ATPase activity and interaction with RAR1 and SGT1B.
Q9NRR6	641	C->A	24166846	Abolishes farnesylation-dependent interaction with PDE6D.
P63322	49	D->N	7623849	Loss of RALBP1 binding.
Q9H0F6	114	V->D	22549881	Abolishes homodimerization.
Q9BPX6	221	R->A	24514027	Abolishes homooligomerization.
Q9BPX6	376	D->A	24514027	Abolishes homooligomerization.
Q9BPX6	463	C->A	26387864	Abolishes interchain disulfide bond and heterodimer formation with MICU2.
Q94148	23	T->N	16394106	Dominant-negative mutant. Mislocalizes to the cytoplasm instead of membranes. Hardly any basolateral endosomal tubules of the intestine. No interaction with catalytically inactive tbc-4 A-155 mutant. Does not rescue rab-10 null mutant, and fails to rescue the proximal PVD defects in rab-10 deletion mutants, but also disrupts the distal dendrite arbor and further reduces branch complexity in the anterior region in wild-type animals.
P08235	785	K->E	16061183	Loss of coactivator binding.
Q96KP1	11	T->A	18756269	Impaired cytokinesis. Loss of RALA-binding. No change in localization to the midbody during cytokinesis.
O43541	471	G->S	9436979	Loss of SMAD1-binding and of inhibition of BMP-SMAD1 signaling. No effect on interaction with BMPR1B and TGFBR1.
Q99828	115	F->A	12023286	Loss of binding to ITGA2B.
Q99828	131	L->A,T	12023286	Loss of binding to ITGA2B.
Q99828	153	I->A	12023286	Loss of binding to ITGA2B.
Q99828	173	F->A	12023286	Loss of binding to ITGA2B. Does not inhibit interaction with PAK1.
Q96DU3	285	Y->F	16920955	Abolishes SLAMF6-mediated cytotoxity, disrupts interaction with SH2D1B and retains interaction with SH2D1A.
P62715	309	L->A	10441131	Loss of binding to PP2A B-alpha regulatory subunit.
Q9FMM3	575	Y->A	29073135	Enhanced cell death phenotype triggered by P.syringae pv. tomato (Pst) DC3000. Abolished interaction with SMG7.
Q94F88	382	F->A	15457214	Loss of binding to H3.
P63330	309	L->A	10441131	Loss of binding to PP2A B-alpha regulatory subunit.
P61972	118	M->E	11846560	Loss of homodimerization. Decreased interaction with GDP-bound RAN. Decreased interaction with nucleoporins. Decreased localization to the nuclear pore complex.
Q9VHA0	836	G->S	15280237	Loss of self- and ph-p binding activity.
P14091	60	C->A	7789521	Abolishes homodimerization.
P57059	575	S->E	29211348	Strongly reduced but still present interaction with 14-3-3 proteins in response to cAMP signaling and, thus, still able to inhibit TORC activity.
Q6PAL8	763	K->E	19141279	Abolishes the interaction with RAP6A and localization to Golgi membrane.
Q9H040	331	Y->F	27084448	Abolished interaction with PCNA.
Q9H040	332	F->Y	27084448	Abolished interaction with PCNA.
P03304	1218	V->A	30312637	Loss of interaction between protein 2C and host IFIH1/MDA5 and loss of inhibition of IRF3 phosphorylation.
Q40253	216	K->E	21402359	Does not affect ability to promote cell death while homooligomerization is abolished.
P51954	997	S->A	28235073	Loss of 14-3-3 protein-binding.
P06400	860	K->R	20870719	Abolishes monomethylation by SMYD2 and subsequent interaction with L3MBTL1.
P40337	98	Y->N	10944113	No interaction with HIF1A. No HIF1A degradation.
P39792	56	K->A	18684995	Cleaves Holliday junctions, no interaction with RecA, greatly increased sensitivity to DNA-damaging agents.
P39792	71	R->A	18684995	Cleaves Holliday junctions, no interaction with RecA, greatly increased sensitivity to DNA-damaging agents.
O65041	215	C->A	9624055	Loss of binding to RUB1.
P46061	525	L->A	11853669	Disrupted binding to UBE2I, and no sumoylation.
P51148	85	S->E	29125462	Phosphomimetic mutant. Loss of GDI1, GDI2, CHML and CHM binding.
Q86YP4	149	K->R	16415179	Disruption of MBD2-binding, loss of enhancement of MBD2-mediated repression and loss of speckled nuclear localization.
Q9UL25	33	T->N	15561770	Defects in GTP-binding. Abolishes the interaction with VAMP8 in response to starvation. Abolishes the interaction with TMED10.
P04605	50	C->S	10364329	Loss of binding to cyclin T.
Q9DAU1	145	M->K	18780723	Loss of HSP90B1-binding. Impairs association with TLR2 and TLR4; does not impair association with TLR9; partially affects responses of TLR2 and TLR4; affects responses of TLR9; does not affect cell-surface expression of TLR2; affects cell-surface expression of TLR4 and TLR9.
Q61627	73	F->D	27418511	Abolishes dimerization. Weakly interacts with C1q domain of CBLN1.
Q3UMR0	509	Q->A	21187289	Disrupts interaction with RAB32 and RAB38; inhibits peripheral distribution of TYRP1 in melanocytes; no effect on dendrite formation in melanocytes.
Q3UMR0	550	Y->A	21187289	Disrupts interaction with RAB32 and RAB38; inhibits peripheral distribution of TYRP1 in melanocytes; no effect on dendrite formation in melanocytes.
P18177	1501	D->A	29748286	Strongly reduced interaction with host FZD2.
P18177	1597	F->D	29748286	Abolished interaction with host FZD2.
P18177	1597	F->G,D	29748286	Abolished interaction with host FZD2.
Q14677	52	F->D	18033301	Abolished binding to VTI1B.
Q14677	96	R->S	18033301	Abolished binding to VTI1B.
Q14677	146	R->E	18033301	Abolished binding to VTI1B. Rescued binding to VTI1B R-23 mutant.
Q15435	148	D->V	12226088	Completely abolishes the interaction with protein phosphatase 1.
Q15435	192	E->A	12226088	Completely abolishes the interaction with protein phosphatase 1.
Q15435	214	F->A	12226088	Completely abolishes the interaction with protein phosphatase 1.
Q15435	300	E->A	12226088	Completely abolishes the interaction with protein phosphatase 1.
Q15435	302	W->A	12226088	Completely abolishes the interaction with protein phosphatase 1.
Q15435	327	Y->A	12226088	Completely abolishes the interaction with protein phosphatase 1.
Q99PJ1	48	I->A	23135401	Strongly reduced interaction with CDH23.
Q9UJW3	261	F->A	17713477	Loss of binding to DNMT3A.
Q45666	108	K->E	25691471	No interaction with glutamine synthetase.
Q9UQF2	160	R->G	12756254	Abolishes MAPK9 interaction.
Q9UQF2	161	P->G	12756254	Abolishes MAPK9 interaction.
P10415	145	G->E	17418785	Loss of BAX-binding and of anti-apoptotic activity. No effect on homodimerization.
P10415	188	W->A	8183370	Loss of BAX-binding and of anti-apoptotic activity. No effect on homodimerization.
Q8R1S4	746	K->A	12482861	Loss of actin-binding.
Q8R1S4	747	K->A	12482861	Loss of actin-binding.
P03246	51	F->S	8600029	No interaction with BAX and loss of anti- apoptotic activity.
P03246	87	G->A	8600029	No interaction with BAX and loss of anti- apoptotic activity.
Q8VDU0	601	L->E	22952234	Disrupts one GNAI3 binding site.
Q8VDU0	635	I->E	22952234	Disrupts one GNAI3 binding site.
Q84LH8	31	E->A	15486100	Loss of binding to PHYB.
Q84LH8	32	L->A	15486100	Loss of binding to PHYB.
Q84LH8	37	G->A	15486100	Loss of binding to PHYB.
Q84LH8	38	Q->A	15486100	Loss of binding to PHYB.
O70361	359	W->E	22331899	Abolishes homodimerization.
O70361	367	I->E	22331899	Abolishes homodimerization.
P08069	1346	Y->F	10454568	Loss of GRB10-binding.
Q99104	1535	I->E	23798443	Strongly reduces affinity for MLPH and SYTL4.
P40075	40	K->N	15668246	Disrupts binding to FFAT motif and causes OPI1 mislocalization.
Q9GZV1	99	S->A	21737686	Loss of interaction and phosphorylation by PKB/AKT2, loss of translocation to the nucleus and loss of function in myocyte differentiation.
Q14289	881	Y->F	20521079	Loss of phosphorylation site. Strongly reduced interaction with GRB2.
Q9UQB8	413	W->G	17115031	Impairs the SH3 domain and abolishes the interaction with EPS8.
Q09715	362	Y->C	14668334	No interaction with fep1.
Q09715	542	L->S	14668334	No interaction with fep1.
P62813	91	F->L	1376242	Strongly decreases the affinity for GABA- dependent channel gating.
Q9NPG3	160	F->E	19029251	Strongly diminishes interaction with HIRA.
Q9NPG3	162	I->E	19029251	Strongly diminishes interaction with HIRA.
P43033	149	H->R	10542206	Loss of binding to the catalytics dimers. Loss of the ability to regulate PAF-AH (I) activity.
Q9U3P2	105	Q->A	24485456	Loss of syg-1 interaction.
Q9H063	35	K->R	23673667	No interaction with RNA pol III and impaired recruitment to tRNA gene promoters.
Q07666	118	F->S	20610388	Disrupts homodimerization, impairs influence on alternative splicing.
Q07666	381	E->K	22000517	Disrupts interaction with APC.
Q07666	384	E->K	22000517	Disrupts interaction with APC.
O60493	22	Y->A	30213940	Loss of VPS35 binding.
O60493	50	E->K	30213940	Loss of VPS35 binding.
O60493	160	R->A	30213940	Loss of VPS35 binding.
Q8NI60	223	G->A,I,L,F	25216398	Strongly impairs homodimerization.
Q9DF69	375	E->Q	14622101	Loss of binding to TNR.
P40343	270	S->D	11988742	Reduces strongly the ubiquitin-binding activity.
P40343	313	S->D	11988742	Reduces strongly the ubiquitin-binding activity.
Q9DEN4	297	F->E	17138566	Abolishes mesoderm inducing activity and interaction with tle4.
Q9H8V3	184	T->A	19468300	Inhibits interaction with RACGAP1. Abolishes targeting to the central spindle.
Q9H8V3	226	K->M	19468300	Inhibits interaction with RACGAP1. Abolishes targeting to the central spindle.
Q9Y4G2	729	E->A	25500191	Disrupts interaction with RAB7A.
Q9Y4G2	769	R->A	25500191	Disrupts interaction with RAB7A.
Q9H792	1707	A->D	29212708	Disrupts homodimerization.
Q9JL04	1571	K->A	21705804	Strongly reduced interaction with SPIRE1.
P69736	87	S->D	12729799	Loss of binding to CALM.
Q92530	6	V->R	18495667	Abolishes homodimerization.
G5EEG7	15	I->R	27150041	Disrupts homodimerization.
G5EEG7	18	F->S,R	27150041	Disrupts homodimerization.
G5EEG7	96	L->R	27150041	Disrupts interaction with smu-2.
Q8QZZ8	78	V->A	21187289	Disrupts interaction with ANKRD27; inhibits peripheral distribution of TYRP1 in melanocytes.
P19524	511	E->K	8188749	In MYO2-66; disrupts actin binding.
O88602	321	T->D,E	11805122	No interaction with DLG1 and DLG4.
O88602	323	V->A	11805122	No interaction with DLG1 and DLG4.
P51681	20	C->A	10383387	Decreases to 40% surface expression. No effect on conformational integrity. Disrupts binding of CCL4. Decreases cell HIV infection.
P51681	101	C->A	10383387	Decreases to 40% surface expression. Disrupts conformational integrity. Disrupts binding of CCL4. Decreases HIV cell infection.
P51681	178	C->A	10383387	Decreases to 40% surface expression. Disrupts conformational integrity. Disrupts binding of CCL4. Decreases HIV cell infection.
P51681	269	C->A	10383387	Decreases to 40% surface expression. No effect on conformational integrity. Disrupts binding of CCL4. Decreases cell HIV infection.
Q99708	327	S->A	15485915	Abolishes BRCA1 interaction and ubiquitination. No activation of CHEK1 after DNA damage.
Q9R1D7	91	K->A	17640864	Disrupts DCB:DCB domain interaction; decreases DCB:HUS domain interaction.
Q9R1D7	130	E->A	17640864	Disrupts DCB:DCB domain and DCB:HUS domain interaction.
Q9R1D7	541	D->A	17640864	Disrupts DCB:HUS domain interaction.
Q8ND56	305	F->A	29510985	Abolished interaction with DDX6.
Q8ND56	396	F->A	29510985	Abolished interaction with DDX6.
P71590	459	R->A	15987910	Abolishes phosphorylation by PknB. Strong decrease in affinity for MviN.
O14216	60	T->A	11937031	Decrease in phosphorylation by cdc2; no interaction with rad4.
O14216	74	T->A	11937031	Decrease in phosphorylation by cdc2; no interaction with rad4.
O14216	87	S->A	11937031	Decrease in phosphorylation by cdc2; no interaction with rad4.
O14216	99	T->A	11937031	Decrease in phosphorylation by cdc2; no interaction with rad4.
O14216	154	T->A	11937031	Decrease in phosphorylation by cdc2; no interaction with rad4.
O74473	947	R->A	11676915	In cdc11-123; no interaction with sid4; does not localize at the SPB.
O74473	1041	T->I	11676915	In cdc11-123; no interaction with sid4; does not localize at the SPB.
Q04637	180	I->A	12086624	Loss of PABPC1 binding.
Q04637	182	I->A	12086624	Loss of PABPC1 binding.
Q04637	192	I->A	12086624	Loss of PABPC1 binding.
Q04637	196	I->A	12086624	Loss of PABPC1 binding.
Q10931	87	D->K	26687600	Abolishes the interaction with lgg-2.
Q10931	91	E->K	26687600	Abolishes the interaction with lgg-2.
X5IWS1	59	K->D	26817840	280-fold decrease of affinity to Nav1.2/SCN2A.
X5IWS1	61	R->D	26817840	133-fold decrease of affinity to Nav1.2/SCN2A.
X5IWS1	63	Y->A	26817840	53-fold decrease of affinity to Nav1.2/SCN2A.
Q15036	470	L->G	28892079	Strongly decreases interaction with CCDC22, CCDC93, VPS26C and VPS35L. No effect on endosomal location.
P49005	217	L->W	18818516	Loss of POLD3-binding in a yeast two-hybrid assay.
P49005	224	G->W	18818516	Loss of POLD3-binding in a yeast two-hybrid assay.
P49005	231	E->W	18818516	Loss of POLD3-binding in a yeast two-hybrid assay.
Q8N4B1	224	F->A	20133602	Loss of OCRL-binding. Drastically reduces membrane targeting.
Q8N4B1	228	H->A	20133602	Loss of OCRL-binding.
P53352	804	W->G	19951914	Disrupts interaction with AURKB.
Q9I2V0	10	H->N	27609419	Does not bind to Mn 1.
O35394	70	N->T	12107180	Retained in endoplasmic reticulum, no interaction with RAB3A or VAMP2.
O35394	73	Y->A	12107180	Retained in endoplasmic reticulum, Golgi and tubular structures, no interaction with RAB3A.
O35394	78	Y->A	12107180	Retained in endoplasmic reticulum, no interaction with RAB3A or VAMP2.
O35394	166	H->A	12107180	Retained in endoplasmic reticulum, Golgi and tubular structures, no interaction with RAB3A.
Q8K1Q4	700	S->G,A	16522626	Abolishes interaction with SHANK3.
Q5EBH1	220	C->D	18596699	Strongly reduced interaction with HRAS.
Q5EBH1	221	L->D	18596699	Strongly reduced interaction with HRAS.
Q5EBH1	303	K->A	18596699	Strongly reduced interaction with HRAS.
Q8CJ27	352	F->A	28436967	Disrupts interaction with KATNA1:KATNB1.
O35158	686	P->A	21802063	Fails to support induction of the Sonic hedgehog/SSH receptors PTCH1 and GLI1. The mutant protein retains very little residual activity even during overexpression and interacts with SHH, but does not interact with PTCH1, BOC, or GAS1.
O35158	777	V->E	21802063	Fails to support induction of the Sonic hedgehog/SSH receptors PTCH1 and GLI1. The mutant protein retains some residual activity during overexpression. The mutant protein interacts with SHH, but does not interact with PTCH1. The mutation protein has a shorted half-life compared to wild-type and may have an altered conformation resulting in destabilization.
O35158	787	I->A	21802063	Fails to support induction of the Sonic hedgehog/SSH receptors PTCH1 and GLI1. The mutant protein retains some residual activity during overexpression. The mutant protein interacts with SHH, but does not interact with GAS1.
O35158	937	S->R	21802063	Fails to support induction of the Sonic hedgehog/SSH receptors PTCH1 and GLI1. The mutant protein retains some residual activity during overexpression. The mutant protein interacts with SHH, but does not interact with PTCH1 or GAS1. The mutation protein has a shorted half-life compared to wild-type and may have an altered conformation resulting in destabilization.
Q07812	74	M->D,E	21199865	Strongly reduced interaction with MCL1, BCL2, BCL2L1 and BCL2L2. No effect on cytochrome c release and subsequent apoptosis triggered by etoposide.
P19491	876	Y->A	20547133	Strongly decreases interaction with IQSEC1. Abolishes activation of ARF6 by IQSEC1.
O60603	681	P->F	11081518	Abolishes the interaction with MYD88. No effect on oligomerization or on the structure of the TIR domain.
Q7KZI7	596	T->A	15084291	Loss of membrane dissociation and binding to YWHAZ.
O14543	71	R->K	10421843	No effect on EPO/LIF-induced signaling suppression. Partial suppression of JAK2 phosphorylation. No effect on binding to JH1. Loss of binding to IL12RB2.
Q92805	2	F->A	29084197	Loss of TBC1D23-binding.
Q92805	5	L->A	29084197	Loss of TBC1D23-binding.
Q92805	697	Y->A	10209123	Loss of RAB6A-binding and of targeting to the Golgi apparatus.
P0C7Q4	352	G->P	9671782	Loss of in vitro activation by denatonium due to disruption of interaction with taste receptors.
Q9HCD5	342	I->A	11113208	Abolishes E2-inducible strong interaction with ESR1, but not basal interaction.
Q9C5S8	368	K->E	15604743	Abolishes the interaction with CRKIPs.
Q13547	421	S->A	11602581	Strongly decreases deacetylase activity, and disrupts interaction with NuRD and SIN3 complexes.
Q13547	423	S->A	11602581	Strongly decreases deacetylase activity, and disrupts interaction with NuRD and SIN3 complexes.
Q9UM82	108	F->A	27458237	Abolished interaction with CYLD.
P22384	37	C->S	10364329	Loss of binding to cyclin T.
P37173	277	K->R	11483955	Abolishes kinase activity, TGF-beta signaling and interaction with DAXX.
Q96E22	200	I->A	32817466	Disrupts NUS1-DHDDS heterodimerization.
Q96E22	226	L->A	32817466	Disrupts NUS1-DHDDS heterodimerization.
Q96E22	230	L->A	32817466	Disrupts NUS1-DHDDS heterodimerization.
Q96E22	252	G->A	32817466	Disrupts NUS1-DHDDS heterodimerization.
Q96E22	253	F->A	32817466	Disrupts NUS1-DHDDS heterodimerization.
Q96E22	255	P->A	32817466	Disrupts NUS1-DHDDS heterodimerization.
P63012	51	F->L	7532276	Disrupts the interaction with RAB3IP.
P63012	55	V->E	7532276	Disrupts the interaction with RAB3IP.
P63012	56	G->D	7532276	Disrupts the interaction with RAB3IP.
P01178	28	G->V	18174156	Gain of antagonist activity on V1aR/AVPR1A (and loss of agonist activity on this receptor). 310-fold decrease in affinity for oxytocin receptor (OXTR), 13-fold decrease in affinity for V1aR/AVPR1A, and complete loss of affinity for V1bR/AVPR1B and V2R/AVPR2.
P15776	211	F->A	18550812	Loss of receptor binding.
Q14653	285	R->S	27302953	Abolished interaction with STING1, MAVS or TICAM1.
Q14653	313	K->S	27302953	Abolished interaction with STING1, MAVS or TICAM1.
P19321	1238	W->A	20704566	Dramatically decreased binding of heavy chain (HC) to synaptosomes, whole toxin is dramatically less neurotoxic. Loss of HC binding to GD1b, GT1b, GD2 and synaptic vesicles, ganglioside-binding loop is disordered in crystal.
P0DI97	137	D->A	21410790	Loss of NLGN1-binding. No effect on CBLN1- binding.
P0DI97	238	N->A	21410790	Loss of NLGN1-binding. No effect on CBLN1- binding.
O14576	148	L->G	27502274	Disrupts interaction with DYNLT1.
O14576	150	V->G	27502274	Disrupts interaction with DYNLT1.
O14576	158	F->G	27502274	Disrupts interaction with DYNLT1.
Q96C92	190	P->A	23108400	Disrupts interaction with PTPN13.
Q96C92	194	E->A	23108400	Disrupts interaction with PTPN13.
Q9NZ09	268	F->S	27839950	Abolished interaction with PTPN23.
Q61701	278	F->A	20064466	Disrupts interaction with EIF4A and fails to stimulate translation.
Q91YX0	660	Y->F	20644716	Loss of phosphorylation. Loss of LYN-binding. Slight decrease in GRB2-binding. No effect on VAV-binding. Partial loss of enhancement of LPS-induced TNF production.
G0SCK6	486	R->E	26476442	Disrupts the interaction with YTM1.
P01050	1	V->E,K	1581311	Strongly decreased affinity for thrombin.
P01050	2	V->E,G	1581311	Strongly decreased affinity for thrombin.
P01050	3	Y->A	1581311	Strongly decreased affinity for thrombin.
P01050	15	L->A	8135762	Strongly decreased affinity for thrombin.
P01050	56	F->I,L,T,V	1911777	Strongly decreased affinity for thrombin.
Q5ZKX9	12	H->A	30846601	Loss of binding to the sequence motif K-D-E- L.
Q5ZKX9	47	R->K	30846601	Loss of binding to the sequence motif K-D-E- L.
Q5ZKX9	127	E->A,Q	30846601	Loss of binding to the sequence motif K-D-E- L.
Q5ZKX9	158	Y->F	30846601	Loss of binding to the sequence motif K-D-E- L.
Q15691	89	K->E	12857735	Loss of binding to microtubules.
Q9H8Y8	441	S->D	21884936	Phosphomimetic mutant. No loss of its ability to mediate unconventional (ER/Golgi-independent) trafficking of CFTR to the cell membrane. Disrupts homodimerization. No loss of ER stress-induced relocalization from Golgi to ER.
Q8IWA4	88	K->A	27920125	Abolishes GTPase activity. Abolishes dimerization.
Q8IWA4	144	H->A	28114303	Abolishes GTPase activity. Abolishes dimerization.
Q8IWA4	245	E->A	28114303	Decreases GTPase activity. Abolishes dimerization. Impairs mitochondrial fusion.
Q8IWA4	336	K->N	27920125	Loss of function in mitochondrial fusion. Abolishes dimerization. Decreases GTPase activity.
Q16637	134	E->K	14715275	Reduces SMN binding to RPP20/POP7. Abolishes the interaction with ELAVL4.
Q62132	338	S->E	10601328	Mimics phosphorylation by PKA, prevents MAPK binding.
Q923U0	457	Y->F	11711534	Abolishes phosphorylation by FYN and interaction with FYN.
O35714	199	S->A	12478477	Does not bind to SIVA1.
O35714	209	P->A	12478477	Does not bind to SIVA1.
O95716	86	T->E	29125462	Phosphomimetic mutant. Loss of CHM and CHML binding.
O13024	837	F->A	15866179	Disrupts interaction with aurkb-a.
Q9BVI0	96	C->S	22864287	Abolishes homodimerization.
Q9BVI0	100	C->S	22864287	Abolishes homodimerization.
O00189	283	R->D	20230749	Strongly reduced interaction with APP.
P31489	156	A->D	10931316	Loss of collagen-binding activity.
P35558	90	S->A	32322062	Abolished phosphorylation by AKT1, interaction with INSIG proteins (INSIG1 and INSIG2) and ability to regulate lipogenesis.
P31386	229	W->A,C	25543256	Abolished interaction with KTI11.
Q14332	77	Y->A	29748286	Strongly reduced interaction with C.difficile toxin TcdB.
Q14332	127	K->A,E	29748286	Strongly reduced interaction with C.difficile toxin TcdB.
P60484	403	V->A	15951562	Loss of DLG1-, MAGI2-, MAGI3-, MAST1-, MAST2- and MAST3-binding.
Q92930	72	T->E	29125462	Phosphomimetic mutant. Loss of binding to GDI1, GDI2, CHM, and CHML.
P05067	757	Y->G	10383380	Loss of binding to MAPK8IP1, APBA1, APBB1, APPBP2 and SHC1.
P05067	762	Y->A	10383380	Loss of binding to APBA1 and APBB1. APP internalization unchanged. No change in amyloid-beta protein 42 secretion.
O82882	447	E->D	12123444	Prevents both cleavage and binding to SERPING1. Unable to aggregate T-cells. Still able to bind zinc.
O14745	355	F->R	15020681	Loss of MSX binding.
Q92609	59	W->A	22354992	Disrupts interaction with VPS29.
Q99380	24	I->K	10677492	Disrupts interaction between OST3 and STT3.
Q10256	330	F->A	16138082	20-fold reduction in binding affinity for Lys- 48-linked diubiquitin (Ub2) compared to that of the wild- type. Significantly reduced binding affinity also for Lys- 48-linked triubiquitin (Ub3) and tetraubiquitin (Ub4). Slightly reduced binding affinity for monoubiquitin. No effect on stability or structure of the UBA domain.
Q96E17	94	T->E	29125462	Phosphomimetic mutant. Loss of GDI2, CHM and CHML binding.
Q6JXI5	109	A->R,W	26551074	Abolished interaction with TAP19/p19.
Q6JXI5	112	E->R	26551074	Abolished interaction with TAP19/p19.
Q6JXI5	113	M->W	26551074	Abolished interaction with TAP19/p19.
P56198	46	R->E	23481402	Abolishes CIDE-N/CIDE-N interaction between the 2 homodimer subunits.
P56198	55	R->E	23481402	Abolishes CIDE-N/CIDE-N interaction between the 2 homodimer subunits.
Q9Y5U4	113	A->W	26160948	Abolished interaction with SCAP even in the presence of 25-hydroxycholesterol.
Q9Y5U4	117	G->F	26160948	Abolished interaction with SCAP even in the presence of 25-hydroxycholesterol.
Q9Y5U4	120	H->F	26160948	Abolished interaction with SCAP even in the presence of 25-hydroxycholesterol.
Q9Y5U4	132	Q->A	17428920	Abolished interaction with SCAP without affecting binding to 25-hydroxycholesterol.
Q9Y5U4	145	W->A	17428920	Abolished interaction with SCAP without affecting binding to 25-hydroxycholesterol.
Q9Y5U4	149	D->A	16606821	Loss of ability to suppress the cleavage of SREBP2 and to accelerate the degradation of HMGCR. Abolished interaction with SCAP without affecting binding to 25-hydroxycholesterol.
Q12142	192	H->L	17178909	Aboloshes interaction with ATG11 and disrupts Cvt, but not bulk autophagy.
Q14451	511	F->R	15841400	Abolishes dimerization. Abolishes activation of HRAS.
Q15004	65	I->A	11313979	Loss of binding to PCNA.
Q15004	68	F->A	11313979	Loss of binding to PCNA.
P06536	481	D->R	8618925	Disrupts dimerization and decreases transcription transactivation.
Q8S8F7	43	W->A	19329567	Loss of binding to protein-phosphatase 1 (PP1).
Q9HBB8	109	R->G	24725409	Loss of binding to CDHR2.
Q6DRP4	197	L->R	19151727	Loss of function in heart development. Loss of HEG-binding.
Q9BXA6	41	K->M	15870294	Loss of kinase activity. Loss of binding to TSACC.
Q9Z2G6	521	L->A	27064360	Abolishes homodimerization.
P05556	778	G->Q	11807098	Loss of beta-1A interaction with FLNA and FLNB.
P05556	786	A->P	11807098	Loss of beta-1A interaction with FLNA and FLNB.
P49773	97	V->D,E	17337452	Loss of dimerization. Strongly reduced enzyme activity.
Q9CWH4	27	R->A	31003867	Strongly reduced interaction with ANKRD31.
Q8QGR0	55	R->A	12488533	105-fold decrease in affinity to M1 muscarinic acetylcholine receptors and change from irreversible to reversible binding.
Q8N9S9	440	L->G	28892079	Strongly decreases interaction with CCDC22, CCDC93, VPS26C and VPS35L.
P09874	826	H->A	32028527	Strongly reduced serine ADP-ribosylation, caused by abolished interaction with HPF1.
P09874	988	E->A,D,Q,K	29220653	Poly-ADP-ribosyltransferase activity is inhibited while mono-ADP-ribosyltransferase activity is not affected; only monomers are added. Disrupts interaction with CHD1L.
P09874	993	D->G	26344098	Abolished interaction with TIMELESS.
P0ACE3	48	D->E,R	21600204	Abolishes the interaction with H-NS.
P0ACE3	48	D->N	21600204	Abolishes the interaction with H-NS. Loss of the ability to repress the expression of the hly operon.
Q9Y6U3	455	F->D	19666531	Loss of actin-binding.
P45432	350	F->A	23818606	Abolishes the interaction with CSN7.
P45432	373	L->D	23818606	Abolishes the interaction with CSN7.
P45432	387	D->L	23818606	Strongly reduced interaction with CSN7.
O54967	464	H->D	16777958	Loss of CDC42-binding and impairment of autophosphorylation.
Q9Y6X9	18	Y->A	29440755	Abolishes homodimerization. No effect on ATPase activity. Loss of HUSH-dependent gene silencing.
Q9SX29	89	D->A	23898032	Loss of interactions with some potential substrates.
Q9SX29	90	N->A	23898032	Loss of interactions with some potential substrates.
Q8MU95	72	D->A	21697086	Loss of binding to laminarin by the N-terminal domain.
Q8MU95	99	W->A	21697086	Loss of binding to laminarin by the N-terminal domain.
P29320	133	V->E	14660665	Loss of EFNA5-binding ability and function.
P29320	152	F->L	14660665	Loss of EFNA5-binding ability and function.
O75340	52	L->A	25667979	Strongly impaired interaction with SEC31A. Slightly reduced interaction with PDCD6IP.
O75340	60	F->A	18256029	Abolishes the interaction with SEC31A, PDCD6IP, ANXA7 and ANXA11.
O75340	85	F->A	25667979	Strongly impaired interaction with SEC31A and TFG. Does not affect interaction with PDCD6IP.
O75340	91	Y->A	18256029	Abolishes the interaction with PDCD6IP, ANXA7 and ANXA11.
O75340	95	W->A	18256029	Abolishes the interaction with PDCD6IP, ANXA7 and ANXA11.
O75340	180	Y->A	18256029	Abolishes the interaction with PDCD6IP, TSG101, ANXA7 and ANXA11. Does not affect interaction with TFG and SEC31A.
O95994	63	Y->A	23274113	Disrupted dimerization.
O95994	64	K->A	23274113	Disrupted dimerization.
Q02908	108	C->A	18986986	Dissociation of the elongator complex following assembly. Abolished interaction with KTI11 and KTI12.
Q96GG9	241	D->N	18826954	Loss of binding to CAND1 and CUL-RBX1 complex but retains binding to UBE2M.
Q8CGU4	187	P->L	14528310	Abolishes interactions with HOMER1C and NF2.
Q9NPJ4	108	P->A	25775514	Abolishes the interaction with DCP1A.
Q9NPJ4	114	W->A	25775514	Abolishes the interaction with DCP1A.
Q80U87	680	S->A	16944949	Abolishes the interaction with YWHAE and leads to accumulation in the nucleus.
O35857	282	K->D	31618756	Abolished interaction with SLC25A4/ANT1.
Q9NZC2	48	K->M	27477018	Loss of LDL, CLU and APOE binding.
H2KZU7	767	K->R	22388962	Abolished interaction with shc-1. Probable loss of kinase activity. Loss of phosphorylation at Y-890. Impaired axon regeneration following injury.
P06729	67	K->R	2444890	Loss of CD58 binding.
P06729	70	Q->K	2444890	Loss of CD58 binding.
P06729	110	Y->D	2444890	Loss of CD58 and CD59 binding.
P06729	111	D->H	2444890	Loss of CD58 and CD59 binding.
A0A0H3MDW1	89	W->E	21775428	Significantly reduced DNA-binding. No dimerization.
Q13671	351	S->A	11784866	Abolishes phosphorylation by PKD and the interaction with 14-3-3 proteins.
Q7L0Q8	83	F->G	17620058	Loss of ARHGAP30-binding.
P76010	223	Q->P	20346719	Significant suppression of the pdeH disruption motility phenotype, no binding to FliM.
P76010	227	I->W	20346719	Some suppression of the pdeH disruption motility phenotype, no binding to FliM.
P0DMM5	273	R->E	30962626	Abolishes dimerization. Large decrease in protein kinase activity.
P0DMM5	282	R->E	30962626	Abolishes dimerization. Large decrease in protein kinase activity.
P0AAM3	2	C->A	10783387	Lack of hydrogenase 3 activity. Cannot interact with pre-HycE or HypD. Does not bind iron.
P0AAM3	2	C->R,S	10783387	Lack of hydrogenase 3 activity. Cannot interact with pre-HycE or HypD.
P17157	53	E->A	10620010	Loss of kinase activity. Abolishes interaction to PHO80 and PCL1 cyclins.
O54943	415	F->E	19402751	Abolishes dimerization.
O54943	419	W->E	19402751	Abolishes dimerization.
O54943	427	I->E	19402751	Abolishes dimerization.
Q9NZ52	247	L->P	14660606	Loss of UBC-binding and ubiquitination.
Q9NZ52	262	L->S	14660606	Loss of UBC-binding and ubiquitination.
Q9NZ52	276	L->S	14660606	Loss of UBC-binding and ubiquitination.
Q9NZ52	280	L->R	14660606	Loss of UBC-binding and ubiquitination.
Q9NZ52	284	D->G	14660606	Loss of UBC-binding and ubiquitination.
Q9NZ52	293	Y->H	14660606	Loss of UBC-binding and ubiquitination.
Q12933	285	I->A	20385093	Strongly reduced interaction with BIRC3.
Q12933	288	V->A	20385093	Strongly reduced interaction with BIRC3.
Q12933	292	E->A	20385093	Strongly reduced interaction with BIRC3.
P56637	48	E->D	15054090	8.3-fold decrease in toxicity and 43.6-fold decrease in binding affinity.
P56637	48	E->L	15054090	29-fold decrease in toxicity and 158-fold decrease in binding affinity.
P56637	48	E->Q	15054090	27.3-fold decrease in toxicity and 74.5-fold decrease in binding affinity.
P56637	48	E->R	15054090	608-fold decrease in toxicity and 11455-fold decrease in binding affinity.
Q9NR12	63	H->A	10359609	Loss of binding to TPM2.
O00560	215	N->D	27386966	Disruption of the cooperative binding of C- terminal peptides from FZD7 and phosphatidylinositol-4,5- bisphosphate.
Q13291	281	Y->F	11313386	Disrupts interaction with INPP5D/SHIP-1 and PTPN11/SHP-2, no effect on interaction with SH2D1A.
Q13291	327	Y->F	11313386	Disrupts interaction with INPP5D/SHIP-1 and PTPN11/SHP-2, no effect on interaction with SH2D1A.
P35279	22	Q->V	9438855	Loss of binding to rabkinesin-6.
P35279	46	I->E	9438855	Loss of binding to rabkinesin-6.
Q00597	249	S->A	11520787	No effect on protective function from mitomycin C-genotoxicity. Loss of IFNG-induced STAT1- binding.
Q00597	251	E->A	11520787	No effect on protective function from mitomycin C-genotoxicity. Loss of IFNG-induced STAT1- binding.
P46675	23	W->A	17355870	Disrupts interaction with tubulin heterodimer. Impairs polymerase activity under microtubule stress.
P46675	151	K->A	17355870	Disrupts interaction with tubulin heterodimer.
P46675	341	W->A	22904013	Disrupts interaction with tubulin heterodimer. Impairs polymerase activity under microtubule stress.
P46675	519	R->A	22904013	Disrupts interaction with tubulin heterodimer. No effect on polymerase activity under normal conditions but impairs polymerase activity under microtubule stress.
Q20646	544	K->L	17581633	Disrupts homodimer formation.
Q20646	551	R->L	17581633	Disrupts homodimer formation.
Q20646	552	E->L	17581633	Disrupts homodimer formation.
Q01804	279	A->R	29395066	Abolishes 'Lys-63'-specific deubiquitinase activity by impairing the affinity for 'Lys-63'-linked ubiquitin chain substrate.
G5EFA2	83	C->A	12707312	Abolishes the interaction with csc-1.
P06447	368	S->R	7491760	Loss of phosphoprotein binding. Complete loss of transcription and replication.
P04797	152	T->A	20972425	Abolishes interaction and subsequent nitrosylation of SIRT1.
G5EC37	298	F->A	26687600	Abolishes the interaction with lgg-1 and lgg- 2.
Q03555	745	P->A	16511563	Loss of GLRB binding.
F4JCC1	209	W->A	19467629	Loss of CTD binding.
D2CVN7	38	R->E	26551074	Abolished interaction with TAP45/p45; overexpression causes telomere 3'-overhang elongation.
D2CVN7	145	Y->A	26551074	Abolished interaction with TAP45/p45.
D2CVN7	147	M->W	26551074	Abolished interaction with TAP45/p45.
D2CVN7	161	I->R	26551074	Abolished interaction with TAP45/p45.
L8EBJ9	20	R->D	25848052	Disrupts interaction with FtsZ.
Q14CM0	102	R->A	19118189	Abolishes the interaction with ARHGEF7. Mutant overexpression in cultured neurons does not induce a significant increase in spine density contrary to wild type.
Q14CM0	1320	T->D	19118189	Abolishes the interaction with DLG4/PSD95. Reduces protein localization to dendritic spines.
Q8R5C8	291	F->A	24590075	Abolished H3.3K36me3 binding.
Q8R5C8	294	W->A	24590075	Abolished H3.3K36me3 binding.
Q8R5C8	310	F->A	24590075	Abolished H3.3K36me3 binding.
Q9WVE8	478	P->L	11082044	Loss of DNM1-, SYNJ1- and WASL-binding.
P23561	59	I->R	15327964	Disrupts interaction with STE50 and abolishes signal transduction.
Q15286	72	T->E	29125462	Phosphomimetic mutant. Loss of binding to GDI1, GDI2, CHM and CHML.
P61026	73	T->E	26824392	Phosphomimetic mutant. Loss of GDI1 and GDI2 binding. Increases localization to the Golgi complex.
P47025	400	F->A	14517324	No interaction with FIS1; slight decrease in interaction with DNM1.
Q9BWT1	160	R->A	23166294	Abolishes phosphorylation and interaction with YHWAE and YHWAZ.
Q9BWT1	163	T->A	23166294	Abolishes phosphorylation, interaction with YHWAE and YHWAZ, and cytoplasmic localization.
Q9BWT1	164	F->A	23166294	Abolishes phosphorylation and interaction with YHWAE and YHWAZ.
Q9BWT1	165	P->A	23166294	Abolishes phosphorylation, interaction with YHWAE and YHWAZ, and cytoplasmic localization.
O45495	8	F->A	21179194	Does not bind to ubc-13.
Q69ZI1	470	E->Q	14504284	Loss of binding to AKT2.
Q69ZI1	489	W->A	14504284	Loss of binding to AKT2 and enhanced binding to MAP3K11.
P17181	535	S->A	24075985	Abolishes phosphorylation at this site and interaction with SHMT2.
Q06259	78	N->W	24141193	No change in binding to EF-Tu, 100-fold decrease of affinity of doc-EF-Tu-GTP complex for AMP-PNP (probably also ATP).
P60266	38	L->A	15569679	157-fold decrease in binding affinity to rat sodium channels.
P60266	41	N->A	15569679	649-fold decrease in binding affinity to rat sodium channels.
P60266	43	Y->A	15569679	886-fold decrease in binding affinity to rat sodium channels.
P60266	46	R->A	15569679	30.8-fold decrease in binding affinity to rat sodium channels.
P60266	46	R->I	15569679	39-fold decrease in binding affinity to rat sodium channels.
P60266	47	E->A	15569679	648-fold decrease in binding affinity to rat sodium channels.
P60266	47	E->L	15569679	45-fold decrease in binding affinity to rat sodium channels.
P60266	47	E->Q	15569679	394-fold decrease in binding affinity to rat sodium channels.
P60266	47	E->R	15569679	962-fold decrease in binding affinity to rat sodium channels.
P60266	51	Q->W	15569679	35.8-fold decrease in binding affinity to rat sodium channels.
P60266	59	Y->A	15569679	1451-fold decrease in binding affinity to rat sodium channels.
P60266	61	Y->A	15569679	1533-fold decrease in binding affinity to rat sodium channels.
P60266	63	F->A	15569679	831-fold decrease in binding affinity to rat sodium channels.
P60266	77	W->A	15569679	87-fold decrease in binding affinity to rat sodium channels.
Q8GYD9	888	W->F	22940249	Loss of binding to AGO1 and AGO4.
Q26292	30	G->N	17166514	55-fold decrease in binding affinity to cockroach sodium channels.
Q26292	32	K->A	17166514	240-fold decrease in binding affinity to cockroach sodium channels.
Q26292	32	K->T	17166514	122-fold decrease in binding affinity to cockroach sodium channels.
Q26292	33	V->R	17166514	50-fold decrease in binding affinity to cockroach sodium channels.
Q26292	34	A->E	17166514	60-fold decrease in binding affinity to cockroach sodium channels.
Q26292	37	I->A	17166514	700-fold decrease in binding affinity to cockroach sodium channels.
Q26292	38	G->A	17166514	33-fold decrease in binding affinity to cockroach sodium channels.
Q26292	39	N->A	17166514	35-fold decrease in binding affinity to cockroach sodium channels.
Q26292	41	G->A	17166514	61-fold decrease in binding affinity to cockroach sodium channels.
Q26292	44	K->A	17166514	600-fold decrease in binding affinity to cockroach sodium channels.
Q26292	45	E->A	17166514	119-fold decrease in binding affinity to cockroach sodium channels.
Q26292	45	E->R	17166514	460-fold decrease in binding affinity to cockroach sodium channels.
Q26292	53	Y->V	17166514	72-fold decrease in binding affinity to cockroach sodium channels.
Q26292	57	W->A	17166514	250-fold decrease in binding affinity to cockroach sodium channels.
Q26292	59	W->A	17166514	250-fold decrease in binding affinity to cockroach sodium channels.
Q26292	74	W->V	17166514	650-fold decrease in binding affinity to cockroach sodium channels.
Q26292	79	N->A	17166514	110-fold decrease in binding affinity to cockroach sodium channels.
Q26292	79	N->D	17166514	950-fold decrease in binding affinity to cockroach sodium channels, and important loss of paralytic activity against Sarcophaga larvae.
Q26292	79	N->G	17166514	590-fold decrease in binding affinity to cockroach sodium channels.
Q26292	79	N->Q	17166514	99-fold decrease in binding affinity to cockroach sodium channels.
P17903	56	S->D	8824586	No interaction with RsbW.
Q15276	441	P->A	14665628	Abolishes the interaction with AP1G2, GGA1 and GGA2.
Q15276	441	P->K,F,G,V	14665628	Abolishes the interaction with AP1G1, AP1G2, GGA1, GGA2 and GGA3.
Q15276	818	Q->W	15378032	Strongly decreases RAB5A binding affinity.
Q15276	820	D->K	15378032	Strongly decreases RAB5A binding affinity.
Q15276	821	F->R	15378032	Strongly decreases RAB5A binding affinity.
Q15276	822	V->D	15378032	Strongly decreases RAB5A binding affinity.
Q15276	826	Q->A	15378032	Strongly decreases RAB5A binding affinity.
Q15276	829	Q->A	15378032	Strongly decreases RAB5A binding affinity.
Q9HC77	375	F->A	27306797	Strongly decreases interaction with alpha/beta-tubulin; causes shorter centrioles and doublet microtubules in cilia.
Q9ULZ3	8	I->A	15641782	Abolishes homooligomerization.
Q9ULZ3	12	L->A	12646168	Abolishes homooligomerization.
Q9ULZ3	15	L->A	15641782	Abolishes homooligomerization.
Q9ULZ3	19	E->A	15641782	Abolishes homooligomerization.
Q9ULZ3	20	L->A	15641782	Abolishes homooligomerization.
Q9ULZ3	21	K->A,E,Q	15641782	Abolishes homooligomerization.
Q9ULZ3	23	F->A	15641782	Abolishes homooligomerization.
Q9ULZ3	25	L->A,E,G,K,N,Q	15641782	Abolishes homooligomerization.
Q9ULZ3	26	K->A,Q	15641782	Abolishes homooligomerization.
Q9ULZ3	27	L->A	15641782	Abolishes homooligomerization.
Q9ULZ3	40	P->A	15641782	Abolishes homooligomerization.
Q9ULZ3	41	R->A,Q,W	15641782	Abolishes homooligomerization.
Q9ULZ3	45	L->A	15641782	Abolishes homooligomerization.
Q9ULZ3	47	M->A,N,Q	15641782	Abolishes homooligomerization.
Q9ULZ3	52	L->A	15641782	Abolishes homooligomerization.
Q9ULZ3	56	L->A	15641782	Abolishes homooligomerization.
Q9ULZ3	62	E->A	15641782	Abolishes homooligomerization.
Q9ULZ3	67	E->A	15641782	Abolishes homooligomerization.
Q9ULZ3	68	L->A	15641782	Abolishes homooligomerization.
Q9ULZ3	72	V->A	15641782	Abolishes homooligomerization.
Q9ULZ3	76	M->A	15641782	Abolishes homooligomerization.
P16554	144	I->A	10747019	Loss of binding affinity to Nak and drop in binding to single helical peptide.
P16554	147	V->A	10747019	Loss of binding affinity to Nak and drop in binding to single helical peptide.
P16554	149	F->V	10747019	Loss of binding affinity to Nak and single helical peptide.
P16554	195	F->V	10747019	Loss of binding affinity to Nak and single helical peptide.
Q13936	1610	L->A	20953164	Loss of a low-affinity interaction with CALM1. No effect on channel inactivation by Ca(2+) and calmodulin.
Q9Y5P4	324	D->A	16895911	Impairs the endoplasmic reticulum-to-Golgi ceramide trafficking and abolishes the interaction with VAPA and MOSPD2.
Q8QG92	822	T->N	11970895	Abrogates binding to dvl2 and abolishes phosphorylation by CaMK1D.
P78423	71	R->A	23125415	Loss of binding to CX3CR1 and ability to induce chemotaxis but no effect on binding to integrins.
P0CY08	10	L->S	7995523	Reduces the ability of ALPHA2 to repress transcription, but binds normally to DNA and MCM1. Disrupts interaction with TUP1.
P0CY08	173	R->A	10759558	Reduces the ability of ALPHA2/MCM1 to repress a-specific genes. Disrupts interaction with SSN6.
Q8BHN3	818	R->E	27462106	Disrupts interaction with PRKCSH. Nearly abolishes enzyme activity.
P05230	133	K->A	11964394	Loss of LRRC59-binding.
O35716	105	R->K	10064597	Loss of LIF signal transduction suppression. Loss of binding to KIT. No effect on binding to VAV.
Q8BHK6	302	Y->F	19151721	Disrupts interaction with SH2D1B, abolishes NK cell activation in presence of SH2D1B, no effect on NK cell inhibition in absence of SH2D1B.
Q60769	103	C->A	15334086	Loss of deubiquitinating activity, does not disassemble TRAF6:UBE2N ubiquitin ligase complex, abolioshes TAX1BP1 interaction with UBE2N.
O95365	61	K->R	17595526	Loss of sumoylation with SUMO1. May decrease interaction with transcriptional corepressors.
P01531	33	W->F	8798612	Major decrease in affinity for both cardiac (Nav1.5) (31-fold) and neuronal (50-fold) channels (tested by ion flux studies). This mutant is the first ApB mutant that displays a significantly altered association rate (K(on)).
Q00914	35	K->D,E	9463363	Drastically decreases affinity of PSI for ferredoxin, limits photoautotrophic growth at medium and greater light. Decreases cross-linking of ferredoxin to PSI-D and PSI-E.
Q00914	35	K->T	9463363	Drastically decreases affinity of PSI for ferredoxin. Decreases cross-linking of ferredoxin to PSI-D and PSI-E.
P83257	8	R->A	15683238	51-fold decrease in binding affinity and nonsignificant differences in lethal dose.
P83257	8	R->D	15683238	More than 80-fold decrease in binding affinity and 5-fold decrease in toxicity.
P83257	12	W->A	15683238	More than 160-fold decrease in binding affinity and nonsignificant differences in lethal dose.
P83257	22	Y->A	15683238	54-fold decrease in binding affinity and nonsignificant differences in lethal dose.
P83257	24	S->A	15683238	40-fold decrease in binding affinity and nonsignificant differences in lethal dose.
P83257	30	Y->A	15683238	58-fold decrease in binding affinity and 5.1- fold decrease in toxicity.
P59823	34	W->A	25908590	Abolishes Interaction with PTPRD. Abolishes synaptogenesis.
Q9EQG6	1760	S->D	15939763	Loss of binding to PDZ domain of SNTA1 and SNTB2.
Q96LC7	119	R->A	19264983	Disrupts interaction with CD24.
P0ACF8	12	R->K	21600204	Abolishes the interaction with Hha.
P0ACF8	32	K->Q	26085102	Loss of Hha binding by fragment 1-64, protein folding is unaffected.
Q99LI8	270	S->E	11988743	No interaction with ubiquitin.
Q9FL28	898	K->H	18158241	Loss of binding with avrPto.
Q9H1I8	506	L->A	29144457	Loss of ubiquitin binding.
Q9VV74	202	G->S	12783845	In allele Smn-73Ao; homozygous lethal at late larval stages and abolishes homodimerization.
P26010	159	D->A	10837471	Loss of integrin alpha-E/beta-7 binding to E- cadherin and of integrin alpha-4/beta-7 binding to MADCAM1.
Q9NS37	303	D->A	10871379	Significantly reduced binding to HCFC1.
Q9NS37	304	H->A	10871379	Significantly reduced binding to HCFC1.
P81030	34	R->A	12488533	Binds with 170-fold reduced affinity to M1 muscarinic acetylcholine receptors.
Q96BN8	55	M->D	24726323	Abolished interaction with RNF31.
Q96BN8	56	Y->A,D	24726323	Abolished interaction with RNF31.
Q96BN8	56	Y->F,W	24726323	Strongly reduced interaction with RNF31.
P31424	1156	P->K	9808459	Disrupts binding to HOMER1.
P31424	1157	P->E	9808459	Disrupts binding to HOMER1.
P31424	1157	P->L	9808459	Disrupts binding to HOMER1.
Q6QA69	132	Q->P	15136565	Exhibits a diffuse cytoplasmic distribution without colocalization to lipid droplets with PLIN and ADPR. Loss of binding to PLIN.
Q6QA69	262	E->K	15136565	Exhibits a diffuse cytoplasmic distribution without colocalization to lipid droplets with PLIN and ADPR. Loss of binding to PLIN.
Q99P58	6	Y->F	18940604	Abolishes the interaction with MLPH.
P0A031	376	F->A	10753635	No interaction with FtsA, but does not affect interaction with FtsZ.
Q9CRB9	2	G->A	21081504	Loss of SAMM50-binding. Reduced affinity toward OPA1. No effect on IMMT-binding.
O70374	105	R->D	26523391	Disrupts interaction with PRDM14.
O70374	109	K->E	26523391	Disrupts interaction with PRDM14.
Q5D0W8	150	C->Y	15986920	Abolishes the interaction with TGA2.2.
Q5D0W8	338	H->Y	15986920	Abolishes the interaction with TGA2.2.
O75920	16	K->A	31034892	Drastically decreases SNCA binding.
O75920	17	K->A	31034892	Drastically decreases SNCA binding.
P49054	98	K->A	8748039	50-fold decrease in plasminogen binding.
Q8YT42	69	R->A	15071498	Abolishes the interaction with KaiC.
P49597	73	R->A	15197253	Loss of binding with PA, no reduction of phosphatase activity.
Q92956	61	Y->A	19915044	Abolishes cis interactions with BTLA.
P00347	60	S->N	17090658	Abolishes sterol-mediated interaction with INSIG1, and no ubiquitination nor degradation.
P00347	87	G->R	17090658	Abolishes sterol-mediated interaction with INSIG1, and no ubiquitination nor degradation.
P00347	333	A->P	17090658	Abolishes sterol-mediated interaction with INSIG1, and no ubiquitination nor degradation.
O43504	36	T->A	9499022	No interaction with XABX14-154 (truncated form of HBX).
P49662	267	W->L,N	32109412	Abolished interaction with Gasdermin-D (GSDMD) and ability to mediate its cleavage.
P49662	291	V->N	32109412	Abolished interaction with Gasdermin-D (GSDMD) and ability to mediate its cleavage.
Q9QZE2	335	R->K	12681493	Loss of binding to FYB1 and MAP4K1. Reduced tyrosine phosphorylation. No effect on the suppression of natural killer cell activation and suppression of interferon-gamma production.
P26038	558	T->D	10212266	Completely abolishes the interaction between N- and C-terminal domains.
P11488	2	G->A	21642972	Abolishes myristoylation, interaction with UNC119 and localization.
Q06418	99	I->R	14623883	Abolishes dimerization.
P13677	697	I->E	11342563	No interaction with inaD.
Q62383	1358	R->K	17234882	Loss of binding to POLR2A. Retains the ability to support transcription elongation but the resulting transcripts contain splicing defects and accumulate to high levels within the nucleus.
P15116	262	D->A	21366346	Abolishes dimerization.
P01116	P01116-2:185	C->S	28619714	Abolished interaction with GPR131.
P54762	928	Y->F	12223469	Disrupts binding with the GRB10 SH2 domain, providing evidence for phosphorylation. Disrupts interaction with GRB7 and ACP1.
Q7Z434	145	Q->N	16153868	No interaction with TRAF2.
O95999	41	L->Q	10187770	Abolishes NF-kappa-B activation and homo/heterodimerization.
Q9PTG8	915	D->K	25262927	Disrupts interactions with ckap5-a.
O44342	28	V->D,N	15252019	Abolishes homodimerization and subcellular targeting of pip.
Q06551	189	C->S	10490616	Abolishes palmitoyltransferase activity and interaction with SHR5.
Q9Y6I4	56	H->A	17980597	Does not reduce monoubiquitinated H2A and H2B stability. Interaction with monoubiquitinated H2A is strongly inhibited.
P20263	347	S->A	29153991	Absence of phosphorylation. Reduced protein degradation. Reduced self-renewal ability in ES cells. No change in FBXW4 binding. Loss of FBXW8 binding.
Q03164	3864	R->A	26886794	Disrupts interaction with ASH2L and RBBP5 and nearly abolishes histone methyltransferase activity.
P32657	220	E->L,W	15647753	No interaction with methylated histone H3 'K-4'.
P32657	316	Y->E	15647753	Disrupts interaction with methylated histone H3 'K-4'; abrogates histone acetylation activity of SLIK.
P57725	23	S->A	20478393	Loss of phosphorylation site. Strongly reduced interaction with YWHAG and YWHAB.
Q9SLH3	341	Q->R	15734906	Causes a semidwarf phenotype by abolishing the interaction with GID2 leading to prevent its degradation.
O88350	63	L->Q	9697699	Loss of binding to RB1 binding.
F4IXE7	732	C->W	22700931	Loss of binding to histone H3 and loss of acetyltransferase activity.
F4IXE7	740	C->W	22700931	Loss of binding to histone H3, but no effect on acetyltransferase activity.
P53349	1394	I->A	14500727	Loss of NF-kappa-B transcription factor activity and reduced ability to activate MAP2K1, MAP2K4, MAP2K7. No effect on AP-1 activity or activation of CHUK and IKBKB. Loss of binding to IKBKB.
P53349	1402	L->A	14500727	Loss of AP-1 transcription factor activity and reduced ability to activate CHUK and IKBKB. No effect on NF-kappa-B activity or activation of MAP2K1, MAP2K4, MAP2K7. Loss of binding to MAP2K4.
O80982	315	K->R	20521085	Loss of sumoylation. Loss of SUMO1 binding.
O15287	7	S->A	18212739	Loss of BRCA2-, FANCD2- and XRCC3-binding. No effect on complex formation with FANCA and FANCF.
Q15046	101	V->D,R,W	23159739	Disrupts interaction with AIMP2 and the multisynthase complex.
Q15046	540	G->Y	23159739	Disrupts interaction with AIMP2 and the multisynthase complex. Increases production of diadenosine tetraphosphate (Ap4A). Almost complete loss of tRNA ligase activity.
Q6IQ22	106	S->E	26824392	Phosphomimetic mutant. Loss of GDI1, GDI2, CHM and CHML binding.
Q16611	164	H->A	17157251	Strongly reduced zinc binding and homodimerization.
Q16643	10	R->D,G	28966017	Loss of binding to ZMYND8. Loss of ZMYND8 cytoplasmic localization.
Q03431	137	D->A	20172855	Abolishes hormone binding. No effect on homodimerization.
P04512	166	Y->I	10799621	Loss of ICP-binding activity.
Q9FN03	144	W->A	23012433	Cannot interact with COP1.
Q9FN03	285	W->F	21454788	Loss of function. Constitutive homodimer and no interaction with COP1.
Q9FN03	352	W->A	23012433	Cannot interact with COP1.
Q9XHZ8	204	I->R	15772280	Abolishes the interaction with CUL3A.
Q9XHZ8	242	Y->A	15772280	Abolishes the interaction with CUL3A.
P0DL51	42	D->A	16846229	317-fold decrease in binding affinity to cockroach sodium channels and correlated loss of toxicity to blowfly larvae.
P0DL51	51	L->A	16846229	209-fold decrease in binding affinity to cockroach sodium channels and correlated loss of toxicity to blowfly larvae.
P0DL49	42	D->A	16846229	317-fold decrease in binding affinity to cockroach sodium channels and correlated loss of toxicity to blowfly larvae.
P0DL49	51	L->A	16846229	209-fold decrease in binding affinity to cockroach sodium channels and correlated loss of toxicity to blowfly larvae.
Q9SE33	153	I->Q	20670895	Disrupts the interaction with SGT1A. No effect on the interaction with barley HSP90.
Q9SE33	170	E->K	20670895	Disrupts the interaction with SGT1A. No effect on the interaction with barley HSP90.
Q9SE33	217	W->T	20670895	Disrupts the interaction with SGT1A. No effect on the interaction with barley HSP90.
P21514	60	K->A	26553851	Does not bind to the PdeL box.
O60880	78	R->E	12545174	Disrupts interaction with FYN.
P35189	80	G->A	27089029	Abolished binding to acylated histone H3.
P35189	81	W->A	26341557	Abolished binding to acetylated histone H3.
Q91783	937	T->A	19079595	Disrupts spindle binding.
P21580	562	R->A	9299557	Abolishes interactionj with YWHAZ AND YWHAH; no effect on inhibitory activity of TNF-induced NF-kappa-B activation.
P21580	565	S->A	9299557	Abolishes interactionj with YWHAZ AND YWHAH; no effect on inhibitory activity of TNF-induced NF-kappa-B activation.
P17693	171	C->S	12874224	Abolishes homodimerization. Decreases functional interaction with LILRB1.
B7ZWR6	185	R->A	21612577	Loss of binding to HSP70-1.
P33313	90	G->D	12788914	In CNS1-1; disrupts interaction with Hsp90, temperature-sensitive defect impairing Hsp90-dependent function.
P33313	140	C->R	12788914	In CNS1-2; disrupts interaction with Hsp90, temperature-sensitive defect impairing Hsp90-dependent function.
O00187	74	Y->A	15117939	Strongly decreases affinity for MBL2. Decreases affinity for FCN2.
O00187	121	Y->A	15117939	Strongly decreases affinity for MBL2, but not for FCN2.
P61020	84	S->E	29125462	Phosphomimetic mutant. Loss of GDI1, GDI2, CHML and CHM binding.
Q9BX63	990	S->A	14576433	Disrupts the interaction with BRCA1.
Q9BX63	991	P->A	14576433	Abolishes phosphorylation of S-990. Impairs the interaction with BRCA1.
Q9BX63	993	F->A	14576433	Abolishes phosphorylation of S-990. Impairs the interaction with BRCA1.
P02724	102	G->L	10926825	Abolishes dimerization.
Q9JHF9	126	F->A	24380872	Abolishes dimerization of the TLR4 complex and stimulation of TNF production in response to bacterial lipopolysaccharide.
P74873	213	T->A	11163217	Loss of RAC1 binding and GAP activity.
P74873	246	Q->A	11163217	Loss of RAC1 binding and GAP activity.
P74873	249	T->A	11163217	Loss of RAC1 binding and GAP activity.
Q15173	52	Y->S	23135275	Loss of KLHL15-binding and enhanced stability.
Q13191	937	A->E	17679095	Loss of ubiquitin binding. Reduced levels of tyrosine phosphorylation.
Q13191	940	M->A	17679095	Loss of ubiquitin binding. Reduced levels of tyrosine phosphorylation.
Q13191	946	F->A	17679095	Loss of ubiquitin binding. Reduced levels of tyrosine phosphorylation.
Q14596	732	Y->A	19250911	Loss of interaction ATG8 family proteins.
Q66K64	90	V->D	31693891	Abolished interaction with DDB1, DDA1 and RBM39 in presence of indisulam.
Q66K64	91	L->P	31693891	Abolished interaction with DDB1, DDA1 and RBM39 in presence of indisulam.
Q66K64	112	W->R	31693891	Abolished interaction with DDB1, DDA1 and RBM39 in presence of indisulam.
Q66K64	129	F->S,V	31693891	Abolished interaction with DDB1, DDA1 and RBM39 in presence of indisulam.
Q70DU8	45	C->S	21166653	Decreased solubility, loss of dimerization and strongly decreased activity.
P20336	86	T->E	29125462	Phosphomimetic mutant. Loss of GDI1, GDI2, CHM and CHML binding.
P15313	513	L->G	12444018	Loss of interactions with SLC9A3R1 and SCL4A7.
Q9LZW4	313	F->A	18237745	Loss of binding to CBL2.
Q9LZW4	322	F->A	18237745	Loss of binding to CBL2.
P38936	145	T->D	11463845	No interaction with PCNA; 59% inhibition of CDK2 binding; modest inhibition of CDK4 binding; no change in subcellular location.
P34709	1392	C->Y	11124807	Prevents binding with tra-1.
P34709	1393	E->K	11124807	Causes weak somatic masculinization; prevents binding with tra-1.
P34709	1400	R->Q	11124807	Causes weak somatic masculinization; prevents binding with tra-1.
Q92990	425	K->A	22748924	Disrupts interaction with RBX1. Loss of inhibition of SCF (SKP1-Cullin-F-box protein) E3 ubiquitin- protein ligase activity.
Q92990	476	N->A	22748924	Disrupts interaction with RBX1. Loss of inhibition of SCF (SKP1-Cullin-F-box protein) E3 ubiquitin- protein ligase activity.
Q92990	567	L->A	22748924	Disrupts interaction with RBX1. Loss of inhibition of SCF (SKP1-Cullin-F-box protein) E3 ubiquitin- protein ligase activity.
Q92990	574	R->A	22748924	Disrupts interaction with RBX1. Loss of inhibition of SCF (SKP1-Cullin-F-box protein) E3 ubiquitin- protein ligase activity.
Q9SVY5	69	D->Y	30948526	Abolished interaction with uridylylated PBL2 and abolished ability to mediate cell death as well as an increased sensitivity to the pathogenic biotrophic bacteria Xanthomonas campestris pv. campestris (Xcc).
Q9SVY5	231	T->Y	30948526	Abolished interaction with uridylylated PBL2 and abolished ability to mediate cell death as well as an increased sensitivity to the pathogenic biotrophic bacteria Xanthomonas campestris pv. campestris (Xcc).
Q9SVY5	232	F->A	30948526	Abolished interaction with uridylylated PBL2 and abolished ability to mediate cell death as well as an increased sensitivity to the pathogenic biotrophic bacteria Xanthomonas campestris pv. campestris (Xcc).
Q9SVY5	235	I->E	30948526	Abolished interaction with uridylylated PBL2 and abolished ability to mediate cell death.
Q9SVY5	240	H->E	30948526	Abolished interaction with uridylylated PBL2 and abolished ability to mediate cell death as well as an increased sensitivity to the pathogenic biotrophic bacteria Xanthomonas campestris pv. campestris (Xcc).
Q9CR95	272	W->A,F,Y	15359277	Loss of binding to AP-2.
Q9CR95	273	V->L,N,P,S	15359277	Loss of binding to AP-2.
Q9UJ71	285	E->A	20026605	Loss of binding to 6'-sulfo-LacNAc and invertase.
Q9UJ71	287	N->A	20026605	Loss of binding to 6'-sulfo-LacNAc and invertase.
P09486	166	R->A,L,K	9501084	Strongly reduced collagen binding.
P09486	173	N->A,Q	9501084	Strongly reduced collagen binding.
P09486	259	L->A	9501084	Loss of collagen binding.
P09486	262	M->A	9501084	Strongly reduced collagen binding.
P09486	263	E->A	9501084	Loss of collagen binding.
Q9GZZ9	341	W->A	26929408	Abolished interaction with UFM1 and GABARAPL2.
Q8IUX4	294	H->D	23001005	Resistant to HIV-1 Vif, reduces Vif binding and abolishes incorporation into the virion.
Q9VU08	2308	F->A	29307555	Loss of 'Lys-63'-linked polyubiquitin chain binding.
P57757	280	K->R	26449607	Abolished cystine transport. Abolished interaction with components of the v-ATPase and Ragulator complexes. Does not affect ability to lysosomal localization of LAMP2A.
P07954	236	T->A	26237645	Abolished interaction with H2AZ1 and localization to chromatin in response to DNA damage.
P16234	720	Y->F	8943348	Strongly reduced interaction with PTPN11 and GRB2.
P0AES6	10	I->G	10734094	No dimerization of residues 2-393, fragment has significantly decreased ATPase activity.
Q9NNX6	320	D->A	11799126	Loss of binding to ICAM3 and HIV-1 gp120.
Q9NNX6	324	E->A	11799126	Loss of binding to ICAM3 and HIV-1 gp120.
Q9NNX6	347	E->Q	11799126	Loss of binding to ICAM3 and HIV-1 gp120.
Q9NNX6	349	N->D	11799126	Loss of binding to ICAM3 and HIV-1 gp120.
Q9NNX6	350	N->A	11799126	Loss of binding to ICAM3 and HIV-1 gp120.
Q9NNX6	355	D->A	11799126	Loss of binding to ICAM3 and HIV-1 gp120.
Q9NNX6	365	N->D	11799126	Loss of binding to ICAM3 and HIV-1 gp120.
Q9NNX6	366	D->A	11799126	Loss of binding to ICAM3 and HIV-1 gp120.
Q04207	310	K->R	21131967	Abolishes monomethylation by SETD6 and interaction with EHMT1.
Q9Y3C5	12	D->A	20676133	Loss of GGA1-binding.
Q9Y3C5	15	L->A	20676133	Loss of GGA1-binding.
Q9Y3C5	16	L->A	20676133	Loss of GGA1-binding.
Q9Y3C5	103	M->A,G	18615712	Loss of UBE2N-binding. No gain of UBE2L3- binding.
A7GBG3	1250	W->L	19476346	Significantly decreased binding of heavy chain (HC) to synaptosomes, significantly decreased binding to ganglioside GT1b. HC no longer inhibits BoNT/F whole-toxin uptake and toxicity. Loss of HC binding to synaptic vesicles, greatly decreased binding to neurons.
O14495	184	D->E	9705349	Loss of binding to integrin. Loss of function in integrin-mediated cell-cell interaction.
P73204	26	R->E	21923764	Significantly decreases interaction of PBS- linker domain with phycocyanin beta subunit (cpcB).
P73204	29	E->R	21923764	Significantly decreases interaction of PBS- linker domain with phycocyanin beta subunit (cpcB).
P73204	31	E->R	21923764	Significantly decreases interaction of PBS- linker domain with phycocyanin beta subunit (cpcB).
P73204	33	D->R	21923764	Significantly decreases interaction of PBS- linker domain with phycocyanin beta subunit (cpcB).
P73204	41	R->E	21923764	Significantly decreases interaction of PBS- linker domain with phycocyanin beta subunit (cpcB).
P73204	47	D->R	21923764	Significantly decreases interaction of PBS- linker domain with phycocyanin beta subunit (cpcB).
P73204	48	H->Y	21923764	Significantly decreases interaction of PBS- linker domain with phycocyanin beta subunit (cpcB).
P73204	54	R->E	21923764	Significantly decreases interaction of PBS- linker domain with phycocyanin beta subunit (cpcB).
Q9NZN9	53	R->W	12374762	No interaction with NUB1.
Q9NZN9	79	M->T	12374762	No interaction with NUB1.
Q9NZN9	96	V->I	12374762	No interaction with NUB1.
Q9NZN9	262	G->S	12374762	No interaction with NUB1.
P17865	280	D->R	25848052	Disrupts interaction with MciZ.
P06731	63	F->R	18086185	Abolishes dimerization. Reduced affinity for E.coli Dr adhesins.
P06731	66	S->N	10864933	Abolishes dimerization.
P06731	68	Y->A	10864933	Abolishes dimerization.
P06731	69	K->A	10864933	Abolishes dimerization.
P06731	73	V->A	18086185	Abolishes dimerization.
P06731	74	D->L,R	18086185	Abolishes dimerization.
P06731	78	Q->L,R	10864933	Abolishes dimerization. Reduced affinity for E.coli Dr adhesins.
P06731	125	I->A	18086185	Abolishes dimerization. Reduced affinity for E.coli Dr adhesins.
P06731	129	L->S	18086185	Abolishes dimerization. Reduced affinity for E.coli Dr adhesins.
P06731	133	E->A	18086185	Abolishes dimerization.
Q9X721	1106	Y->A	12682007	S3b fragment has 40-fold decreased affinity for collagen.
Q14974	178	I->F,D	10929717	Loss of binding to FxFG repeats and reduced nuclear import.
Q99689	254	L->P	22354037	Loss of SCOC-binding. No effect on ULK1- binding.
Q99689	260	L->P	22354037	Loss of SCOC-binding. No effect on ULK1- binding.
P9WIC7	209	L->E	24914210	Disrupts dimerization of the enzyme, which exists as a monomer and has lost its ability to perform dephosphorylation.
P97756	172	R->E	10336483	Loss of substrate recognition and interaction with CAMK4.
P97756	177	R->E	10336483	Loss of substrate recognition and interaction with CAMK4.
P97756	459	F->D	10467092	Loss of binding to Ca(2+)/calmodulin.
P97756	463	F->D	10467092	Loss of binding to Ca(2+)/calmodulin.
Q9D8T2	292	L->D	31097341	Disrupts intramolecular interactions and autoinhibition, leading to spontaneous pyroptosis-inducing activity.
Q9D8T2	295	E->R	31097341	Disrupts intramolecular interactions and autoinhibition, leading to spontaneous pyroptosis-inducing activity.
Q9D8T2	380	A->D	31097341	Disrupts intramolecular interactions and autoinhibition, leading to spontaneous pyroptosis-inducing activity.
Q9D8T2	470	S->R	31097341	Disrupts intramolecular interactions and autoinhibition, leading to spontaneous pyroptosis-inducing activity.
Q9D8T2	474	A->D	31097341	Disrupts intramolecular interactions and autoinhibition, leading to spontaneous pyroptosis-inducing activity.
P20340	46	I->E	19141279	Loss of RAB6IP1-binding.
O35464	322	I->E	20877282	Abolishes homodimerization.
P24522	77	L->E	20460379	Abolishes dimerization.
P16794	79	L->A	25339763	Loss of interaction and co-localization with NEC1.
Q8N163	454	T->A	22735644	Significantly reduces association with SIRT1. Decreases sumoylation and the interaction of the sumoylated form with SIRT1. Inhibits CCAR2-PSIA3 interaction. Increases CCAR2-SENP1 interaction. Down-regulation of the signals related with the epithelial-mesenchymal transition of gastric cancer cells.
Q8N163	454	T->D	22735644	Significantly increases association with SIRT1 and induces p53 acetylation and apoptosis. Increases sumoylation and the interaction of the sumoylated form with SIRT1. Promotes CCAR2-PSIA3 interaction. Decreases CCAR2- SENP1 interaction.
P27709	253	E->A	26576507	Loss of PatS6 binding, PatS6 no longer blocks DNA-binding.
P18848	219	S->N	16219772	Abolished phosphorylation on the betaTrCP degron motif, interaction with BTRC and subsequent ubiquitination.
P0ABV6	23	D->R	11722743	Abolishes TolA-Pal interaction.
O43157	139	D->K	20877282	Strongly reduced interaction with SEMA4D.
Q09490	116	G->A	22767594	Diffuse cytosolic localization in 500-cell embryos with no punctate pattern of distribution which is in contrast to wild-type. Not cleaved by atg-4.1 and atg- 4.2. Does not rescue the protein degradation defect in the atg-4.1 bp501 mutant. Reduces lgg-2 lipidation and the accumulation of sqst-1-containing aggregates. Abolishes the interaction with atg-3.
Q14457	120	G->E	24443581	Decreases interaction with MUHV-4 M11, disrupts interaction with BCL2L1 isoform Bcl-X(L).
Q14457	121	D->A	24443581	No effect on interaction with MUHV-4 M11, disrupts interaction with BCL2L1 isoform Bcl-X(L).
Q14457	123	F->A	16179260	Weakly decreases interaction with MUHV-4 M11, disrupts interaction with BCL2 and decreases interaction with BCL2L1 isoform Bcl-X(L).
Q9XYF4	118	F->E	14517550	Disrupts interaction with Diap1.
Q13976	12	L->A	10567269	Loss of binding to PPP1R12A.
Q13976	19	I->A	10567269	Loss of binding to PPP1R12A.
Q13976	26	L->P	10567269	Loss of binding to PPP1R12A.
Q13976	33	I->A	10567269	Loss of binding to PPP1R12A.
Q13976	40	L->A	10567269	Loss of binding to PPP1R12A.
P62937	125	K->R	25678563	Loss of acetylation and interaction with TARDBP.
P62937	126	H->A	11943775	Loss of peptidyl-prolyl cis-trans isomerase activity and interaction with HCV NS5A. Loss of ability to stimulate MAPK/ERK phosphorylation.
Q92560	493	T->A,L	25451922	Abolished interaction with FOXK1 and FOXK2.
Q9CQD1	34	S->N	18425118	Inhibits endosome localization. Disrupts interaction of RAB5A and OCRL with INPP5F. Prevents its localization to apoptotic cell corpse-containing early phagosomes. Maturation of apoptotic cell-containing phagosome into acidic phagosomes is decreased. Interacts with PIK3C3.
Q4V3E2	87	Y->A	25211338	Loss of H3K4me3/H3K36me3 binding capacity and loss of activity.
P18433	798	Y->F	22801373	Abolishes integrin-mediated interaction with BCAR1 and BCAR3 and reduces interaction between BCAR1 and CRK and, BCAR1 and SRC. Abolishes integrin-induced SRC- mediated tyrosine phosphorylation of BCAR1. Abolishes integrin-mediated recruitment of BCAR1, BCAR3, CRK and PTPRA to focal adhesions. Reduces integrin-mediated activation and membrane recruitment of RAC1 and CDC42.
Q44176	462	F->A	17574029	Does not assemble into RbcL8, does not interact with RbcX2.
P53762	112	L->E	26245371	Impairs heterodimer formation with EPAS1. Impairs heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Compromise NPAS4:ARNT heterodimer stability. Compromise AHR:ARNT heterodimer stability.
P53762	132	L->E	26245371	Impairs heterodimer formation with EPAS1. Impairs heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Compromise NPAS4:ARNT heterodimer stability. Compromise AHR:ARNT heterodimer stability.
P53762	136	V->D	26245371	Impairs heterodimer formation with EPAS1. Impairs heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Compromise NPAS4:ARNT heterodimer stability. Compromise AHR:ARNT heterodimer stability.
P53762	264	I->D	26245371	Impairs heterodimer formation with EPAS1. Markedly decreases heterodimer formation with HIF1A. Significantly destabilizes ARNT?s heterodimeric interactions with both NPAS1 and NPAS3. Compromises SIM1:ARNT heterodimer stability. Does not compromise NPAS4:ARNT heterodimer stability. Does not compromise AHR:ARNT heterodimer stability.
Q61483	613	K->R	21985982	Highly decreases Notch signaling pathway. Multi-ubiquitination pattern is reduced, although it does appear to be mono-ubiquitinated. Interacts with MIB1. Loss of cis and trans interaction with NOTCH1. Increases its association with lipid raft microdomains.
O50147	117	K->E	25392000	Does not bind LysW.
O50147	123	K->E	25392000	Does not bind LysW.
O50147	125	K->E	25392000	Does not bind LysW.
O50147	128	R->E	25392000	Does not bind LysW.
O95714	4827	T->A	20023648	Prevents HERC2 C-terminal fragment binding to endogenous RNF8.
P20337	86	T->E	29125462	Phosphomimetic mutant. Loss of GDI2, CHM and CHML binding.
Q99JL1	31	R->A	30535028	Disruption of its microtubule-binding and microtubule bundling activities. Failure to rescue ciliary central apparatus formation in SPEF1-depleted ependymal cilia.
Q9UKT7	358	C->A	17463251	Loss of binding with CRY1.
P08195	210	C->S	11696247	Abolishes dimerization, leucine uptake and interaction with beta-1 integrins.
P32357	253	S->D,E	21764848	Disrupts interaction with PRP8.
O60939	55	C->A,S	26894959	Does not bind alpha subunit. Loss of ability to protect alpha subunit from inhibition by the spider protoxin-II.
Q969Q1	39	C->A	11283016	Loss of SUMO2-binding.
Q969Q1	41	H->A	11283016	Loss of SUMO2-binding.
Q969Q1	44	C->A	11283016	Loss of SUMO2-binding.
Q969Q1	47	C->A	11283016	Loss of SUMO2-binding.
O00429	668	K->E	23584531	Abolishes homodimerization and formation of higher order oligomers.
P67775	309	L->A	10191253	Loss of binding to PP2A B-alpha regulatory subunit.
O15392	18	R->A	20929775	Disrupts interaction with histone H3pT3, no effect on interaction with INCENP.
O15392	25	W->A	20929775	Disrupts interaction with histone H3pT3, no effect on interaction with INCENP.
O15392	33	C->R	20929775	Disrupts interaction with histone H3pT3, no effect on interaction with INCENP.
O15392	34	T->A	12773388	Loss of LAMTOR5 binding.
O15392	57	C->A	20929775	Disrupts interaction with histone H3pT3, no effect on interaction with INCENP.
O15392	67	W->A	20929775	Disrupts interaction with histone H3pT3, no effect on interaction with INCENP.
O15392	117	T->E	14610074	Mimics phosphorylation. Disrupts subcellular localization during mitosis and prevents interaction with INCENP.
O15392	126	E->A	25778398	Loss of FBXL7 binding.
P17679	203	E->V	10078204	Disrupts interaction with ZFPM1. Binds normally to DNA.
P17679	204	C->R	10078204	Disrupts interaction with ZFPM1 and binding to DNA.
P17679	205	V->G	10078204	Disrupts interaction with ZFPM1. Binds normally to DNA.
P17679	205	V->M	10078204	Disrupts interaction with ZFPM1. Binds normally to DNA.
P17679	207	C->G,R,W	10078204	Disrupts interaction with ZFPM1.
P17679	208	G->E,V	10078204	Disrupts interaction with ZFPM1 and binding to DNA.
P17679	222	H->R	10078204	Disrupts interaction with ZFPM1. Binds normally to DNA.
P17679	224	L->P	10078204	Disrupts interaction with ZFPM1 and binding to DNA.
P17679	225	C->R,S,Y	10078204	Disrupts interaction with ZFPM1.
P17679	228	C->R,S	10078204	Disrupts interaction with ZFPM1.
P29348	352	G->P	11447270	Loss of activation by both bitter and sweet compounds due to disruption of interaction with taste receptors.
P0CS90	442	P->S	12032075	No interaction with TIM44.
P48598	117	W->A	14723848	Disrupts interaction with cup, eIF4G and mxt.
Q504Y3	30	W->C,D,E,H,K,R	26933034	Significantly reduced histone H3K4me3 binding.
Q504Y3	30	W->P	26933034	Loss of histone H3K4me3 binding.
Q501J7	650	R->P	17609112	In humdy; failure to close the neural tube and optic fissure, causing exencephaly and retinal coloboma and common birth defects. Specifically disrupts interaction with PPP1CA while it does not affect interaction with actin.
Q01196	106	M->V	19202074	Disrupts interaction of AML1-MTG8/ETO with CBFB, no effect on AML1-MTG8/ETO-mediated transformation activity.
Q01196	107	A->T	10404214	Loss of heterodimerization. Disrupts interactionof AML1-MTG8/ETO with CBFB, no effect on AML1- MTG8/ETO-mediated transformation activity.
P78380	140	C->S	15000751	Abolishes homodimerization.
Q16602	72	W->A	22102369	Strongly reduced affinity for adrenomedullin.
Q16602	92	F->A	22102369	Strongly reduced affinity for adrenomedullin.
Q16602	121	W->A	22102369	Strongly reduced affinity for adrenomedullin.
Q04660	465	E->R	26476442	Disrupts the interaction with YTM1 and cannot sustain growth.
O00330	183	R->A	16442803	Strongly decreased DLD binding.
O00330	185	S->A	16442803	Strongly decreased DLD binding.
O00330	186	P->A	16442803	Strongly decreased DLD binding.
O00330	187	A->M	16442803	Strongly decreased DLD binding.
O00330	189	R->A	16442803	Strongly decreased DLD binding.
O00330	193	E->A	16442803	Strongly decreased DLD binding.
O00330	208	R->A	16442803	Strongly decreased DLD binding.
O00330	210	I->A	16442803	Strongly decreased DLD binding.
O00330	213	K->A	16442803	Strongly decreased DLD binding.
O00330	214	E->A	16442803	Strongly decreased DLD binding.
A3KQH2	313	Q->A	24787902	Loss of calmodulin binding.
Q8C0E2	42	D->A	25136126	Disrupts interaction with SNX27.
Q8C0E2	152	L->A	25136126	Disrupts interaction with SNX27.
P98170	87	S->D,E	17698078	Abolishes dimerization. Interferes with ubiquitination.
Q9QZ85	83	S->N	15075236	Abrogates interaction with HOOK3. Greatly reduces binding affinity for GDP and GTP. Abolishes GTP- dependent oligomer formation.
O35425	76	D->A	23429263	Disrupts homodimerization. Positively regulates intrinsic apoptotic signaling pathway.
P19785	362	I->D	10207113	Abolishes transcriptional activity and estrogen-induced interaction with NCOA1.
P19785	366	K->D	10207113	Abolishes transcriptional activity and estrogen-induced interaction with NCOA1.
P19785	371	F->A	10840033	Abolishes estrogen-dependent NF-kappa B transcriptional repression, impairs transcriptional activity, abolishes estrogen-induced interaction with NCOA1.
P19785	380	V->D	10207113	Abolishes transcriptional activity and estrogen-induced interaction with NCOA1.
P19785	451	C->A	22031296	Loss of ZDHHC7 and ZDHHC21 binding. Loss of palmitoylation.
P19785	543	L->A	10207113	Abolishes estrogen-induced interaction with NCOA1.
Q96NA2	251	I->A	15933719	Abolishes dimerization, interaction with RAB7A and localization to late endosomal/lysosomal compartments.
Q96NA2	255	R->A	15933719	Abolishes dimerization, interaction with RAB7A and localization to late endosomal/lysosomal compartments.
Q9TYU9	213	I->A	25771894	Loss of actin binding and organization.
Q9TYU9	360	K->A	25771894	Loss of actin binding and organization.
Q94F62	32	L->E	19277500	Loss of binding to BRI1, but no effect on kinase activity.
Q94F62	46	L->E	19277500	Loss of binding to BRI1 and loss of kinase activity.
O43324	69	A->R	26472928	Disrupts interaction with MARS1.
O43324	73	Q->R	26472928	Disrupts interaction with MARS1.
O43324	144	R->A	26472928	Disrupts interaction with EPRS1.
Q9Z214	24	W->A	10798399	Disrupts binding to both GRM1 and SHANK3. Does not form the high-order complex with SHANK1.
Q9Z214	24	W->Y	10798399	Disrupts binding to GRM1.
Q9Z214	70	T->E	10798399	Disrupts binding to SHANK3.
Q9NRF2	29	F->R	15767667	Abolishes self-association and interaction with INSR and IGF1R.
Q9NRF2	34	A->D	15767667	Abolishes self-association and interaction with INSR and IGF1R.
Q9NRF2	38	A->D	15767667	Abolishes self-association and interaction with INSR and IGF1R.
Q9NRF2	41	F->A	15767667	Abolishes self-association and interaction with INSR and IGF1R.
Q9NRF2	42	A->D	15767667	Abolishes self-association and interaction with INSR and IGF1R.
Q9NRF2	48	Y->A	15767667	Abolishes self-association and interaction with INSR and IGF1R.
Q9NRF2	68	F->A	15767667	Abolishes self-association and interaction with INSR and IGF1R.
Q9NRF2	72	F->A	15767667	Abolishes self-association and interaction with INSR and IGF1R.
Q9NRF2	555	R->A	15767667	Abolishes self-association and interaction with INSR and IGF1R.
Q16236	82	E->G	15601839	Abolished interaction with KEAP1.
Q8NFA2	202	W->R	15824103	Loss of ability to activate NOX3 and interact with CYBA. Induces interaction with NOXA1 in vitro.
Q8NFA2	332	P->A	17126813	Loss of intramolecular interaction.
Q8NFA2	334	R->A	17126813	Loss of intramolecular interaction.
O76064	403	C->S	11322894	Marked reduction of E2-dependent ubiquitination of histone H2A. Loss of UBE2E2- and UBE2N- binding. Loss of nuclear localization.
O43043	617	R->E	25771684	In Scp1-M1; strongly reduced interaction with sre1.
P11439	82	K->E	1618748	Loss of toxicity, no binding to LRP1 receptor.
P04585	220	A->G	9223641	44-fold decrease of PPIA-binding affinity.
P04585	221	G->A	9223641	31-fold decrease of PPIA-binding affinity.
P04585	221	G->V	9223641	154-fold decrease of PPIA-binding affinity.
P04585	222	P->A	9223641	36-fold decrease of PPIA-binding affinity.
P04585	222	P->V	9223641	More than 150-fold decrease of PPIA-binding affinity.
Q8N608	257	N->Q	22387313	Abolishes sorting to the cell surface and dimerization.
Q9UK23	486	Y->A	26544806	Interaction with AP4M1 is abolished.
Q9UK23	488	Y->A	26544806	Interaction with AP4M1 is abolished.
Q9UK23	491	L->A	26544806	Interaction with AP4M1 is abolished.
P50542	118	W->A	11438541	Strongly reduced interaction with PEX14.
P50542	122	F->A	11438541	Strongly reduced interaction with PEX14.
Q8TCJ0	244	S->L	16278047	Loss of SKP1-binding.
Q9ULM3	283	G->A	27103431	Abolished binding to histone H3 crotonylated at 'Lys-27' (H3K27cr).
Q9ULM3	284	E->A	27103431	Abolished binding to histone H3 crotonylated at 'Lys-27' (H3K27cr).
Q9WIJ4	10	P->L	10708410	Loss of binding to host SKP1. No effect on viral replication stimulation.
Q9WIJ4	17	I->A	10708410	Loss of binding to host SKP1. No effect on viral replication stimulation.
Q9NPD8	60	R->E	24389026	Loss of FANCL-binding and of FANCL-dependent monoubiquitination of FANCD2.
Q95XR4	684	W->A	26687600	Abolishes the interaction with lgg-1.
Q95XR4	684	W->F	26687600	Abolishes the interaction with lgg-2, but not with lgg-1.
Q95XR4	685	E->K	26687600	Abolishes the interaction with lgg-1.
Q95XR4	687	V->A	26687600	Abolishes the interaction with lgg-1.
P58301	793	S->R	10892749	Prevents ATP binding and disrupts the communication among the other ATP-binding loops. Prevents also Rad50 dimerization. Decreases both ATPase and adenylate kinase activities.
Q9ULU4	311	H->A	28966017	Loss of binding to DBN1. Loss of cytoplasmic localization.
Q9ULU4	312	D->R	28966017	Loss of binding to DBN1.
Q9UGN5	394	H->A	32028527	Strongly reduced serine ADP-ribosylation, caused by abolished interaction with HPF1.
P30561	115	F->A	24001774	Highly disrupts the dimerization ability of AHR.
P30561	115	F->D	24001774	Highly disrupts the dimerization ability of AHR. Reduces the AHR transcription factor activity induction by 50%.
P30561	116	L->E	24001774	Highly disrupts the dimerization ability of AHR. Reduces transcription activity. Decreases interaction with ARNT.
Q2PEG7	224	E->K	24400899	Abolishes the interaction with IPN2; abolishes transactivation activity.
B8GX14	13	L->A	24239291	Disrupts interaction with SocA but not self- association.
B8GX14	47	I->A	24239291	Disrupts interaction with SocA but not self- association.
Q96NW4	509	Q->A	24856514	Disrupts interaction with RAB32.
Q96NW4	513	L->D	24856514	Disrupts interaction with RAB32.
Q96NW4	679	D->A	23104059	Disrupts interaction with VAMP7.
Q96NW4	681	D->A	23104059	Disrupts interaction with VAMP7.
Q96NW4	684	M->D	23104059	Disrupts interaction with VAMP7.
Q96NW4	687	Y->S	23104059	Disrupts interaction with VAMP7.
P38398	26	I->A	16818604	Disrupts the interaction with E2 enzymes, thereby abolishing the E3 ubiquitin-protein ligase activity.
P38398	1662	F->S	26778126	Does not abolish ABRAXAS1 binding, but abolishes formation of a heterotetramer with ABRAXAS1.
P38398	1663	M->K	26778126	Does not abolish ABRAXAS1 binding, but abolishes formation of a heterotetramer with ABRAXAS1.
P38398	1666	Y->A	26778126	Does not abolish ABRAXAS1 binding, but impairs formation of a heterotetramer with ABRAXAS1.
Q4V8G5	61	S->N	17685441	Abolishes homodimerization.
Q62406	66	T->A	12138165	Abolishes dimerization.
Q62406	66	T->E	12138165	Abolishes dimerization.
P09052	187	N->A	17189197	Strongly decreases interaction with gus.
P09052	188	N->A	17189197	Strongly decreases interaction with gus.
P25359	212	V->A	12364597	Interaction with RRP46 abolished.
Q86WV6	150	K->R	19285439	Abolishes ubiquitination, homodimerization and subsequent production of IFN-beta.
Q7LXP6	416	C->G	22950735	Abolishes metalloprotease activity and homodimerization.
P30995	1214	K->A	21849494	Loss of heavy chain binding to ganglioside GD1a.
P30874	139	D->A	22495673	Expression levels reduced by 50%. Significantly reduced ligand binding capacity but increased affinity. Reduced G protein-mediated cAMP release but no effect on G-protein mediated calcium release.
P30874	140	R->L	22495673	Slightly reduced expression levels. Significantly reduced ligand binding capacity but increased affinity. Reduced G protein-mediated cAMP release but no effect on G protein-mediated calcium release.
Q86YV5	955	L->A	29079850	Decreases homodimerization. Abolished interaction with PEAK1. No effect on cell migration.
Q86YV5	966	L->A	29079850	Decreases homodimerization. Abolished interaction with PEAK1. Decreases cell migration.
Q86YV5	1366	F->A	29079850	Decreases homodimerization. Abolished interaction with PEAK1. Decreases cell migration.
Q86YV5	1382	W->A	29079850	Decreases homodimerization. Abolished interaction with PEAK1. Decreases cell migration.
O14098	306	K->R	17502918	No kinase activity. No interaction with ctk2/lsc1. Mislocalization of ctk2/lsc1.
Q7YZT0	147	C->R	15326597	Abolishes formation of tetramers. No effect on dimerization.
P63104	58	S->E	15883165	Loss of homodimerization. Reduced dimerization with YWHAE. Significantly reduced interaction with P53. No enhancement of P53 transcriptional activity.
O95071	2768	C->A	11287654	Loss of ubiquitin binding.
P28375	43	R->A	16798616	This mutation alters integrin binding selectivity. It provokes 95-fold loss of ability to inhibit ADP-induced platelet aggregation, 71-fold loss of ability to inhibit A375 cell adhesion to fibrinogen, and almost complete loss of ability to inhibit HEL cell adhesion to fibrinogen.
P28375	43	R->Q	16798616	This mutation alters integrin binding selectivity. It provokes 33-fold loss of ability to inhibit ADP-induced platelet aggregation, 5-fold loss of ability to inhibit A375 cell adhesion to fibrinogen, and almost complete loss of ability to inhibit HEL cell adhesion to fibrinogen.
Q8N5J2	412	D->A	28082312	Loss of binding to 'Lys-48' tetraubiquitin chains.
Q8N5J2	415	L->A	28082312	Loss of binding to 'Lys-48' tetraubiquitin chains.
Q8N5J2	416	A->G,D	28082312	Loss of binding to 'Lys-48' tetraubiquitin chains.
Q8N5J2	419	L->A	28082312	Loss of binding to 'Lys-48' tetraubiquitin chains.
Q8N5J2	420	Q->A	28082312	Loss of binding to 'Lys-48' tetraubiquitin chains.
Q8N5J2	423	E->A	28082312	Loss of binding to 'Lys-48' tetraubiquitin chains.
Q8SWV6	271	I->D	29089387	Disrupts homodimerization, leading to increased adenylyltransferase activity and reduced phosphodiesterase activity.
F4JN35	487	W->R	17947243	Loss of binding to calmodulin.
Q9Y679	382	R->A	23223569	Significantly reduced interaction with UBE2G2.
Q9Y679	383	Q->A	23223569	Significantly reduced interaction with UBE2G2.
Q9Y679	389	R->A	23223569	Significantly reduced interaction with UBE2G2.
Q9Y679	398	R->A	23223569	Significantly reduced interaction with UBE2G2.
Q9Y679	408	E->A	23223569	Significantly reduced interaction with UBE2G2.
Q93009	165	W->A	16474402	Loss of binding to p53/TP53 and MDM2.
Q2G2Y0	147	D->K	20545943	Loss of host complement C5 binding.
Q23529	367	Q->P	14697201	In or577; temperature-sensitive allele. Induces aberrant centrosome attachment and nuclear positioning when transferred to nonpermissive temperature. Abolishes homodimerization.
Q9UG22	54	S->A	21059949	Abolishes GTP-induced dimerization.
Q9UG22	117	R->D	21059949	Abolishes GTP-induced dimerization.
Q9VDE6	659	N->A	16155582	Disrupts interaction with RAB11.
Q9VDE6	663	M->A	16155582	Disrupts interaction with RAB11.
Q9VDE6	667	F->A	16155582	Disrupts interaction with RAB11.
Q9UNP9	49	F->A	20460131	Strongly decreased affinity for KMT2A. Decreased affinity for RNA.
O04350	20	E->A	20638386	Loss of beta-tubulin binding.
O04350	24	Y->A	20638386	Loss of beta-tubulin binding.
P43254	465	R->E	11226162	No interaction with BBX24/STO and BBX25/STH, and at low light intensity shorter hypocotyl.
P43254	467	W->A	11226162	No interaction with HY5, BBX24/STO and BBX25/STH and at low light intensity shorter hypocotyl.
P43254	550	K->E	11226162	No interaction with HY5, BBX24/STO and BBX25/STH and at low light intensity shorter hypocotyl.
Q9SUM4	182	W->A	20837520	Abolished histone-binding.
Q9SUM4	204	C->A	20837520	Abolished histone-binding.
Q6UWZ7	404	S->P	26778126	Abolishes formation of a heterotetramer with BRCA1. Does not affect interaction with a first BRCA1 chain.
Q6UWZ7	406	S->A	17525340	Abolishes phosphorylation of the pSXXF motif and the interaction with BRCA1 but does not affect the interaction with UIMC1/RAP80. Strongly decreases recruitment of BRCA1 to sites of DNA damage. No effect on homodimerization.
O43865	71	S->A	16769890	Abolishes interaction with ITPR1. Highly decreases phosphorylation. Abolishes interaction with SLC4A4. Abolishes interaction with FIP1L1. Highly decreases interaction with SLC9A3; when associated whith A-68 and A- 74.
O43865	74	S->G	16769890	Abolishes interaction with ITPR1. Slightly decreases phosphorylation. Strongly decreases interaction with SLC4A4. Abolishes interaction with FIP1L1. Highly decreases interaction with SLC9A3; when associated whith A- 68 and A-71.
Q9Y4E1	1010	R->A	20498093	Disrupts interaction with F-actin-capping protein subunit alpha (CAPZA1 or CAPZA2 or CAPZA3).
Q9Y4E1	1312	D->A	23331060	Disrupts interaction with VPS35.
Q9EPR5	630	F->N	30061605	Introduces an N-glycosylation site and disrupts interaction with NGF and BDNF.
O60704	101	R->A	23481380	Prevents dimerization and strongly decreases enzyme activity.
Q811T9	822	L->Q	31444471	Abolished interaction with ATF4.
P35226	170	M->E	27827373	Strongly decreases affinity for PHC2.
Q8WXH0	6876	L->A	22632968	Disrupts interaction with SUN2.
Q8WXH0	6878	Y->A	22632968	Disrupts interaction with SUN2.
Q8WXH0	6883	P->A	22632968	Disrupts interaction with SUN2.
P25322	286	T->A	17081987	Constitutively nuclear. Strongly reduced interaction with FBXO4. Strongly reduced ubiquitination.
Q8BG40	538	S->L	28436967	Disrupts KATNA1:KATNB1 interaction with ASPM.
Q8BG40	574	Y->A	28436967	Disrupts KATNA1:KATNB1 interaction with ASPM; abolishes localization to microtubules minus ends; decreases ASPM localization to microtubules minus ends; no enhancement of ASPM activity in blocking microtubule minus- end growth.
P34252	84	T->A	16619031	No interaction with DPB11.
P34252	100	S->A	16619031	No interaction with DPB11.
Q9UBK5	57	D->A	10426994	Abolishes stable interaction with KLRK1.
P97260	449	L->A	15899885	Loss of SREBF maturation and interaction with COPII coat.
Q93073	721	G->R	22530054	Loss of binding to SELV and TXNRD1 SECIS elements.
P56279	16	D->G	11839817	Greatly reduced binding to AKT1, AKT2 and AKT3. Abolishes nuclear transport of AKT1.
P56279	74	I->V	11839817	Greatly reduced binding to AKT2. Abolishes nuclear transport of AKT1.
P01241	198	K->A	7504735	Asedb.
P01241	204	R->A	7504735	Asedb.
P01241	201	T->A	7504735	Asedb.
O95998	95	F->A	11278524	Asedb.
O95998	99	Y->A	11278524	Asedb.
O95998	106	F->A	11278524	Asedb.
P00982	26	K->A	9201909	Asedb.
P00982	3	K->A	9201909	Asedb.
P15692	90	E->A	9207067	Asedb.
P15692	43	F->A	9207067	Asedb.
P15692	109	I->A	9207067	Asedb.
P15692	72	I->A	9207067	Asedb.
P15692	111	P->A	9207067	Asedb.
P15692	105	Q->A	9207067	Asedb.
P20783	206	R->A	7529173	Asedb.
P20783	149	Y->A	7529173	Asedb.
P20783	241	R->A	7529173	Asedb.
P03950	29	R->A	1281426	Asedb.
P00974	50	K->A	8784199	Asedb.
P13487	58	Y->A	7516689	Asedb.
P06213	733	E->A	8576204	Asedb.
P06213	741	F->A	8576204	Asedb.
P06213	732	F->A	8576204	Asedb.
P06213	737	H->A	8576204	Asedb.
P06213	736	L->A	8576204	Asedb.
P06213	738	N->A	8576204	Asedb.
P06213	731	T->A	8576204	Asedb.
P06213	740	V->A	8576204	Asedb.
P06213	735	Y->A	8576204	Asedb.
P06213	91	F->A	7852381	Asedb.
P06213	42	N->A	7852381	Asedb.
P06213	41	R->A	7852381	Asedb.
P60775	68	K->A	8940141	Asedb.
P60775	31	Q->A	8940141	Asedb.
P13489	436	D->A	9050852	Asedb.
P13489	435	Y->A	9050852	Asedb.
P13726	92	T->A	7756258	Asedb.
P13726	90	D->A	7654692	Asedb.
P13726	52	K->A	7654692	Asedb.
P04482	51	D->A	9718299	Asedb.
P04482	41	E->A	9718299	Asedb.
P04482	56	P->A	9718299	Asedb.
P04482	50	S->A	9718299	Asedb.
P04482	37	V->A	9718299	Asedb.
P04482	54	Y->A	9718299	Asedb.
P04482	55	Y->A	9718299	Asedb.
P13479	51	D->A	9425068	Asedb.
P13479	41	E->A	9425068	Asedb.
P13479	33	L->A	9425068	Asedb.
P13479	50	S->A	9425068	Asedb.
P13479	34	V->A	9425068	Asedb.
P13479	55	Y->A	9425068	Asedb.
P05112	147	K->A	9799097	Asedb.
P05112	148	Y->A	9799097	Asedb.
P46111	30	N->A	8562077	Asedb.
P46111	24	R->A	8562077	Asedb.
P04351	103	V->A	8262055	Asedb.
P04351	79	Y->A	8262055	Asedb.
P08510	448	M->A	8562077	Asedb.
P10912	123	I->A	7529940	Asedb.
P10912	183	I->A	7529940	Asedb.
P10912	61	R->A	7529940	Asedb.
P10912	122	W->A	7529940	Asedb.
P10912	187	W->A	7529940	Asedb.
P00648	74	K->A	7739054	Asedb.
P00648	106	R->A	7739054	Asedb.
P00648	134	R->A	7739054	Asedb.
P00648	120	E->A	8494892	Asedb.
P00648	149	H->A	8494892	Asedb.
P00648	105	N->A	8494892	Asedb.
P01241	200	E->A	2014261	Asedb.
P01241	47	H->A	2014261	Asedb.
P01241	44	H->A	2014261	Asedb.
P01241	193	R->A	2014261	Asedb.
P01241	198	K->A	2014261	Asedb.
P09038	238	E->A	7665610	Asedb.
P09038	282	L->A	7929426	Asedb.
P09038	166	Y->A	7929426	Asedb.
P09038	245	Y->A	7929426	Asedb.
P11540	36	D->A	7739054	Asedb.
P11540	40	D->A	7739054	Asedb.
P11540	30	Y->A	7739054	Asedb.
P30403	458	D->A	8456099	Asedb.
P30403	456	R->A	8456099	Asedb.
P10145	31	E->A	1918013	Asedb.
P10145	32	L->A	1918013	Asedb.
P10145	33	R->A	1918013	Asedb.
P10775	431	D->A	9050852	Asedb.
P10775	433	Y->A	9050852	Asedb.
P10775	430	Y->A	9050852	Asedb.
P10775	259	W->A	10970748	Asedb.
P05112	33	E->A	9050834	Asedb.
P05112	112	R->A	9050834	Asedb.
P56633	47	R->A	10818087	Asedb.
P56633	52	K->A	10818087	Asedb.
P56633	54	F->A	10818087	Asedb.
P56633	70	K->A	10818087	Asedb.
P35804	77	H->A	12933802	SKEMPI2
P15879	99	G->D	16177825	SKEMPI2
P68390	146	T->P	11171964	SKEMPI2
P05112	33	E->K	9050834	SKEMPI2
A6ND01	81	L->A	27309818	SKEMPI2
P68390	149	Y->R	11171964	SKEMPI2
P05112	112	R->Q	9050834	SKEMPI2
P16471	212	H->A	20889499	SKEMPI2
P35804	196	R->A	17430899	SKEMPI2
P43631	208	E->A	24550293	SKEMPI2
P35804	186	W->A	17430899	SKEMPI2
Q8JL80	144	Y->S	20727575	SKEMPI2
O54901	124	N->K	23602662	SKEMPI2
P59594	491	Y->A	21411533	SKEMPI2
P68390	147	L->P	9047374	SKEMPI2
Q40059	66	R->A	10065709	SKEMPI2
P07363	214	F->A	21642453	SKEMPI2
O95633	87	L->E	22052913	SKEMPI2
P43631	93	D->A	24550293	SKEMPI2
P01563	56	R->A	21854986	SKEMPI2
P35225	47	I->A	20223216	SKEMPI2
O87916	74	F->A	23625930	SKEMPI2
P05000	53	L->A	21854986	SKEMPI2
P01033	25	T->R	12515831	SKEMPI2
P00974	50	K->A	10339415	SKEMPI2
P00648	105	N->A	8494892	SKEMPI2
P68390	165	N->Y	11171964	SKEMPI2
P68390	150	R->I	11171964	SKEMPI2
P68390	146	T->K	11171964	SKEMPI2
P00648	149	H->L	8507637	SKEMPI2
P00974	74	R->A	8784199	SKEMPI2
Q9P289	134	Y->A	23434407	SKEMPI2
P04049	84	K->A	15236966	SKEMPI2
P68390	148	E->W	11171964	SKEMPI2
P01241	198	K->A	2014261	SKEMPI2
O87916	304	N->A	23625930	SKEMPI2
P68390	161	G->I	11171964	SKEMPI2
P13726	52	K->A	7654692	SKEMPI2
P68390	148	E->F	11171964	SKEMPI2
P01730	104	S->A	2402498	SKEMPI2
P59594	479	N->K	15791205	SKEMPI2
Q5D734	48	I->R	18477456	SKEMPI2
P04626	547	L->A	23527120	SKEMPI2
Q8BGT1	160	F->N	26235031	SKEMPI2
Q9HXB1	86	H->D	17405861	SKEMPI2
P01730	62	L->A	2402498	SKEMPI2
O43157	1815	L->K	21610070	SKEMPI2
P15509	211	D->R	27396825	SKEMPI2
P13127	256	K->E	20625546	SKEMPI2
P35804	196	R->A	17070843	SKEMPI2
P68390	150	R->T	11171964	SKEMPI2
P68390	161	G->Y	11171964	SKEMPI2
P15509	302	R->D	27396825	SKEMPI2
P59823	34	W->A	25908590	SKEMPI2
P01062	22	I->A	20656696	SKEMPI2
O95633	86	F->E	22052913	SKEMPI2
P0CG48	616	L->A	10518943	SKEMPI2
P35804	72	F->A	15284234	SKEMPI2
P46672	100	R->A	17976650	SKEMPI2
Q13485	493	D->A	15350224	SKEMPI2
P43631	127	E->A	24550293	SKEMPI2
P59594	487	T->A	21411533	SKEMPI2
P68390	144	A->N	11171964	SKEMPI2
P04482	50	S->A	9718299	SKEMPI2
P01730	105	D->A	2402498	SKEMPI2
P68390	144	A->G	11171964	SKEMPI2
P35804	178	F->A	17430899	SKEMPI2
P0C1Z0	27	R->Y	24613488	SKEMPI2
P68390	147	L->I	9047374	SKEMPI2
P01112	38	D->A	15236966	SKEMPI2
P63000	33	I->N	9228059	SKEMPI2
Q8JL80	131	R->E	20727575	SKEMPI2
P13479	54	Y->A	9425068	SKEMPI2
P01730	53	W->A	2402498	SKEMPI2
P00974	50	K->Q	10339415	SKEMPI2
P05112	33	E->Q	9050834	SKEMPI2
P43631	205	S->A	24550293	SKEMPI2
P60953	32	Y->K	9632678	SKEMPI2
P68390	148	E->N	11171964	SKEMPI2
P00648	74	K->A	7739054	SKEMPI2
P48551	73	M->A	10556041	SKEMPI2
P13479	34	V->A	9425068	SKEMPI2
P01051	45	L->G	9048543	SKEMPI2
P54860	107	F->A	20427284	SKEMPI2
P01730	87	W->A	2402498	SKEMPI2
P68390	165	N->F	11171964	SKEMPI2
P15509	213	K->A	27396825	SKEMPI2
Q7A260	24	E->Q	17138564	SKEMPI2
P68390	144	A->R	11171964	SKEMPI2
Q40059	59	T->A	15865427	SKEMPI2
P35804	72	F->A	17070843	SKEMPI2
P09883	523	N->A	18471830	SKEMPI2
Q03386	784	R->A	15236966	SKEMPI2
P13489	436	D->A	9050852	SKEMPI2
P01563	56	R->K	10984492	SKEMPI2
P35804	198	W->A	12933802	SKEMPI2
P15509	300	D->E	27396825	SKEMPI2
P01236	208	H->A	20889499	SKEMPI2
P35804	85	D->A	17430899	SKEMPI2
P13489	435	Y->A	9050852	SKEMPI2
P0A7H3	228	F->D	21504984	SKEMPI2
P48551	73	M->A	21854986	SKEMPI2
P12497	222	P->A	9223641	SKEMPI2
O95633	87	L->A	22052913	SKEMPI2
P00974	55	R->A	8784199	SKEMPI2
P68390	149	Y->I	11171964	SKEMPI2
P01563	53	L->A	10556041	SKEMPI2
P0C1Z0	27	R->M	24613488	SKEMPI2
P04482	55	Y->A	9718299	SKEMPI2
P68390	149	Y->E	11171964	SKEMPI2
P01241	200	E->A	2014261	SKEMPI2
P04141	129	D->R	9166423	SKEMPI2
P00974	46	T->A	8784199	SKEMPI2
P0A7H3	132	R->A	21504984	SKEMPI2
P68390	161	G->R	11171964	SKEMPI2
Q13951	104	N->A	10984496	SKEMPI2
P68390	150	R->L	11171964	SKEMPI2
P68390	150	R->P	11171964	SKEMPI2
Q8NW39	128	F->A	18984582	SKEMPI2
P68390	147	L->D	9047374	SKEMPI2
P04637	181	R->E	16887812	SKEMPI2
P00974	68	F->A	8784199	SKEMPI2
P00648	149	H->D	8507637	SKEMPI2
P10912	187	W->A	9571026	SKEMPI2
P68390	148	E->L	11171964	SKEMPI2
P04141	129	D->K	27396825	SKEMPI2
P68390	149	Y->A	11171964	SKEMPI2
P68390	161	G->H	11171964	SKEMPI2
A0A0H3CIX8	63	L->A	23288853	SKEMPI2
P68390	148	E->C	11171964	SKEMPI2
P38507	242	I->A	8588944	SKEMPI2
P81274	228	R->E	22074847	SKEMPI2
P04626	574	V->A	23527120	SKEMPI2
P35804	178	F->A	17070843	SKEMPI2
P68390	165	N->W	11171964	SKEMPI2
Q01196	109	N->A	12807883	SKEMPI2
P68390	165	N->E	11171964	SKEMPI2
P68390	150	R->C	11171964	SKEMPI2
O95633	86	F->A	22052913	SKEMPI2
P35804	148	W->A	17430899	SKEMPI2
Q40059	68	R->C	10065709	SKEMPI2
P19909	398	E->A	10452608	SKEMPI2
P10912	183	I->A	9571026	SKEMPI2
A3DGE8	2167	I->A	27924829	SKEMPI2
P01563	172	R->A	21854986	SKEMPI2
P68390	161	G->E	11171964	SKEMPI2
P10912	122	W->A	9571026	SKEMPI2
P10912	183	I->A	7529940	SKEMPI2
P01075	36	P->G	10691989	SKEMPI2
P04049	84	K->E	15236966	SKEMPI2
P68390	147	L->E	9047374	SKEMPI2
P68390	150	R->E	11171964	SKEMPI2
P35804	89	Y->A	15284234	SKEMPI2
O87916	52	D->A	23625930	SKEMPI2
P13479	55	Y->A	9425068	SKEMPI2
P62593	127	M->A	24947275	SKEMPI2
Q40059	68	R->A	10065709	SKEMPI2
P01730	61	I->A	2402498	SKEMPI2
P68390	149	Y->P	11171964	SKEMPI2
P01112	35	T->A	15236966	SKEMPI2
Q03386	816	K->A	15236966	SKEMPI2
P62593	102	E->A	24947275	SKEMPI2
Q40059	68	R->A	15865427	SKEMPI2
O95633	50	L->E	22052913	SKEMPI2
P68390	147	L->H	9047374	SKEMPI2
O15392	67	W->A	22244766	SKEMPI2
P11540	40	D->A	7739054	SKEMPI2
P15509	213	K->D	27396825	SKEMPI2
O87916	152	W->A	23625930	SKEMPI2
Q93034	53	W->A	23897481	SKEMPI2
P68390	150	R->Y	11171964	SKEMPI2
Q8IYV9	148	W->A	27309818	SKEMPI2
P00974	72	G->A	8784199	SKEMPI2
Q6Q1S2	535	S->T	21411533	SKEMPI2
P32628	45	I->A	20427284	SKEMPI2
P00974	50	K->Y	10339415	SKEMPI2
P15879	109	E->A	16177825	SKEMPI2
Q8NW39	129	F->A	18984582	SKEMPI2
P00974	50	K->H	10339415	SKEMPI2
P11540	36	D->A	7739054	SKEMPI2
Q9BYF1	353	K->A	21411533	SKEMPI2
Q810C0	167	D->A	25989451	SKEMPI2
P01033	91	S->R	12515831	SKEMPI2
P37173	53	F->A	16300789	SKEMPI2
Q40059	61	E->S	15865427	SKEMPI2
P04049	68	T->A	15236966	SKEMPI2
Q2V8X0	65	L->G	25792743	SKEMPI2
P00648	149	H->A	8494892	SKEMPI2
P35804	110	K->A	15618400	SKEMPI2
P80060	86	L->V	7592720	SKEMPI2
P00974	50	K->G	10339415	SKEMPI2
O75326	213	Y->S	20727575	SKEMPI2
O87916	209	F->A	23625930	SKEMPI2
P01563	53	L->V	21854986	SKEMPI2
Q8IYV9	160	R->E	27309818	SKEMPI2
P62593	108	E->A	17070843	SKEMPI2
P68390	146	T->G	11171964	SKEMPI2
P00648	106	R->A	8494892	SKEMPI2
Q9Y5Y6	828	D->A	17475279	SKEMPI2
Q9Y6E0	107	L->E	24746913	SKEMPI2
P04141	132	L->A	27396825	SKEMPI2
P01241	198	K->A	7504735	SKEMPI2
P38507	227	I->W	7716157	SKEMPI2
P01563	53	L->A	21854986	SKEMPI2
P35225	140	F->A	20223216	SKEMPI2
P15509	214	K->D	27396825	SKEMPI2
P68390	144	A->D	11171964	SKEMPI2
P48551	104	E->A	21854986	SKEMPI2
P15509	302	R->M	9166423	SKEMPI2
P04049	59	R->A	11292826	SKEMPI2
P01051	45	L->P	9048543	SKEMPI2
P28829	83	R->A	11709168	SKEMPI2
P13127	266	R->A	20625546	SKEMPI2
P68390	147	L->R	9047374	SKEMPI2
Q7A260	24	E->A	17138564	SKEMPI2
P05112	112	R->A	9050834	SKEMPI2
O00506	91	L->A	24746913	SKEMPI2
Q64487	229	R->E	25989451	SKEMPI2
P13127	266	R->E	20625546	SKEMPI2
P0A7H3	210	R->E	21504984	SKEMPI2
P35225	137	K->A	20223216	SKEMPI2
P68390	146	T->Q	11171964	SKEMPI2
P68390	161	G->L	11171964	SKEMPI2
P00648	74	K->A	8494892	SKEMPI2
O87916	230	F->A	23625930	SKEMPI2
P04141	38	E->R	8204877	SKEMPI2
P68390	146	T->Y	11171964	SKEMPI2
P00974	50	K->V	10339415	SKEMPI2
P68390	146	T->W	11171964	SKEMPI2
Q9Y376	178	F->E	24746913	SKEMPI2
P01112	35	T->S	15236966	SKEMPI2
P13479	33	L->A	9425068	SKEMPI2
P35804	72	F->A	12933802	SKEMPI2
P01241	193	R->A	2014261	SKEMPI2
P13127	256	K->A	20625546	SKEMPI2
Q9UK55	314	D->A	25713144	SKEMPI2
P00974	71	G->A	8784199	SKEMPI2
Q8NW39	125	Y->A	18984582	SKEMPI2
P35804	72	F->A	17430899	SKEMPI2
P54860	44	L->A	20427284	SKEMPI2
P15509	211	D->A	27396825	SKEMPI2
Q9U3P2	105	Q->A	24485456	SKEMPI2
P0A9A6	374	I->A	10880432	SKEMPI2
P35804	186	W->A	12933802	SKEMPI2
P68390	148	E->G	11171964	SKEMPI2
P62834	38	D->A	8636102	SKEMPI2
P05112	33	E->A	9050834	SKEMPI2
P63000	38	D->N	9228059	SKEMPI2
P68390	149	Y->V	11171964	SKEMPI2
P68390	142	K->P	11171964	SKEMPI2
P01730	38	E->A	2402498	SKEMPI2
P00648	120	E->C	9126847	SKEMPI2
P68799	131	R->A	18687868	SKEMPI2
P04141	65	D->A	27396825	SKEMPI2
Q8JL80	206	R->E	20727575	SKEMPI2
P62593	102	E->K	9891008	SKEMPI2
P68390	165	N->K	11171964	SKEMPI2
O15392	71	D->A	22244766	SKEMPI2
P13127	260	R->E	20625546	SKEMPI2
Q9Y376	223	Y->A	24746913	SKEMPI2
P00974	50	K->F	10339415	SKEMPI2
P01563	56	R->K	21854986	SKEMPI2
P68390	147	L->Y	9047374	SKEMPI2
P01112	38	D->E	11709168	SKEMPI2
A0AEF4	435	A->Q	28389644	SKEMPI2
P43631	156	D->A	24550293	SKEMPI2
O87916	206	D->A	23625930	SKEMPI2
P68390	146	T->S	11171964	SKEMPI2
P54860	40	D->A	20427284	SKEMPI2
P01563	171	M->A	11698684	SKEMPI2
P35804	89	Y->A	17070843	SKEMPI2
Q03386	796	K->A	15236966	SKEMPI2
P01241	47	H->A	2014261	SKEMPI2
Q2V8X0	62	R->A	25792743	SKEMPI2
P00974	50	K->L	10339415	SKEMPI2
Q80TS3	323	Y->A	26235031	SKEMPI2
P01730	103	D->A	2402498	SKEMPI2
P68390	148	E->P	11171964	SKEMPI2
P12497	221	G->V	9223641	SKEMPI2
P00648	149	H->A	8507637	SKEMPI2
P04141	129	D->K	9166423	SKEMPI2
P35804	148	W->A	17070843	SKEMPI2
P43631	125	L->A	24550293	SKEMPI2
P68390	149	Y->L	11171964	SKEMPI2
Q7A260	74	Q->A	17138564	SKEMPI2
Q810C0	215	E->A	25989451	SKEMPI2
P62593	102	E->K	21294157	SKEMPI2
P04141	62	E->K	27396825	SKEMPI2
P68390	147	L->F	9047374	SKEMPI2
P01563	167	R->A	21854986	SKEMPI2
P68390	148	E->Y	11171964	SKEMPI2
P15509	189	R->A	27396825	SKEMPI2
P68390	161	G->Q	11171964	SKEMPI2
P04482	51	D->A	9718299	SKEMPI2
P68390	149	Y->Q	11171964	SKEMPI2
P00648	134	R->A	7739054	SKEMPI2
P68390	150	R->D	11171964	SKEMPI2
P00648	120	E->A	9126847	SKEMPI2
P68390	147	L->G	9047374	SKEMPI2
P11540	30	Y->A	7739054	SKEMPI2
P10912	61	R->A	7529940	SKEMPI2
P35804	89	Y->A	12933802	SKEMPI2
P68390	146	T->E	11171964	SKEMPI2
P21836	155	Y->Q	8157652	SKEMPI2
P00974	52	R->A	8784199	SKEMPI2
P12497	221	G->A	9223641	SKEMPI2
O87916	229	I->A	23625930	SKEMPI2
P04049	59	R->A	15236966	SKEMPI2
Q9Y376	260	M->E	23434407	SKEMPI2
P12497	222	P->V	9223641	SKEMPI2
P68390	147	L->V	9047374	SKEMPI2
Q9Y376	260	M->E	24746913	SKEMPI2
O54901	126	F->A	23602662	SKEMPI2
P26949	26	F->A	22981947	SKEMPI2
P00974	50	K->I	10339415	SKEMPI2
P01112	38	D->A	8636102	SKEMPI2
P68390	161	G->T	11171964	SKEMPI2
Q40059	59	T->D	7947796	SKEMPI2
O54901	130	K->E	23602662	SKEMPI2
P00974	50	K->T	10339415	SKEMPI2
P01563	53	L->A	11698684	SKEMPI2
B1Q236	60	F->A	24485456	SKEMPI2
P35225	138	K->A	20223216	SKEMPI2
P15509	300	D->A	27396825	SKEMPI2
P01033	25	T->L	12515831	SKEMPI2
P01112	40	Y->C	11709168	SKEMPI2
P46655	109	T->R	17976650	SKEMPI2
P01563	172	R->A	10984492	SKEMPI2
A3DGE8	2137	F->A	27924829	SKEMPI2
P15509	250	D->K	27396825	SKEMPI2
P04482	37	V->A	9718299	SKEMPI2
P46655	148	R->A	17976650	SKEMPI2
Q9UK55	261	Y->A	25713144	SKEMPI2
P68390	146	T->R	11171964	SKEMPI2
P68390	161	G->V	11171964	SKEMPI2
P09883	534	F->A	28794496	SKEMPI2
P01563	171	M->A	10984492	SKEMPI2
P68390	148	E->T	11171964	SKEMPI2
P01563	167	R->A	11698684	SKEMPI2
Q40059	59	T->A	7947796	SKEMPI2
Q15223	80	I->A	25231300	SKEMPI2
O54901	60	L->K	23602662	SKEMPI2
P04141	136	F->A	27396825	SKEMPI2
P68390	146	T->L	11171964	SKEMPI2
P01051	45	L->I	9048543	SKEMPI2
P68390	161	G->C	11171964	SKEMPI2
P19909	406	N->A	10452608	SKEMPI2
O15392	80	H->A	22244766	SKEMPI2
P62593	109	K->A	24947275	SKEMPI2
Q9U3P2	61	L->A	24485456	SKEMPI2
P29320	53	E->K	22242939	SKEMPI2
P68390	146	T->C	11171964	SKEMPI2
P54860	97	Y->A	20427284	SKEMPI2
P01062	19	T->A	20656696	SKEMPI2
P68390	147	L->W	9047374	SKEMPI2
O54901	126	F->D	23602662	SKEMPI2
Q40059	59	T->P	15865427	SKEMPI2
P68390	149	Y->S	11171964	SKEMPI2
O87916	191	Y->A	23625930	SKEMPI2
P00974	70	Y->A	8784199	SKEMPI2
P01241	204	R->A	7504735	SKEMPI2
P43631	66	Y->A	24550293	SKEMPI2
P68390	146	T->I	11171964	SKEMPI2
P21836	103	Y->N	8157652	SKEMPI2
P00974	50	K->W	10339415	SKEMPI2
P68390	147	L->C	9047374	SKEMPI2
P0A9A6	378	L->A	10880432	SKEMPI2
P00974	50	K->D	10339415	SKEMPI2
P68390	146	T->A	11171964	SKEMPI2
P48551	71	T->A	11698684	SKEMPI2
O87916	73	Y->A	23625930	SKEMPI2
P68390	148	E->I	11171964	SKEMPI2
P35804	77	H->A	17430899	SKEMPI2
P68390	147	L->A	9047374	SKEMPI2
P01563	53	L->V	10984492	SKEMPI2
P00648	130	R->Q	7739054	SKEMPI2
P38507	242	I->A	8332602	SKEMPI2
P68390	148	E->A	11171964	SKEMPI2
P68390	146	T->F	11171964	SKEMPI2
P32851	233	I->A	18337752	SKEMPI2
P35804	178	F->A	9891008	SKEMPI2
P19909	402	K->A	10452608	SKEMPI2
Q13191	937	A->E	18596201	SKEMPI2
P68390	150	R->G	11171964	SKEMPI2
A6ND01	45	E->K	27309818	SKEMPI2
P01563	56	R->Q	10984492	SKEMPI2
P01563	56	R->A	10984492	SKEMPI2
P05112	113	N->R	9050834	SKEMPI2
P04482	54	Y->A	9718299	SKEMPI2
Q40059	61	E->A	15865427	SKEMPI2
P00974	48	P->A	8784199	SKEMPI2
P68390	147	L->N	9047374	SKEMPI2
P68390	161	G->F	11171964	SKEMPI2
P00648	120	E->A	8494892	SKEMPI2
P01051	45	L->E	9048543	SKEMPI2
Q8VDU0	228	R->E	22074847	SKEMPI2
P01730	79	R->A	2402498	SKEMPI2
P0C1Z0	9	T->N	24613488	SKEMPI2
O95633	83	L->E	22052913	SKEMPI2
P50542	600	S->W	17157249	SKEMPI2
P00648	106	R->A	8507637	SKEMPI2
P68390	149	Y->H	11171964	SKEMPI2
P01563	171	M->A	21854986	SKEMPI2
P10600	394	R->K	19161338	SKEMPI2
P68390	150	R->W	11171964	SKEMPI2
P15509	302	R->A	27396825	SKEMPI2
Q64487	266	Y->A	25908590	SKEMPI2
Q7A260	75	D->E	17138564	SKEMPI2
P13479	51	D->A	9425068	SKEMPI2
P68390	148	E->V	11171964	SKEMPI2
P68390	161	G->N	11171964	SKEMPI2
P15509	189	R->D	27396825	SKEMPI2
O87916	50	N->A	23625930	SKEMPI2
P10912	124	P->A	2034689	SKEMPI2
P01051	45	L->D	9048543	SKEMPI2
Q9U3P2	115	R->A	24485456	SKEMPI2
Q810C0	187	D->A	25989451	SKEMPI2
P00648	120	E->S	9126847	SKEMPI2
P68390	148	E->K	11171964	SKEMPI2
P68390	150	R->V	11171964	SKEMPI2
P13726	76	D->A	7947809	SKEMPI2
P01033	91	S->Y	12515831	SKEMPI2
P54760	95	L->R	16867992	SKEMPI2
P09883	534	F->A	18471830	SKEMPI2
P00974	50	K->M	10339415	SKEMPI2
P13726	92	T->A	7756258	SKEMPI2
G0SCK6	486	R->E	26476442	SKEMPI2
P13726	172	F->A	7947809	SKEMPI2
P01112	35	T->A	20361980	SKEMPI2
P01051	45	L->S	9048543	SKEMPI2
P01563	168	A->G	21854986	SKEMPI2
P35804	186	W->A	17070843	SKEMPI2
P01075	38	V->A	8063780	SKEMPI2
Q40059	66	R->A	15865427	SKEMPI2
P12497	220	A->G	9223641	SKEMPI2
P01033	25	T->A	9268350	SKEMPI2
P0A9A6	377	F->A	10880432	SKEMPI2
P68390	150	R->Q	11171964	SKEMPI2
P00974	50	K->A	8784199	SKEMPI2
P04141	65	D->K	27396825	SKEMPI2
P35804	89	Y->A	17430899	SKEMPI2
P01730	82	S->A	2402498	SKEMPI2
P10912	122	W->F	2034689	SKEMPI2
Q40059	62	Y->A	10065709	SKEMPI2
P04141	129	D->A	27396825	SKEMPI2
P48551	104	E->A	11698684	SKEMPI2
Q9U3P2	53	Q->A	24485456	SKEMPI2
P68390	146	T->M	11171964	SKEMPI2
P68390	150	R->N	11171964	SKEMPI2
A3DGE8	2160	L->A	27924829	SKEMPI2
P35804	184	H->A	17070843	SKEMPI2
O15392	63	E->A	22244766	SKEMPI2
P68390	146	T->V	11171964	SKEMPI2
Q8NW39	127	H->A	18984582	SKEMPI2
P0A9A6	373	D->S	11278571	SKEMPI2
P01563	167	R->A	10984492	SKEMPI2
O15392	64	L->A	22244766	SKEMPI2
P68390	144	A->P	11171964	SKEMPI2
P46672	55	T->R	17976650	SKEMPI2
P00431	264	V->A	11148036	SKEMPI2
P68390	144	A->K	11171964	SKEMPI2
P68390	149	Y->K	11171964	SKEMPI2
P68390	147	L->T	9047374	SKEMPI2
P48551	73	M->V	11698684	SKEMPI2
P03950	64	K->G	10413501	SKEMPI2
P01112	40	Y->F	15236966	SKEMPI2
P01563	168	A->G	11698684	SKEMPI2
P04637	245	G->S	16887812	SKEMPI2
P01563	53	L->A	10984492	SKEMPI2
P46672	104	Y->A	17976650	SKEMPI2
Q8BGT1	160	F->A	26235031	SKEMPI2
P28829	101	K->A	11709168	SKEMPI2
P00974	50	K->S	10339415	SKEMPI2
P59594	487	T->S	21411533	SKEMPI2
P04049	66	Q->A	15236966	SKEMPI2
P68390	149	Y->M	11171964	SKEMPI2
P35804	110	K->A	17430899	SKEMPI2
P19909	414	W->A	10452608	SKEMPI2
P68390	161	G->D	11171964	SKEMPI2
P01062	20	K->A	20656696	SKEMPI2
P00974	50	K->E	10339415	SKEMPI2
P10912	124	P->A	9571026	SKEMPI2
Q40059	62	Y->G	10065709	SKEMPI2
P00648	134	R->A	8494892	SKEMPI2
P62593	103	Y->A	24947275	SKEMPI2
P68390	150	R->F	11171964	SKEMPI2
P68390	146	T->D	11171964	SKEMPI2
P62593	102	E->D	21294157	SKEMPI2
O87916	269	W->A	23625930	SKEMPI2
P10600	394	R->A	19161338	SKEMPI2
P13479	50	S->A	9425068	SKEMPI2
P68390	147	L->Q	9047374	SKEMPI2
Q96RK0	37	W->A	23512657	SKEMPI2
P68390	144	A->E	11171964	SKEMPI2
Q1MX18	78	W->A	22074847	SKEMPI2
P35804	184	H->A	17430899	SKEMPI2
P58546	44	D->A	20625546	SKEMPI2
P00648	106	R->A	7739054	SKEMPI2
P68390	150	R->M	11171964	SKEMPI2
P04482	56	P->A	9718299	SKEMPI2
P00648	149	H->G	8507637	SKEMPI2
P35804	85	D->A	12933802	SKEMPI2
P68390	150	R->H	11171964	SKEMPI2
Q01196	161	T->A	12807883	SKEMPI2
P00648	149	H->A	7739054	SKEMPI2
P35804	77	H->A	17070843	SKEMPI2
P00648	120	E->F	9126847	SKEMPI2
P04626	577	F->A	23527120	SKEMPI2
P58546	8	W->A	20625546	SKEMPI2
P13489	438	Y->A	9050852	SKEMPI2
P00648	106	R->K	8507637	SKEMPI2
P68390	148	E->R	11171964	SKEMPI2
Q2V8X0	66	V->D	25792743	SKEMPI2
P05112	112	R->D	9050834	SKEMPI2
Q40059	62	Y->A	15504027	SKEMPI2
P68390	149	Y->C	11171964	SKEMPI2
P68390	148	E->H	11171964	SKEMPI2
P07596	110	T->V	18556023	SKEMPI2
O87916	268	E->A	23625930	SKEMPI2
O54901	74	N->A	23602662	SKEMPI2
P13726	52	K->A	7947809	SKEMPI2
P04482	41	E->A	9718299	SKEMPI2
P15509	250	D->A	27396825	SKEMPI2
P03950	29	R->A	1281426	SKEMPI2
P54860	100	V->A	20427284	SKEMPI2
P58546	44	D->R	20625546	SKEMPI2
P27870	637	W->Y	11406576	SKEMPI2
O48541	749	D->R	25792743	SKEMPI2
P35804	178	F->A	12933802	SKEMPI2
P03950	64	K->Q	2742853	SKEMPI2
P68390	149	Y->D	11171964	SKEMPI2
P68390	146	T->N	11171964	SKEMPI2
P00974	47	G->A	8784199	SKEMPI2
P10912	122	W->A	2034689	SKEMPI2
P04049	89	R->L	15236966	SKEMPI2
P01730	106	T->A	2402498	SKEMPI2
P68390	149	Y->N	11171964	SKEMPI2
A3DGE8	2161	F->A	27924829	SKEMPI2
Q9P289	95	L->E	23434407	SKEMPI2
P13489	438	Y->F	10413501	SKEMPI2
Q7A260	76	W->A	17138564	SKEMPI2
P0CG48	682	R->L	10518943	SKEMPI2
O54901	61	I->E	23602662	SKEMPI2
P00431	357	E->A	11148036	SKEMPI2
P04049	67	R->A	15236966	SKEMPI2
Q40059	61	E->A	7947796	SKEMPI2
P35804	184	H->A	12933802	SKEMPI2
Q7A260	75	D->N	17138564	SKEMPI2
Q40059	60	M->G	15504027	SKEMPI2
P00974	69	V->A	8784199	SKEMPI2
P00974	53	I->A	8784199	SKEMPI2
P68390	161	G->W	11171964	SKEMPI2
P01033	93	C->S	9268350	SKEMPI2
P68390	161	G->M	11171964	SKEMPI2
P13489	264	W->A	10970748	SKEMPI2
P68390	148	E->M	11171964	SKEMPI2
P68036	63	F->A	17433363	SKEMPI2
P01033	91	S->A	12515831	SKEMPI2
P15509	300	D->A	9166423	SKEMPI2
P00974	81	K->A	8784199	SKEMPI2
Q03386	795	Y->A	15236966	SKEMPI2
P68390	147	L->S	9047374	SKEMPI2
P13479	41	E->A	9425068	SKEMPI2
P00974	50	K->N	10339415	SKEMPI2
P00648	120	E->Y	9126847	SKEMPI2
P68390	148	E->S	11171964	SKEMPI2
P13127	260	R->A	20625546	SKEMPI2
Q8H0K8	395	H->K	16279951	SKEMPI2
O95633	83	L->A	22052913	SKEMPI2
P35804	178	F->A	15618400	SKEMPI2
P01241	44	H->A	2014261	SKEMPI2
Q9UK55	95	D->A	25713144	SKEMPI2
P43631	92	Q->K	24550293	SKEMPI2
P35804	198	W->A	17070843	SKEMPI2
P35804	85	D->A	9891008	SKEMPI2
P68390	147	L->K	9047374	SKEMPI2
P01075	38	V->G	10691989	SKEMPI2
P21836	328	F->I	8157652	SKEMPI2
P01033	91	S->E	12515831	SKEMPI2
O87916	53	W->A	23625930	SKEMPI2
Q8NW39	126	Y->A	18984582	SKEMPI2
P37173	75	S->L	16300789	SKEMPI2
P00648	149	H->Q	8507637	SKEMPI2
P68390	150	R->A	11171964	SKEMPI2
O87916	208	Y->A	23625930	SKEMPI2
P68390	149	Y->T	11171964	SKEMPI2
P01563	172	R->A	11698684	SKEMPI2
P04049	84	K->A	11292826	SKEMPI2
P35804	110	K->A	17070843	SKEMPI2
O54901	74	N->D	23602662	SKEMPI2
P01563	56	R->A	10556041	SKEMPI2
P68390	149	Y->G	11171964	SKEMPI2
P35804	110	K->A	12933802	SKEMPI2
P68390	161	G->K	11171964	SKEMPI2
P68390	165	N->L	11171964	SKEMPI2
P48551	107	V->A	21854986	SKEMPI2
P0C1Z0	27	R->F	24613488	SKEMPI2
P13726	77	W->A	7947809	SKEMPI2
O60486	222	R->S	20727575	SKEMPI2
P21836	317	W->R	8157652	SKEMPI2
Q92956	55	P->A	21959263	SKEMPI2
P36894	109	Q->A	15064755	SKEMPI2
P01112	40	Y->A	15236966	SKEMPI2
P68390	150	R->S	11171964	SKEMPI2
P58546	78	E->R	20625546	SKEMPI2
P01563	168	A->G	10984492	SKEMPI2
P10912	61	R->A	9571026	SKEMPI2
P68390	146	T->H	11171964	SKEMPI2
P00974	54	I->A	8784199	SKEMPI2